id	sid	tid	token	lemma	pos
ajmpe-94	1	1	american	american	PROPN
ajmpe-94	1	2	journal	journal	PROPN
ajmpe-94	1	3	of	of	ADP
ajmpe-94	1	4	medical	medical	ADJ
ajmpe-94	1	5	and	and	CCONJ
ajmpe-94	1	6	physical	physical	ADJ
ajmpe-94	1	7	education	education	NOUN
ajmpe-94	1	8	vol.1	vol.1	PROPN
ajmpe-94	1	9	,	,	PUNCT
ajmpe-94	1	10	issue	issue	NOUN
ajmpe-94	1	11	1	1	NUM
ajmpe-94	1	12	;	;	PUNCT
ajmpe-94	1	13	july	july	PROPN
ajmpe-94	1	14	2023	2023	NUM
ajmpe-94	1	15	;	;	PUNCT
ajmpe-94	1	16	1252	1252	NUM
ajmpe-94	1	17	columbia	columbia	PROPN
ajmpe-94	1	18	rd	rd	PROPN
ajmpe-94	1	19	nw	nw	PROPN
ajmpe-94	1	20	,	,	PUNCT
ajmpe-94	1	21	washington	washington	PROPN
ajmpe-94	1	22	dc	dc	PROPN
ajmpe-94	1	23	,	,	PUNCT
ajmpe-94	1	24	united	united	PROPN
ajmpe-94	1	25	states	states	PROPN
ajmpe-94	1	26	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	1	27	;	;	PUNCT
ajmpe-94	1	28	mail	mail	NOUN
ajmpe-94	1	29	:	:	PUNCT
ajmpe-94	1	30	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	1	31	69	69	NUM
ajmpe-94	2	1	|	|	ADV
ajmpe-94	2	2	a	a	DET
ajmpe-94	2	3	m	m	NOUN
ajmpe-94	2	4	e	e	NOUN
ajmpe-94	2	5	r	r	NOUN
ajmpe-94	2	6	i	i	NOUN
ajmpe-94	2	7	c	c	VERB
ajmpe-94	2	8	a	a	DET
ajmpe-94	2	9	n	n	NOUN
ajmpe-94	3	1	j	j	NOUN
ajmpe-94	3	2	o	o	X
ajmpe-94	3	3	u	u	NOUN
ajmpe-94	3	4	r	r	NOUN
ajmpe-94	3	5	n	n	NOUN
ajmpe-94	3	6	a	a	DET
ajmpe-94	3	7	l	l	NOUN
ajmpe-94	3	8	o	o	X
ajmpe-94	4	1	f	f	X
ajmpe-94	4	2	m	m	NOUN
ajmpe-94	4	3	e	e	NOUN
ajmpe-94	5	1	d	d	NOUN
ajmpe-94	5	2	i	i	PRON
ajmpe-94	5	3	c	c	VERB
ajmpe-94	5	4	a	a	DET
ajmpe-94	5	5	l	l	NOUN
ajmpe-94	5	6	a	a	X
ajmpe-94	5	7	n	n	NOUN
ajmpe-94	6	1	d	d	NOUN
ajmpe-94	6	2	p	p	NOUN
ajmpe-94	6	3	h	h	NOUN
ajmpe-94	6	4	y	y	NOUN
ajmpe-94	6	5	s	s	VERB
ajmpe-94	7	1	i	i	INTJ
ajmpe-94	7	2	c	c	VERB
ajmpe-94	7	3	a	a	DET
ajmpe-94	7	4	l	l	NOUN
ajmpe-94	7	5	e	e	NOUN
ajmpe-94	7	6	d	d	X
ajmpe-94	7	7	u	u	X
ajmpe-94	7	8	c	c	PROPN
ajmpe-94	8	1	a	a	DET
ajmpe-94	8	2	t	t	NOUN
ajmpe-94	9	1	i	i	PRON
ajmpe-94	9	2	o	o	VERB
ajmpe-94	9	3	n	n	CCONJ
ajmpe-94	9	4	|	|	ADV
ajmpe-94	9	5	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	NUM
ajmpe-94	9	6	biochemical	biochemical	ADJ
ajmpe-94	9	7	changes	change	NOUN
ajmpe-94	9	8	of	of	ADP
ajmpe-94	9	9	electrolytes	electrolyte	NOUN
ajmpe-94	9	10	and	and	CCONJ
ajmpe-94	9	11	trace	trace	NOUN
ajmpe-94	9	12	elements	element	NOUN
ajmpe-94	9	13	among	among	ADP
ajmpe-94	9	14	patient	patient	NOUN
ajmpe-94	9	15	with	with	ADP
ajmpe-94	9	16	coronavirus	coronavirus	NOUN
ajmpe-94	9	17	disease	disease	NOUN
ajmpe-94	9	18	-19	-19	PRON
ajmpe-94	9	19	(	(	PUNCT
ajmpe-94	9	20	covid	covid	NOUN
ajmpe-94	9	21	-19	-19	NUM
ajmpe-94	9	22	)	)	PUNCT
ajmpe-94	9	23	in	in	ADP
ajmpe-94	9	24	khartoum	khartoum	PROPN
ajmpe-94	9	25	state	state	PROPN
ajmpe-94	9	26	abdallah	abdallah	PROPN
ajmpe-94	9	27	eltoum	eltoum	PROPN
ajmpe-94	9	28	ali1	ali1	PROPN
ajmpe-94	9	29	,	,	PUNCT
ajmpe-94	9	30	ahmed	ahmed	PROPN
ajmpe-94	9	31	jbril	jbril	PROPN
ajmpe-94	9	32	aldooma	aldooma	PROPN
ajmpe-94	9	33	sabil	sabil	PROPN
ajmpe-94	9	34	1	1	NUM
ajmpe-94	9	35	,	,	PUNCT
ajmpe-94	9	36	mohammed	mohammed	PROPN
ajmpe-94	9	37	abd	abd	PROPN
ajmpe-94	9	38	elfatah	elfatah	PROPN
ajmpe-94	9	39	elamin	elamin	PROPN
ajmpe-94	9	40	ali1	ali1	PROPN
ajmpe-94	9	41	ahmed	ahme	VERB
ajmpe-94	9	42	ibn	ibn	PROPN
ajmpe-94	9	43	edriss	edriss	VERB
ajmpe-94	9	44	mohammed2	mohammed2	PROPN
ajmpe-94	9	45	salih	salih	PROPN
ajmpe-94	9	46	a.	a.	PROPN
ajmpe-94	9	47	elmahdi	elmahdi	PROPN
ajmpe-94	9	48	3	3	PROPN
ajmpe-94	9	49	university	university	PROPN
ajmpe-94	9	50	of	of	ADP
ajmpe-94	9	51	alzaeim	alzaeim	PROPN
ajmpe-94	9	52	al	al	PROPN
ajmpe-94	9	53	azhari	azhari	PROPN
ajmpe-94	9	54	faculty	faculty	NOUN
ajmpe-94	9	55	of	of	ADP
ajmpe-94	9	56	medical	medical	ADJ
ajmpe-94	9	57	laboratory	laboratory	NOUN
ajmpe-94	9	58	sciences	sciences	PROPN
ajmpe-94	9	59	,	,	PUNCT
ajmpe-94	9	60	department	department	NOUN
ajmpe-94	9	61	of	of	ADP
ajmpe-94	9	62	clinical	clinical	ADJ
ajmpe-94	9	63	chemistry	chemistry	NOUN
ajmpe-94	9	64	university	university	NOUN
ajmpe-94	9	65	of	of	ADP
ajmpe-94	9	66	elimam	elimam	PROPN
ajmpe-94	9	67	elmahdi	elmahdi	PROPN
ajmpe-94	9	68	department	department	PROPN
ajmpe-94	9	69	of	of	ADP
ajmpe-94	9	70	medical	medical	PROPN
ajmpe-94	9	71	laboratory	laboratory	PROPN
ajmpe-94	9	72	sciences	sciences	PROPN
ajmpe-94	9	73	college	college	PROPN
ajmpe-94	9	74	of	of	ADP
ajmpe-94	9	75	medical	medical	ADJ
ajmpe-94	9	76	laboratory	laboratory	NOUN
ajmpe-94	9	77	sciences	sciences	PROPN
ajmpe-94	9	78	.	.	PUNCT
ajmpe-94	10	1	department	department	NOUN
ajmpe-94	10	2	of	of	ADP
ajmpe-94	10	3	clinical	clinical	ADJ
ajmpe-94	10	4	chemistry	chemistry	NOUN
ajmpe-94	10	5	.	.	PUNCT
ajmpe-94	11	1	the	the	DET
ajmpe-94	11	2	national	national	PROPN
ajmpe-94	11	3	ribat	ribat	PROPN
ajmpe-94	11	4	university	university	PROPN
ajmpe-94	11	5	,	,	PUNCT
ajmpe-94	11	6	khartoum	khartoum	PROPN
ajmpe-94	11	7	,	,	PUNCT
ajmpe-94	11	8	sudan	sudan	PROPN
ajmpe-94	11	9	.	.	PUNCT
ajmpe-94	12	1	abstract	abstract	ADJ
ajmpe-94	12	2	background	background	NOUN
ajmpe-94	12	3	:	:	PUNCT
ajmpe-94	12	4	coronavirus	coronavirus	NOUN
ajmpe-94	12	5	disease	disease	NOUN
ajmpe-94	12	6	2019	2019	NUM
ajmpe-94	12	7	covid-19	covid-19	PROPN
ajmpe-94	12	8	is	be	AUX
ajmpe-94	12	9	a	a	DET
ajmpe-94	12	10	pandemic	pandemic	NOUN
ajmpe-94	12	11	caused	cause	VERB
ajmpe-94	12	12	by	by	ADP
ajmpe-94	12	13	severe	severe	ADJ
ajmpe-94	12	14	acute	acute	PROPN
ajmpe-94	12	15	syndrome	syndrome	NOUN
ajmpe-94	12	16	coronavirus	coronavirus	NOUN
ajmpe-94	12	17	2	2	NUM
ajmpe-94	12	18	(	(	PUNCT
ajmpe-94	12	19	sars	sar	NOUN
ajmpe-94	12	20	-	-	PUNCT
ajmpe-94	12	21	cov-2	cov-2	NOUN
ajmpe-94	12	22	)	)	PUNCT
ajmpe-94	12	23	is	be	AUX
ajmpe-94	12	24	respiratory	respiratory	ADJ
ajmpe-94	12	25	and	and	CCONJ
ajmpe-94	12	26	can	can	AUX
ajmpe-94	12	27	be	be	AUX
ajmpe-94	12	28	involved	involve	VERB
ajmpe-94	12	29	in	in	ADP
ajmpe-94	12	30	multiorgan	multiorgan	NOUN
ajmpe-94	12	31	failure	failure	NOUN
ajmpe-94	12	32	causes	cause	VERB
ajmpe-94	12	33	many	many	ADJ
ajmpe-94	12	34	biochemical	biochemical	ADJ
ajmpe-94	12	35	changes	change	NOUN
ajmpe-94	12	36	in	in	ADP
ajmpe-94	12	37	the	the	DET
ajmpe-94	12	38	human	human	ADJ
ajmpe-94	12	39	body	body	NOUN
ajmpe-94	12	40	,	,	PUNCT
ajmpe-94	12	41	our	our	PRON
ajmpe-94	12	42	study	study	NOUN
ajmpe-94	12	43	was	be	AUX
ajmpe-94	12	44	designed	design	VERB
ajmpe-94	12	45	to	to	PART
ajmpe-94	12	46	examine	examine	VERB
ajmpe-94	12	47	the	the	DET
ajmpe-94	12	48	serum	serum	NOUN
ajmpe-94	12	49	level	level	NOUN
ajmpe-94	12	50	electrolytes	electrolyte	NOUN
ajmpe-94	12	51	and	and	CCONJ
ajmpe-94	12	52	trace	trace	NOUN
ajmpe-94	12	53	elements	element	NOUN
ajmpe-94	12	54	in	in	ADP
ajmpe-94	12	55	covid19	covid19	NOUN
ajmpe-94	12	56	patients	patient	NOUN
ajmpe-94	12	57	and	and	CCONJ
ajmpe-94	12	58	associated	associate	VERB
ajmpe-94	12	59	with	with	ADP
ajmpe-94	12	60	severity	severity	NOUN
ajmpe-94	12	61	of	of	ADP
ajmpe-94	12	62	the	the	DET
ajmpe-94	12	63	disease	disease	NOUN
ajmpe-94	12	64	.	.	PUNCT
ajmpe-94	13	1	materials	material	NOUN
ajmpe-94	13	2	and	and	CCONJ
ajmpe-94	13	3	methods	method	NOUN
ajmpe-94	13	4	:	:	PUNCT
ajmpe-94	13	5	cross	cross	ADJ
ajmpe-94	13	6	-	-	ADJ
ajmpe-94	13	7	sectional	sectional	ADJ
ajmpe-94	13	8	study	study	NOUN
ajmpe-94	13	9	includes	include	VERB
ajmpe-94	13	10	50	50	NUM
ajmpe-94	13	11	covid-19	covid-19	PROPN
ajmpe-94	13	12	patients	patient	NOUN
ajmpe-94	13	13	conducted	conduct	VERB
ajmpe-94	13	14	during	during	ADP
ajmpe-94	13	15	the	the	DET
ajmpe-94	13	16	period	period	NOUN
ajmpe-94	13	17	from	from	ADP
ajmpe-94	13	18	december	december	PROPN
ajmpe-94	13	19	2020	2020	NUM
ajmpe-94	13	20	to	to	ADP
ajmpe-94	13	21	april	april	PROPN
ajmpe-94	13	22	2021	2021	NUM
ajmpe-94	13	23	and	and	CCONJ
ajmpe-94	13	24	50	50	NUM
ajmpe-94	13	25	healthy	healthy	ADJ
ajmpe-94	13	26	as	as	ADP
ajmpe-94	13	27	control	control	NOUN
ajmpe-94	13	28	group	group	NOUN
ajmpe-94	13	29	.	.	PUNCT
ajmpe-94	14	1	blood	blood	NOUN
ajmpe-94	14	2	samples	sample	NOUN
ajmpe-94	14	3	were	be	AUX
ajmpe-94	14	4	collected	collect	VERB
ajmpe-94	14	5	from	from	ADP
ajmpe-94	14	6	the	the	DET
ajmpe-94	14	7	study	study	NOUN
ajmpe-94	14	8	group	group	NOUN
ajmpe-94	14	9	and	and	CCONJ
ajmpe-94	14	10	measured	measure	VERB
ajmpe-94	14	11	electrolytes	electrolyte	NOUN
ajmpe-94	14	12	sodium	sodium	NOUN
ajmpe-94	14	13	and	and	CCONJ
ajmpe-94	14	14	potassium	potassium	NOUN
ajmpe-94	14	15	by	by	ADP
ajmpe-94	14	16	easy	easy	ADJ
ajmpe-94	14	17	lite	lite	NOUN
ajmpe-94	14	18	,	,	PUNCT
ajmpe-94	14	19	calcium	calcium	NOUN
ajmpe-94	14	20	,	,	PUNCT
ajmpe-94	14	21	phosphate	phosphate	NOUN
ajmpe-94	14	22	,	,	PUNCT
ajmpe-94	14	23	zinc	zinc	NOUN
ajmpe-94	14	24	,	,	PUNCT
ajmpe-94	14	25	and	and	CCONJ
ajmpe-94	14	26	copper	copper	NOUN
ajmpe-94	14	27	by	by	ADP
ajmpe-94	14	28	using	use	VERB
ajmpe-94	14	29	calorimeter	calorimeter	NOUN
ajmpe-94	14	30	methods	method	NOUN
ajmpe-94	14	31	,	,	PUNCT
ajmpe-94	14	32	statistical	statistical	ADJ
ajmpe-94	14	33	analysis	analysis	NOUN
ajmpe-94	14	34	was	be	AUX
ajmpe-94	14	35	conducted	conduct	VERB
ajmpe-94	14	36	using	use	VERB
ajmpe-94	14	37	the	the	DET
ajmpe-94	14	38	spss	spss	PROPN
ajmpe-94	14	39	version	version	NOUN
ajmpe-94	14	40	.	.	PUNCT
ajmpe-94	15	1	results	result	NOUN
ajmpe-94	15	2	:	:	PUNCT
ajmpe-94	15	3	the	the	DET
ajmpe-94	15	4	study	study	NOUN
ajmpe-94	15	5	showed	show	VERB
ajmpe-94	15	6	that	that	SCONJ
ajmpe-94	15	7	in	in	ADP
ajmpe-94	15	8	covid-19	covid-19	PROPN
ajmpe-94	15	9	patients	patient	NOUN
ajmpe-94	15	10	there	there	PRON
ajmpe-94	15	11	was	be	VERB
ajmpe-94	15	12	a	a	DET
ajmpe-94	15	13	significantly	significantly	ADV
ajmpe-94	15	14	low	low	ADJ
ajmpe-94	15	15	level	level	NOUN
ajmpe-94	15	16	of	of	ADP
ajmpe-94	15	17	sodium	sodium	NOUN
ajmpe-94	15	18	(	(	PUNCT
ajmpe-94	15	19	132	132	NUM
ajmpe-94	15	20	±	±	NUM
ajmpe-94	15	21	4.3	4.3	NUM
ajmpe-94	15	22	)	)	PUNCT
ajmpe-94	15	23	,	,	PUNCT
ajmpe-94	15	24	potassium	potassium	NOUN
ajmpe-94	15	25	(	(	PUNCT
ajmpe-94	15	26	3.2	3.2	NUM
ajmpe-94	15	27	±	±	NUM
ajmpe-94	15	28	0.4	0.4	NUM
ajmpe-94	15	29	)	)	PUNCT
ajmpe-94	15	30	,	,	PUNCT
ajmpe-94	15	31	and	and	CCONJ
ajmpe-94	15	32	calcium	calcium	NOUN
ajmpe-94	15	33	(	(	PUNCT
ajmpe-94	15	34	7.8	7.8	NUM
ajmpe-94	15	35	±	±	NUM
ajmpe-94	15	36	.98	.98	NUM
ajmpe-94	15	37	)	)	PUNCT
ajmpe-94	15	38	in	in	ADP
ajmpe-94	15	39	comparison	comparison	NOUN
ajmpe-94	15	40	to	to	ADP
ajmpe-94	15	41	control	control	NOUN
ajmpe-94	15	42	,	,	PUNCT
ajmpe-94	15	43	insignificant	insignificant	ADJ
ajmpe-94	15	44	in	in	ADP
ajmpe-94	15	45	level	level	NOUN
ajmpe-94	15	46	of	of	ADP
ajmpe-94	15	47	phosphorus	phosphorus	NOUN
ajmpe-94	15	48	and	and	CCONJ
ajmpe-94	15	49	magnesium	magnesium	NOUN
ajmpe-94	15	50	when	when	SCONJ
ajmpe-94	15	51	compared	compare	VERB
ajmpe-94	15	52	with	with	ADP
ajmpe-94	15	53	control	control	NOUN
ajmpe-94	15	54	group	group	NOUN
ajmpe-94	15	55	respectively	respectively	ADV
ajmpe-94	15	56	(	(	PUNCT
ajmpe-94	15	57	p.value	p.value	NOUN
ajmpe-94	15	58	=	=	SYM
ajmpe-94	15	59	0.15	0.15	NUM
ajmpe-94	15	60	,	,	PUNCT
ajmpe-94	15	61	0.8	0.8	NUM
ajmpe-94	15	62	.	.	PUNCT
ajmpe-94	15	63	)	)	PUNCT
ajmpe-94	15	64	.	.	PUNCT
ajmpe-94	16	1	there	there	PRON
ajmpe-94	16	2	is	be	VERB
ajmpe-94	16	3	significant	significant	ADJ
ajmpe-94	16	4	decrease	decrease	NOUN
ajmpe-94	16	5	in	in	ADP
ajmpe-94	16	6	the	the	DET
ajmpe-94	16	7	mean	mean	ADJ
ajmpe-94	16	8	level	level	NOUN
ajmpe-94	16	9	of	of	ADP
ajmpe-94	16	10	zinc	zinc	NOUN
ajmpe-94	16	11	and	and	CCONJ
ajmpe-94	16	12	increase	increase	NOUN
ajmpe-94	16	13	in	in	ADP
ajmpe-94	16	14	the	the	DET
ajmpe-94	16	15	mean	mean	ADJ
ajmpe-94	16	16	level	level	NOUN
ajmpe-94	16	17	of	of	ADP
ajmpe-94	16	18	copper	copper	NOUN
ajmpe-94	16	19	in	in	ADP
ajmpe-94	16	20	covid-19	covid-19	PROPN
ajmpe-94	16	21	patients	patient	NOUN
ajmpe-94	16	22	when	when	SCONJ
ajmpe-94	16	23	were	be	AUX
ajmpe-94	16	24	compared	compare	VERB
ajmpe-94	16	25	to	to	ADP
ajmpe-94	16	26	control	control	NOUN
ajmpe-94	16	27	group	group	NOUN
ajmpe-94	16	28	(	(	PUNCT
ajmpe-94	16	29	p	p	NOUN
ajmpe-94	16	30	value	value	NOUN
ajmpe-94	16	31	=	=	NOUN
ajmpe-94	16	32	0.000	0.000	NUM
ajmpe-94	16	33	)	)	PUNCT
ajmpe-94	16	34	,	,	PUNCT
ajmpe-94	16	35	.	.	PUNCT
ajmpe-94	17	1	however	however	ADV
ajmpe-94	17	2	there	there	PRON
ajmpe-94	17	3	was	be	VERB
ajmpe-94	17	4	strong	strong	ADJ
ajmpe-94	17	5	correlation	correlation	NOUN
ajmpe-94	17	6	between	between	ADP
ajmpe-94	17	7	sodium	sodium	NOUN
ajmpe-94	17	8	(	(	PUNCT
ajmpe-94	17	9	r=-.753	r=-.753	PROPN
ajmpe-94	17	10	,	,	PUNCT
ajmpe-94	17	11	p=	p=	NOUN
ajmpe-94	17	12	.000	.000	NUM
ajmpe-94	17	13	)	)	PUNCT
ajmpe-94	17	14	,	,	PUNCT
ajmpe-94	17	15	potassium	potassium	NOUN
ajmpe-94	17	16	(	(	PUNCT
ajmpe-94	17	17	r=	r=	PROPN
ajmpe-94	17	18	-.736	-.736	PROPN
ajmpe-94	17	19	,	,	PUNCT
ajmpe-94	17	20	p=.000	p=.000	PROPN
ajmpe-94	17	21	)	)	PUNCT
ajmpe-94	17	22	,	,	PUNCT
ajmpe-94	17	23	zinc	zinc	NOUN
ajmpe-94	17	24	(	(	PUNCT
ajmpe-94	17	25	r=	r=	NOUN
ajmpe-94	17	26	-.819	-.819	ADJ
ajmpe-94	17	27	,	,	PUNCT
ajmpe-94	17	28	p=	p=	NOUN
ajmpe-94	17	29	.000	.000	NUM
ajmpe-94	17	30	)	)	PUNCT
ajmpe-94	17	31	and	and	CCONJ
ajmpe-94	17	32	copper	copper	NOUN
ajmpe-94	17	33	(	(	PUNCT
ajmpe-94	17	34	r=	r=	ADJ
ajmpe-94	17	35	.700	.700	NUM
ajmpe-94	17	36	,	,	PUNCT
ajmpe-94	17	37	p=	p=	NOUN
ajmpe-94	17	38	.000	.000	NUM
ajmpe-94	17	39	)	)	PUNCT
ajmpe-94	17	40	with	with	ADP
ajmpe-94	17	41	severity	severity	NOUN
ajmpe-94	17	42	of	of	ADP
ajmpe-94	17	43	disease	disease	NOUN
ajmpe-94	17	44	.	.	PUNCT
ajmpe-94	18	1	conclusions	conclusion	NOUN
ajmpe-94	18	2	:	:	PUNCT
ajmpe-94	18	3	covid-19	covid-19	PROPN
ajmpe-94	18	4	infection	infection	NOUN
ajmpe-94	18	5	cause	cause	VERB
ajmpe-94	18	6	hypernatremia	hypernatremia	NOUN
ajmpe-94	18	7	,	,	PUNCT
ajmpe-94	18	8	hypokalemia	hypokalemia	NOUN
ajmpe-94	18	9	,	,	PUNCT
ajmpe-94	18	10	and	and	CCONJ
ajmpe-94	18	11	hypocalcaemia	hypocalcaemia	NOUN
ajmpe-94	18	12	.	.	PUNCT
ajmpe-94	19	1	low	low	ADJ
ajmpe-94	19	2	zinc	zinc	NOUN
ajmpe-94	19	3	and	and	CCONJ
ajmpe-94	19	4	high	high	ADJ
ajmpe-94	19	5	copper	copper	NOUN
ajmpe-94	19	6	levels	level	NOUN
ajmpe-94	19	7	,	,	PUNCT
ajmpe-94	19	8	the	the	DET
ajmpe-94	19	9	level	level	NOUN
ajmpe-94	19	10	of	of	ADP
ajmpe-94	19	11	parameters	parameter	NOUN
ajmpe-94	19	12	is	be	AUX
ajmpe-94	19	13	correlated	correlate	VERB
ajmpe-94	19	14	with	with	ADP
ajmpe-94	19	15	the	the	DET
ajmpe-94	19	16	severity	severity	NOUN
ajmpe-94	19	17	of	of	ADP
ajmpe-94	19	18	the	the	DET
ajmpe-94	19	19	disease	disease	NOUN
ajmpe-94	19	20	.	.	PUNCT
ajmpe-94	20	1	keywords	keyword	NOUN
ajmpe-94	20	2	:	:	PUNCT
ajmpe-94	20	3	covid	covid	PROPN
ajmpe-94	20	4	-19	-19	PROPN
ajmpe-94	20	5	,	,	PUNCT
ajmpe-94	20	6	sodium	sodium	NOUN
ajmpe-94	20	7	,	,	PUNCT
ajmpe-94	20	8	potassium	potassium	NOUN
ajmpe-94	20	9	,	,	PUNCT
ajmpe-94	20	10	calcium	calcium	NOUN
ajmpe-94	20	11	,	,	PUNCT
ajmpe-94	20	12	phosphate	phosphate	NOUN
ajmpe-94	20	13	,	,	PUNCT
ajmpe-94	20	14	magnesium	magnesium	NOUN
ajmpe-94	20	15	,	,	PUNCT
ajmpe-94	20	16	copper	copper	NOUN
ajmpe-94	20	17	zinc	zinc	NOUN
ajmpe-94	20	18	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	20	19	american	american	PROPN
ajmpe-94	20	20	journal	journal	PROPN
ajmpe-94	20	21	of	of	ADP
ajmpe-94	20	22	medical	medical	ADJ
ajmpe-94	20	23	and	and	CCONJ
ajmpe-94	20	24	physical	physical	ADJ
ajmpe-94	20	25	education	education	NOUN
ajmpe-94	20	26	vol.1	vol.1	PROPN
ajmpe-94	20	27	,	,	PUNCT
ajmpe-94	20	28	issue	issue	NOUN
ajmpe-94	20	29	1	1	NUM
ajmpe-94	20	30	;	;	PUNCT
ajmpe-94	20	31	july	july	PROPN
ajmpe-94	20	32	2023	2023	NUM
ajmpe-94	20	33	;	;	PUNCT
ajmpe-94	20	34	1252	1252	NUM
ajmpe-94	20	35	columbia	columbia	PROPN
ajmpe-94	20	36	rd	rd	PROPN
ajmpe-94	20	37	nw	nw	PROPN
ajmpe-94	20	38	,	,	PUNCT
ajmpe-94	20	39	washington	washington	PROPN
ajmpe-94	20	40	dc	dc	PROPN
ajmpe-94	20	41	,	,	PUNCT
ajmpe-94	20	42	united	united	PROPN
ajmpe-94	20	43	states	states	PROPN
ajmpe-94	20	44	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	20	45	;	;	PUNCT
ajmpe-94	20	46	mail	mail	NOUN
ajmpe-94	20	47	:	:	PUNCT
ajmpe-94	20	48	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	21	1	70	70	NUM
ajmpe-94	22	1	|	|	ADV
ajmpe-94	22	2	a	a	DET
ajmpe-94	22	3	m	m	NOUN
ajmpe-94	22	4	e	e	NOUN
ajmpe-94	22	5	r	r	NOUN
ajmpe-94	22	6	i	i	NOUN
ajmpe-94	22	7	c	c	VERB
ajmpe-94	22	8	a	a	DET
ajmpe-94	22	9	n	n	NOUN
ajmpe-94	23	1	j	j	NOUN
ajmpe-94	23	2	o	o	X
ajmpe-94	23	3	u	u	NOUN
ajmpe-94	23	4	r	r	NOUN
ajmpe-94	23	5	n	n	NOUN
ajmpe-94	23	6	a	a	DET
ajmpe-94	23	7	l	l	NOUN
ajmpe-94	23	8	o	o	X
ajmpe-94	24	1	f	f	X
ajmpe-94	24	2	m	m	NOUN
ajmpe-94	24	3	e	e	NOUN
ajmpe-94	25	1	d	d	NOUN
ajmpe-94	25	2	i	i	PRON
ajmpe-94	25	3	c	c	VERB
ajmpe-94	25	4	a	a	DET
ajmpe-94	25	5	l	l	NOUN
ajmpe-94	25	6	a	a	X
ajmpe-94	25	7	n	n	NOUN
ajmpe-94	26	1	d	d	NOUN
ajmpe-94	26	2	p	p	NOUN
ajmpe-94	26	3	h	h	NOUN
ajmpe-94	26	4	y	y	NOUN
ajmpe-94	26	5	s	s	VERB
ajmpe-94	27	1	i	i	INTJ
ajmpe-94	27	2	c	c	VERB
ajmpe-94	27	3	a	a	DET
ajmpe-94	27	4	l	l	NOUN
ajmpe-94	27	5	e	e	NOUN
ajmpe-94	27	6	d	d	X
ajmpe-94	27	7	u	u	X
ajmpe-94	27	8	c	c	PROPN
ajmpe-94	28	1	a	a	DET
ajmpe-94	28	2	t	t	NOUN
ajmpe-94	29	1	i	i	PRON
ajmpe-94	29	2	o	o	VERB
ajmpe-94	29	3	n	n	CCONJ
ajmpe-94	29	4	|	|	ADV
ajmpe-94	29	5	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	29	6	introduction	introduction	NOUN
ajmpe-94	29	7	:	:	PUNCT
ajmpe-94	29	8	the	the	DET
ajmpe-94	29	9	term	term	NOUN
ajmpe-94	29	10	"	"	PUNCT
ajmpe-94	29	11	coronavirus	coronavirus	NOUN
ajmpe-94	29	12	"	"	PUNCT
ajmpe-94	29	13	means	mean	VERB
ajmpe-94	29	14	"	"	PUNCT
ajmpe-94	29	15	halo	halo	NOUN
ajmpe-94	29	16	"	"	PUNCT
ajmpe-94	29	17	or	or	CCONJ
ajmpe-94	29	18	"	"	PUNCT
ajmpe-94	29	19	crown	crown	NOUN
ajmpe-94	29	20	.	.	PUNCT
ajmpe-94	29	21	"	"	PUNCT
ajmpe-94	30	1	coronaviruses	coronaviruse	NOUN
ajmpe-94	30	2	are	be	AUX
ajmpe-94	30	3	enveloped	envelop	VERB
ajmpe-94	30	4	,	,	PUNCT
ajmpe-94	30	5	positive	positive	ADJ
ajmpe-94	30	6	-	-	PUNCT
ajmpe-94	30	7	sense	sense	NOUN
ajmpe-94	30	8	singlestranded	singlestranded	ADJ
ajmpe-94	30	9	rna	rna	NOUN
ajmpe-94	30	10	viruses	virus	NOUN
ajmpe-94	30	11	with	with	ADP
ajmpe-94	30	12	a	a	DET
ajmpe-94	30	13	genome	genome	NOUN
ajmpe-94	30	14	size	size	NOUN
ajmpe-94	30	15	range	range	NOUN
ajmpe-94	30	16	of	of	ADP
ajmpe-94	30	17	26	26	NUM
ajmpe-94	30	18	and	and	CCONJ
ajmpe-94	30	19	32	32	NUM
ajmpe-94	30	20	kbs	kbs	PROPN
ajmpe-94	30	21	(	(	PUNCT
ajmpe-94	30	22	1,2	1,2	NUM
ajmpe-94	30	23	)	)	PUNCT
ajmpe-94	30	24	.	.	PUNCT
ajmpe-94	31	1	coronaviruses	coronaviruse	NOUN
ajmpe-94	31	2	are	be	AUX
ajmpe-94	31	3	zoonotic	zoonotic	ADJ
ajmpe-94	31	4	infections	infection	NOUN
ajmpe-94	31	5	that	that	PRON
ajmpe-94	31	6	originate	originate	VERB
ajmpe-94	31	7	in	in	ADP
ajmpe-94	31	8	animals	animal	NOUN
ajmpe-94	31	9	and	and	CCONJ
ajmpe-94	31	10	can	can	AUX
ajmpe-94	31	11	be	be	AUX
ajmpe-94	31	12	transmitted	transmit	VERB
ajmpe-94	31	13	directly	directly	ADV
ajmpe-94	31	14	from	from	ADP
ajmpe-94	31	15	one	one	NUM
ajmpe-94	31	16	person	person	NOUN
ajmpe-94	31	17	to	to	ADP
ajmpe-94	31	18	another	another	PRON
ajmpe-94	31	19	.	.	PUNCT
ajmpe-94	32	1	the	the	DET
ajmpe-94	32	2	seafood	seafood	NOUN
ajmpe-94	32	3	market	market	NOUN
ajmpe-94	32	4	in	in	ADP
ajmpe-94	32	5	wuhan	wuhan	PROPN
ajmpe-94	32	6	,	,	PUNCT
ajmpe-94	32	7	china	china	PROPN
ajmpe-94	32	8	,	,	PUNCT
ajmpe-94	32	9	where	where	SCONJ
ajmpe-94	32	10	covid-19	covid-19	PROPN
ajmpe-94	32	11	is	be	AUX
ajmpe-94	32	12	said	say	VERB
ajmpe-94	32	13	to	to	PART
ajmpe-94	32	14	have	have	AUX
ajmpe-94	32	15	first	first	ADV
ajmpe-94	32	16	appeared	appear	VERB
ajmpe-94	32	17	,	,	PUNCT
ajmpe-94	32	18	was	be	AUX
ajmpe-94	32	19	later	later	ADV
ajmpe-94	32	20	closed	close	VERB
ajmpe-94	32	21	down	down	ADP
ajmpe-94	32	22	by	by	ADP
ajmpe-94	32	23	chinese	chinese	ADJ
ajmpe-94	32	24	authorities	authority	NOUN
ajmpe-94	32	25	(	(	PUNCT
ajmpe-94	32	26	3	3	NUM
ajmpe-94	32	27	)	)	PUNCT
ajmpe-94	32	28	.	.	PUNCT
ajmpe-94	33	1	infection	infection	NOUN
ajmpe-94	33	2	is	be	AUX
ajmpe-94	33	3	primarily	primarily	ADV
ajmpe-94	33	4	spread	spread	VERB
ajmpe-94	33	5	from	from	ADP
ajmpe-94	33	6	person	person	NOUN
ajmpe-94	33	7	to	to	ADP
ajmpe-94	33	8	person	person	NOUN
ajmpe-94	33	9	through	through	ADP
ajmpe-94	33	10	respiratory	respiratory	ADJ
ajmpe-94	33	11	droplets	droplet	NOUN
ajmpe-94	33	12	,	,	PUNCT
ajmpe-94	33	13	close	close	ADJ
ajmpe-94	33	14	personal	personal	ADJ
ajmpe-94	33	15	contact	contact	NOUN
ajmpe-94	33	16	,	,	PUNCT
ajmpe-94	33	17	like	like	ADP
ajmpe-94	33	18	touching	touch	VERB
ajmpe-94	33	19	or	or	CCONJ
ajmpe-94	33	20	shaking	shake	VERB
ajmpe-94	33	21	hands	hand	NOUN
ajmpe-94	33	22	,	,	PUNCT
ajmpe-94	33	23	and	and	CCONJ
ajmpe-94	33	24	fecaloral	fecaloral	ADJ
ajmpe-94	33	25	routes	route	NOUN
ajmpe-94	33	26	are	be	AUX
ajmpe-94	33	27	rarely	rarely	ADV
ajmpe-94	33	28	used	use	VERB
ajmpe-94	33	29	.	.	PUNCT
ajmpe-94	34	1	therefore	therefore	ADV
ajmpe-94	34	2	,	,	PUNCT
ajmpe-94	34	3	it	it	PRON
ajmpe-94	34	4	has	have	AUX
ajmpe-94	34	5	been	be	AUX
ajmpe-94	34	6	advised	advise	VERB
ajmpe-94	34	7	to	to	PART
ajmpe-94	34	8	place	place	VERB
ajmpe-94	34	9	persons	person	NOUN
ajmpe-94	34	10	who	who	PRON
ajmpe-94	34	11	have	have	AUX
ajmpe-94	34	12	been	be	AUX
ajmpe-94	34	13	exposed	expose	VERB
ajmpe-94	34	14	to	to	ADP
ajmpe-94	34	15	infection	infection	NOUN
ajmpe-94	34	16	under	under	ADP
ajmpe-94	34	17	quarantine	quarantine	NOUN
ajmpe-94	34	18	for	for	ADP
ajmpe-94	34	19	14	14	NUM
ajmpe-94	34	20	days	day	NOUN
ajmpe-94	34	21	(	(	PUNCT
ajmpe-94	34	22	4,5	4,5	NUM
ajmpe-94	34	23	)	)	PUNCT
ajmpe-94	34	24	.	.	PUNCT
ajmpe-94	35	1	electrolytes	electrolyte	NOUN
ajmpe-94	35	2	are	be	AUX
ajmpe-94	35	3	compounds	compound	NOUN
ajmpe-94	35	4	that	that	PRON
ajmpe-94	35	5	dissolve	dissolve	VERB
ajmpe-94	35	6	in	in	ADP
ajmpe-94	35	7	body	body	NOUN
ajmpe-94	35	8	fluids	fluid	NOUN
ajmpe-94	35	9	and	and	CCONJ
ajmpe-94	35	10	can	can	AUX
ajmpe-94	35	11	conduct	conduct	VERB
ajmpe-94	35	12	an	an	DET
ajmpe-94	35	13	electrical	electrical	ADJ
ajmpe-94	35	14	current	current	NOUN
ajmpe-94	35	15	.	.	PUNCT
ajmpe-94	36	1	the	the	DET
ajmpe-94	36	2	extracellular	extracellular	ADJ
ajmpe-94	36	3	fluid	fluid	NOUN
ajmpe-94	36	4	and	and	CCONJ
ajmpe-94	36	5	intracellular	intracellular	ADJ
ajmpe-94	36	6	fluid	fluid	NOUN
ajmpe-94	36	7	include	include	VERB
ajmpe-94	36	8	these	these	DET
ajmpe-94	36	9	substances	substance	NOUN
ajmpe-94	36	10	,	,	PUNCT
ajmpe-94	36	11	therefore	therefore	ADV
ajmpe-94	36	12	electrolytes	electrolyte	NOUN
ajmpe-94	36	13	are	be	AUX
ajmpe-94	36	14	essential	essential	ADJ
ajmpe-94	36	15	for	for	ADP
ajmpe-94	36	16	regulating	regulate	VERB
ajmpe-94	36	17	homeostasis	homeostasis	NOUN
ajmpe-94	36	18	(	(	PUNCT
ajmpe-94	36	19	6	6	NUM
ajmpe-94	36	20	)	)	PUNCT
ajmpe-94	36	21	.	.	PUNCT
ajmpe-94	37	1	neurological	neurological	ADJ
ajmpe-94	37	2	symptoms	symptom	NOUN
ajmpe-94	37	3	of	of	ADP
ajmpe-94	37	4	hyponatremia	hyponatremia	NOUN
ajmpe-94	37	5	,	,	PUNCT
ajmpe-94	37	6	one	one	NUM
ajmpe-94	37	7	of	of	ADP
ajmpe-94	37	8	the	the	DET
ajmpe-94	37	9	electrolyte	electrolyte	NOUN
ajmpe-94	37	10	diseases	disease	NOUN
ajmpe-94	37	11	,	,	PUNCT
ajmpe-94	37	12	are	be	AUX
ajmpe-94	37	13	present	present	ADJ
ajmpe-94	37	14	.	.	PUNCT
ajmpe-94	38	1	headaches	headache	NOUN
ajmpe-94	38	2	,	,	PUNCT
ajmpe-94	38	3	disorientation	disorientation	NOUN
ajmpe-94	38	4	,	,	PUNCT
ajmpe-94	38	5	confusion	confusion	NOUN
ajmpe-94	38	6	,	,	PUNCT
ajmpe-94	38	7	and	and	CCONJ
ajmpe-94	38	8	nausea	nausea	NOUN
ajmpe-94	38	9	are	be	AUX
ajmpe-94	38	10	common	common	ADJ
ajmpe-94	38	11	patient	patient	ADJ
ajmpe-94	38	12	complaints	complaint	NOUN
ajmpe-94	38	13	.	.	PUNCT
ajmpe-94	39	1	when	when	SCONJ
ajmpe-94	39	2	the	the	DET
ajmpe-94	39	3	serum	serum	NOUN
ajmpe-94	39	4	sodium	sodium	NOUN
ajmpe-94	39	5	levels	level	NOUN
ajmpe-94	39	6	are	be	AUX
ajmpe-94	39	7	higher	high	ADJ
ajmpe-94	39	8	than	than	ADP
ajmpe-94	39	9	145	145	NUM
ajmpe-94	39	10	mmol	mmol	NOUN
ajmpe-94	39	11	/	/	SYM
ajmpe-94	39	12	l	l	NOUN
ajmpe-94	39	13	,	,	PUNCT
ajmpe-94	39	14	hypernatremia	hypernatremia	NOUN
ajmpe-94	39	15	manifests	manifest	NOUN
ajmpe-94	39	16	.	.	PUNCT
ajmpe-94	40	1	tachypnea	tachypnea	PROPN
ajmpe-94	40	2	,	,	PUNCT
ajmpe-94	40	3	trouble	trouble	NOUN
ajmpe-94	40	4	falling	fall	VERB
ajmpe-94	40	5	asleep	asleep	ADJ
ajmpe-94	40	6	,	,	PUNCT
ajmpe-94	40	7	and	and	CCONJ
ajmpe-94	40	8	agitation	agitation	NOUN
ajmpe-94	40	9	are	be	AUX
ajmpe-94	40	10	all	all	PRON
ajmpe-94	40	11	signs	sign	NOUN
ajmpe-94	40	12	of	of	ADP
ajmpe-94	40	13	hypernatremia	hypernatremia	NOUN
ajmpe-94	40	14	(	(	PUNCT
ajmpe-94	40	15	7	7	NUM
ajmpe-94	40	16	)	)	PUNCT
ajmpe-94	40	17	.	.	PUNCT
ajmpe-94	41	1	the	the	DET
ajmpe-94	41	2	virus	virus	NOUN
ajmpe-94	41	3	's	's	PART
ajmpe-94	41	4	entry	entry	NOUN
ajmpe-94	41	5	reduces	reduce	VERB
ajmpe-94	41	6	ace2	ace2	NOUN
ajmpe-94	41	7	and	and	CCONJ
ajmpe-94	41	8	stops	stop	VERB
ajmpe-94	41	9	angiotensin	angiotensin	PROPN
ajmpe-94	41	10	ii	ii	PROPN
ajmpe-94	41	11	from	from	ADP
ajmpe-94	41	12	degrading	degrade	VERB
ajmpe-94	41	13	,	,	PUNCT
ajmpe-94	41	14	which	which	PRON
ajmpe-94	41	15	leads	lead	VERB
ajmpe-94	41	16	to	to	ADP
ajmpe-94	41	17	an	an	DET
ajmpe-94	41	18	increase	increase	NOUN
ajmpe-94	41	19	in	in	ADP
ajmpe-94	41	20	the	the	DET
ajmpe-94	41	21	production	production	NOUN
ajmpe-94	41	22	of	of	ADP
ajmpe-94	41	23	aldosterone	aldosterone	NOUN
ajmpe-94	41	24	and	and	CCONJ
ajmpe-94	41	25	potassium	potassium	NOUN
ajmpe-94	41	26	loss	loss	NOUN
ajmpe-94	41	27	from	from	ADP
ajmpe-94	41	28	urine	urine	NOUN
ajmpe-94	41	29	(	(	PUNCT
ajmpe-94	41	30	8,9	8,9	NUM
ajmpe-94	41	31	)	)	PUNCT
ajmpe-94	41	32	.	.	PUNCT
ajmpe-94	42	1	despite	despite	SCONJ
ajmpe-94	42	2	the	the	DET
ajmpe-94	42	3	rarity	rarity	NOUN
ajmpe-94	42	4	of	of	ADP
ajmpe-94	42	5	reports	report	NOUN
ajmpe-94	42	6	of	of	ADP
ajmpe-94	42	7	hypocalcemia	hypocalcemia	NOUN
ajmpe-94	42	8	during	during	ADP
ajmpe-94	42	9	covid-19	covid-19	PROPN
ajmpe-94	42	10	infection	infection	NOUN
ajmpe-94	42	11	,	,	PUNCT
ajmpe-94	42	12	we	we	PRON
ajmpe-94	42	13	should	should	AUX
ajmpe-94	42	14	therefore	therefore	ADV
ajmpe-94	42	15	pay	pay	VERB
ajmpe-94	42	16	greater	great	ADJ
ajmpe-94	42	17	attention	attention	NOUN
ajmpe-94	42	18	to	to	ADP
ajmpe-94	42	19	changes	change	NOUN
ajmpe-94	42	20	in	in	ADP
ajmpe-94	42	21	calcium	calcium	NOUN
ajmpe-94	42	22	/	/	SYM
ajmpe-94	42	23	phosphorus	phosphorus	NOUN
ajmpe-94	42	24	metabolism	metabolism	NOUN
ajmpe-94	42	25	in	in	ADP
ajmpe-94	42	26	covid-19	covid-19	PROPN
ajmpe-94	42	27	patients	patient	NOUN
ajmpe-94	42	28	and	and	CCONJ
ajmpe-94	42	29	closely	closely	ADV
ajmpe-94	42	30	monitor	monitor	VERB
ajmpe-94	42	31	calcium	calcium	NOUN
ajmpe-94	42	32	levels	level	NOUN
ajmpe-94	42	33	,	,	PUNCT
ajmpe-94	42	34	especially	especially	ADV
ajmpe-94	42	35	in	in	ADP
ajmpe-94	42	36	those	those	PRON
ajmpe-94	42	37	with	with	ADP
ajmpe-94	42	38	a	a	DET
ajmpe-94	42	39	history	history	NOUN
ajmpe-94	42	40	of	of	ADP
ajmpe-94	42	41	hypocalcemia	hypocalcemia	NOUN
ajmpe-94	42	42	,	,	PUNCT
ajmpe-94	42	43	to	to	PART
ajmpe-94	42	44	prevent	prevent	VERB
ajmpe-94	42	45	the	the	DET
ajmpe-94	42	46	condition	condition	NOUN
ajmpe-94	42	47	from	from	ADP
ajmpe-94	42	48	getting	get	VERB
ajmpe-94	42	49	worse	bad	ADJ
ajmpe-94	42	50	and	and	CCONJ
ajmpe-94	42	51	to	to	PART
ajmpe-94	42	52	start	start	VERB
ajmpe-94	42	53	the	the	DET
ajmpe-94	42	54	right	right	ADJ
ajmpe-94	42	55	treatment	treatment	NOUN
ajmpe-94	42	56	as	as	ADV
ajmpe-94	42	57	soon	soon	ADV
ajmpe-94	42	58	as	as	ADP
ajmpe-94	42	59	possible	possible	ADJ
ajmpe-94	42	60	.	.	PUNCT
ajmpe-94	43	1	(	(	PUNCT
ajmpe-94	43	2	6,8,9	6,8,9	NUM
ajmpe-94	43	3	)	)	PUNCT
ajmpe-94	43	4	.	.	PUNCT
ajmpe-94	44	1	in	in	ADP
ajmpe-94	44	2	the	the	DET
ajmpe-94	44	3	pathophysiology	pathophysiology	NOUN
ajmpe-94	44	4	of	of	ADP
ajmpe-94	44	5	covid-19	covid-19	PROPN
ajmpe-94	44	6	,	,	PUNCT
ajmpe-94	44	7	trace	trace	NOUN
ajmpe-94	44	8	elements	element	NOUN
ajmpe-94	44	9	play	play	VERB
ajmpe-94	44	10	a	a	DET
ajmpe-94	44	11	significant	significant	ADJ
ajmpe-94	44	12	role	role	NOUN
ajmpe-94	44	13	.	.	PUNCT
ajmpe-94	45	1	recent	recent	ADJ
ajmpe-94	45	2	assessments	assessment	NOUN
ajmpe-94	45	3	have	have	AUX
ajmpe-94	45	4	noted	note	VERB
ajmpe-94	45	5	that	that	SCONJ
ajmpe-94	45	6	amounts	amount	NOUN
ajmpe-94	45	7	of	of	ADP
ajmpe-94	45	8	zinc	zinc	NOUN
ajmpe-94	45	9	are	be	AUX
ajmpe-94	45	10	necessary	necessary	ADJ
ajmpe-94	45	11	for	for	ADP
ajmpe-94	45	12	both	both	CCONJ
ajmpe-94	45	13	the	the	DET
ajmpe-94	45	14	innate	innate	ADJ
ajmpe-94	45	15	and	and	CCONJ
ajmpe-94	45	16	adaptive	adaptive	ADJ
ajmpe-94	45	17	immune	immune	ADJ
ajmpe-94	45	18	systems	system	NOUN
ajmpe-94	45	19	(	(	PUNCT
ajmpe-94	45	20	10	10	NUM
ajmpe-94	45	21	)	)	PUNCT
ajmpe-94	45	22	.	.	PUNCT
ajmpe-94	46	1	for	for	ADP
ajmpe-94	46	2	instance	instance	NOUN
ajmpe-94	46	3	,	,	PUNCT
ajmpe-94	46	4	low	low	ADJ
ajmpe-94	46	5	levels	level	NOUN
ajmpe-94	46	6	of	of	ADP
ajmpe-94	46	7	zinc	zinc	NOUN
ajmpe-94	46	8	impair	impair	VERB
ajmpe-94	46	9	the	the	DET
ajmpe-94	46	10	activity	activity	NOUN
ajmpe-94	46	11	of	of	ADP
ajmpe-94	46	12	natural	natural	ADJ
ajmpe-94	46	13	killer	killer	NOUN
ajmpe-94	46	14	(	(	PUNCT
ajmpe-94	46	15	nk)cells	nk)cell	NOUN
ajmpe-94	46	16	,	,	PUNCT
ajmpe-94	46	17	which	which	PRON
ajmpe-94	46	18	are	be	AUX
ajmpe-94	46	19	essential	essential	ADJ
ajmpe-94	46	20	for	for	ADP
ajmpe-94	46	21	maintaining	maintain	VERB
ajmpe-94	46	22	the	the	DET
ajmpe-94	46	23	immune	immune	ADJ
ajmpe-94	46	24	response	response	NOUN
ajmpe-94	46	25	against	against	ADP
ajmpe-94	46	26	viruses	virus	NOUN
ajmpe-94	46	27	and	and	CCONJ
ajmpe-94	46	28	tumors	tumor	NOUN
ajmpe-94	46	29	(	(	PUNCT
ajmpe-94	46	30	11	11	NUM
ajmpe-94	46	31	)	)	PUNCT
ajmpe-94	46	32	.	.	PUNCT
ajmpe-94	47	1	zinc	zinc	NOUN
ajmpe-94	47	2	must	must	AUX
ajmpe-94	47	3	be	be	AUX
ajmpe-94	47	4	in	in	ADP
ajmpe-94	47	5	balance	balance	NOUN
ajmpe-94	47	6	with	with	ADP
ajmpe-94	47	7	copper	copper	NOUN
ajmpe-94	47	8	in	in	ADP
ajmpe-94	47	9	order	order	NOUN
ajmpe-94	47	10	to	to	PART
ajmpe-94	47	11	neutralize	neutralize	VERB
ajmpe-94	47	12	any	any	DET
ajmpe-94	47	13	negative	negative	ADJ
ajmpe-94	47	14	impacts	impact	NOUN
ajmpe-94	47	15	that	that	PRON
ajmpe-94	47	16	copper	copper	NOUN
ajmpe-94	47	17	may	may	AUX
ajmpe-94	47	18	have	have	VERB
ajmpe-94	47	19	.	.	PUNCT
ajmpe-94	48	1	additionally	additionally	ADV
ajmpe-94	48	2	,	,	PUNCT
ajmpe-94	48	3	copper	copper	NOUN
ajmpe-94	48	4	is	be	AUX
ajmpe-94	48	5	an	an	DET
ajmpe-94	48	6	essential	essential	ADJ
ajmpe-94	48	7	trace	trace	NOUN
ajmpe-94	48	8	element	element	NOUN
ajmpe-94	48	9	for	for	ADP
ajmpe-94	48	10	both	both	DET
ajmpe-94	48	11	humans	human	NOUN
ajmpe-94	48	12	and	and	CCONJ
ajmpe-94	48	13	pathogens	pathogen	NOUN
ajmpe-94	48	14	(	(	PUNCT
ajmpe-94	48	15	12	12	NUM
ajmpe-94	48	16	)	)	PUNCT
ajmpe-94	48	17	.	.	PUNCT
ajmpe-94	49	1	no	no	ADV
ajmpe-94	49	2	matter	matter	ADV
ajmpe-94	49	3	the	the	DET
ajmpe-94	49	4	causative	causative	ADJ
ajmpe-94	49	5	agent	agent	NOUN
ajmpe-94	49	6	(	(	PUNCT
ajmpe-94	49	7	virus	virus	NOUN
ajmpe-94	49	8	,	,	PUNCT
ajmpe-94	49	9	bacterium	bacterium	NOUN
ajmpe-94	49	10	,	,	PUNCT
ajmpe-94	49	11	or	or	CCONJ
ajmpe-94	49	12	fungus	fungus	NOUN
ajmpe-94	49	13	)	)	PUNCT
ajmpe-94	49	14	,	,	PUNCT
ajmpe-94	49	15	a	a	DET
ajmpe-94	49	16	steady	steady	ADJ
ajmpe-94	49	17	rise	rise	NOUN
ajmpe-94	49	18	in	in	ADP
ajmpe-94	49	19	serum	serum	NOUN
ajmpe-94	49	20	copper	copper	NOUN
ajmpe-94	49	21	is	be	AUX
ajmpe-94	49	22	a	a	DET
ajmpe-94	49	23	characteristic	characteristic	NOUN
ajmpe-94	49	24	of	of	ADP
ajmpe-94	49	25	infection	infection	NOUN
ajmpe-94	49	26	(	(	PUNCT
ajmpe-94	49	27	13–15	13–15	NUM
ajmpe-94	49	28	)	)	PUNCT
ajmpe-94	49	29	.	.	PUNCT
ajmpe-94	50	1	however	however	ADV
ajmpe-94	50	2	,	,	PUNCT
ajmpe-94	50	3	there	there	PRON
ajmpe-94	50	4	is	be	VERB
ajmpe-94	50	5	no	no	DET
ajmpe-94	50	6	data	datum	NOUN
ajmpe-94	50	7	on	on	ADP
ajmpe-94	50	8	copper	copper	NOUN
ajmpe-94	50	9	levels	level	NOUN
ajmpe-94	50	10	in	in	ADP
ajmpe-94	50	11	people	people	NOUN
ajmpe-94	50	12	who	who	PRON
ajmpe-94	50	13	have	have	VERB
ajmpe-94	50	14	covid-19	covid-19	PROPN
ajmpe-94	50	15	infection	infection	NOUN
ajmpe-94	50	16	.	.	PUNCT
ajmpe-94	51	1	one	one	NUM
ajmpe-94	51	2	of	of	ADP
ajmpe-94	51	3	the	the	DET
ajmpe-94	51	4	significant	significant	ADJ
ajmpe-94	51	5	ions	ion	NOUN
ajmpe-94	51	6	needed	need	VERB
ajmpe-94	51	7	as	as	ADP
ajmpe-94	51	8	a	a	DET
ajmpe-94	51	9	cofactor	cofactor	NOUN
ajmpe-94	51	10	for	for	ADP
ajmpe-94	51	11	the	the	DET
ajmpe-94	51	12	atp	atp	PROPN
ajmpe-94	51	13	enzyme	enzyme	NOUN
ajmpe-94	51	14	,	,	PUNCT
ajmpe-94	51	15	which	which	PRON
ajmpe-94	51	16	is	be	AUX
ajmpe-94	51	17	involved	involve	VERB
ajmpe-94	51	18	in	in	ADP
ajmpe-94	51	19	numerous	numerous	ADJ
ajmpe-94	51	20	crucial	crucial	ADJ
ajmpe-94	51	21	enzymatic	enzymatic	ADJ
ajmpe-94	51	22	activities	activity	NOUN
ajmpe-94	51	23	,	,	PUNCT
ajmpe-94	51	24	is	be	AUX
ajmpe-94	51	25	magnesium	magnesium	NOUN
ajmpe-94	51	26	.	.	PUNCT
ajmpe-94	52	1	by	by	ADP
ajmpe-94	52	2	controlling	control	VERB
ajmpe-94	52	3	the	the	DET
ajmpe-94	52	4	active	active	ADJ
ajmpe-94	52	5	sites	site	NOUN
ajmpe-94	52	6	of	of	ADP
ajmpe-94	52	7	particular	particular	ADJ
ajmpe-94	52	8	kinases	kinase	NOUN
ajmpe-94	52	9	,	,	PUNCT
ajmpe-94	52	10	mg2	mg2	PROPN
ajmpe-94	52	11	+	+	PROPN
ajmpe-94	52	12	has	have	AUX
ajmpe-94	52	13	also	also	ADV
ajmpe-94	52	14	been	be	AUX
ajmpe-94	52	15	shown	show	VERB
ajmpe-94	52	16	to	to	PART
ajmpe-94	52	17	play	play	VERB
ajmpe-94	52	18	a	a	DET
ajmpe-94	52	19	crucial	crucial	ADJ
ajmpe-94	52	20	immunological	immunological	ADJ
ajmpe-94	52	21	function	function	NOUN
ajmpe-94	52	22	in	in	ADP
ajmpe-94	52	23	cd8	cd8	PROPN
ajmpe-94	52	24	+	+	PROPN
ajmpe-94	52	25	t	t	PROPN
ajmpe-94	52	26	cell	cell	NOUN
ajmpe-94	52	27	activation	activation	NOUN
ajmpe-94	52	28	in	in	ADP
ajmpe-94	52	29	infection	infection	NOUN
ajmpe-94	52	30	[	[	X
ajmpe-94	52	31	16	16	NUM
ajmpe-94	52	32	]	]	PUNCT
ajmpe-94	52	33	.	.	PUNCT
ajmpe-94	53	1	understanding	understand	VERB
ajmpe-94	53	2	the	the	DET
ajmpe-94	53	3	potential	potential	ADJ
ajmpe-94	53	4	connection	connection	NOUN
ajmpe-94	53	5	between	between	ADP
ajmpe-94	53	6	magnesium	magnesium	NOUN
ajmpe-94	53	7	and	and	CCONJ
ajmpe-94	53	8	pulmonary	pulmonary	ADJ
ajmpe-94	53	9	outcomes	outcome	NOUN
ajmpe-94	53	10	of	of	ADP
ajmpe-94	53	11	covid-19	covid-19	PROPN
ajmpe-94	53	12	disease	disease	NOUN
ajmpe-94	53	13	depends	depend	VERB
ajmpe-94	53	14	on	on	ADP
ajmpe-94	53	15	the	the	DET
ajmpe-94	53	16	finding	finding	NOUN
ajmpe-94	53	17	from	from	ADP
ajmpe-94	53	18	a	a	DET
ajmpe-94	53	19	recent	recent	ADJ
ajmpe-94	53	20	study	study	NOUN
ajmpe-94	53	21	that	that	PRON
ajmpe-94	53	22	serum	serum	NOUN
ajmpe-94	53	23	magnesium	magnesium	NOUN
ajmpe-94	53	24	levels	level	NOUN
ajmpe-94	53	25	may	may	AUX
ajmpe-94	53	26	have	have	VERB
ajmpe-94	53	27	a	a	DET
ajmpe-94	53	28	protective	protective	ADJ
ajmpe-94	53	29	impact	impact	NOUN
ajmpe-94	53	30	against	against	ADP
ajmpe-94	53	31	lung	lung	NOUN
ajmpe-94	53	32	function	function	NOUN
ajmpe-94	53	33	loss	loss	NOUN
ajmpe-94	53	34	in	in	ADP
ajmpe-94	53	35	asthmachronic	asthmachronic	ADJ
ajmpe-94	53	36	obstructive	obstructive	ADJ
ajmpe-94	53	37	pulmonary	pulmonary	ADJ
ajmpe-94	53	38	disease	disease	NOUN
ajmpe-94	53	39	[	[	X
ajmpe-94	53	40	17	17	NUM
ajmpe-94	53	41	]	]	PUNCT
ajmpe-94	53	42	.	.	PUNCT
ajmpe-94	54	1	material	material	NOUN
ajmpe-94	54	2	and	and	CCONJ
ajmpe-94	54	3	methods	method	NOUN
ajmpe-94	54	4	study	study	NOUN
ajmpe-94	54	5	group	group	PROPN
ajmpe-94	54	6	a	a	DET
ajmpe-94	54	7	cross	cross	ADJ
ajmpe-94	54	8	-	-	ADJ
ajmpe-94	54	9	sectional	sectional	ADJ
ajmpe-94	54	10	study	study	NOUN
ajmpe-94	54	11	was	be	AUX
ajmpe-94	54	12	conducted	conduct	VERB
ajmpe-94	54	13	during	during	ADP
ajmpe-94	54	14	the	the	DET
ajmpe-94	54	15	period	period	NOUN
ajmpe-94	54	16	from	from	ADP
ajmpe-94	54	17	december	december	PROPN
ajmpe-94	54	18	2020	2020	NUM
ajmpe-94	54	19	to	to	ADP
ajmpe-94	54	20	april	april	PROPN
ajmpe-94	54	21	2021	2021	NUM
ajmpe-94	54	22	in	in	ADP
ajmpe-94	54	23	khartoum	khartoum	PROPN
ajmpe-94	54	24	state	state	NOUN
ajmpe-94	54	25	.	.	PUNCT
ajmpe-94	55	1	sudanese	sudanese	ADJ
ajmpe-94	55	2	patients	patient	NOUN
ajmpe-94	55	3	with	with	ADP
ajmpe-94	55	4	covid-19	covid-19	PROPN
ajmpe-94	55	5	and	and	CCONJ
ajmpe-94	55	6	patients	patient	NOUN
ajmpe-94	55	7	who	who	PRON
ajmpe-94	55	8	were	be	AUX
ajmpe-94	55	9	diagnosed	diagnose	VERB
ajmpe-94	55	10	with	with	ADP
ajmpe-94	55	11	covid-19	covid-19	PROPN
ajmpe-94	55	12	during	during	ADP
ajmpe-94	55	13	the	the	DET
ajmpe-94	55	14	study	study	NOUN
ajmpe-94	55	15	period	period	NOUN
ajmpe-94	55	16	were	be	AUX
ajmpe-94	55	17	enrolled	enrol	VERB
ajmpe-94	55	18	to	to	PART
ajmpe-94	55	19	participate	participate	VERB
ajmpe-94	55	20	in	in	ADP
ajmpe-94	55	21	this	this	DET
ajmpe-94	55	22	study	study	NOUN
ajmpe-94	55	23	.	.	PUNCT
ajmpe-94	56	1	the	the	DET
ajmpe-94	56	2	confirmation	confirmation	NOUN
ajmpe-94	56	3	of	of	ADP
ajmpe-94	56	4	covid-19	covid-19	PROPN
ajmpe-94	56	5	will	will	AUX
ajmpe-94	56	6	be	be	AUX
ajmpe-94	56	7	based	base	VERB
ajmpe-94	56	8	on	on	ADP
ajmpe-94	56	9	a	a	PRON
ajmpe-94	56	10	ct	ct	PROPN
ajmpe-94	56	11	scan	scan	NOUN
ajmpe-94	56	12	and/or	and/or	CCONJ
ajmpe-94	56	13	rt	rt	PROPN
ajmpe-94	56	14	-	-	PUNCT
ajmpe-94	56	15	pcr	pcr	NOUN
ajmpe-94	56	16	.	.	PUNCT
ajmpe-94	57	1	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	57	2	american	american	PROPN
ajmpe-94	57	3	journal	journal	PROPN
ajmpe-94	57	4	of	of	ADP
ajmpe-94	57	5	medical	medical	ADJ
ajmpe-94	57	6	and	and	CCONJ
ajmpe-94	57	7	physical	physical	ADJ
ajmpe-94	57	8	education	education	NOUN
ajmpe-94	57	9	vol.1	vol.1	PROPN
ajmpe-94	57	10	,	,	PUNCT
ajmpe-94	57	11	issue	issue	NOUN
ajmpe-94	57	12	1	1	NUM
ajmpe-94	57	13	;	;	PUNCT
ajmpe-94	57	14	july	july	PROPN
ajmpe-94	57	15	2023	2023	NUM
ajmpe-94	57	16	;	;	PUNCT
ajmpe-94	57	17	1252	1252	NUM
ajmpe-94	57	18	columbia	columbia	PROPN
ajmpe-94	57	19	rd	rd	PROPN
ajmpe-94	57	20	nw	nw	PROPN
ajmpe-94	57	21	,	,	PUNCT
ajmpe-94	57	22	washington	washington	PROPN
ajmpe-94	57	23	dc	dc	PROPN
ajmpe-94	57	24	,	,	PUNCT
ajmpe-94	57	25	united	united	PROPN
ajmpe-94	57	26	states	states	PROPN
ajmpe-94	57	27	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	57	28	;	;	PUNCT
ajmpe-94	57	29	mail	mail	NOUN
ajmpe-94	57	30	:	:	PUNCT
ajmpe-94	57	31	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	58	1	71	71	NUM
ajmpe-94	59	1	|	|	ADV
ajmpe-94	59	2	a	a	DET
ajmpe-94	59	3	m	m	NOUN
ajmpe-94	59	4	e	e	NOUN
ajmpe-94	59	5	r	r	NOUN
ajmpe-94	59	6	i	i	NOUN
ajmpe-94	59	7	c	c	VERB
ajmpe-94	59	8	a	a	DET
ajmpe-94	59	9	n	n	NOUN
ajmpe-94	60	1	j	j	NOUN
ajmpe-94	60	2	o	o	X
ajmpe-94	60	3	u	u	NOUN
ajmpe-94	60	4	r	r	NOUN
ajmpe-94	60	5	n	n	NOUN
ajmpe-94	60	6	a	a	DET
ajmpe-94	60	7	l	l	NOUN
ajmpe-94	60	8	o	o	X
ajmpe-94	61	1	f	f	X
ajmpe-94	61	2	m	m	NOUN
ajmpe-94	61	3	e	e	NOUN
ajmpe-94	62	1	d	d	NOUN
ajmpe-94	62	2	i	i	PRON
ajmpe-94	62	3	c	c	VERB
ajmpe-94	62	4	a	a	DET
ajmpe-94	62	5	l	l	NOUN
ajmpe-94	62	6	a	a	X
ajmpe-94	62	7	n	n	NOUN
ajmpe-94	63	1	d	d	NOUN
ajmpe-94	63	2	p	p	NOUN
ajmpe-94	63	3	h	h	NOUN
ajmpe-94	63	4	y	y	NOUN
ajmpe-94	63	5	s	s	VERB
ajmpe-94	64	1	i	i	INTJ
ajmpe-94	64	2	c	c	VERB
ajmpe-94	64	3	a	a	DET
ajmpe-94	64	4	l	l	NOUN
ajmpe-94	64	5	e	e	NOUN
ajmpe-94	64	6	d	d	X
ajmpe-94	64	7	u	u	X
ajmpe-94	64	8	c	c	PROPN
ajmpe-94	65	1	a	a	DET
ajmpe-94	65	2	t	t	NOUN
ajmpe-94	66	1	i	i	PRON
ajmpe-94	66	2	o	o	VERB
ajmpe-94	67	1	n	n	CCONJ
ajmpe-94	67	2	|	|	ADV
ajmpe-94	67	3	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	67	4	the	the	DET
ajmpe-94	67	5	total	total	ADJ
ajmpe-94	67	6	study	study	NOUN
ajmpe-94	67	7	group	group	NOUN
ajmpe-94	67	8	was	be	AUX
ajmpe-94	67	9	100	100	NUM
ajmpe-94	67	10	,	,	PUNCT
ajmpe-94	67	11	50	50	NUM
ajmpe-94	67	12	patients	patient	NOUN
ajmpe-94	67	13	with	with	ADP
ajmpe-94	67	14	covid-19	covid-19	PROPN
ajmpe-94	67	15	as	as	ADP
ajmpe-94	67	16	a	a	DET
ajmpe-94	67	17	case	case	NOUN
ajmpe-94	67	18	study	study	NOUN
ajmpe-94	67	19	,	,	PUNCT
ajmpe-94	67	20	and	and	CCONJ
ajmpe-94	67	21	50	50	NUM
ajmpe-94	67	22	healthy	healthy	ADJ
ajmpe-94	67	23	individuals	individual	NOUN
ajmpe-94	67	24	were	be	AUX
ajmpe-94	67	25	enrolled	enrol	VERB
ajmpe-94	67	26	as	as	ADP
ajmpe-94	67	27	a	a	DET
ajmpe-94	67	28	control	control	NOUN
ajmpe-94	67	29	group	group	NOUN
ajmpe-94	67	30	.	.	PUNCT
ajmpe-94	68	1	criteria	criterion	NOUN
ajmpe-94	68	2	for	for	ADP
ajmpe-94	68	3	inclusion	inclusion	NOUN
ajmpe-94	68	4	and	and	CCONJ
ajmpe-94	68	5	exclusion	exclusion	NOUN
ajmpe-94	68	6	patients	patient	NOUN
ajmpe-94	68	7	with	with	ADP
ajmpe-94	68	8	any	any	DET
ajmpe-94	68	9	chronic	chronic	ADJ
ajmpe-94	68	10	disease	disease	NOUN
ajmpe-94	68	11	that	that	PRON
ajmpe-94	68	12	may	may	AUX
ajmpe-94	68	13	have	have	VERB
ajmpe-94	68	14	an	an	DET
ajmpe-94	68	15	impact	impact	NOUN
ajmpe-94	68	16	on	on	ADP
ajmpe-94	68	17	serum	serum	NOUN
ajmpe-94	68	18	electrolytes	electrolyte	NOUN
ajmpe-94	68	19	calcium	calcium	NOUN
ajmpe-94	68	20	phosphate	phosphate	NOUN
ajmpe-94	68	21	magnesium	magnesium	NOUN
ajmpe-94	68	22	zinc	zinc	NOUN
ajmpe-94	68	23	and	and	CCONJ
ajmpe-94	68	24	copper	copper	NOUN
ajmpe-94	68	25	levels	level	NOUN
ajmpe-94	68	26	will	will	AUX
ajmpe-94	68	27	be	be	AUX
ajmpe-94	68	28	excluded	exclude	VERB
ajmpe-94	68	29	.	.	PUNCT
ajmpe-94	69	1	ethical	ethical	ADJ
ajmpe-94	69	2	considerations	consideration	NOUN
ajmpe-94	69	3	:	:	PUNCT
ajmpe-94	69	4	the	the	DET
ajmpe-94	69	5	study	study	NOUN
ajmpe-94	69	6	was	be	AUX
ajmpe-94	69	7	revised	revise	VERB
ajmpe-94	69	8	and	and	CCONJ
ajmpe-94	69	9	ethically	ethically	ADV
ajmpe-94	69	10	approved	approve	VERB
ajmpe-94	69	11	by	by	ADP
ajmpe-94	69	12	the	the	DET
ajmpe-94	69	13	ethical	ethical	ADJ
ajmpe-94	69	14	and	and	CCONJ
ajmpe-94	69	15	scientific	scientific	ADJ
ajmpe-94	69	16	committee	committee	NOUN
ajmpe-94	69	17	of	of	ADP
ajmpe-94	69	18	the	the	DET
ajmpe-94	69	19	faculty	faculty	NOUN
ajmpe-94	69	20	of	of	ADP
ajmpe-94	69	21	medical	medical	ADJ
ajmpe-94	69	22	laboratory	laboratory	NOUN
ajmpe-94	69	23	sciences	sciences	PROPN
ajmpe-94	69	24	,	,	PUNCT
ajmpe-94	69	25	university	university	NOUN
ajmpe-94	69	26	of	of	ADP
ajmpe-94	69	27	alzaiem	alzaiem	NOUN
ajmpe-94	69	28	alazhari	alazhari	NOUN
ajmpe-94	69	29	.	.	PUNCT
ajmpe-94	70	1	samples	sample	NOUN
ajmpe-94	70	2	were	be	AUX
ajmpe-94	70	3	taken	take	VERB
ajmpe-94	70	4	with	with	ADP
ajmpe-94	70	5	verbal	verbal	ADJ
ajmpe-94	70	6	consent	consent	NOUN
ajmpe-94	70	7	from	from	ADP
ajmpe-94	70	8	patients	patient	NOUN
ajmpe-94	70	9	or	or	CCONJ
ajmpe-94	70	10	their	their	PRON
ajmpe-94	70	11	relatives	relative	NOUN
ajmpe-94	70	12	.	.	PUNCT
ajmpe-94	71	1	data	datum	NOUN
ajmpe-94	71	2	collection	collection	NOUN
ajmpe-94	71	3	:	:	PUNCT
ajmpe-94	71	4	a	a	DET
ajmpe-94	71	5	direct	direct	ADJ
ajmpe-94	71	6	interview	interview	NOUN
ajmpe-94	71	7	questionnaire	questionnaire	NOUN
ajmpe-94	71	8	was	be	AUX
ajmpe-94	71	9	used	use	VERB
ajmpe-94	71	10	to	to	PART
ajmpe-94	71	11	collect	collect	VERB
ajmpe-94	71	12	data	datum	NOUN
ajmpe-94	71	13	.	.	PUNCT
ajmpe-94	72	1	medical	medical	ADJ
ajmpe-94	72	2	information	information	NOUN
ajmpe-94	72	3	was	be	AUX
ajmpe-94	72	4	collected	collect	VERB
ajmpe-94	72	5	from	from	ADP
ajmpe-94	72	6	the	the	DET
ajmpe-94	72	7	patient	patient	NOUN
ajmpe-94	72	8	's	's	PART
ajmpe-94	72	9	file	file	NOUN
ajmpe-94	72	10	with	with	ADP
ajmpe-94	72	11	the	the	DET
ajmpe-94	72	12	help	help	NOUN
ajmpe-94	72	13	of	of	ADP
ajmpe-94	72	14	the	the	DET
ajmpe-94	72	15	treating	treat	VERB
ajmpe-94	72	16	physician	physician	NOUN
ajmpe-94	72	17	.	.	PUNCT
ajmpe-94	73	1	collection	collection	NOUN
ajmpe-94	73	2	of	of	ADP
ajmpe-94	73	3	specimens	specimen	NOUN
ajmpe-94	73	4	:	:	PUNCT
ajmpe-94	73	5	venous	venous	ADJ
ajmpe-94	73	6	blood	blood	NOUN
ajmpe-94	73	7	samples	sample	NOUN
ajmpe-94	73	8	were	be	AUX
ajmpe-94	73	9	collected	collect	VERB
ajmpe-94	73	10	by	by	ADP
ajmpe-94	73	11	using	use	VERB
ajmpe-94	73	12	sterile	sterile	ADJ
ajmpe-94	73	13	,	,	PUNCT
ajmpe-94	73	14	dry	dry	ADJ
ajmpe-94	73	15	,	,	PUNCT
ajmpe-94	73	16	plastic	plastic	ADJ
ajmpe-94	73	17	syringes	syrinx	NOUN
ajmpe-94	73	18	and	and	CCONJ
ajmpe-94	73	19	a	a	DET
ajmpe-94	73	20	tourniquet	tourniquet	NOUN
ajmpe-94	73	21	to	to	PART
ajmpe-94	73	22	make	make	VERB
ajmpe-94	73	23	the	the	DET
ajmpe-94	73	24	veins	vein	NOUN
ajmpe-94	73	25	more	more	ADV
ajmpe-94	73	26	prominent	prominent	ADJ
ajmpe-94	73	27	.	.	PUNCT
ajmpe-94	74	1	the	the	DET
ajmpe-94	74	2	puncture	puncture	NOUN
ajmpe-94	74	3	sites	site	NOUN
ajmpe-94	74	4	are	be	AUX
ajmpe-94	74	5	cleaned	clean	VERB
ajmpe-94	74	6	with	with	ADP
ajmpe-94	74	7	70	70	NUM
ajmpe-94	74	8	%	%	NOUN
ajmpe-94	74	9	ethanol	ethanol	NOUN
ajmpe-94	74	10	and	and	CCONJ
ajmpe-94	74	11	5	5	NUM
ajmpe-94	74	12	ml	ml	NOUN
ajmpe-94	74	13	of	of	ADP
ajmpe-94	74	14	blood	blood	NOUN
ajmpe-94	74	15	is	be	AUX
ajmpe-94	74	16	collected	collect	VERB
ajmpe-94	74	17	in	in	ADP
ajmpe-94	74	18	lithium	lithium	NOUN
ajmpe-94	74	19	heparin	heparin	ADJ
ajmpe-94	74	20	containers	container	NOUN
ajmpe-94	74	21	.	.	PUNCT
ajmpe-94	75	1	the	the	DET
ajmpe-94	75	2	lithium	lithium	NOUN
ajmpe-94	75	3	heparin	heparin	ADJ
ajmpe-94	75	4	blood	blood	NOUN
ajmpe-94	75	5	sample	sample	NOUN
ajmpe-94	75	6	was	be	AUX
ajmpe-94	75	7	centrifuged	centrifuge	VERB
ajmpe-94	75	8	at	at	ADP
ajmpe-94	75	9	4000	4000	NUM
ajmpe-94	75	10	rpm	rpm	NOUN
ajmpe-94	75	11	to	to	PART
ajmpe-94	75	12	obtain	obtain	VERB
ajmpe-94	75	13	the	the	DET
ajmpe-94	75	14	plasma	plasma	NOUN
ajmpe-94	75	15	and	and	CCONJ
ajmpe-94	75	16	then	then	ADV
ajmpe-94	75	17	stored	store	VERB
ajmpe-94	75	18	at	at	ADP
ajmpe-94	75	19	(	(	PUNCT
ajmpe-94	75	20	-4	-4	INTJ
ajmpe-94	75	21	c	c	X
ajmpe-94	75	22	)	)	PUNCT
ajmpe-94	75	23	until	until	ADP
ajmpe-94	75	24	the	the	DET
ajmpe-94	75	25	analysis	analysis	NOUN
ajmpe-94	75	26	.	.	PUNCT
ajmpe-94	76	1	measurement	measurement	NOUN
ajmpe-94	76	2	of	of	ADP
ajmpe-94	76	3	biochemical	biochemical	ADJ
ajmpe-94	76	4	parameters	parameter	NOUN
ajmpe-94	76	5	:	:	PUNCT
ajmpe-94	76	6	the	the	DET
ajmpe-94	76	7	serum	serum	NOUN
ajmpe-94	76	8	electrolytes	electrolyte	VERB
ajmpe-94	76	9	sodium	sodium	NOUN
ajmpe-94	76	10	potassium	potassium	NOUN
ajmpe-94	76	11	is	be	AUX
ajmpe-94	76	12	measured	measure	VERB
ajmpe-94	76	13	by	by	ADP
ajmpe-94	76	14	easylyte	easylyte	NOUN
ajmpe-94	76	15	analyzer	analyzer	NOUN
ajmpe-94	76	16	ion	ion	NOUN
ajmpe-94	76	17	selective	selective	ADJ
ajmpe-94	76	18	electrode	electrode	NOUN
ajmpe-94	76	19	technology	technology	NOUN
ajmpe-94	76	20	,	,	PUNCT
ajmpe-94	76	21	the	the	DET
ajmpe-94	76	22	flow	flow	NOUN
ajmpe-94	76	23	-	-	PUNCT
ajmpe-94	76	24	through	through	ADP
ajmpe-94	76	25	sodium	sodium	NOUN
ajmpe-94	76	26	electrode	electrode	NOUN
ajmpe-94	76	27	uses	use	VERB
ajmpe-94	76	28	a	a	DET
ajmpe-94	76	29	selective	selective	ADJ
ajmpe-94	76	30	membrane	membrane	NOUN
ajmpe-94	76	31	that	that	PRON
ajmpe-94	76	32	is	be	AUX
ajmpe-94	76	33	specially	specially	ADV
ajmpe-94	76	34	formulated	formulate	VERB
ajmpe-94	76	35	to	to	PART
ajmpe-94	76	36	be	be	AUX
ajmpe-94	76	37	sensitive	sensitive	ADJ
ajmpe-94	76	38	to	to	ADP
ajmpe-94	76	39	sodium	sodium	NOUN
ajmpe-94	76	40	ions	ion	NOUN
ajmpe-94	76	41	,	,	PUNCT
ajmpe-94	76	42	and	and	CCONJ
ajmpe-94	76	43	the	the	DET
ajmpe-94	76	44	potassium	potassium	NOUN
ajmpe-94	76	45	electrode	electrode	NOUN
ajmpe-94	76	46	employs	employ	VERB
ajmpe-94	76	47	a	a	DET
ajmpe-94	76	48	similar	similar	ADJ
ajmpe-94	76	49	design	design	NOUN
ajmpe-94	76	50	with	with	ADP
ajmpe-94	76	51	the	the	DET
ajmpe-94	76	52	appropriate	appropriate	ADJ
ajmpe-94	76	53	selective	selective	ADJ
ajmpe-94	76	54	membrane	membrane	NOUN
ajmpe-94	76	55	material	material	NOUN
ajmpe-94	76	56	.	.	PUNCT
ajmpe-94	77	1	each	each	DET
ajmpe-94	77	2	electrode	electrode	NOUN
ajmpe-94	77	3	's	's	PART
ajmpe-94	77	4	potential	potential	NOUN
ajmpe-94	77	5	is	be	AUX
ajmpe-94	77	6	measured	measure	VERB
ajmpe-94	77	7	in	in	ADP
ajmpe-94	77	8	relation	relation	NOUN
ajmpe-94	77	9	to	to	ADP
ajmpe-94	77	10	a	a	DET
ajmpe-94	77	11	fixed	fix	VERB
ajmpe-94	77	12	and	and	CCONJ
ajmpe-94	77	13	stable	stable	ADJ
ajmpe-94	77	14	voltage	voltage	NOUN
ajmpe-94	77	15	set	set	VERB
ajmpe-94	77	16	by	by	ADP
ajmpe-94	77	17	the	the	DET
ajmpe-94	77	18	double	double	ADJ
ajmpe-94	77	19	-	-	PUNCT
ajmpe-94	77	20	junction	junction	NOUN
ajmpe-94	77	21	silver	silver	NOUN
ajmpe-94	77	22	silver	silver	NOUN
ajmpe-94	77	23	chloride	chloride	NOUN
ajmpe-94	77	24	reference	reference	NOUN
ajmpe-94	77	25	electrode.an	electrode.an	NOUN
ajmpe-94	77	26	ion	ion	NOUN
ajmpe-94	77	27	-	-	PUNCT
ajmpe-94	77	28	selective	selective	ADJ
ajmpe-94	77	29	electrode	electrode	NOUN
ajmpe-94	77	30	develops	develop	VERB
ajmpe-94	77	31	a	a	DET
ajmpe-94	77	32	voltage	voltage	NOUN
ajmpe-94	77	33	that	that	PRON
ajmpe-94	77	34	varies	vary	VERB
ajmpe-94	77	35	with	with	ADP
ajmpe-94	77	36	the	the	DET
ajmpe-94	77	37	concentration	concentration	NOUN
ajmpe-94	77	38	of	of	ADP
ajmpe-94	77	39	the	the	DET
ajmpe-94	77	40	ion	ion	NOUN
ajmpe-94	77	41	to	to	PART
ajmpe-94	77	42	which	which	PRON
ajmpe-94	77	43	it	it	PRON
ajmpe-94	77	44	responds	respond	VERB
ajmpe-94	77	45	.	.	PUNCT
ajmpe-94	78	1	(	(	PUNCT
ajmpe-94	78	2	18	18	NUM
ajmpe-94	78	3	)	)	PUNCT
ajmpe-94	78	4	the	the	DET
ajmpe-94	78	5	colorimetric	colorimetric	ADJ
ajmpe-94	78	6	method	method	NOUN
ajmpe-94	78	7	is	be	AUX
ajmpe-94	78	8	used	use	VERB
ajmpe-94	78	9	for	for	ADP
ajmpe-94	78	10	measuring	measure	VERB
ajmpe-94	78	11	zinc	zinc	NOUN
ajmpe-94	78	12	and	and	CCONJ
ajmpe-94	78	13	copper	copper	NOUN
ajmpe-94	78	14	by	by	ADP
ajmpe-94	78	15	a	a	DET
ajmpe-94	78	16	single	single	ADJ
ajmpe-94	78	17	reagent	reagent	ADJ
ajmpe-94	78	18	colorimetric	colorimetric	ADJ
ajmpe-94	78	19	test	test	NOUN
ajmpe-94	78	20	with	with	ADP
ajmpe-94	78	21	dibromo	dibromo	NOUN
ajmpe-94	78	22	-	-	PUNCT
ajmpe-94	78	23	paesa	paesa	NOUN
ajmpe-94	78	24	)	)	PUNCT
ajmpe-94	78	25	.	.	PUNCT
ajmpe-94	79	1	the	the	DET
ajmpe-94	79	2	assay	assay	PROPN
ajmpe-94	79	3	principle	principle	NOUN
ajmpe-94	79	4	consists	consist	VERB
ajmpe-94	79	5	of	of	ADP
ajmpe-94	79	6	dissociating	dissociate	VERB
ajmpe-94	79	7	copper	copper	NOUN
ajmpe-94	79	8	from	from	ADP
ajmpe-94	79	9	ceruloplasmin	ceruloplasmin	PROPN
ajmpe-94	79	10	and	and	CCONJ
ajmpe-94	79	11	other	other	ADJ
ajmpe-94	79	12	coppercontaining	coppercontaining	NOUN
ajmpe-94	79	13	proteins	protein	NOUN
ajmpe-94	79	14	,	,	PUNCT
ajmpe-94	79	15	by	by	ADP
ajmpe-94	79	16	a	a	DET
ajmpe-94	79	17	denaturalizing	denaturalize	VERB
ajmpe-94	79	18	agent	agent	NOUN
ajmpe-94	79	19	in	in	ADP
ajmpe-94	79	20	acidic	acidic	ADJ
ajmpe-94	79	21	conditions	condition	NOUN
ajmpe-94	79	22	.	.	PUNCT
ajmpe-94	80	1	free	free	ADJ
ajmpe-94	80	2	and	and	CCONJ
ajmpe-94	80	3	the	the	DET
ajmpe-94	80	4	portion	portion	NOUN
ajmpe-94	80	5	associated	associate	VERB
ajmpe-94	80	6	with	with	ADP
ajmpe-94	80	7	copper	copper	NOUN
ajmpe-94	80	8	will	will	AUX
ajmpe-94	80	9	form	form	VERB
ajmpe-94	80	10	the	the	DET
ajmpe-94	80	11	copper-3	copper-3	NUM
ajmpe-94	80	12	-	-	PUNCT
ajmpe-94	80	13	5dibr	5dibr	NUM
ajmpe-94	80	14	-	-	PUNCT
ajmpe-94	80	15	paesa	paesa	NOUN
ajmpe-94	80	16	complex	complex	NOUN
ajmpe-94	80	17	.	.	PUNCT
ajmpe-94	81	1	which	which	PRON
ajmpe-94	81	2	is	be	AUX
ajmpe-94	81	3	detected	detect	VERB
ajmpe-94	81	4	by	by	ADP
ajmpe-94	81	5	absorbance	absorbance	NOUN
ajmpe-94	81	6	at	at	ADP
ajmpe-94	81	7	580	580	NUM
ajmpe-94	81	8	nm	nm	NOUN
ajmpe-94	81	9	.	.	PUNCT
ajmpe-94	82	1	(	(	PUNCT
ajmpe-94	82	2	19	19	NUM
ajmpe-94	82	3	)	)	PUNCT
ajmpe-94	82	4	.	.	PUNCT
ajmpe-94	83	1	zinc	zinc	NOUN
ajmpe-94	83	2	forms	form	NOUN
ajmpe-94	83	3	a	a	DET
ajmpe-94	83	4	red	red	ADJ
ajmpe-94	83	5	chelate	chelate	NOUN
ajmpe-94	83	6	complex	complex	NOUN
ajmpe-94	83	7	with	with	ADP
ajmpe-94	83	8	2-(5	2-(5	NOUN
ajmpe-94	83	9	-	-	PUNCT
ajmpe-94	83	10	bromo-2pyridylase)-5-(n	bromo-2pyridylase)-5-(n	NOUN
ajmpe-94	83	11	-	-	PUNCT
ajmpe-94	83	12	propyl	propyl	NOUN
ajmpe-94	83	13	-	-	PUNCT
ajmpe-94	83	14	n	n	CCONJ
ajmpe-94	83	15	-	-	PUNCT
ajmpe-94	83	16	sulfopropylamino)-phenol	sulfopropylamino)-phenol	NOUN
ajmpe-94	83	17	in	in	ADP
ajmpe-94	83	18	a	a	DET
ajmpe-94	83	19	single	single	ADJ
ajmpe-94	83	20	reagent	reagent	ADJ
ajmpe-94	83	21	calorimetric	calorimetric	ADJ
ajmpe-94	83	22	test	test	NOUN
ajmpe-94	83	23	with	with	ADP
ajmpe-94	83	24	5	5	NUM
ajmpe-94	83	25	-	-	PUNCT
ajmpe-94	83	26	bromo	bromo	NOUN
ajmpe-94	83	27	-	-	PUNCT
ajmpe-94	83	28	paps	pap	NOUN
ajmpe-94	83	29	.	.	PUNCT
ajmpe-94	84	1	(	(	PUNCT
ajmpe-94	84	2	20	20	NUM
ajmpe-94	84	3	)	)	PUNCT
ajmpe-94	84	4	calcium	calcium	NOUN
ajmpe-94	84	5	,	,	PUNCT
ajmpe-94	84	6	phosphate	phosphate	NOUN
ajmpe-94	84	7	,	,	PUNCT
ajmpe-94	84	8	and	and	CCONJ
ajmpe-94	84	9	magnesium	magnesium	NOUN
ajmpe-94	84	10	blood	blood	NOUN
ajmpe-94	84	11	levels	level	NOUN
ajmpe-94	84	12	were	be	AUX
ajmpe-94	84	13	measured	measure	VERB
ajmpe-94	84	14	by	by	ADP
ajmpe-94	84	15	the	the	DET
ajmpe-94	84	16	cobas	cobas	PROPN
ajmpe-94	84	17	6000	6000	NUM
ajmpe-94	84	18	fully	fully	ADV
ajmpe-94	84	19	automated	automate	VERB
ajmpe-94	84	20	analyzer	analyzer	NOUN
ajmpe-94	84	21	(	(	PUNCT
ajmpe-94	84	22	roche	roche	PROPN
ajmpe-94	84	23	-	-	PUNCT
ajmpe-94	84	24	germany	germany	PROPN
ajmpe-94	84	25	)	)	PUNCT
ajmpe-94	84	26	.	.	PUNCT
ajmpe-94	85	1	data	datum	NOUN
ajmpe-94	85	2	examination	examination	NOUN
ajmpe-94	85	3	the	the	DET
ajmpe-94	85	4	statistical	statistical	ADJ
ajmpe-94	85	5	analysis	analysis	NOUN
ajmpe-94	85	6	of	of	ADP
ajmpe-94	85	7	the	the	DET
ajmpe-94	85	8	results	result	NOUN
ajmpe-94	85	9	was	be	AUX
ajmpe-94	85	10	performed	perform	VERB
ajmpe-94	85	11	by	by	ADP
ajmpe-94	85	12	using	use	VERB
ajmpe-94	85	13	the	the	DET
ajmpe-94	85	14	statistical	statistical	ADJ
ajmpe-94	85	15	package	package	NOUN
ajmpe-94	85	16	for	for	ADP
ajmpe-94	85	17	social	social	ADJ
ajmpe-94	85	18	sciences	science	NOUN
ajmpe-94	85	19	(	(	PUNCT
ajmpe-94	85	20	spss	spss	PROPN
ajmpe-94	85	21	)	)	PUNCT
ajmpe-94	85	22	version	version	NOUN
ajmpe-94	85	23	15.0	15.0	NUM
ajmpe-94	85	24	for	for	ADP
ajmpe-94	85	25	windows	window	NOUN
ajmpe-94	85	26	version	version	NOUN
ajmpe-94	85	27	10	10	NUM
ajmpe-94	85	28	using	use	VERB
ajmpe-94	85	29	a	a	DET
ajmpe-94	85	30	t	t	NOUN
ajmpe-94	85	31	-	-	PUNCT
ajmpe-94	85	32	test	test	NOUN
ajmpe-94	85	33	for	for	ADP
ajmpe-94	85	34	testing	testing	NOUN
ajmpe-94	85	35	difference	difference	NOUN
ajmpe-94	85	36	significance	significance	NOUN
ajmpe-94	85	37	and	and	CCONJ
ajmpe-94	85	38	a	a	DET
ajmpe-94	85	39	pearson	pearson	NOUN
ajmpe-94	85	40	correlation	correlation	NOUN
ajmpe-94	85	41	test	test	NOUN
ajmpe-94	85	42	(	(	PUNCT
ajmpe-94	85	43	rvalue	rvalue	NOUN
ajmpe-94	85	44	as	as	ADP
ajmpe-94	85	45	the	the	DET
ajmpe-94	85	46	coefficient	coefficient	NOUN
ajmpe-94	85	47	)	)	PUNCT
ajmpe-94	85	48	.	.	PUNCT
ajmpe-94	86	1	a	a	DET
ajmpe-94	86	2	p	p	NOUN
ajmpe-94	86	3	value	value	NOUN
ajmpe-94	86	4	of	of	ADP
ajmpe-94	86	5	0.05	0.05	NUM
ajmpe-94	86	6	was	be	AUX
ajmpe-94	86	7	considered	consider	VERB
ajmpe-94	86	8	statistically	statistically	ADV
ajmpe-94	86	9	significant	significant	ADJ
ajmpe-94	86	10	.	.	PUNCT
ajmpe-94	87	1	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	87	2	american	american	PROPN
ajmpe-94	87	3	journal	journal	PROPN
ajmpe-94	87	4	of	of	ADP
ajmpe-94	87	5	medical	medical	ADJ
ajmpe-94	87	6	and	and	CCONJ
ajmpe-94	87	7	physical	physical	ADJ
ajmpe-94	87	8	education	education	NOUN
ajmpe-94	87	9	vol.1	vol.1	PROPN
ajmpe-94	87	10	,	,	PUNCT
ajmpe-94	87	11	issue	issue	NOUN
ajmpe-94	87	12	1	1	NUM
ajmpe-94	87	13	;	;	PUNCT
ajmpe-94	87	14	july	july	PROPN
ajmpe-94	87	15	2023	2023	NUM
ajmpe-94	87	16	;	;	PUNCT
ajmpe-94	87	17	1252	1252	NUM
ajmpe-94	87	18	columbia	columbia	PROPN
ajmpe-94	87	19	rd	rd	PROPN
ajmpe-94	87	20	nw	nw	PROPN
ajmpe-94	87	21	,	,	PUNCT
ajmpe-94	87	22	washington	washington	PROPN
ajmpe-94	87	23	dc	dc	PROPN
ajmpe-94	87	24	,	,	PUNCT
ajmpe-94	87	25	united	united	PROPN
ajmpe-94	87	26	states	states	PROPN
ajmpe-94	87	27	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	87	28	;	;	PUNCT
ajmpe-94	87	29	mail	mail	NOUN
ajmpe-94	87	30	:	:	PUNCT
ajmpe-94	87	31	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	88	1	72	72	NUM
ajmpe-94	89	1	|	|	ADV
ajmpe-94	89	2	a	a	DET
ajmpe-94	89	3	m	m	NOUN
ajmpe-94	89	4	e	e	NOUN
ajmpe-94	89	5	r	r	NOUN
ajmpe-94	90	1	i	i	NOUN
ajmpe-94	90	2	c	c	VERB
ajmpe-94	90	3	a	a	DET
ajmpe-94	90	4	n	n	NOUN
ajmpe-94	91	1	j	j	NOUN
ajmpe-94	91	2	o	o	X
ajmpe-94	91	3	u	u	NOUN
ajmpe-94	91	4	r	r	NOUN
ajmpe-94	91	5	n	n	NOUN
ajmpe-94	91	6	a	a	DET
ajmpe-94	91	7	l	l	NOUN
ajmpe-94	91	8	o	o	X
ajmpe-94	92	1	f	f	X
ajmpe-94	92	2	m	m	NOUN
ajmpe-94	92	3	e	e	NOUN
ajmpe-94	93	1	d	d	NOUN
ajmpe-94	93	2	i	i	PRON
ajmpe-94	93	3	c	c	VERB
ajmpe-94	93	4	a	a	DET
ajmpe-94	93	5	l	l	NOUN
ajmpe-94	93	6	a	a	X
ajmpe-94	93	7	n	n	NOUN
ajmpe-94	94	1	d	d	NOUN
ajmpe-94	94	2	p	p	NOUN
ajmpe-94	94	3	h	h	NOUN
ajmpe-94	94	4	y	y	NOUN
ajmpe-94	94	5	s	s	VERB
ajmpe-94	95	1	i	i	INTJ
ajmpe-94	95	2	c	c	VERB
ajmpe-94	95	3	a	a	DET
ajmpe-94	95	4	l	l	NOUN
ajmpe-94	95	5	e	e	NOUN
ajmpe-94	95	6	d	d	X
ajmpe-94	95	7	u	u	X
ajmpe-94	95	8	c	c	PROPN
ajmpe-94	96	1	a	a	DET
ajmpe-94	96	2	t	t	NOUN
ajmpe-94	97	1	i	i	PRON
ajmpe-94	97	2	o	o	VERB
ajmpe-94	97	3	n	n	CCONJ
ajmpe-94	97	4	|	|	ADV
ajmpe-94	97	5	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	NUM
ajmpe-94	97	6	results	result	NOUN
ajmpe-94	97	7	this	this	DET
ajmpe-94	97	8	study	study	NOUN
ajmpe-94	97	9	described	describe	VERB
ajmpe-94	97	10	50	50	NUM
ajmpe-94	97	11	adult	adult	NOUN
ajmpe-94	97	12	patients	patient	NOUN
ajmpe-94	97	13	(	(	PUNCT
ajmpe-94	97	14	21–81	21–81	NUM
ajmpe-94	97	15	years	year	NOUN
ajmpe-94	97	16	old	old	ADJ
ajmpe-94	97	17	)	)	PUNCT
ajmpe-94	97	18	who	who	PRON
ajmpe-94	97	19	were	be	AUX
ajmpe-94	97	20	hospitalized	hospitalize	VERB
ajmpe-94	97	21	with	with	ADP
ajmpe-94	97	22	covid-19	covid-19	PROPN
ajmpe-94	97	23	in	in	ADP
ajmpe-94	97	24	an	an	DET
ajmpe-94	97	25	isolation	isolation	NOUN
ajmpe-94	97	26	center	center	NOUN
ajmpe-94	97	27	in	in	ADP
ajmpe-94	97	28	sudan	sudan	PROPN
ajmpe-94	97	29	.	.	PUNCT
ajmpe-94	98	1	the	the	DET
ajmpe-94	98	2	study	study	NOUN
ajmpe-94	98	3	aimed	aim	VERB
ajmpe-94	98	4	to	to	PART
ajmpe-94	98	5	determine	determine	VERB
ajmpe-94	98	6	the	the	DET
ajmpe-94	98	7	serum	serum	NOUN
ajmpe-94	98	8	levels	level	NOUN
ajmpe-94	98	9	of	of	ADP
ajmpe-94	98	10	sodium	sodium	NOUN
ajmpe-94	98	11	,	,	PUNCT
ajmpe-94	98	12	potassium	potassium	NOUN
ajmpe-94	98	13	,	,	PUNCT
ajmpe-94	98	14	calcium	calcium	NOUN
ajmpe-94	98	15	,	,	PUNCT
ajmpe-94	98	16	phosphate	phosphate	NOUN
ajmpe-94	98	17	,	,	PUNCT
ajmpe-94	98	18	magnesium	magnesium	NOUN
ajmpe-94	98	19	,	,	PUNCT
ajmpe-94	98	20	copper	copper	NOUN
ajmpe-94	98	21	,	,	PUNCT
ajmpe-94	98	22	and	and	CCONJ
ajmpe-94	98	23	zinc	zinc	NOUN
ajmpe-94	98	24	in	in	ADP
ajmpe-94	98	25	covid-19	covid-19	PROPN
ajmpe-94	98	26	patients	patient	NOUN
ajmpe-94	98	27	and	and	CCONJ
ajmpe-94	98	28	compare	compare	VERB
ajmpe-94	98	29	the	the	DET
ajmpe-94	98	30	results	result	NOUN
ajmpe-94	98	31	with	with	ADP
ajmpe-94	98	32	a	a	DET
ajmpe-94	98	33	control	control	NOUN
ajmpe-94	98	34	group	group	NOUN
ajmpe-94	98	35	.	.	PUNCT
ajmpe-94	99	1	the	the	DET
ajmpe-94	99	2	covid-19	covid-19	PROPN
ajmpe-94	99	3	patients	patient	NOUN
ajmpe-94	99	4	are	be	AUX
ajmpe-94	99	5	classified	classify	VERB
ajmpe-94	99	6	into	into	ADP
ajmpe-94	99	7	mild	mild	ADJ
ajmpe-94	99	8	(	(	PUNCT
ajmpe-94	99	9	n	n	NOUN
ajmpe-94	99	10	=	=	SYM
ajmpe-94	99	11	19	19	NUM
ajmpe-94	99	12	)	)	PUNCT
ajmpe-94	99	13	,	,	PUNCT
ajmpe-94	99	14	moderate	moderate	ADJ
ajmpe-94	99	15	(	(	PUNCT
ajmpe-94	99	16	n	n	NOUN
ajmpe-94	99	17	=	=	SYM
ajmpe-94	99	18	9	9	NUM
ajmpe-94	99	19	)	)	PUNCT
ajmpe-94	99	20	and	and	CCONJ
ajmpe-94	99	21	severe	severe	ADJ
ajmpe-94	99	22	(	(	PUNCT
ajmpe-94	99	23	n	n	NOUN
ajmpe-94	99	24	=	=	SYM
ajmpe-94	99	25	22	22	NUM
ajmpe-94	99	26	)	)	PUNCT
ajmpe-94	99	27	according	accord	VERB
ajmpe-94	99	28	to	to	ADP
ajmpe-94	99	29	disease	disease	NOUN
ajmpe-94	99	30	severity	severity	NOUN
ajmpe-94	99	31	in	in	ADP
ajmpe-94	99	32	figure	figure	NOUN
ajmpe-94	99	33	(	(	PUNCT
ajmpe-94	99	34	1	1	NUM
ajmpe-94	99	35	)	)	PUNCT
ajmpe-94	99	36	.	.	PUNCT
ajmpe-94	100	1	in	in	ADP
ajmpe-94	100	2	the	the	DET
ajmpe-94	100	3	present	present	ADJ
ajmpe-94	100	4	study	study	NOUN
ajmpe-94	100	5	,	,	PUNCT
ajmpe-94	100	6	the	the	DET
ajmpe-94	100	7	majority	majority	NOUN
ajmpe-94	100	8	of	of	ADP
ajmpe-94	100	9	covid-19	covid-19	PROPN
ajmpe-94	100	10	cases	case	NOUN
ajmpe-94	100	11	were	be	AUX
ajmpe-94	100	12	males	male	NOUN
ajmpe-94	100	13	(	(	PUNCT
ajmpe-94	100	14	52	52	NUM
ajmpe-94	100	15	%	%	NOUN
ajmpe-94	100	16	)	)	PUNCT
ajmpe-94	100	17	,	,	PUNCT
ajmpe-94	100	18	which	which	PRON
ajmpe-94	100	19	demonstrated	demonstrate	VERB
ajmpe-94	100	20	that	that	SCONJ
ajmpe-94	100	21	the	the	DET
ajmpe-94	100	22	incidence	incidence	NOUN
ajmpe-94	100	23	of	of	ADP
ajmpe-94	100	24	covid-19	covid-19	PROPN
ajmpe-94	100	25	is	be	AUX
ajmpe-94	100	26	higher	high	ADJ
ajmpe-94	100	27	in	in	ADP
ajmpe-94	100	28	males	male	NOUN
ajmpe-94	100	29	than	than	ADP
ajmpe-94	100	30	in	in	ADP
ajmpe-94	100	31	females	female	NOUN
ajmpe-94	100	32	.	.	PUNCT
ajmpe-94	101	1	abnormal	abnormal	ADJ
ajmpe-94	101	2	laboratory	laboratory	NOUN
ajmpe-94	101	3	parameters	parameter	NOUN
ajmpe-94	101	4	were	be	AUX
ajmpe-94	101	5	more	more	ADV
ajmpe-94	101	6	frequently	frequently	ADV
ajmpe-94	101	7	observed	observe	VERB
ajmpe-94	101	8	in	in	ADP
ajmpe-94	101	9	confirmed	confirm	VERB
ajmpe-94	101	10	covid19	covid19	NOUN
ajmpe-94	101	11	patients	patient	NOUN
ajmpe-94	101	12	,	,	PUNCT
ajmpe-94	101	13	particularly	particularly	ADV
ajmpe-94	101	14	in	in	ADP
ajmpe-94	101	15	mild	mild	ADJ
ajmpe-94	101	16	,	,	PUNCT
ajmpe-94	101	17	moderate	moderate	ADJ
ajmpe-94	101	18	and	and	CCONJ
ajmpe-94	101	19	severe	severe	ADJ
ajmpe-94	101	20	or	or	CCONJ
ajmpe-94	101	21	critical	critical	ADJ
ajmpe-94	101	22	patients	patient	NOUN
ajmpe-94	101	23	,	,	PUNCT
ajmpe-94	101	24	as	as	SCONJ
ajmpe-94	101	25	shown	show	VERB
ajmpe-94	101	26	in	in	ADP
ajmpe-94	101	27	tables	table	NOUN
ajmpe-94	101	28	(	(	PUNCT
ajmpe-94	101	29	1,2	1,2	NUM
ajmpe-94	101	30	)	)	PUNCT
ajmpe-94	101	31	and	and	CCONJ
ajmpe-94	101	32	figures	figure	NOUN
ajmpe-94	101	33	(	(	PUNCT
ajmpe-94	101	34	2,3,4,5	2,3,4,5	NUM
ajmpe-94	101	35	)	)	PUNCT
ajmpe-94	101	36	.	.	PUNCT
ajmpe-94	102	1	table	table	NOUN
ajmpe-94	102	2	(	(	PUNCT
ajmpe-94	102	3	1	1	X
ajmpe-94	102	4	)	)	PUNCT
ajmpe-94	102	5	showed	show	VERB
ajmpe-94	102	6	hyponatremia	hyponatremia	NOUN
ajmpe-94	102	7	and	and	CCONJ
ajmpe-94	102	8	hypokalemia	hypokalemia	NOUN
ajmpe-94	102	9	that	that	SCONJ
ajmpe-94	102	10	there	there	PRON
ajmpe-94	102	11	was	be	VERB
ajmpe-94	102	12	a	a	DET
ajmpe-94	102	13	significant	significant	ADJ
ajmpe-94	102	14	decrease	decrease	NOUN
ajmpe-94	102	15	in	in	ADP
ajmpe-94	102	16	the	the	DET
ajmpe-94	102	17	mean	mean	ADJ
ajmpe-94	102	18	level	level	NOUN
ajmpe-94	102	19	of	of	ADP
ajmpe-94	102	20	sodium	sodium	NOUN
ajmpe-94	102	21	,	,	PUNCT
ajmpe-94	102	22	potassium	potassium	NOUN
ajmpe-94	102	23	,	,	PUNCT
ajmpe-94	102	24	and	and	CCONJ
ajmpe-94	102	25	calcium	calcium	NOUN
ajmpe-94	102	26	in	in	ADP
ajmpe-94	102	27	covid-19	covid-19	PROPN
ajmpe-94	102	28	patients	patient	NOUN
ajmpe-94	102	29	when	when	SCONJ
ajmpe-94	102	30	compared	compare	VERB
ajmpe-94	102	31	with	with	ADP
ajmpe-94	102	32	the	the	DET
ajmpe-94	102	33	control	control	NOUN
ajmpe-94	102	34	group	group	NOUN
ajmpe-94	102	35	(	(	PUNCT
ajmpe-94	102	36	p	p	NOUN
ajmpe-94	102	37	-	-	PUNCT
ajmpe-94	102	38	value	value	NOUN
ajmpe-94	102	39	=	=	NOUN
ajmpe-94	102	40	0.000	0.000	NUM
ajmpe-94	102	41	)	)	PUNCT
ajmpe-94	102	42	.	.	PUNCT
ajmpe-94	103	1	insignificant	insignificant	ADJ
ajmpe-94	103	2	differences	difference	NOUN
ajmpe-94	103	3	were	be	AUX
ajmpe-94	103	4	found	find	VERB
ajmpe-94	103	5	in	in	ADP
ajmpe-94	103	6	the	the	DET
ajmpe-94	103	7	levels	level	NOUN
ajmpe-94	103	8	of	of	ADP
ajmpe-94	103	9	phosphorus	phosphorus	NOUN
ajmpe-94	103	10	and	and	CCONJ
ajmpe-94	103	11	magnesium	magnesium	NOUN
ajmpe-94	103	12	among	among	ADP
ajmpe-94	103	13	covid-19	covid-19	PROPN
ajmpe-94	103	14	patients	patient	NOUN
ajmpe-94	103	15	.	.	PUNCT
ajmpe-94	104	1	there	there	PRON
ajmpe-94	104	2	was	be	VERB
ajmpe-94	104	3	no	no	DET
ajmpe-94	104	4	significant	significant	ADJ
ajmpe-94	104	5	difference	difference	NOUN
ajmpe-94	104	6	in	in	ADP
ajmpe-94	104	7	the	the	DET
ajmpe-94	104	8	levels	level	NOUN
ajmpe-94	104	9	of	of	ADP
ajmpe-94	104	10	phosphorus	phosphorus	NOUN
ajmpe-94	104	11	and	and	CCONJ
ajmpe-94	104	12	magnesium	magnesium	NOUN
ajmpe-94	104	13	when	when	SCONJ
ajmpe-94	104	14	compared	compare	VERB
ajmpe-94	104	15	with	with	ADP
ajmpe-94	104	16	the	the	DET
ajmpe-94	104	17	control	control	NOUN
ajmpe-94	104	18	group	group	NOUN
ajmpe-94	104	19	.	.	PUNCT
ajmpe-94	105	1	this	this	DET
ajmpe-94	105	2	study	study	NOUN
ajmpe-94	105	3	showed	show	VERB
ajmpe-94	105	4	that	that	SCONJ
ajmpe-94	105	5	there	there	PRON
ajmpe-94	105	6	was	be	VERB
ajmpe-94	105	7	a	a	DET
ajmpe-94	105	8	significant	significant	ADJ
ajmpe-94	105	9	decrease	decrease	NOUN
ajmpe-94	105	10	in	in	ADP
ajmpe-94	105	11	the	the	DET
ajmpe-94	105	12	mean	mean	ADJ
ajmpe-94	105	13	level	level	NOUN
ajmpe-94	105	14	of	of	ADP
ajmpe-94	105	15	zinc	zinc	NOUN
ajmpe-94	105	16	and	and	CCONJ
ajmpe-94	105	17	an	an	DET
ajmpe-94	105	18	increase	increase	NOUN
ajmpe-94	105	19	in	in	ADP
ajmpe-94	105	20	the	the	DET
ajmpe-94	105	21	mean	mean	ADJ
ajmpe-94	105	22	level	level	NOUN
ajmpe-94	105	23	of	of	ADP
ajmpe-94	105	24	copper	copper	NOUN
ajmpe-94	105	25	in	in	ADP
ajmpe-94	105	26	covid-19	covid-19	PROPN
ajmpe-94	105	27	patients	patient	NOUN
ajmpe-94	105	28	when	when	SCONJ
ajmpe-94	105	29	compared	compare	VERB
ajmpe-94	105	30	to	to	ADP
ajmpe-94	105	31	the	the	DET
ajmpe-94	105	32	control	control	NOUN
ajmpe-94	105	33	group	group	NOUN
ajmpe-94	105	34	(	(	PUNCT
ajmpe-94	105	35	p	p	NOUN
ajmpe-94	105	36	-	-	PUNCT
ajmpe-94	105	37	value	value	NOUN
ajmpe-94	105	38	=	=	NOUN
ajmpe-94	105	39	0.000	0.000	NUM
ajmpe-94	105	40	)	)	PUNCT
ajmpe-94	105	41	,	,	PUNCT
ajmpe-94	105	42	table	table	NOUN
ajmpe-94	105	43	1	1	NUM
ajmpe-94	105	44	.	.	PUNCT
ajmpe-94	105	45	pearson	pearson	PROPN
ajmpe-94	105	46	correlation	correlation	NOUN
ajmpe-94	105	47	investigates	investigate	VERB
ajmpe-94	105	48	the	the	DET
ajmpe-94	105	49	relationship	relationship	NOUN
ajmpe-94	105	50	between	between	ADP
ajmpe-94	105	51	covid-19	covid-19	PROPN
ajmpe-94	105	52	disease	disease	NOUN
ajmpe-94	105	53	stages	stage	NOUN
ajmpe-94	105	54	and	and	CCONJ
ajmpe-94	105	55	biochemical	biochemical	ADJ
ajmpe-94	105	56	changes	change	NOUN
ajmpe-94	105	57	in	in	ADP
ajmpe-94	105	58	plasma	plasma	NOUN
ajmpe-94	105	59	parameters	parameter	NOUN
ajmpe-94	105	60	in	in	ADP
ajmpe-94	105	61	table	table	NOUN
ajmpe-94	105	62	(	(	PUNCT
ajmpe-94	105	63	2	2	NUM
ajmpe-94	105	64	)	)	PUNCT
ajmpe-94	105	65	and	and	CCONJ
ajmpe-94	105	66	figures	figure	NOUN
ajmpe-94	105	67	(	(	PUNCT
ajmpe-94	105	68	2	2	NUM
ajmpe-94	105	69	,	,	PUNCT
ajmpe-94	105	70	3	3	NUM
ajmpe-94	105	71	,	,	PUNCT
ajmpe-94	105	72	4	4	NUM
ajmpe-94	105	73	,	,	PUNCT
ajmpe-94	105	74	)	)	PUNCT
ajmpe-94	105	75	and	and	CCONJ
ajmpe-94	105	76	(	(	PUNCT
ajmpe-94	105	77	5	5	NUM
ajmpe-94	105	78	)	)	PUNCT
ajmpe-94	105	79	.	.	PUNCT
ajmpe-94	106	1	negative	negative	ADJ
ajmpe-94	106	2	correlation	correlation	NOUN
ajmpe-94	106	3	between	between	ADP
ajmpe-94	106	4	sodium	sodium	NOUN
ajmpe-94	106	5	levels	level	NOUN
ajmpe-94	106	6	and	and	CCONJ
ajmpe-94	106	7	disease	disease	NOUN
ajmpe-94	106	8	severity	severity	NOUN
ajmpe-94	106	9	stages	stage	NOUN
ajmpe-94	106	10	,	,	PUNCT
ajmpe-94	106	11	r	r	NOUN
ajmpe-94	106	12	=	=	SYM
ajmpe-94	106	13	-0.75	-0.75	NUM
ajmpe-94	106	14	,	,	PUNCT
ajmpe-94	106	15	p	p	NOUN
ajmpe-94	106	16	=	=	NOUN
ajmpe-94	106	17	.000	.000	NUM
ajmpe-94	106	18	;	;	PUNCT
ajmpe-94	106	19	negative	negative	ADJ
ajmpe-94	106	20	correlation	correlation	NOUN
ajmpe-94	106	21	between	between	ADP
ajmpe-94	106	22	serum	serum	NOUN
ajmpe-94	106	23	potassium	potassium	NOUN
ajmpe-94	106	24	levels	level	NOUN
ajmpe-94	106	25	and	and	CCONJ
ajmpe-94	106	26	disease	disease	NOUN
ajmpe-94	106	27	stages	stage	NOUN
ajmpe-94	106	28	,	,	PUNCT
ajmpe-94	106	29	r	r	NOUN
ajmpe-94	106	30	=	=	SYM
ajmpe-94	106	31	-0.74	-0.74	X
ajmpe-94	106	32	,	,	PUNCT
ajmpe-94	106	33	p	p	NOUN
ajmpe-94	106	34	=	=	NOUN
ajmpe-94	106	35	0.000	0.000	NUM
ajmpe-94	106	36	.	.	PUNCT
ajmpe-94	107	1	negative	negative	ADJ
ajmpe-94	107	2	correlation	correlation	NOUN
ajmpe-94	107	3	between	between	ADP
ajmpe-94	107	4	plasma	plasma	NOUN
ajmpe-94	107	5	zinc	zinc	NOUN
ajmpe-94	107	6	level	level	NOUN
ajmpe-94	107	7	and	and	CCONJ
ajmpe-94	107	8	stages	stage	NOUN
ajmpe-94	107	9	of	of	ADP
ajmpe-94	107	10	the	the	DET
ajmpe-94	107	11	disease	disease	NOUN
ajmpe-94	107	12	,	,	PUNCT
ajmpe-94	107	13	r=	r=	ADJ
ajmpe-94	107	14	-0.8	-0.8	PROPN
ajmpe-94	107	15	p.	p.	NOUN
ajmpe-94	107	16	value	value	NOUN
ajmpe-94	108	1	=	=	NOUN
ajmpe-94	108	2	0.000	0.000	NUM
ajmpe-94	108	3	,	,	PUNCT
ajmpe-94	108	4	positive	positive	ADJ
ajmpe-94	108	5	correlation	correlation	NOUN
ajmpe-94	108	6	between	between	ADP
ajmpe-94	108	7	plasma	plasma	NOUN
ajmpe-94	108	8	copper	copper	NOUN
ajmpe-94	108	9	and	and	CCONJ
ajmpe-94	108	10	stages	stage	NOUN
ajmpe-94	108	11	of	of	ADP
ajmpe-94	108	12	covid-19	covid-19	PROPN
ajmpe-94	108	13	disease	disease	NOUN
ajmpe-94	108	14	,	,	PUNCT
ajmpe-94	108	15	r=	r=	ADJ
ajmpe-94	108	16	0.7	0.7	NUM
ajmpe-94	108	17	,	,	PUNCT
ajmpe-94	108	18	p.	p.	NOUN
ajmpe-94	108	19	value	value	NOUN
ajmpe-94	109	1	=	=	NOUN
ajmpe-94	109	2	0.000	0.000	NUM
ajmpe-94	109	3	,	,	PUNCT
ajmpe-94	109	4	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	109	5	american	american	PROPN
ajmpe-94	109	6	journal	journal	PROPN
ajmpe-94	109	7	of	of	ADP
ajmpe-94	109	8	medical	medical	ADJ
ajmpe-94	109	9	and	and	CCONJ
ajmpe-94	109	10	physical	physical	ADJ
ajmpe-94	109	11	education	education	NOUN
ajmpe-94	109	12	vol.1	vol.1	PROPN
ajmpe-94	109	13	,	,	PUNCT
ajmpe-94	109	14	issue	issue	NOUN
ajmpe-94	109	15	1	1	NUM
ajmpe-94	109	16	;	;	PUNCT
ajmpe-94	109	17	july	july	PROPN
ajmpe-94	109	18	2023	2023	NUM
ajmpe-94	109	19	;	;	PUNCT
ajmpe-94	109	20	1252	1252	NUM
ajmpe-94	109	21	columbia	columbia	PROPN
ajmpe-94	109	22	rd	rd	PROPN
ajmpe-94	109	23	nw	nw	PROPN
ajmpe-94	109	24	,	,	PUNCT
ajmpe-94	109	25	washington	washington	PROPN
ajmpe-94	109	26	dc	dc	PROPN
ajmpe-94	109	27	,	,	PUNCT
ajmpe-94	109	28	united	united	PROPN
ajmpe-94	109	29	states	states	PROPN
ajmpe-94	109	30	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	109	31	;	;	PUNCT
ajmpe-94	109	32	mail	mail	NOUN
ajmpe-94	109	33	:	:	PUNCT
ajmpe-94	109	34	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	110	1	73	73	NUM
ajmpe-94	111	1	|	|	ADV
ajmpe-94	111	2	a	a	DET
ajmpe-94	111	3	m	m	NOUN
ajmpe-94	111	4	e	e	NOUN
ajmpe-94	111	5	r	r	NOUN
ajmpe-94	112	1	i	i	NOUN
ajmpe-94	112	2	c	c	VERB
ajmpe-94	112	3	a	a	DET
ajmpe-94	112	4	n	n	NOUN
ajmpe-94	113	1	j	j	NOUN
ajmpe-94	113	2	o	o	X
ajmpe-94	113	3	u	u	NOUN
ajmpe-94	113	4	r	r	NOUN
ajmpe-94	113	5	n	n	NOUN
ajmpe-94	113	6	a	a	DET
ajmpe-94	113	7	l	l	NOUN
ajmpe-94	113	8	o	o	X
ajmpe-94	114	1	f	f	X
ajmpe-94	114	2	m	m	NOUN
ajmpe-94	114	3	e	e	NOUN
ajmpe-94	115	1	d	d	NOUN
ajmpe-94	115	2	i	i	PRON
ajmpe-94	115	3	c	c	VERB
ajmpe-94	115	4	a	a	DET
ajmpe-94	115	5	l	l	NOUN
ajmpe-94	115	6	a	a	X
ajmpe-94	115	7	n	n	NOUN
ajmpe-94	116	1	d	d	NOUN
ajmpe-94	116	2	p	p	NOUN
ajmpe-94	116	3	h	h	NOUN
ajmpe-94	116	4	y	y	NOUN
ajmpe-94	116	5	s	s	VERB
ajmpe-94	117	1	i	i	INTJ
ajmpe-94	117	2	c	c	VERB
ajmpe-94	117	3	a	a	DET
ajmpe-94	117	4	l	l	NOUN
ajmpe-94	117	5	e	e	NOUN
ajmpe-94	117	6	d	d	X
ajmpe-94	117	7	u	u	X
ajmpe-94	117	8	c	c	PROPN
ajmpe-94	118	1	a	a	DET
ajmpe-94	118	2	t	t	NOUN
ajmpe-94	119	1	i	i	PRON
ajmpe-94	119	2	o	o	VERB
ajmpe-94	119	3	n	n	CCONJ
ajmpe-94	119	4	|	|	ADV
ajmpe-94	119	5	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	NUM
ajmpe-94	119	6	table	table	NOUN
ajmpe-94	119	7	(	(	PUNCT
ajmpe-94	119	8	1	1	X
ajmpe-94	119	9	)	)	PUNCT
ajmpe-94	119	10	comparison	comparison	NOUN
ajmpe-94	119	11	of	of	ADP
ajmpe-94	119	12	biochemical	biochemical	ADJ
ajmpe-94	119	13	parameters	parameter	NOUN
ajmpe-94	119	14	means	mean	VERB
ajmpe-94	119	15	and	and	CCONJ
ajmpe-94	119	16	sd	sd	NOUN
ajmpe-94	119	17	.	.	PUNCT
ajmpe-94	120	1	among	among	ADP
ajmpe-94	120	2	of	of	ADP
ajmpe-94	120	3	the	the	DET
ajmpe-94	120	4	study	study	NOUN
ajmpe-94	120	5	groups	group	NOUN
ajmpe-94	120	6	test	test	NOUN
ajmpe-94	120	7	cases	case	NOUN
ajmpe-94	120	8	(	(	PUNCT
ajmpe-94	120	9	covid19	covid19	NOUN
ajmpe-94	120	10	patients	patient	NOUN
ajmpe-94	120	11	)	)	PUNCT
ajmpe-94	120	12	control	control	NOUN
ajmpe-94	120	13	(	(	PUNCT
ajmpe-94	120	14	healthy	healthy	ADJ
ajmpe-94	120	15	)	)	PUNCT
ajmpe-94	120	16	p	p	NOUN
ajmpe-94	120	17	value	value	NOUN
ajmpe-94	120	18	sodium	sodium	NOUN
ajmpe-94	120	19	(	(	PUNCT
ajmpe-94	120	20	na	na	INTJ
ajmpe-94	120	21	mmol\l	mmol\l	PROPN
ajmpe-94	120	22	)	)	PUNCT
ajmpe-94	120	23	132	132	NUM
ajmpe-94	120	24	±4.3	±4.3	NOUN
ajmpe-94	120	25	139±2.9	139±2.9	NUM
ajmpe-94	120	26	0.000	0.000	NUM
ajmpe-94	120	27	potassium	potassium	NOUN
ajmpe-94	120	28	(	(	PUNCT
ajmpe-94	120	29	k	k	PROPN
ajmpe-94	120	30	mmol\l	mmol\l	PROPN
ajmpe-94	120	31	)	)	PUNCT
ajmpe-94	120	32	3.2±.40	3.2±.40	NUM
ajmpe-94	120	33	4.3±.46	4.3±.46	NUM
ajmpe-94	120	34	0.000	0.000	NUM
ajmpe-94	120	35	calcium	calcium	NOUN
ajmpe-94	120	36	(	(	PUNCT
ajmpe-94	120	37	ca	ca	NOUN
ajmpe-94	120	38	mg\dl	mg\dl	PROPN
ajmpe-94	120	39	)	)	PUNCT
ajmpe-94	121	1	7.8±.98	7.8±.98	NUM
ajmpe-94	121	2	9.2±.60	9.2±.60	NUM
ajmpe-94	121	3	0.000	0.000	NUM
ajmpe-94	121	4	phosphate	phosphate	NOUN
ajmpe-94	121	5	(	(	PUNCT
ajmpe-94	121	6	ph	ph	NOUN
ajmpe-94	121	7	mg\dl	mg\dl	PROPN
ajmpe-94	121	8	)	)	PUNCT
ajmpe-94	121	9	4.5±2.2	4.5±2.2	NUM
ajmpe-94	121	10	3	3	NUM
ajmpe-94	121	11	.	.	PUNCT
ajmpe-94	121	12	9±.024	9±.024	NUM
ajmpe-94	121	13	0.15	0.15	NUM
ajmpe-94	121	14	magnesium	magnesium	NOUN
ajmpe-94	121	15	(	(	PUNCT
ajmpe-94	121	16	mg	mg	PROPN
ajmpe-94	121	17	mg	mg	PROPN
ajmpe-94	121	18	/	/	SYM
ajmpe-94	121	19	dl	dl	PROPN
ajmpe-94	121	20	)	)	PUNCT
ajmpe-94	121	21	2.2	2.2	NUM
ajmpe-94	121	22	±0.5	±0.5	PROPN
ajmpe-94	121	23	2.2±0.2	2.2±0.2	NUM
ajmpe-94	121	24	0.8	0.8	NUM
ajmpe-94	121	25	zinc	zinc	NOUN
ajmpe-94	121	26	(	(	PUNCT
ajmpe-94	121	27	zn	zn	NOUN
ajmpe-94	121	28	µg	µg	PROPN
ajmpe-94	121	29	/	/	SYM
ajmpe-94	121	30	dl	dl	NOUN
ajmpe-94	121	31	)	)	PUNCT
ajmpe-94	121	32	60±26.8	60±26.8	NUM
ajmpe-94	122	1	85±23.4	85±23.4	NUM
ajmpe-94	122	2	0.000	0.000	NUM
ajmpe-94	122	3	copper	copper	NOUN
ajmpe-94	122	4	(	(	PUNCT
ajmpe-94	122	5	cu	cu	PROPN
ajmpe-94	122	6	µg	µg	PROPN
ajmpe-94	122	7	/	/	SYM
ajmpe-94	122	8	dl	dl	NOUN
ajmpe-94	122	9	)	)	PUNCT
ajmpe-94	122	10	219	219	NUM
ajmpe-94	122	11	±89	±89	NOUN
ajmpe-94	122	12	93	93	NUM
ajmpe-94	122	13	±23	±23	NUM
ajmpe-94	122	14	0.000	0.000	NUM
ajmpe-94	122	15	table	table	NOUN
ajmpe-94	122	16	(	(	PUNCT
ajmpe-94	122	17	2	2	NUM
ajmpe-94	122	18	)	)	PUNCT
ajmpe-94	122	19	correlation	correlation	NOUN
ajmpe-94	122	20	between	between	ADP
ajmpe-94	122	21	the	the	DET
ajmpe-94	122	22	stages	stage	NOUN
ajmpe-94	122	23	of	of	ADP
ajmpe-94	122	24	the	the	DET
ajmpe-94	122	25	disease	disease	NOUN
ajmpe-94	122	26	and	and	CCONJ
ajmpe-94	122	27	biochemical	biochemical	ADJ
ajmpe-94	122	28	changes	change	NOUN
ajmpe-94	122	29	in	in	ADP
ajmpe-94	122	30	the	the	DET
ajmpe-94	122	31	plasma	plasma	NOUN
ajmpe-94	122	32	parameters	parameter	NOUN
ajmpe-94	122	33	test	test	VERB
ajmpe-94	122	34	correlation(r-+	correlation(r-+	NOUN
ajmpe-94	122	35	)	)	PUNCT
ajmpe-94	122	36	p.value	p.value	NOUN
ajmpe-94	122	37	na	na	INTJ
ajmpe-94	122	38	mmol\l	mmol\l	PROPN
ajmpe-94	122	39	-.753	-.753	PROPN
ajmpe-94	122	40	*	*	NOUN
ajmpe-94	122	41	*	*	NOUN
ajmpe-94	122	42	.000	.000	NUM
ajmpe-94	123	1	k	k	X
ajmpe-94	123	2	mmol\l	mmol\l	PROPN
ajmpe-94	124	1	-.736	-.736	PROPN
ajmpe-94	124	2	*	*	PROPN
ajmpe-94	124	3	*	*	PROPN
ajmpe-94	124	4	.000	.000	NUM
ajmpe-94	124	5	zn	zn	NUM
ajmpe-94	124	6	μg	μg	PROPN
ajmpe-94	124	7	\dl	\dl	PROPN
ajmpe-94	124	8	-.819	-.819	PROPN
ajmpe-94	124	9	*	*	PUNCT
ajmpe-94	124	10	*	*	NOUN
ajmpe-94	124	11	.000	.000	NUM
ajmpe-94	124	12	cu	cu	INTJ
ajmpe-94	124	13	μg	μg	PROPN
ajmpe-94	124	14	\dl	\dl	PROPN
ajmpe-94	124	15	+	+	PROPN
ajmpe-94	124	16	.700	.700	NUM
ajmpe-94	124	17	*	*	SYM
ajmpe-94	124	18	.000	.000	NUM
ajmpe-94	124	19	figure	figure	NOUN
ajmpe-94	124	20	(	(	PUNCT
ajmpe-94	124	21	1	1	NUM
ajmpe-94	124	22	)	)	PUNCT
ajmpe-94	124	23	distribution	distribution	NOUN
ajmpe-94	124	24	of	of	ADP
ajmpe-94	124	25	stages	stage	NOUN
ajmpe-94	124	26	of	of	ADP
ajmpe-94	124	27	the	the	DET
ajmpe-94	124	28	disease	disease	NOUN
ajmpe-94	124	29	in	in	ADP
ajmpe-94	124	30	the	the	DET
ajmpe-94	124	31	case	case	NOUN
ajmpe-94	124	32	study	study	NOUN
ajmpe-94	124	33	mild	mild	ADJ
ajmpe-94	124	34	38	38	NUM
ajmpe-94	124	35	%	%	NOUN
ajmpe-94	124	36	moderate	moderate	ADJ
ajmpe-94	124	37	18	18	NUM
ajmpe-94	124	38	%	%	NOUN
ajmpe-94	124	39	severe	severe	ADJ
ajmpe-94	124	40	44	44	NUM
ajmpe-94	124	41	%	%	NOUN
ajmpe-94	124	42	mild	mild	ADJ
ajmpe-94	124	43	moderate	moderate	ADJ
ajmpe-94	124	44	severe	severe	ADJ
ajmpe-94	124	45	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	124	46	american	american	PROPN
ajmpe-94	124	47	journal	journal	PROPN
ajmpe-94	124	48	of	of	ADP
ajmpe-94	124	49	medical	medical	ADJ
ajmpe-94	124	50	and	and	CCONJ
ajmpe-94	124	51	physical	physical	ADJ
ajmpe-94	124	52	education	education	NOUN
ajmpe-94	124	53	vol.1	vol.1	PROPN
ajmpe-94	124	54	,	,	PUNCT
ajmpe-94	124	55	issue	issue	NOUN
ajmpe-94	124	56	1	1	NUM
ajmpe-94	124	57	;	;	PUNCT
ajmpe-94	124	58	july	july	PROPN
ajmpe-94	124	59	2023	2023	NUM
ajmpe-94	124	60	;	;	PUNCT
ajmpe-94	124	61	1252	1252	NUM
ajmpe-94	124	62	columbia	columbia	PROPN
ajmpe-94	124	63	rd	rd	PROPN
ajmpe-94	124	64	nw	nw	PROPN
ajmpe-94	124	65	,	,	PUNCT
ajmpe-94	124	66	washington	washington	PROPN
ajmpe-94	124	67	dc	dc	PROPN
ajmpe-94	124	68	,	,	PUNCT
ajmpe-94	124	69	united	united	PROPN
ajmpe-94	124	70	states	states	PROPN
ajmpe-94	124	71	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	124	72	;	;	PUNCT
ajmpe-94	124	73	mail	mail	NOUN
ajmpe-94	124	74	:	:	PUNCT
ajmpe-94	125	1	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	125	2	74	74	NUM
ajmpe-94	126	1	|	|	ADV
ajmpe-94	126	2	a	a	DET
ajmpe-94	126	3	m	m	NOUN
ajmpe-94	126	4	e	e	NOUN
ajmpe-94	126	5	r	r	NOUN
ajmpe-94	127	1	i	i	NOUN
ajmpe-94	127	2	c	c	VERB
ajmpe-94	127	3	a	a	DET
ajmpe-94	127	4	n	n	NOUN
ajmpe-94	128	1	j	j	NOUN
ajmpe-94	128	2	o	o	X
ajmpe-94	128	3	u	u	NOUN
ajmpe-94	128	4	r	r	NOUN
ajmpe-94	128	5	n	n	NOUN
ajmpe-94	128	6	a	a	DET
ajmpe-94	128	7	l	l	NOUN
ajmpe-94	128	8	o	o	X
ajmpe-94	129	1	f	f	X
ajmpe-94	129	2	m	m	NOUN
ajmpe-94	129	3	e	e	NOUN
ajmpe-94	130	1	d	d	NOUN
ajmpe-94	130	2	i	i	PRON
ajmpe-94	130	3	c	c	VERB
ajmpe-94	130	4	a	a	DET
ajmpe-94	130	5	l	l	NOUN
ajmpe-94	130	6	a	a	X
ajmpe-94	130	7	n	n	NOUN
ajmpe-94	131	1	d	d	NOUN
ajmpe-94	131	2	p	p	NOUN
ajmpe-94	131	3	h	h	NOUN
ajmpe-94	131	4	y	y	NOUN
ajmpe-94	131	5	s	s	VERB
ajmpe-94	132	1	i	i	INTJ
ajmpe-94	132	2	c	c	VERB
ajmpe-94	132	3	a	a	DET
ajmpe-94	132	4	l	l	NOUN
ajmpe-94	132	5	e	e	NOUN
ajmpe-94	132	6	d	d	X
ajmpe-94	132	7	u	u	X
ajmpe-94	132	8	c	c	PROPN
ajmpe-94	133	1	a	a	DET
ajmpe-94	133	2	t	t	NOUN
ajmpe-94	134	1	i	i	PRON
ajmpe-94	134	2	o	o	VERB
ajmpe-94	134	3	n	n	CCONJ
ajmpe-94	134	4	|	|	ADV
ajmpe-94	134	5	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	NUM
ajmpe-94	134	6	figure	figure	NOUN
ajmpe-94	134	7	(	(	PUNCT
ajmpe-94	134	8	2	2	NUM
ajmpe-94	134	9	)	)	PUNCT
ajmpe-94	134	10	correlation	correlation	NOUN
ajmpe-94	134	11	between	between	ADP
ajmpe-94	134	12	plasma	plasma	NOUN
ajmpe-94	134	13	sodium	sodium	NOUN
ajmpe-94	134	14	(	(	PUNCT
ajmpe-94	134	15	na	na	NOUN
ajmpe-94	134	16	)	)	PUNCT
ajmpe-94	134	17	level	level	NOUN
ajmpe-94	134	18	and	and	CCONJ
ajmpe-94	134	19	stages	stage	NOUN
ajmpe-94	134	20	of	of	ADP
ajmpe-94	134	21	covid	covid	PROPN
ajmpe-94	134	22	19	19	NUM
ajmpe-94	134	23	disease	disease	NOUN
ajmpe-94	134	24	,	,	PUNCT
ajmpe-94	134	25	r=	r=	ADJ
ajmpe-94	134	26	-0.75	-0.75	NUM
ajmpe-94	134	27	,	,	PUNCT
ajmpe-94	134	28	p.value	p.value	ADJ
ajmpe-94	134	29	=	=	SYM
ajmpe-94	134	30	.000	.000	NUM
ajmpe-94	134	31	figure	figure	NOUN
ajmpe-94	134	32	(	(	PUNCT
ajmpe-94	134	33	3	3	NUM
ajmpe-94	134	34	)	)	PUNCT
ajmpe-94	134	35	correlation	correlation	NOUN
ajmpe-94	134	36	between	between	ADP
ajmpe-94	134	37	plasma	plasma	NOUN
ajmpe-94	134	38	level	level	NOUN
ajmpe-94	134	39	of	of	ADP
ajmpe-94	134	40	potassium	potassium	NOUN
ajmpe-94	134	41	(	(	PUNCT
ajmpe-94	134	42	k	k	NOUN
ajmpe-94	134	43	)	)	PUNCT
ajmpe-94	134	44	and	and	CCONJ
ajmpe-94	134	45	stages	stage	NOUN
ajmpe-94	134	46	of	of	ADP
ajmpe-94	134	47	covid	covid	PROPN
ajmpe-94	134	48	19	19	NUM
ajmpe-94	134	49	disease	disease	NOUN
ajmpe-94	134	50	,	,	PUNCT
ajmpe-94	134	51	r=	r=	ADJ
ajmpe-94	134	52	0.74p.value	0.74p.value	NOUN
ajmpe-94	134	53	=	=	SYM
ajmpe-94	134	54	0.000	0.000	NUM
ajmpe-94	134	55	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	134	56	american	american	PROPN
ajmpe-94	134	57	journal	journal	PROPN
ajmpe-94	134	58	of	of	ADP
ajmpe-94	134	59	medical	medical	ADJ
ajmpe-94	134	60	and	and	CCONJ
ajmpe-94	134	61	physical	physical	ADJ
ajmpe-94	134	62	education	education	NOUN
ajmpe-94	134	63	vol.1	vol.1	PROPN
ajmpe-94	134	64	,	,	PUNCT
ajmpe-94	134	65	issue	issue	NOUN
ajmpe-94	134	66	1	1	NUM
ajmpe-94	134	67	;	;	PUNCT
ajmpe-94	134	68	july	july	PROPN
ajmpe-94	134	69	2023	2023	NUM
ajmpe-94	134	70	;	;	PUNCT
ajmpe-94	134	71	1252	1252	NUM
ajmpe-94	134	72	columbia	columbia	PROPN
ajmpe-94	134	73	rd	rd	PROPN
ajmpe-94	134	74	nw	nw	PROPN
ajmpe-94	134	75	,	,	PUNCT
ajmpe-94	134	76	washington	washington	PROPN
ajmpe-94	134	77	dc	dc	PROPN
ajmpe-94	134	78	,	,	PUNCT
ajmpe-94	134	79	united	united	PROPN
ajmpe-94	134	80	states	states	PROPN
ajmpe-94	134	81	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	134	82	;	;	PUNCT
ajmpe-94	134	83	mail	mail	NOUN
ajmpe-94	134	84	:	:	PUNCT
ajmpe-94	134	85	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	135	1	75	75	NUM
ajmpe-94	136	1	|	|	ADV
ajmpe-94	136	2	a	a	DET
ajmpe-94	136	3	m	m	NOUN
ajmpe-94	136	4	e	e	NOUN
ajmpe-94	136	5	r	r	NOUN
ajmpe-94	137	1	i	i	NOUN
ajmpe-94	137	2	c	c	VERB
ajmpe-94	137	3	a	a	DET
ajmpe-94	137	4	n	n	NOUN
ajmpe-94	138	1	j	j	NOUN
ajmpe-94	138	2	o	o	X
ajmpe-94	138	3	u	u	NOUN
ajmpe-94	138	4	r	r	NOUN
ajmpe-94	138	5	n	n	NOUN
ajmpe-94	138	6	a	a	DET
ajmpe-94	138	7	l	l	NOUN
ajmpe-94	138	8	o	o	X
ajmpe-94	139	1	f	f	X
ajmpe-94	139	2	m	m	NOUN
ajmpe-94	139	3	e	e	NOUN
ajmpe-94	140	1	d	d	NOUN
ajmpe-94	140	2	i	i	PRON
ajmpe-94	140	3	c	c	VERB
ajmpe-94	140	4	a	a	DET
ajmpe-94	140	5	l	l	NOUN
ajmpe-94	140	6	a	a	X
ajmpe-94	140	7	n	n	NOUN
ajmpe-94	141	1	d	d	NOUN
ajmpe-94	141	2	p	p	NOUN
ajmpe-94	141	3	h	h	NOUN
ajmpe-94	141	4	y	y	NOUN
ajmpe-94	141	5	s	s	VERB
ajmpe-94	142	1	i	i	INTJ
ajmpe-94	142	2	c	c	VERB
ajmpe-94	142	3	a	a	DET
ajmpe-94	142	4	l	l	NOUN
ajmpe-94	142	5	e	e	NOUN
ajmpe-94	142	6	d	d	X
ajmpe-94	142	7	u	u	X
ajmpe-94	142	8	c	c	PROPN
ajmpe-94	143	1	a	a	DET
ajmpe-94	143	2	t	t	NOUN
ajmpe-94	144	1	i	i	PRON
ajmpe-94	144	2	o	o	VERB
ajmpe-94	144	3	n	n	CCONJ
ajmpe-94	144	4	|	|	ADV
ajmpe-94	144	5	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	NUM
ajmpe-94	144	6	figure	figure	NOUN
ajmpe-94	144	7	(	(	PUNCT
ajmpe-94	144	8	4	4	NUM
ajmpe-94	144	9	)	)	PUNCT
ajmpe-94	144	10	correlation	correlation	NOUN
ajmpe-94	144	11	between	between	ADP
ajmpe-94	144	12	plasma	plasma	NOUN
ajmpe-94	144	13	zinc	zinc	NOUN
ajmpe-94	144	14	(	(	PUNCT
ajmpe-94	144	15	zn	zn	NOUN
ajmpe-94	144	16	)	)	PUNCT
ajmpe-94	144	17	level	level	NOUN
ajmpe-94	144	18	and	and	CCONJ
ajmpe-94	144	19	stages	stage	NOUN
ajmpe-94	144	20	of	of	ADP
ajmpe-94	144	21	covid	covid	PROPN
ajmpe-94	144	22	19	19	NUM
ajmpe-94	144	23	disease	disease	NOUN
ajmpe-94	144	24	,	,	PUNCT
ajmpe-94	144	25	r=	r=	ADJ
ajmpe-94	144	26	-0.8	-0.8	ADJ
ajmpe-94	144	27	p.value	p.value	NOUN
ajmpe-94	144	28	=	=	NOUN
ajmpe-94	144	29	0.000	0.000	NUM
ajmpe-94	144	30	figure	figure	NOUN
ajmpe-94	144	31	(	(	PUNCT
ajmpe-94	144	32	5	5	NUM
ajmpe-94	144	33	)	)	PUNCT
ajmpe-94	144	34	correlation	correlation	NOUN
ajmpe-94	144	35	between	between	ADP
ajmpe-94	144	36	plasma	plasma	NOUN
ajmpe-94	144	37	copper	copper	NOUN
ajmpe-94	144	38	(	(	PUNCT
ajmpe-94	144	39	cu	cu	PROPN
ajmpe-94	144	40	)	)	PUNCT
ajmpe-94	144	41	and	and	CCONJ
ajmpe-94	144	42	stages	stage	NOUN
ajmpe-94	144	43	of	of	ADP
ajmpe-94	144	44	covid	covid	PROPN
ajmpe-94	144	45	19	19	NUM
ajmpe-94	144	46	disease	disease	NOUN
ajmpe-94	144	47	,	,	PUNCT
ajmpe-94	144	48	r=	r=	VERB
ajmpe-94	144	49	0.7	0.7	NUM
ajmpe-94	144	50	p.value	p.value	NOUN
ajmpe-94	144	51	=	=	NOUN
ajmpe-94	144	52	0.000	0.000	NUM
ajmpe-94	144	53	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	144	54	american	american	PROPN
ajmpe-94	144	55	journal	journal	PROPN
ajmpe-94	144	56	of	of	ADP
ajmpe-94	144	57	medical	medical	ADJ
ajmpe-94	144	58	and	and	CCONJ
ajmpe-94	144	59	physical	physical	ADJ
ajmpe-94	144	60	education	education	NOUN
ajmpe-94	144	61	vol.1	vol.1	PROPN
ajmpe-94	144	62	,	,	PUNCT
ajmpe-94	144	63	issue	issue	NOUN
ajmpe-94	144	64	1	1	NUM
ajmpe-94	144	65	;	;	PUNCT
ajmpe-94	144	66	july	july	PROPN
ajmpe-94	144	67	2023	2023	NUM
ajmpe-94	144	68	;	;	PUNCT
ajmpe-94	144	69	1252	1252	NUM
ajmpe-94	144	70	columbia	columbia	PROPN
ajmpe-94	144	71	rd	rd	PROPN
ajmpe-94	144	72	nw	nw	PROPN
ajmpe-94	144	73	,	,	PUNCT
ajmpe-94	144	74	washington	washington	PROPN
ajmpe-94	144	75	dc	dc	PROPN
ajmpe-94	144	76	,	,	PUNCT
ajmpe-94	144	77	united	united	PROPN
ajmpe-94	144	78	states	states	PROPN
ajmpe-94	144	79	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	144	80	;	;	PUNCT
ajmpe-94	144	81	mail	mail	NOUN
ajmpe-94	144	82	:	:	PUNCT
ajmpe-94	144	83	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	145	1	76	76	NUM
ajmpe-94	146	1	|	|	ADV
ajmpe-94	146	2	a	a	DET
ajmpe-94	146	3	m	m	NOUN
ajmpe-94	146	4	e	e	NOUN
ajmpe-94	146	5	r	r	NOUN
ajmpe-94	147	1	i	i	NOUN
ajmpe-94	147	2	c	c	VERB
ajmpe-94	147	3	a	a	DET
ajmpe-94	147	4	n	n	NOUN
ajmpe-94	148	1	j	j	NOUN
ajmpe-94	148	2	o	o	X
ajmpe-94	148	3	u	u	NOUN
ajmpe-94	148	4	r	r	NOUN
ajmpe-94	148	5	n	n	NOUN
ajmpe-94	148	6	a	a	DET
ajmpe-94	148	7	l	l	NOUN
ajmpe-94	148	8	o	o	X
ajmpe-94	149	1	f	f	X
ajmpe-94	149	2	m	m	NOUN
ajmpe-94	149	3	e	e	NOUN
ajmpe-94	150	1	d	d	NOUN
ajmpe-94	150	2	i	i	PRON
ajmpe-94	150	3	c	c	VERB
ajmpe-94	150	4	a	a	DET
ajmpe-94	150	5	l	l	NOUN
ajmpe-94	150	6	a	a	X
ajmpe-94	150	7	n	n	NOUN
ajmpe-94	151	1	d	d	NOUN
ajmpe-94	151	2	p	p	NOUN
ajmpe-94	151	3	h	h	NOUN
ajmpe-94	151	4	y	y	NOUN
ajmpe-94	151	5	s	s	VERB
ajmpe-94	152	1	i	i	INTJ
ajmpe-94	152	2	c	c	VERB
ajmpe-94	152	3	a	a	DET
ajmpe-94	152	4	l	l	NOUN
ajmpe-94	152	5	e	e	NOUN
ajmpe-94	152	6	d	d	X
ajmpe-94	152	7	u	u	X
ajmpe-94	152	8	c	c	PROPN
ajmpe-94	153	1	a	a	DET
ajmpe-94	153	2	t	t	NOUN
ajmpe-94	154	1	i	i	PRON
ajmpe-94	154	2	o	o	VERB
ajmpe-94	154	3	n	n	CCONJ
ajmpe-94	154	4	|	|	ADV
ajmpe-94	154	5	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	NUM
ajmpe-94	154	6	figure	figure	NOUN
ajmpe-94	154	7	(	(	PUNCT
ajmpe-94	154	8	6	6	NUM
ajmpe-94	154	9	)	)	PUNCT
ajmpe-94	154	10	correlation	correlation	NOUN
ajmpe-94	154	11	between	between	ADP
ajmpe-94	154	12	serum	serum	NOUN
ajmpe-94	154	13	calcium	calcium	NOUN
ajmpe-94	154	14	(	(	PUNCT
ajmpe-94	154	15	ca	ca	NOUN
ajmpe-94	154	16	)	)	PUNCT
ajmpe-94	154	17	level	level	NOUN
ajmpe-94	154	18	and	and	CCONJ
ajmpe-94	154	19	stages	stage	NOUN
ajmpe-94	154	20	of	of	ADP
ajmpe-94	154	21	covid	covid	PROPN
ajmpe-94	154	22	19	19	NUM
ajmpe-94	154	23	disease	disease	NOUN
ajmpe-94	154	24	r=	r=	ADJ
ajmpe-94	154	25	0.02	0.02	NUM
ajmpe-94	154	26	and	and	CCONJ
ajmpe-94	154	27	p.value	p.value	NOUN
ajmpe-94	154	28	=	=	SYM
ajmpe-94	154	29	0.8	0.8	NUM
ajmpe-94	154	30	.	.	PUNCT
ajmpe-94	155	1	discussion	discussion	NOUN
ajmpe-94	155	2	a	a	DET
ajmpe-94	155	3	new	new	ADJ
ajmpe-94	155	4	coronavirus	coronavirus	NOUN
ajmpe-94	155	5	known	know	VERB
ajmpe-94	155	6	as	as	ADP
ajmpe-94	155	7	covid-19	covid-19	PROPN
ajmpe-94	155	8	was	be	AUX
ajmpe-94	155	9	discovered	discover	VERB
ajmpe-94	155	10	in	in	ADP
ajmpe-94	155	11	wuhan	wuhan	PROPN
ajmpe-94	155	12	,	,	PUNCT
ajmpe-94	155	13	china	china	PROPN
ajmpe-94	155	14	,	,	PUNCT
ajmpe-94	155	15	at	at	ADP
ajmpe-94	155	16	the	the	DET
ajmpe-94	155	17	end	end	NOUN
ajmpe-94	155	18	of	of	ADP
ajmpe-94	155	19	2019	2019	NUM
ajmpe-94	155	20	.	.	PUNCT
ajmpe-94	156	1	it	it	PRON
ajmpe-94	156	2	caused	cause	VERB
ajmpe-94	156	3	havoc	havoc	NOUN
ajmpe-94	156	4	there	there	ADV
ajmpe-94	156	5	,	,	PUNCT
ajmpe-94	156	6	with	with	ADP
ajmpe-94	156	7	an	an	DET
ajmpe-94	156	8	overall	overall	ADJ
ajmpe-94	156	9	case	case	NOUN
ajmpe-94	156	10	-	-	PUNCT
ajmpe-94	156	11	fatality	fatality	NOUN
ajmpe-94	156	12	rate	rate	NOUN
ajmpe-94	156	13	(	(	PUNCT
ajmpe-94	156	14	cfr	cfr	NOUN
ajmpe-94	156	15	)	)	PUNCT
ajmpe-94	156	16	of	of	ADP
ajmpe-94	156	17	2.3	2.3	NUM
ajmpe-94	156	18	%	%	NOUN
ajmpe-94	156	19	(	(	PUNCT
ajmpe-94	156	20	4512	4512	NUM
ajmpe-94	156	21	deaths	death	NOUN
ajmpe-94	156	22	among	among	ADP
ajmpe-94	156	23	68151	68151	NUM
ajmpe-94	156	24	confirmed	confirm	VERB
ajmpe-94	156	25	cases	case	NOUN
ajmpe-94	156	26	(	(	PUNCT
ajmpe-94	156	27	21	21	NUM
ajmpe-94	156	28	)	)	PUNCT
ajmpe-94	156	29	found	find	VERB
ajmpe-94	156	30	to	to	PART
ajmpe-94	156	31	spread	spread	VERB
ajmpe-94	156	32	from	from	ADP
ajmpe-94	156	33	person	person	NOUN
ajmpe-94	156	34	to	to	ADP
ajmpe-94	156	35	person	person	NOUN
ajmpe-94	156	36	like	like	ADP
ajmpe-94	156	37	droplet	droplet	ADJ
ajmpe-94	156	38	infections	infection	NOUN
ajmpe-94	156	39	(	(	PUNCT
ajmpe-94	156	40	22	22	NUM
ajmpe-94	156	41	)	)	PUNCT
ajmpe-94	156	42	and	and	CCONJ
ajmpe-94	156	43	was	be	AUX
ajmpe-94	156	44	highly	highly	ADV
ajmpe-94	156	45	contagious	contagious	ADJ
ajmpe-94	156	46	,	,	PUNCT
ajmpe-94	156	47	leading	lead	VERB
ajmpe-94	156	48	to	to	ADP
ajmpe-94	156	49	a	a	DET
ajmpe-94	156	50	city	city	NOUN
ajmpe-94	156	51	lockdown	lockdown	NOUN
ajmpe-94	156	52	to	to	PART
ajmpe-94	156	53	stop	stop	VERB
ajmpe-94	156	54	the	the	DET
ajmpe-94	156	55	spread	spread	NOUN
ajmpe-94	156	56	of	of	ADP
ajmpe-94	156	57	the	the	DET
ajmpe-94	156	58	illness	illness	NOUN
ajmpe-94	156	59	(	(	PUNCT
ajmpe-94	156	60	23	23	NUM
ajmpe-94	156	61	)	)	PUNCT
ajmpe-94	156	62	it	it	PRON
ajmpe-94	156	63	began	begin	VERB
ajmpe-94	156	64	to	to	PART
ajmpe-94	156	65	spread	spread	VERB
ajmpe-94	156	66	over	over	ADP
ajmpe-94	156	67	the	the	DET
ajmpe-94	156	68	world	world	NOUN
ajmpe-94	156	69	,	,	PUNCT
ajmpe-94	156	70	and	and	CCONJ
ajmpe-94	156	71	in	in	ADP
ajmpe-94	156	72	march	march	PROPN
ajmpe-94	156	73	2020	2020	NUM
ajmpe-94	156	74	it	it	PRON
ajmpe-94	156	75	reached	reach	VERB
ajmpe-94	156	76	sudan	sudan	PROPN
ajmpe-94	156	77	(	(	PUNCT
ajmpe-94	156	78	24	24	NUM
ajmpe-94	156	79	)	)	PUNCT
ajmpe-94	156	80	.	.	PUNCT
ajmpe-94	157	1	covid-19	covid-19	PROPN
ajmpe-94	157	2	is	be	AUX
ajmpe-94	157	3	a	a	DET
ajmpe-94	157	4	huge	huge	ADJ
ajmpe-94	157	5	global	global	ADJ
ajmpe-94	157	6	health	health	NOUN
ajmpe-94	157	7	problem	problem	NOUN
ajmpe-94	157	8	due	due	ADP
ajmpe-94	157	9	to	to	ADP
ajmpe-94	157	10	its	its	PRON
ajmpe-94	157	11	high	high	ADJ
ajmpe-94	157	12	rate	rate	NOUN
ajmpe-94	157	13	of	of	ADP
ajmpe-94	157	14	transmission	transmission	NOUN
ajmpe-94	157	15	and	and	CCONJ
ajmpe-94	157	16	its	its	PRON
ajmpe-94	157	17	high	high	ADJ
ajmpe-94	157	18	morbidity	morbidity	NOUN
ajmpe-94	157	19	and	and	CCONJ
ajmpe-94	157	20	mortality	mortality	NOUN
ajmpe-94	157	21	rates	rate	NOUN
ajmpe-94	157	22	.	.	PUNCT
ajmpe-94	158	1	among	among	ADP
ajmpe-94	158	2	the	the	DET
ajmpe-94	158	3	numerous	numerous	ADJ
ajmpe-94	158	4	pathophysiological	pathophysiological	ADJ
ajmpe-94	158	5	effects	effect	NOUN
ajmpe-94	158	6	associated	associate	VERB
ajmpe-94	158	7	with	with	ADP
ajmpe-94	158	8	the	the	DET
ajmpe-94	158	9	virus	virus	NOUN
ajmpe-94	158	10	,	,	PUNCT
ajmpe-94	158	11	endocrine	endocrine	NOUN
ajmpe-94	158	12	and	and	CCONJ
ajmpe-94	158	13	metabolic	metabolic	NOUN
ajmpe-94	158	14	disorders	disorder	NOUN
ajmpe-94	158	15	stand	stand	VERB
ajmpe-94	158	16	out	out	ADP
ajmpe-94	158	17	.	.	PUNCT
ajmpe-94	159	1	however	however	ADV
ajmpe-94	159	2	,	,	PUNCT
ajmpe-94	159	3	the	the	DET
ajmpe-94	159	4	particular	particular	ADJ
ajmpe-94	159	5	consequences	consequence	NOUN
ajmpe-94	159	6	on	on	ADP
ajmpe-94	159	7	the	the	DET
ajmpe-94	159	8	electrolytes	electrolyte	NOUN
ajmpe-94	159	9	,	,	PUNCT
ajmpe-94	159	10	calcium	calcium	NOUN
ajmpe-94	159	11	,	,	PUNCT
ajmpe-94	159	12	phosphorus	phosphorus	NOUN
ajmpe-94	159	13	,	,	PUNCT
ajmpe-94	159	14	and	and	CCONJ
ajmpe-94	159	15	trace	trace	NOUN
ajmpe-94	159	16	elements	element	NOUN
ajmpe-94	159	17	metabolism	metabolism	NOUN
ajmpe-94	159	18	system	system	NOUN
ajmpe-94	159	19	are	be	AUX
ajmpe-94	159	20	still	still	ADV
ajmpe-94	159	21	not	not	PART
ajmpe-94	159	22	fully	fully	ADV
ajmpe-94	159	23	understood	understand	VERB
ajmpe-94	159	24	.	.	PUNCT
ajmpe-94	159	25	,	,	PUNCT
ajmpe-94	159	26	electrolyte	electrolyte	ADJ
ajmpe-94	159	27	and	and	CCONJ
ajmpe-94	159	28	trace	trace	NOUN
ajmpe-94	159	29	elements	element	NOUN
ajmpe-94	159	30	disturbances	disturbance	NOUN
ajmpe-94	159	31	are	be	AUX
ajmpe-94	159	32	commonly	commonly	ADV
ajmpe-94	159	33	observed	observe	VERB
ajmpe-94	159	34	in	in	ADP
ajmpe-94	159	35	patients	patient	NOUN
ajmpe-94	159	36	with	with	ADP
ajmpe-94	159	37	coronavirus	coronavirus	NOUN
ajmpe-94	159	38	disease	disease	NOUN
ajmpe-94	159	39	2019	2019	NUM
ajmpe-94	159	40	(	(	PUNCT
ajmpe-94	159	41	covid-19	covid-19	PROPN
ajmpe-94	159	42	)	)	PUNCT
ajmpe-94	159	43	and	and	CCONJ
ajmpe-94	159	44	associated	associate	VERB
ajmpe-94	159	45	with	with	ADP
ajmpe-94	159	46	outcomes	outcome	NOUN
ajmpe-94	159	47	in	in	ADP
ajmpe-94	159	48	these	these	DET
ajmpe-94	159	49	patients	patient	NOUN
ajmpe-94	159	50	.	.	PUNCT
ajmpe-94	160	1	our	our	PRON
ajmpe-94	160	2	study	study	NOUN
ajmpe-94	160	3	was	be	AUX
ajmpe-94	160	4	designed	design	VERB
ajmpe-94	160	5	to	to	PART
ajmpe-94	160	6	examine	examine	VERB
ajmpe-94	160	7	whether	whether	SCONJ
ajmpe-94	160	8	abnormal	abnormal	ADJ
ajmpe-94	160	9	levels	level	NOUN
ajmpe-94	160	10	of	of	ADP
ajmpe-94	160	11	electrolyte	electrolyte	NOUN
ajmpe-94	160	12	and	and	CCONJ
ajmpe-94	160	13	trace	trace	NOUN
ajmpe-94	160	14	elements	element	NOUN
ajmpe-94	160	15	are	be	AUX
ajmpe-94	160	16	associated	associate	VERB
ajmpe-94	160	17	with	with	ADP
ajmpe-94	160	18	mortality	mortality	NOUN
ajmpe-94	160	19	in	in	ADP
ajmpe-94	160	20	covid-19	covid-19	PROPN
ajmpe-94	160	21	patients	patient	NOUN
ajmpe-94	160	22	.	.	PUNCT
ajmpe-94	161	1	serum	serum	NOUN
ajmpe-94	161	2	levels	level	NOUN
ajmpe-94	161	3	of	of	ADP
ajmpe-94	161	4	electrolytes	electrolyte	NOUN
ajmpe-94	161	5	essential	essential	ADJ
ajmpe-94	161	6	and	and	CCONJ
ajmpe-94	161	7	trace	trace	NOUN
ajmpe-94	161	8	elements	element	NOUN
ajmpe-94	161	9	are	be	AUX
ajmpe-94	161	10	necessary	necessary	ADJ
ajmpe-94	161	11	for	for	ADP
ajmpe-94	161	12	the	the	DET
ajmpe-94	161	13	well	well	ADV
ajmpe-94	161	14	-	-	PUNCT
ajmpe-94	161	15	functioning	function	VERB
ajmpe-94	161	16	and	and	CCONJ
ajmpe-94	161	17	maintenance	maintenance	NOUN
ajmpe-94	161	18	of	of	ADP
ajmpe-94	161	19	the	the	DET
ajmpe-94	161	20	immune	immune	ADJ
ajmpe-94	161	21	system	system	NOUN
ajmpe-94	161	22	during	during	ADP
ajmpe-94	161	23	any	any	DET
ajmpe-94	161	24	infection	infection	NOUN
ajmpe-94	161	25	.	.	PUNCT
ajmpe-94	162	1	in	in	ADP
ajmpe-94	162	2	this	this	DET
ajmpe-94	162	3	present	present	ADJ
ajmpe-94	162	4	study	study	NOUN
ajmpe-94	162	5	,	,	PUNCT
ajmpe-94	162	6	we	we	PRON
ajmpe-94	162	7	measured	measure	VERB
ajmpe-94	162	8	serum	serum	NOUN
ajmpe-94	162	9	levels	level	NOUN
ajmpe-94	162	10	of	of	ADP
ajmpe-94	162	11	electrolytes	electrolyte	NOUN
ajmpe-94	162	12	and	and	CCONJ
ajmpe-94	162	13	trace	trace	NOUN
ajmpe-94	162	14	elements	element	NOUN
ajmpe-94	162	15	and	and	CCONJ
ajmpe-94	162	16	their	their	PRON
ajmpe-94	162	17	association	association	NOUN
ajmpe-94	162	18	with	with	ADP
ajmpe-94	162	19	the	the	DET
ajmpe-94	162	20	severity	severity	NOUN
ajmpe-94	162	21	of	of	ADP
ajmpe-94	162	22	covid-19	covid-19	PROPN
ajmpe-94	162	23	patients	patient	NOUN
ajmpe-94	162	24	.	.	PUNCT
ajmpe-94	163	1	the	the	DET
ajmpe-94	163	2	results	result	NOUN
ajmpe-94	163	3	indicate	indicate	VERB
ajmpe-94	163	4	that	that	SCONJ
ajmpe-94	163	5	these	these	DET
ajmpe-94	163	6	metal	metal	NOUN
ajmpe-94	163	7	levels	level	NOUN
ajmpe-94	163	8	are	be	AUX
ajmpe-94	163	9	altered	alter	VERB
ajmpe-94	163	10	in	in	ADP
ajmpe-94	163	11	a	a	DET
ajmpe-94	163	12	severity	severity	NOUN
ajmpe-94	163	13	-	-	PUNCT
ajmpe-94	163	14	dependent	dependent	ADJ
ajmpe-94	163	15	manner	manner	NOUN
ajmpe-94	163	16	.	.	PUNCT
ajmpe-94	164	1	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	164	2	american	american	PROPN
ajmpe-94	164	3	journal	journal	PROPN
ajmpe-94	164	4	of	of	ADP
ajmpe-94	164	5	medical	medical	ADJ
ajmpe-94	164	6	and	and	CCONJ
ajmpe-94	164	7	physical	physical	ADJ
ajmpe-94	164	8	education	education	NOUN
ajmpe-94	164	9	vol.1	vol.1	PROPN
ajmpe-94	164	10	,	,	PUNCT
ajmpe-94	164	11	issue	issue	NOUN
ajmpe-94	164	12	1	1	NUM
ajmpe-94	164	13	;	;	PUNCT
ajmpe-94	164	14	july	july	PROPN
ajmpe-94	164	15	2023	2023	NUM
ajmpe-94	164	16	;	;	PUNCT
ajmpe-94	164	17	1252	1252	NUM
ajmpe-94	164	18	columbia	columbia	PROPN
ajmpe-94	164	19	rd	rd	PROPN
ajmpe-94	164	20	nw	nw	PROPN
ajmpe-94	164	21	,	,	PUNCT
ajmpe-94	164	22	washington	washington	PROPN
ajmpe-94	164	23	dc	dc	PROPN
ajmpe-94	164	24	,	,	PUNCT
ajmpe-94	164	25	united	united	PROPN
ajmpe-94	164	26	states	states	PROPN
ajmpe-94	164	27	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	164	28	;	;	PUNCT
ajmpe-94	164	29	mail	mail	NOUN
ajmpe-94	164	30	:	:	PUNCT
ajmpe-94	165	1	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	165	2	77	77	NUM
ajmpe-94	166	1	|	|	ADV
ajmpe-94	166	2	a	a	DET
ajmpe-94	166	3	m	m	NOUN
ajmpe-94	166	4	e	e	NOUN
ajmpe-94	166	5	r	r	NOUN
ajmpe-94	167	1	i	i	NOUN
ajmpe-94	167	2	c	c	VERB
ajmpe-94	167	3	a	a	DET
ajmpe-94	167	4	n	n	NOUN
ajmpe-94	168	1	j	j	NOUN
ajmpe-94	168	2	o	o	X
ajmpe-94	168	3	u	u	NOUN
ajmpe-94	168	4	r	r	NOUN
ajmpe-94	168	5	n	n	NOUN
ajmpe-94	168	6	a	a	DET
ajmpe-94	168	7	l	l	NOUN
ajmpe-94	168	8	o	o	X
ajmpe-94	169	1	f	f	X
ajmpe-94	169	2	m	m	NOUN
ajmpe-94	169	3	e	e	NOUN
ajmpe-94	170	1	d	d	NOUN
ajmpe-94	170	2	i	i	PRON
ajmpe-94	170	3	c	c	VERB
ajmpe-94	170	4	a	a	DET
ajmpe-94	170	5	l	l	NOUN
ajmpe-94	170	6	a	a	X
ajmpe-94	170	7	n	n	NOUN
ajmpe-94	171	1	d	d	NOUN
ajmpe-94	171	2	p	p	NOUN
ajmpe-94	171	3	h	h	NOUN
ajmpe-94	171	4	y	y	NOUN
ajmpe-94	171	5	s	s	VERB
ajmpe-94	172	1	i	i	INTJ
ajmpe-94	172	2	c	c	VERB
ajmpe-94	172	3	a	a	DET
ajmpe-94	172	4	l	l	NOUN
ajmpe-94	172	5	e	e	NOUN
ajmpe-94	172	6	d	d	X
ajmpe-94	172	7	u	u	X
ajmpe-94	172	8	c	c	PROPN
ajmpe-94	173	1	a	a	DET
ajmpe-94	173	2	t	t	NOUN
ajmpe-94	174	1	i	i	PRON
ajmpe-94	174	2	o	o	VERB
ajmpe-94	175	1	n	n	CCONJ
ajmpe-94	175	2	|	|	ADV
ajmpe-94	175	3	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	NOUN
ajmpe-94	175	4	this	this	DET
ajmpe-94	175	5	study	study	NOUN
ajmpe-94	175	6	described	describe	VERB
ajmpe-94	175	7	adult	adult	NOUN
ajmpe-94	175	8	patients	patient	NOUN
ajmpe-94	175	9	who	who	PRON
ajmpe-94	175	10	were	be	AUX
ajmpe-94	175	11	hospitalized	hospitalize	VERB
ajmpe-94	175	12	with	with	ADP
ajmpe-94	175	13	covid-19	covid-19	PROPN
ajmpe-94	175	14	in	in	ADP
ajmpe-94	175	15	an	an	DET
ajmpe-94	175	16	isolation	isolation	NOUN
ajmpe-94	175	17	center	center	NOUN
ajmpe-94	175	18	in	in	ADP
ajmpe-94	175	19	sudan	sudan	PROPN
ajmpe-94	175	20	.	.	PUNCT
ajmpe-94	176	1	in	in	ADP
ajmpe-94	176	2	the	the	DET
ajmpe-94	176	3	present	present	ADJ
ajmpe-94	176	4	study	study	NOUN
ajmpe-94	176	5	,	,	PUNCT
ajmpe-94	176	6	the	the	DET
ajmpe-94	176	7	majority	majority	NOUN
ajmpe-94	176	8	of	of	ADP
ajmpe-94	176	9	covid-19	covid-19	PROPN
ajmpe-94	176	10	cases	case	NOUN
ajmpe-94	176	11	were	be	AUX
ajmpe-94	176	12	males	male	NOUN
ajmpe-94	176	13	(	(	PUNCT
ajmpe-94	176	14	52	52	NUM
ajmpe-94	176	15	%	%	NOUN
ajmpe-94	176	16	)	)	PUNCT
ajmpe-94	176	17	,	,	PUNCT
ajmpe-94	176	18	which	which	PRON
ajmpe-94	176	19	agrees	agree	VERB
ajmpe-94	176	20	with	with	ADP
ajmpe-94	176	21	the	the	DET
ajmpe-94	176	22	study	study	NOUN
ajmpe-94	176	23	of	of	ADP
ajmpe-94	176	24	team	team	NOUN
ajmpe-94	176	25	tncpere	tncpere	ADP
ajmpe-94	176	26	(	(	PUNCT
ajmpe-94	176	27	25	25	NUM
ajmpe-94	176	28	)	)	PUNCT
ajmpe-94	176	29	which	which	PRON
ajmpe-94	176	30	demonstrated	demonstrate	VERB
ajmpe-94	176	31	that	that	SCONJ
ajmpe-94	176	32	the	the	DET
ajmpe-94	176	33	incidence	incidence	NOUN
ajmpe-94	176	34	of	of	ADP
ajmpe-94	176	35	covid-19	covid-19	PROPN
ajmpe-94	176	36	is	be	AUX
ajmpe-94	176	37	higher	high	ADJ
ajmpe-94	176	38	in	in	ADP
ajmpe-94	176	39	males	male	NOUN
ajmpe-94	176	40	than	than	ADP
ajmpe-94	176	41	in	in	ADP
ajmpe-94	176	42	females	female	NOUN
ajmpe-94	176	43	.	.	PUNCT
ajmpe-94	177	1	this	this	PRON
ajmpe-94	177	2	is	be	AUX
ajmpe-94	177	3	due	due	ADJ
ajmpe-94	177	4	to	to	ADP
ajmpe-94	177	5	dissimilar	dissimilar	ADJ
ajmpe-94	177	6	innate	innate	ADJ
ajmpe-94	177	7	immunity	immunity	NOUN
ajmpe-94	177	8	,	,	PUNCT
ajmpe-94	177	9	steroid	steroid	NOUN
ajmpe-94	177	10	hormones	hormone	NOUN
ajmpe-94	177	11	,	,	PUNCT
ajmpe-94	177	12	and	and	CCONJ
ajmpe-94	177	13	factors	factor	NOUN
ajmpe-94	177	14	related	relate	VERB
ajmpe-94	177	15	to	to	ADP
ajmpe-94	177	16	sex	sex	NOUN
ajmpe-94	177	17	chromosomes	chromosome	NOUN
ajmpe-94	177	18	.	.	PUNCT
ajmpe-94	178	1	the	the	DET
ajmpe-94	178	2	findings	finding	NOUN
ajmpe-94	178	3	of	of	ADP
ajmpe-94	178	4	this	this	DET
ajmpe-94	178	5	study	study	NOUN
ajmpe-94	178	6	,	,	PUNCT
ajmpe-94	178	7	there	there	PRON
ajmpe-94	178	8	was	be	VERB
ajmpe-94	178	9	a	a	DET
ajmpe-94	178	10	significantly	significantly	ADV
ajmpe-94	178	11	lower	low	ADJ
ajmpe-94	178	12	mean	mean	NOUN
ajmpe-94	178	13	sodium	sodium	NOUN
ajmpe-94	178	14	and	and	CCONJ
ajmpe-94	178	15	potassium	potassium	NOUN
ajmpe-94	178	16	levels	level	NOUN
ajmpe-94	178	17	in	in	ADP
ajmpe-94	178	18	covid-19	covid-19	PROPN
ajmpe-94	178	19	patients	patient	NOUN
ajmpe-94	178	20	when	when	SCONJ
ajmpe-94	178	21	compared	compare	VERB
ajmpe-94	178	22	to	to	ADP
ajmpe-94	178	23	the	the	DET
ajmpe-94	178	24	control	control	NOUN
ajmpe-94	178	25	group	group	NOUN
ajmpe-94	178	26	,	,	PUNCT
ajmpe-94	178	27	these	these	DET
ajmpe-94	178	28	results	result	NOUN
ajmpe-94	178	29	corroborated	corroborate	VERB
ajmpe-94	178	30	those	those	PRON
ajmpe-94	178	31	of	of	ADP
ajmpe-94	178	32	carvalho	carvalho	NOUN
ajmpe-94	178	33	et	et	PROPN
ajmpe-94	178	34	al	al	PROPN
ajmpe-94	178	35	.	.	PROPN
ajmpe-94	179	1	(	(	PUNCT
ajmpe-94	179	2	26	26	NUM
ajmpe-94	179	3	)	)	PUNCT
ajmpe-94	179	4	who	who	PRON
ajmpe-94	179	5	found	find	VERB
ajmpe-94	179	6	that	that	SCONJ
ajmpe-94	179	7	hyponatremia	hyponatremia	PROPN
ajmpe-94	179	8	and	and	CCONJ
ajmpe-94	179	9	hypokalemia	hypokalemia	NOUN
ajmpe-94	179	10	were	be	AUX
ajmpe-94	179	11	different	different	ADJ
ajmpe-94	179	12	associations	association	NOUN
ajmpe-94	179	13	with	with	ADP
ajmpe-94	179	14	covid-19	covid-19	PROPN
ajmpe-94	179	15	in	in	ADP
ajmpe-94	179	16	comparison	comparison	NOUN
ajmpe-94	179	17	to	to	ADP
ajmpe-94	179	18	controls	control	NOUN
ajmpe-94	179	19	.	.	PUNCT
ajmpe-94	180	1	the	the	DET
ajmpe-94	180	2	enhanced	enhanced	ADJ
ajmpe-94	180	3	production	production	NOUN
ajmpe-94	180	4	of	of	ADP
ajmpe-94	180	5	antidiuretic	antidiuretic	ADJ
ajmpe-94	180	6	hormone	hormone	NOUN
ajmpe-94	180	7	(	(	PUNCT
ajmpe-94	180	8	adh	adh	PROPN
ajmpe-94	180	9	)	)	PUNCT
ajmpe-94	180	10	in	in	ADP
ajmpe-94	180	11	response	response	NOUN
ajmpe-94	180	12	to	to	PART
ajmpe-94	180	13	volume	volume	VERB
ajmpe-94	180	14	depletion	depletion	NOUN
ajmpe-94	180	15	after	after	SCONJ
ajmpe-94	180	16	gastrointestinal	gastrointestinal	ADJ
ajmpe-94	180	17	fluid	fluid	NOUN
ajmpe-94	180	18	losses	loss	NOUN
ajmpe-94	180	19	is	be	AUX
ajmpe-94	180	20	thought	think	VERB
ajmpe-94	180	21	to	to	PART
ajmpe-94	180	22	be	be	AUX
ajmpe-94	180	23	responsible	responsible	ADJ
ajmpe-94	180	24	for	for	ADP
ajmpe-94	180	25	these	these	DET
ajmpe-94	180	26	outcomes	outcome	NOUN
ajmpe-94	180	27	,	,	PUNCT
ajmpe-94	180	28	severe	severe	ADJ
ajmpe-94	180	29	illnesses	illness	NOUN
ajmpe-94	180	30	have	have	AUX
ajmpe-94	180	31	been	be	AUX
ajmpe-94	180	32	linked	link	VERB
ajmpe-94	180	33	to	to	ADP
ajmpe-94	180	34	hyponatremia	hyponatremia	PROPN
ajmpe-94	180	35	,	,	PUNCT
ajmpe-94	180	36	hypokalemia	hypokalemia	NOUN
ajmpe-94	180	37	,	,	PUNCT
ajmpe-94	180	38	and	and	CCONJ
ajmpe-94	180	39	hypocalcemia	hypocalcemia	NOUN
ajmpe-94	180	40	[	[	X
ajmpe-94	180	41	27	27	NUM
ajmpe-94	180	42	]	]	PUNCT
ajmpe-94	180	43	.	.	PUNCT
ajmpe-94	181	1	some	some	DET
ajmpe-94	181	2	theories	theory	NOUN
ajmpe-94	181	3	have	have	AUX
ajmpe-94	181	4	developed	develop	VERB
ajmpe-94	181	5	,	,	PUNCT
ajmpe-94	181	6	despite	despite	SCONJ
ajmpe-94	181	7	the	the	DET
ajmpe-94	181	8	fact	fact	NOUN
ajmpe-94	181	9	that	that	SCONJ
ajmpe-94	181	10	the	the	DET
ajmpe-94	181	11	pathophysiological	pathophysiological	ADJ
ajmpe-94	181	12	mechanisms	mechanism	NOUN
ajmpe-94	181	13	behind	behind	ADP
ajmpe-94	181	14	such	such	ADJ
ajmpe-94	181	15	alterations	alteration	NOUN
ajmpe-94	181	16	are	be	AUX
ajmpe-94	181	17	still	still	ADV
ajmpe-94	181	18	not	not	PART
ajmpe-94	181	19	completely	completely	ADV
ajmpe-94	181	20	known	know	VERB
ajmpe-94	181	21	.	.	PUNCT
ajmpe-94	182	1	sars	sar	NOUN
ajmpe-94	182	2	-	-	PUNCT
ajmpe-94	182	3	interaction	interaction	NOUN
ajmpe-94	182	4	of	of	ADP
ajmpe-94	182	5	cov-2	cov-2	NOUN
ajmpe-94	182	6	's	's	PART
ajmpe-94	182	7	with	with	ADP
ajmpe-94	182	8	the	the	DET
ajmpe-94	182	9	ace2	ace2	PROPN
ajmpe-94	182	10	receptor	receptor	NOUN
ajmpe-94	182	11	may	may	AUX
ajmpe-94	182	12	result	result	VERB
ajmpe-94	182	13	in	in	ADP
ajmpe-94	182	14	decreased	decrease	VERB
ajmpe-94	182	15	ace2	ace2	NOUN
ajmpe-94	182	16	expression	expression	NOUN
ajmpe-94	182	17	and	and	CCONJ
ajmpe-94	182	18	increased	increase	VERB
ajmpe-94	182	19	angiotensin	angiotensin	PROPN
ajmpe-94	182	20	ii	ii	PROPN
ajmpe-94	182	21	,	,	PUNCT
ajmpe-94	182	22	which	which	PRON
ajmpe-94	182	23	stimulates	stimulate	VERB
ajmpe-94	182	24	potassium	potassium	NOUN
ajmpe-94	182	25	excretion	excretion	NOUN
ajmpe-94	182	26	and	and	CCONJ
ajmpe-94	182	27	causes	cause	VERB
ajmpe-94	182	28	hypokalemia	hypokalemia	NOUN
ajmpe-94	183	1	[	[	X
ajmpe-94	183	2	28	28	NUM
ajmpe-94	183	3	]	]	PUNCT
ajmpe-94	183	4	.	.	PUNCT
ajmpe-94	184	1	additionally	additionally	ADV
ajmpe-94	184	2	,	,	PUNCT
ajmpe-94	184	3	diarrhea	diarrhea	NOUN
ajmpe-94	184	4	brought	bring	VERB
ajmpe-94	184	5	on	on	ADP
ajmpe-94	184	6	by	by	ADP
ajmpe-94	184	7	gastrointestinal	gastrointestinal	ADJ
ajmpe-94	184	8	dysfunction	dysfunction	NOUN
ajmpe-94	184	9	may	may	AUX
ajmpe-94	184	10	be	be	AUX
ajmpe-94	184	11	a	a	DET
ajmpe-94	184	12	cause	cause	NOUN
ajmpe-94	184	13	in	in	ADP
ajmpe-94	184	14	electrolyte	electrolyte	ADJ
ajmpe-94	184	15	imbalance	imbalance	NOUN
ajmpe-94	184	16	(	(	PUNCT
ajmpe-94	184	17	28	28	NUM
ajmpe-94	184	18	)	)	PUNCT
ajmpe-94	184	19	.	.	PUNCT
ajmpe-94	185	1	the	the	DET
ajmpe-94	185	2	kidneys	kidney	NOUN
ajmpe-94	185	3	and	and	CCONJ
ajmpe-94	185	4	gi	gi	NOUN
ajmpe-94	185	5	tract	tract	NOUN
ajmpe-94	185	6	are	be	AUX
ajmpe-94	185	7	key	key	ADJ
ajmpe-94	185	8	players	player	NOUN
ajmpe-94	185	9	in	in	ADP
ajmpe-94	185	10	various	various	ADJ
ajmpe-94	185	11	processes	process	NOUN
ajmpe-94	185	12	that	that	PRON
ajmpe-94	185	13	regulate	regulate	VERB
ajmpe-94	185	14	fluid	fluid	ADJ
ajmpe-94	185	15	and	and	CCONJ
ajmpe-94	185	16	electrolyte	electrolyte	NOUN
ajmpe-94	185	17	balance	balance	NOUN
ajmpe-94	185	18	.	.	PUNCT
ajmpe-94	186	1	because	because	SCONJ
ajmpe-94	186	2	of	of	ADP
ajmpe-94	186	3	this	this	PRON
ajmpe-94	186	4	,	,	PUNCT
ajmpe-94	186	5	damage	damage	NOUN
ajmpe-94	186	6	to	to	ADP
ajmpe-94	186	7	them	they	PRON
ajmpe-94	186	8	usually	usually	ADV
ajmpe-94	186	9	throws	throw	VERB
ajmpe-94	186	10	off	off	ADP
ajmpe-94	186	11	the	the	DET
ajmpe-94	186	12	balance	balance	NOUN
ajmpe-94	186	13	of	of	ADP
ajmpe-94	186	14	fluid	fluid	NOUN
ajmpe-94	186	15	and	and	CCONJ
ajmpe-94	186	16	electrolytes	electrolyte	NOUN
ajmpe-94	186	17	[	[	X
ajmpe-94	186	18	29	29	NUM
ajmpe-94	186	19	]	]	PUNCT
ajmpe-94	186	20	.	.	PUNCT
ajmpe-94	187	1	electrolyte	electrolyte	ADJ
ajmpe-94	187	2	changes	change	NOUN
ajmpe-94	187	3	in	in	ADP
ajmpe-94	187	4	patients	patient	NOUN
ajmpe-94	187	5	,	,	PUNCT
ajmpe-94	187	6	including	include	VERB
ajmpe-94	187	7	sodium	sodium	NOUN
ajmpe-94	187	8	,	,	PUNCT
ajmpe-94	187	9	potassium	potassium	NOUN
ajmpe-94	187	10	,	,	PUNCT
ajmpe-94	187	11	chlorine	chlorine	NOUN
ajmpe-94	187	12	,	,	PUNCT
ajmpe-94	187	13	and	and	CCONJ
ajmpe-94	187	14	calcium	calcium	NOUN
ajmpe-94	187	15	imbalances	imbalance	NOUN
ajmpe-94	187	16	,	,	PUNCT
ajmpe-94	187	17	are	be	AUX
ajmpe-94	187	18	confirmed	confirm	VERB
ajmpe-94	187	19	by	by	ADP
ajmpe-94	187	20	similar	similar	ADJ
ajmpe-94	187	21	studies	study	NOUN
ajmpe-94	187	22	of	of	ADP
ajmpe-94	187	23	covid-19	covid-19	PROPN
ajmpe-94	187	24	[	[	X
ajmpe-94	187	25	30	30	NUM
ajmpe-94	187	26	,	,	PUNCT
ajmpe-94	187	27	31	31	NUM
ajmpe-94	187	28	]	]	PUNCT
ajmpe-94	187	29	.	.	PUNCT
ajmpe-94	188	1	hyponatremia	hyponatremia	PROPN
ajmpe-94	188	2	is	be	AUX
ajmpe-94	188	3	one	one	NUM
ajmpe-94	188	4	of	of	ADP
ajmpe-94	188	5	the	the	DET
ajmpe-94	188	6	most	most	ADV
ajmpe-94	188	7	frequent	frequent	ADJ
ajmpe-94	188	8	electrolyte	electrolyte	ADJ
ajmpe-94	188	9	abnormalities	abnormality	NOUN
ajmpe-94	188	10	and	and	CCONJ
ajmpe-94	188	11	is	be	AUX
ajmpe-94	188	12	associated	associate	VERB
ajmpe-94	188	13	with	with	ADP
ajmpe-94	188	14	a	a	DET
ajmpe-94	188	15	higher	high	ADJ
ajmpe-94	188	16	mortality	mortality	NOUN
ajmpe-94	188	17	risk	risk	NOUN
ajmpe-94	188	18	in	in	ADP
ajmpe-94	188	19	hospitalized	hospitalize	VERB
ajmpe-94	188	20	patients	patient	NOUN
ajmpe-94	188	21	[	[	X
ajmpe-94	188	22	32	32	NUM
ajmpe-94	188	23	]	]	PUNCT
ajmpe-94	188	24	.	.	PUNCT
ajmpe-94	189	1	patients	patient	NOUN
ajmpe-94	189	2	with	with	ADP
ajmpe-94	189	3	covid-19	covid-19	PROPN
ajmpe-94	189	4	who	who	PRON
ajmpe-94	189	5	take	take	VERB
ajmpe-94	189	6	ras	ra	VERB
ajmpe-94	189	7	-	-	ADJ
ajmpe-94	189	8	inhibiting	inhibit	VERB
ajmpe-94	189	9	medications	medication	NOUN
ajmpe-94	189	10	experience	experience	NOUN
ajmpe-94	189	11	decreased	decrease	VERB
ajmpe-94	189	12	aldosterone	aldosterone	NOUN
ajmpe-94	189	13	production	production	NOUN
ajmpe-94	189	14	,	,	PUNCT
ajmpe-94	189	15	which	which	PRON
ajmpe-94	189	16	can	can	AUX
ajmpe-94	189	17	result	result	VERB
ajmpe-94	189	18	in	in	ADP
ajmpe-94	189	19	fluid	fluid	ADJ
ajmpe-94	189	20	and	and	CCONJ
ajmpe-94	189	21	electrolyte	electrolyte	ADJ
ajmpe-94	189	22	imbalances	imbalance	NOUN
ajmpe-94	189	23	.	.	PUNCT
ajmpe-94	190	1	the	the	DET
ajmpe-94	190	2	central	central	ADJ
ajmpe-94	190	3	nervous	nervous	ADJ
ajmpe-94	190	4	system	system	NOUN
ajmpe-94	190	5	(	(	PUNCT
ajmpe-94	190	6	cns	cns	NOUN
ajmpe-94	190	7	)	)	PUNCT
ajmpe-94	190	8	,	,	PUNCT
ajmpe-94	190	9	the	the	DET
ajmpe-94	190	10	heart	heart	NOUN
ajmpe-94	190	11	,	,	PUNCT
ajmpe-94	190	12	the	the	DET
ajmpe-94	190	13	kidneys	kidney	NOUN
ajmpe-94	190	14	,	,	PUNCT
ajmpe-94	190	15	and	and	CCONJ
ajmpe-94	190	16	other	other	ADJ
ajmpe-94	190	17	gi	gi	VERB
ajmpe-94	190	18	tracts	tract	NOUN
ajmpe-94	190	19	like	like	ADP
ajmpe-94	190	20	the	the	DET
ajmpe-94	190	21	colon	colon	NOUN
ajmpe-94	190	22	all	all	PRON
ajmpe-94	190	23	express	express	VERB
ajmpe-94	190	24	the	the	DET
ajmpe-94	190	25	mineralocorticoid	mineralocorticoid	NOUN
ajmpe-94	190	26	receptor	receptor	NOUN
ajmpe-94	190	27	(	(	PUNCT
ajmpe-94	190	28	mr	mr	PROPN
ajmpe-94	190	29	)	)	PUNCT
ajmpe-94	190	30	,	,	PUNCT
ajmpe-94	190	31	also	also	ADV
ajmpe-94	190	32	known	know	VERB
ajmpe-94	190	33	as	as	ADP
ajmpe-94	190	34	the	the	DET
ajmpe-94	190	35	aldosterone	aldosterone	NOUN
ajmpe-94	190	36	receptor	receptor	NOUN
ajmpe-94	190	37	.	.	PUNCT
ajmpe-94	191	1	changes	change	NOUN
ajmpe-94	191	2	in	in	ADP
ajmpe-94	191	3	ion	ion	NOUN
ajmpe-94	191	4	concentration	concentration	NOUN
ajmpe-94	191	5	occur	occur	VERB
ajmpe-94	191	6	as	as	ADP
ajmpe-94	191	7	a	a	DET
ajmpe-94	191	8	result	result	NOUN
ajmpe-94	191	9	of	of	ADP
ajmpe-94	191	10	mr	mr	PROPN
ajmpe-94	191	11	activation	activation	NOUN
ajmpe-94	191	12	(	(	PUNCT
ajmpe-94	191	13	such	such	ADJ
ajmpe-94	191	14	as	as	ADP
ajmpe-94	191	15	sodium	sodium	NOUN
ajmpe-94	191	16	and	and	CCONJ
ajmpe-94	191	17	potassium	potassium	NOUN
ajmpe-94	191	18	)	)	PUNCT
ajmpe-94	191	19	.	.	PUNCT
ajmpe-94	192	1	these	these	DET
ajmpe-94	192	2	adjustments	adjustment	NOUN
ajmpe-94	192	3	are	be	AUX
ajmpe-94	192	4	required	require	VERB
ajmpe-94	192	5	to	to	PART
ajmpe-94	192	6	keep	keep	VERB
ajmpe-94	192	7	the	the	DET
ajmpe-94	192	8	body	body	NOUN
ajmpe-94	192	9	's	's	PART
ajmpe-94	192	10	fluid	fluid	ADJ
ajmpe-94	192	11	and	and	CCONJ
ajmpe-94	192	12	electrolyte	electrolyte	ADJ
ajmpe-94	192	13	equilibrium	equilibrium	NOUN
ajmpe-94	192	14	.	.	PUNCT
ajmpe-94	193	1	in	in	ADP
ajmpe-94	193	2	spite	spite	NOUN
ajmpe-94	193	3	of	of	ADP
ajmpe-94	193	4	this	this	PRON
ajmpe-94	193	5	,	,	PUNCT
ajmpe-94	193	6	mr	mr	PROPN
ajmpe-94	193	7	is	be	AUX
ajmpe-94	193	8	present	present	ADJ
ajmpe-94	193	9	in	in	ADP
ajmpe-94	193	10	the	the	DET
ajmpe-94	193	11	large	large	ADJ
ajmpe-94	193	12	intestine	intestine	NOUN
ajmpe-94	193	13	[	[	X
ajmpe-94	193	14	33–35	33–35	NUM
ajmpe-94	193	15	]	]	PUNCT
ajmpe-94	193	16	.	.	PUNCT
ajmpe-94	194	1	fluid	fluid	ADJ
ajmpe-94	194	2	and	and	CCONJ
ajmpe-94	194	3	electrolyte	electrolyte	ADJ
ajmpe-94	194	4	imbalances	imbalance	NOUN
ajmpe-94	194	5	result	result	VERB
ajmpe-94	194	6	from	from	ADP
ajmpe-94	194	7	a	a	DET
ajmpe-94	194	8	disruption	disruption	NOUN
ajmpe-94	194	9	of	of	ADP
ajmpe-94	194	10	the	the	DET
ajmpe-94	194	11	aldosterone	aldosterone	NOUN
ajmpe-94	194	12	pathway	pathway	NOUN
ajmpe-94	194	13	,	,	PUNCT
ajmpe-94	194	14	which	which	PRON
ajmpe-94	194	15	also	also	ADV
ajmpe-94	194	16	affects	affect	VERB
ajmpe-94	194	17	the	the	DET
ajmpe-94	194	18	absorption	absorption	NOUN
ajmpe-94	194	19	and	and	CCONJ
ajmpe-94	194	20	secretion	secretion	NOUN
ajmpe-94	194	21	of	of	ADP
ajmpe-94	194	22	ions	ion	NOUN
ajmpe-94	194	23	in	in	ADP
ajmpe-94	194	24	the	the	DET
ajmpe-94	194	25	colon	colon	NOUN
ajmpe-94	194	26	.	.	PUNCT
ajmpe-94	195	1	electrolyte	electrolyte	ADJ
ajmpe-94	195	2	abnormalities	abnormality	NOUN
ajmpe-94	195	3	,	,	PUNCT
ajmpe-94	195	4	such	such	ADJ
ajmpe-94	195	5	as	as	ADP
ajmpe-94	195	6	hyponatremia	hyponatremia	PROPN
ajmpe-94	195	7	,	,	PUNCT
ajmpe-94	195	8	hypokalemia	hypokalemia	NOUN
ajmpe-94	195	9	,	,	PUNCT
ajmpe-94	195	10	and	and	CCONJ
ajmpe-94	195	11	hypochloremia	hypochloremia	NOUN
ajmpe-94	195	12	,	,	PUNCT
ajmpe-94	195	13	were	be	AUX
ajmpe-94	195	14	more	more	ADV
ajmpe-94	195	15	prevalent	prevalent	ADJ
ajmpe-94	195	16	in	in	ADP
ajmpe-94	195	17	covid-19	covid-19	PROPN
ajmpe-94	195	18	patients	patient	NOUN
ajmpe-94	195	19	than	than	ADP
ajmpe-94	195	20	in	in	ADP
ajmpe-94	195	21	controls	control	NOUN
ajmpe-94	195	22	,	,	PUNCT
ajmpe-94	195	23	according	accord	VERB
ajmpe-94	195	24	to	to	ADP
ajmpe-94	195	25	a	a	DET
ajmpe-94	195	26	case	case	NOUN
ajmpe-94	195	27	study	study	NOUN
ajmpe-94	195	28	[	[	X
ajmpe-94	195	29	36	36	NUM
ajmpe-94	195	30	]	]	PUNCT
ajmpe-94	195	31	.	.	PUNCT
ajmpe-94	196	1	a	a	DET
ajmpe-94	196	2	covid-19	covid-19	PROPN
ajmpe-94	196	3	consequence	consequence	NOUN
ajmpe-94	196	4	called	call	VERB
ajmpe-94	196	5	hypokalemia	hypokalemia	NOUN
ajmpe-94	196	6	can	can	AUX
ajmpe-94	196	7	increase	increase	VERB
ajmpe-94	196	8	acute	acute	ADJ
ajmpe-94	196	9	respiratory	respiratory	ADJ
ajmpe-94	196	10	distress	distress	NOUN
ajmpe-94	196	11	syndrome	syndrome	NOUN
ajmpe-94	196	12	(	(	PUNCT
ajmpe-94	196	13	ards	ard	NOUN
ajmpe-94	196	14	)	)	PUNCT
ajmpe-94	196	15	and	and	CCONJ
ajmpe-94	196	16	put	put	VERB
ajmpe-94	196	17	patients	patient	NOUN
ajmpe-94	196	18	at	at	ADP
ajmpe-94	196	19	risk	risk	NOUN
ajmpe-94	196	20	for	for	ADP
ajmpe-94	196	21	cardiac	cardiac	ADJ
ajmpe-94	196	22	damage	damage	NOUN
ajmpe-94	196	23	[	[	X
ajmpe-94	196	24	37	37	NUM
ajmpe-94	196	25	]	]	PUNCT
ajmpe-94	196	26	.	.	PUNCT
ajmpe-94	197	1	in	in	ADP
ajmpe-94	197	2	patients	patient	NOUN
ajmpe-94	197	3	with	with	ADP
ajmpe-94	197	4	acute	acute	PROPN
ajmpe-94	197	5	covid-19	covid-19	PROPN
ajmpe-94	197	6	,	,	PUNCT
ajmpe-94	197	7	hypernatremia	hypernatremia	NOUN
ajmpe-94	197	8	is	be	AUX
ajmpe-94	197	9	rather	rather	ADV
ajmpe-94	197	10	prevalent	prevalent	ADJ
ajmpe-94	197	11	.	.	PUNCT
ajmpe-94	198	1	patients	patient	NOUN
ajmpe-94	198	2	with	with	ADP
ajmpe-94	198	3	hypernatremia	hypernatremia	NOUN
ajmpe-94	198	4	have	have	AUX
ajmpe-94	198	5	spent	spend	VERB
ajmpe-94	198	6	more	more	ADJ
ajmpe-94	198	7	time	time	NOUN
ajmpe-94	198	8	in	in	ADP
ajmpe-94	198	9	intensive	intensive	ADJ
ajmpe-94	198	10	care	care	NOUN
ajmpe-94	198	11	and	and	CCONJ
ajmpe-94	198	12	are	be	AUX
ajmpe-94	198	13	at	at	ADP
ajmpe-94	198	14	greater	great	ADJ
ajmpe-94	198	15	risk	risk	NOUN
ajmpe-94	198	16	of	of	ADP
ajmpe-94	198	17	passing	pass	VERB
ajmpe-94	198	18	away	away	ADV
ajmpe-94	198	19	.	.	PUNCT
ajmpe-94	199	1	as	as	ADP
ajmpe-94	199	2	a	a	DET
ajmpe-94	199	3	result	result	NOUN
ajmpe-94	199	4	,	,	PUNCT
ajmpe-94	199	5	in	in	ADP
ajmpe-94	199	6	covid-19	covid-19	PROPN
ajmpe-94	199	7	patients	patient	NOUN
ajmpe-94	199	8	,	,	PUNCT
ajmpe-94	199	9	the	the	DET
ajmpe-94	199	10	level	level	NOUN
ajmpe-94	199	11	of	of	ADP
ajmpe-94	199	12	ions	ion	NOUN
ajmpe-94	199	13	,	,	PUNCT
ajmpe-94	199	14	especially	especially	ADV
ajmpe-94	199	15	sodium	sodium	NOUN
ajmpe-94	199	16	and	and	CCONJ
ajmpe-94	199	17	potassium	potassium	NOUN
ajmpe-94	199	18	,	,	PUNCT
ajmpe-94	199	19	is	be	AUX
ajmpe-94	199	20	an	an	DET
ajmpe-94	199	21	important	important	ADJ
ajmpe-94	199	22	signal	signal	NOUN
ajmpe-94	199	23	[	[	X
ajmpe-94	199	24	38	38	NUM
ajmpe-94	199	25	]	]	PUNCT
ajmpe-94	199	26	.	.	PUNCT
ajmpe-94	200	1	according	accord	VERB
ajmpe-94	200	2	to	to	ADP
ajmpe-94	200	3	this	this	DET
ajmpe-94	200	4	study	study	NOUN
ajmpe-94	200	5	,	,	PUNCT
ajmpe-94	200	6	there	there	PRON
ajmpe-94	200	7	was	be	VERB
ajmpe-94	200	8	a	a	DET
ajmpe-94	200	9	significantly	significantly	ADV
ajmpe-94	200	10	lower	low	ADJ
ajmpe-94	200	11	mean	mean	NOUN
ajmpe-94	200	12	calcium	calcium	NOUN
ajmpe-94	200	13	level	level	NOUN
ajmpe-94	200	14	in	in	ADP
ajmpe-94	200	15	covid-19	covid-19	PROPN
ajmpe-94	200	16	patients	patient	NOUN
ajmpe-94	200	17	than	than	ADP
ajmpe-94	200	18	in	in	ADP
ajmpe-94	200	19	the	the	DET
ajmpe-94	200	20	control	control	NOUN
ajmpe-94	200	21	group	group	NOUN
ajmpe-94	200	22	,	,	PUNCT
ajmpe-94	200	23	these	these	DET
ajmpe-94	200	24	findings	finding	NOUN
ajmpe-94	200	25	supported	support	VERB
ajmpe-94	200	26	by	by	ADP
ajmpe-94	200	27	yang	yang	PROPN
ajmpe-94	200	28	's	's	PART
ajmpe-94	200	29	(	(	PUNCT
ajmpe-94	200	30	39	39	NUM
ajmpe-94	200	31	)	)	PUNCT
ajmpe-94	200	32	finding	find	VERB
ajmpe-94	200	33	that	that	SCONJ
ajmpe-94	200	34	covid-19	covid-19	PROPN
ajmpe-94	200	35	was	be	AUX
ajmpe-94	200	36	independently	independently	ADV
ajmpe-94	200	37	related	relate	VERB
ajmpe-94	200	38	with	with	ADP
ajmpe-94	200	39	hypocalcemia	hypocalcemia	NOUN
ajmpe-94	200	40	more	more	ADV
ajmpe-94	200	41	so	so	ADV
ajmpe-94	200	42	than	than	ADP
ajmpe-94	200	43	the	the	DET
ajmpe-94	200	44	control	control	NOUN
ajmpe-94	200	45	group	group	NOUN
ajmpe-94	200	46	.	.	PUNCT
ajmpe-94	201	1	increased	increase	VERB
ajmpe-94	201	2	neuromuscular	neuromuscular	ADJ
ajmpe-94	201	3	irritability	irritability	NOUN
ajmpe-94	201	4	,	,	PUNCT
ajmpe-94	201	5	which	which	PRON
ajmpe-94	201	6	is	be	AUX
ajmpe-94	201	7	characterized	characterize	VERB
ajmpe-94	201	8	by	by	ADP
ajmpe-94	201	9	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	201	10	american	american	PROPN
ajmpe-94	201	11	journal	journal	PROPN
ajmpe-94	201	12	of	of	ADP
ajmpe-94	201	13	medical	medical	ADJ
ajmpe-94	201	14	and	and	CCONJ
ajmpe-94	201	15	physical	physical	ADJ
ajmpe-94	201	16	education	education	NOUN
ajmpe-94	201	17	vol.1	vol.1	PROPN
ajmpe-94	201	18	,	,	PUNCT
ajmpe-94	201	19	issue	issue	NOUN
ajmpe-94	201	20	1	1	NUM
ajmpe-94	201	21	;	;	PUNCT
ajmpe-94	201	22	july	july	PROPN
ajmpe-94	201	23	2023	2023	NUM
ajmpe-94	201	24	;	;	PUNCT
ajmpe-94	201	25	1252	1252	NUM
ajmpe-94	201	26	columbia	columbia	PROPN
ajmpe-94	201	27	rd	rd	PROPN
ajmpe-94	201	28	nw	nw	PROPN
ajmpe-94	201	29	,	,	PUNCT
ajmpe-94	201	30	washington	washington	PROPN
ajmpe-94	201	31	dc	dc	PROPN
ajmpe-94	201	32	,	,	PUNCT
ajmpe-94	201	33	united	united	PROPN
ajmpe-94	201	34	states	states	PROPN
ajmpe-94	201	35	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	201	36	;	;	PUNCT
ajmpe-94	201	37	mail	mail	NOUN
ajmpe-94	201	38	:	:	PUNCT
ajmpe-94	201	39	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	202	1	78	78	NUM
ajmpe-94	203	1	|	|	ADV
ajmpe-94	203	2	a	a	DET
ajmpe-94	203	3	m	m	NOUN
ajmpe-94	203	4	e	e	NOUN
ajmpe-94	203	5	r	r	NOUN
ajmpe-94	203	6	i	i	NOUN
ajmpe-94	203	7	c	c	VERB
ajmpe-94	203	8	a	a	DET
ajmpe-94	203	9	n	n	NOUN
ajmpe-94	204	1	j	j	NOUN
ajmpe-94	204	2	o	o	X
ajmpe-94	204	3	u	u	NOUN
ajmpe-94	204	4	r	r	NOUN
ajmpe-94	204	5	n	n	NOUN
ajmpe-94	204	6	a	a	DET
ajmpe-94	204	7	l	l	NOUN
ajmpe-94	204	8	o	o	X
ajmpe-94	205	1	f	f	X
ajmpe-94	205	2	m	m	NOUN
ajmpe-94	205	3	e	e	NOUN
ajmpe-94	206	1	d	d	NOUN
ajmpe-94	206	2	i	i	PRON
ajmpe-94	206	3	c	c	VERB
ajmpe-94	206	4	a	a	DET
ajmpe-94	206	5	l	l	NOUN
ajmpe-94	206	6	a	a	X
ajmpe-94	206	7	n	n	NOUN
ajmpe-94	207	1	d	d	NOUN
ajmpe-94	207	2	p	p	NOUN
ajmpe-94	207	3	h	h	NOUN
ajmpe-94	207	4	y	y	NOUN
ajmpe-94	207	5	s	s	VERB
ajmpe-94	208	1	i	i	INTJ
ajmpe-94	208	2	c	c	VERB
ajmpe-94	208	3	a	a	DET
ajmpe-94	208	4	l	l	NOUN
ajmpe-94	208	5	e	e	NOUN
ajmpe-94	208	6	d	d	X
ajmpe-94	208	7	u	u	X
ajmpe-94	208	8	c	c	PROPN
ajmpe-94	209	1	a	a	DET
ajmpe-94	209	2	t	t	NOUN
ajmpe-94	210	1	i	i	PRON
ajmpe-94	210	2	o	o	VERB
ajmpe-94	210	3	n	n	CCONJ
ajmpe-94	210	4	|	|	ADV
ajmpe-94	210	5	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	ADJ
ajmpe-94	210	6	muscle	muscle	NOUN
ajmpe-94	210	7	spasms	spasm	NOUN
ajmpe-94	210	8	,	,	PUNCT
ajmpe-94	210	9	tingling	tingle	VERB
ajmpe-94	210	10	in	in	ADP
ajmpe-94	210	11	the	the	DET
ajmpe-94	210	12	limbs	limb	NOUN
ajmpe-94	210	13	,	,	PUNCT
ajmpe-94	210	14	and	and	CCONJ
ajmpe-94	210	15	perioral	perioral	ADJ
ajmpe-94	210	16	numbness	numbness	NOUN
ajmpe-94	210	17	,	,	PUNCT
ajmpe-94	210	18	was	be	AUX
ajmpe-94	210	19	found	find	VERB
ajmpe-94	210	20	to	to	PART
ajmpe-94	210	21	be	be	AUX
ajmpe-94	210	22	the	the	DET
ajmpe-94	210	23	most	most	ADV
ajmpe-94	210	24	frequent	frequent	ADJ
ajmpe-94	210	25	side	side	NOUN
ajmpe-94	210	26	effect	effect	NOUN
ajmpe-94	210	27	of	of	ADP
ajmpe-94	210	28	hypocalcemia	hypocalcemia	NOUN
ajmpe-94	210	29	in	in	ADP
ajmpe-94	210	30	a	a	DET
ajmpe-94	210	31	prior	prior	ADJ
ajmpe-94	210	32	study	study	NOUN
ajmpe-94	210	33	.	.	PUNCT
ajmpe-94	211	1	a	a	DET
ajmpe-94	211	2	rare	rare	ADJ
ajmpe-94	211	3	complication	complication	NOUN
ajmpe-94	211	4	of	of	ADP
ajmpe-94	211	5	hypocalcemia	hypocalcemia	NOUN
ajmpe-94	211	6	is	be	AUX
ajmpe-94	211	7	reversible	reversible	ADJ
ajmpe-94	211	8	cardiomyopathy	cardiomyopathy	ADJ
ajmpe-94	211	9	[	[	X
ajmpe-94	211	10	40	40	NUM
ajmpe-94	211	11	]	]	PUNCT
ajmpe-94	211	12	.	.	PUNCT
ajmpe-94	212	1	the	the	DET
ajmpe-94	212	2	findings	finding	NOUN
ajmpe-94	212	3	of	of	ADP
ajmpe-94	212	4	the	the	DET
ajmpe-94	212	5	current	current	ADJ
ajmpe-94	212	6	study	study	NOUN
ajmpe-94	212	7	are	be	AUX
ajmpe-94	212	8	similar	similar	ADJ
ajmpe-94	212	9	with	with	ADP
ajmpe-94	212	10	those	those	PRON
ajmpe-94	212	11	of	of	ADP
ajmpe-94	212	12	ramesh	ramesh	PROPN
ajmpe-94	212	13	(	(	PUNCT
ajmpe-94	212	14	41	41	NUM
ajmpe-94	212	15	)	)	PUNCT
ajmpe-94	212	16	who	who	PRON
ajmpe-94	212	17	found	find	VERB
ajmpe-94	212	18	that	that	SCONJ
ajmpe-94	212	19	covid-19	covid-19	PROPN
ajmpe-94	212	20	was	be	AUX
ajmpe-94	212	21	significantly	significantly	ADV
ajmpe-94	212	22	associated	associate	VERB
ajmpe-94	212	23	with	with	ADP
ajmpe-94	212	24	hypocalcemia	hypocalcemia	NOUN
ajmpe-94	212	25	more	more	ADV
ajmpe-94	212	26	so	so	ADV
ajmpe-94	212	27	than	than	ADP
ajmpe-94	212	28	among	among	ADP
ajmpe-94	212	29	controls	control	NOUN
ajmpe-94	212	30	.	.	PUNCT
ajmpe-94	213	1	when	when	SCONJ
ajmpe-94	213	2	compared	compare	VERB
ajmpe-94	213	3	to	to	ADP
ajmpe-94	213	4	the	the	DET
ajmpe-94	213	5	control	control	NOUN
ajmpe-94	213	6	group	group	NOUN
ajmpe-94	213	7	in	in	ADP
ajmpe-94	213	8	this	this	DET
ajmpe-94	213	9	investigation	investigation	NOUN
ajmpe-94	213	10	,	,	PUNCT
ajmpe-94	213	11	covid-19	covid-19	PROPN
ajmpe-94	213	12	patients	patient	NOUN
ajmpe-94	213	13	had	have	VERB
ajmpe-94	213	14	normal	normal	ADJ
ajmpe-94	213	15	levels	level	NOUN
ajmpe-94	213	16	of	of	ADP
ajmpe-94	213	17	phosphate	phosphate	ADJ
ajmpe-94	213	18	see	see	NOUN
ajmpe-94	213	19	table	table	NOUN
ajmpe-94	213	20	(	(	PUNCT
ajmpe-94	213	21	1	1	NUM
ajmpe-94	213	22	)	)	PUNCT
ajmpe-94	213	23	.	.	PUNCT
ajmpe-94	214	1	disagree	disagree	VERB
ajmpe-94	214	2	with	with	ADP
ajmpe-94	214	3	previous	previous	ADJ
ajmpe-94	214	4	studies	study	NOUN
ajmpe-94	214	5	findings	finding	NOUN
ajmpe-94	214	6	that	that	SCONJ
ajmpe-94	214	7	hypophosphatemia	hypophosphatemia	NOUN
ajmpe-94	214	8	was	be	AUX
ajmpe-94	214	9	more	more	ADV
ajmpe-94	214	10	significantly	significantly	ADV
ajmpe-94	214	11	linked	link	VERB
ajmpe-94	214	12	with	with	ADP
ajmpe-94	214	13	covid-19	covid-19	PROPN
ajmpe-94	214	14	than	than	ADP
ajmpe-94	214	15	the	the	DET
ajmpe-94	214	16	control	control	NOUN
ajmpe-94	214	17	group	group	NOUN
ajmpe-94	214	18	(	(	PUNCT
ajmpe-94	214	19	39	39	NUM
ajmpe-94	214	20	,	,	PUNCT
ajmpe-94	214	21	41	41	NUM
ajmpe-94	214	22	)	)	PUNCT
ajmpe-94	214	23	.	.	PUNCT
ajmpe-94	215	1	nutritional	nutritional	ADJ
ajmpe-94	215	2	phosphate	phosphate	PROPN
ajmpe-94	215	3	intake	intake	NOUN
ajmpe-94	215	4	,	,	PUNCT
ajmpe-94	215	5	intracellular	intracellular	ADJ
ajmpe-94	215	6	to	to	ADP
ajmpe-94	215	7	extracellular	extracellular	ADJ
ajmpe-94	215	8	phosphate	phosphate	NOUN
ajmpe-94	215	9	transfer	transfer	NOUN
ajmpe-94	215	10	,	,	PUNCT
ajmpe-94	215	11	renal	renal	ADJ
ajmpe-94	215	12	glomerular	glomerular	ADJ
ajmpe-94	215	13	function	function	NOUN
ajmpe-94	215	14	,	,	PUNCT
ajmpe-94	215	15	and	and	CCONJ
ajmpe-94	215	16	tubular	tubular	ADJ
ajmpe-94	215	17	phosphate	phosphate	NOUN
ajmpe-94	215	18	reabsorption	reabsorption	NOUN
ajmpe-94	215	19	all	all	PRON
ajmpe-94	215	20	affect	affect	VERB
ajmpe-94	215	21	serum	serum	NOUN
ajmpe-94	215	22	phosphate	phosphate	NOUN
ajmpe-94	215	23	levels	level	NOUN
ajmpe-94	215	24	.	.	PUNCT
ajmpe-94	216	1	diets	diet	NOUN
ajmpe-94	216	2	and	and	CCONJ
ajmpe-94	216	3	environmental	environmental	ADJ
ajmpe-94	216	4	changes	change	NOUN
ajmpe-94	216	5	are	be	AUX
ajmpe-94	216	6	likely	likely	ADJ
ajmpe-94	216	7	to	to	PART
ajmpe-94	216	8	be	be	AUX
ajmpe-94	216	9	to	to	PART
ajmpe-94	216	10	responsible	responsible	ADJ
ajmpe-94	216	11	for	for	ADP
ajmpe-94	216	12	the	the	DET
ajmpe-94	216	13	discrepancy	discrepancy	NOUN
ajmpe-94	216	14	.	.	PUNCT
ajmpe-94	217	1	other	other	ADJ
ajmpe-94	217	2	earlier	early	ADJ
ajmpe-94	217	3	studies	study	NOUN
ajmpe-94	217	4	discovered	discover	VERB
ajmpe-94	217	5	that	that	SCONJ
ajmpe-94	217	6	the	the	DET
ajmpe-94	217	7	link	link	NOUN
ajmpe-94	217	8	between	between	ADP
ajmpe-94	217	9	hypophosphatemia	hypophosphatemia	NOUN
ajmpe-94	217	10	and	and	CCONJ
ajmpe-94	217	11	poor	poor	ADJ
ajmpe-94	217	12	outcomes	outcome	NOUN
ajmpe-94	217	13	was	be	AUX
ajmpe-94	217	14	likely	likely	ADV
ajmpe-94	217	15	mediated	mediate	VERB
ajmpe-94	217	16	by	by	ADP
ajmpe-94	217	17	the	the	DET
ajmpe-94	217	18	risk	risk	NOUN
ajmpe-94	217	19	factors	factor	NOUN
ajmpe-94	217	20	for	for	ADP
ajmpe-94	217	21	hypophosphatemia	hypophosphatemia	NOUN
ajmpe-94	217	22	,	,	PUNCT
ajmpe-94	217	23	which	which	PRON
ajmpe-94	217	24	are	be	AUX
ajmpe-94	217	25	excessive	excessive	ADJ
ajmpe-94	217	26	energy	energy	NOUN
ajmpe-94	217	27	consumption	consumption	NOUN
ajmpe-94	217	28	and	and	CCONJ
ajmpe-94	217	29	catabolism	catabolism	NOUN
ajmpe-94	217	30	as	as	ADV
ajmpe-94	217	31	well	well	ADV
ajmpe-94	217	32	as	as	ADP
ajmpe-94	217	33	inadequate	inadequate	ADJ
ajmpe-94	217	34	nutritional	nutritional	ADJ
ajmpe-94	217	35	intake	intake	NOUN
ajmpe-94	217	36	.	.	PUNCT
ajmpe-94	218	1	individuals	individual	NOUN
ajmpe-94	218	2	with	with	ADP
ajmpe-94	218	3	covid-19	covid-19	PROPN
ajmpe-94	218	4	frequently	frequently	ADV
ajmpe-94	218	5	suffered	suffer	VERB
ajmpe-94	218	6	from	from	ADP
ajmpe-94	218	7	malnutrition	malnutrition	NOUN
ajmpe-94	218	8	,	,	PUNCT
ajmpe-94	218	9	which	which	PRON
ajmpe-94	218	10	has	have	AUX
ajmpe-94	218	11	been	be	AUX
ajmpe-94	218	12	linked	link	VERB
ajmpe-94	218	13	to	to	ADP
ajmpe-94	218	14	a	a	DET
ajmpe-94	218	15	poor	poor	ADJ
ajmpe-94	218	16	outcome	outcome	NOUN
ajmpe-94	218	17	for	for	ADP
ajmpe-94	218	18	these	these	DET
ajmpe-94	218	19	patients	patient	NOUN
ajmpe-94	218	20	.	.	PUNCT
ajmpe-94	219	1	(	(	PUNCT
ajmpe-94	219	2	4247	4247	NUM
ajmpe-94	219	3	)	)	PUNCT
ajmpe-94	219	4	.	.	PUNCT
ajmpe-94	220	1	additionally	additionally	ADV
ajmpe-94	220	2	,	,	PUNCT
ajmpe-94	220	3	the	the	DET
ajmpe-94	220	4	regular	regular	ADJ
ajmpe-94	220	5	operation	operation	NOUN
ajmpe-94	220	6	of	of	ADP
ajmpe-94	220	7	immune	immune	ADJ
ajmpe-94	220	8	cells	cell	NOUN
ajmpe-94	220	9	may	may	AUX
ajmpe-94	220	10	be	be	AUX
ajmpe-94	220	11	impacted	impact	VERB
ajmpe-94	220	12	by	by	ADP
ajmpe-94	220	13	cellular	cellular	ADJ
ajmpe-94	220	14	atp	atp	PROPN
ajmpe-94	220	15	depletion	depletion	NOUN
ajmpe-94	220	16	,	,	PUNCT
ajmpe-94	220	17	which	which	PRON
ajmpe-94	220	18	may	may	AUX
ajmpe-94	220	19	be	be	AUX
ajmpe-94	220	20	indicated	indicate	VERB
ajmpe-94	220	21	by	by	ADP
ajmpe-94	220	22	the	the	DET
ajmpe-94	220	23	low	low	ADJ
ajmpe-94	220	24	serum	serum	NOUN
ajmpe-94	220	25	phosphorus	phosphorus	NOUN
ajmpe-94	220	26	level	level	NOUN
ajmpe-94	220	27	,	,	PUNCT
ajmpe-94	220	28	which	which	PRON
ajmpe-94	220	29	could	could	AUX
ajmpe-94	220	30	affect	affect	VERB
ajmpe-94	220	31	the	the	DET
ajmpe-94	220	32	immune	immune	ADJ
ajmpe-94	220	33	system	system	NOUN
ajmpe-94	220	34	's	's	PART
ajmpe-94	220	35	capacity	capacity	NOUN
ajmpe-94	220	36	to	to	PART
ajmpe-94	220	37	defend	defend	VERB
ajmpe-94	220	38	against	against	ADP
ajmpe-94	220	39	viral	viral	ADJ
ajmpe-94	220	40	infection	infection	NOUN
ajmpe-94	220	41	.	.	PUNCT
ajmpe-94	221	1	(	(	PUNCT
ajmpe-94	221	2	42	42	NUM
ajmpe-94	221	3	-	-	SYM
ajmpe-94	221	4	47	47	NUM
ajmpe-94	221	5	)	)	PUNCT
ajmpe-94	221	6	.	.	PUNCT
ajmpe-94	222	1	the	the	DET
ajmpe-94	222	2	current	current	ADJ
ajmpe-94	222	3	study	study	NOUN
ajmpe-94	222	4	shows	show	VERB
ajmpe-94	222	5	the	the	DET
ajmpe-94	222	6	case	case	NOUN
ajmpe-94	222	7	study	study	NOUN
ajmpe-94	222	8	's	's	PART
ajmpe-94	222	9	normal	normal	ADJ
ajmpe-94	222	10	serum	serum	NOUN
ajmpe-94	222	11	magnesium	magnesium	NOUN
ajmpe-94	222	12	level	level	NOUN
ajmpe-94	222	13	.	.	PUNCT
ajmpe-94	223	1	low	low	ADJ
ajmpe-94	223	2	of	of	ADP
ajmpe-94	223	3	magnesium	magnesium	NOUN
ajmpe-94	223	4	makes	make	VERB
ajmpe-94	223	5	endothelium	endothelium	NOUN
ajmpe-94	223	6	cells	cell	NOUN
ajmpe-94	223	7	more	more	ADV
ajmpe-94	223	8	susceptible	susceptible	ADJ
ajmpe-94	223	9	to	to	ADP
ajmpe-94	223	10	oxidative	oxidative	ADJ
ajmpe-94	223	11	stress	stress	NOUN
ajmpe-94	223	12	and	and	CCONJ
ajmpe-94	223	13	encourages	encourage	VERB
ajmpe-94	223	14	endothelial	endothelial	ADJ
ajmpe-94	223	15	dysfunction	dysfunction	NOUN
ajmpe-94	223	16	.	.	PUNCT
ajmpe-94	224	1	low	low	ADJ
ajmpe-94	224	2	intracellular	intracellular	ADJ
ajmpe-94	224	3	magnesium	magnesium	NOUN
ajmpe-94	224	4	increases	increase	NOUN
ajmpe-94	224	5	platelet	platelet	ADJ
ajmpe-94	224	6	-	-	PUNCT
ajmpe-94	224	7	dependent	dependent	ADJ
ajmpe-94	224	8	thrombosis	thrombosis	NOUN
ajmpe-94	224	9	,	,	PUNCT
ajmpe-94	224	10	and	and	CCONJ
ajmpe-94	224	11	low	low	ADJ
ajmpe-94	224	12	serum	serum	NOUN
ajmpe-94	224	13	magnesium	magnesium	NOUN
ajmpe-94	224	14	is	be	AUX
ajmpe-94	224	15	linked	link	VERB
ajmpe-94	224	16	to	to	ADP
ajmpe-94	224	17	increased	increase	VERB
ajmpe-94	224	18	thrombotic	thrombotic	ADJ
ajmpe-94	224	19	risk	risk	NOUN
ajmpe-94	224	20	and	and	CCONJ
ajmpe-94	224	21	slower	slow	ADJ
ajmpe-94	224	22	fibrinolysis	fibrinolysis	NOUN
ajmpe-94	224	23	(	(	PUNCT
ajmpe-94	224	24	48,49,50	48,49,50	NUM
ajmpe-94	224	25	,	,	PUNCT
ajmpe-94	224	26	51	51	NUM
ajmpe-94	224	27	)	)	PUNCT
ajmpe-94	224	28	.	.	PUNCT
ajmpe-94	225	1	additionally	additionally	ADV
ajmpe-94	225	2	,	,	PUNCT
ajmpe-94	225	3	magnesium	magnesium	NOUN
ajmpe-94	225	4	decreases	decrease	VERB
ajmpe-94	225	5	mortality	mortality	NOUN
ajmpe-94	225	6	in	in	ADP
ajmpe-94	225	7	vivo	vivo	ADJ
ajmpe-94	225	8	trials	trial	NOUN
ajmpe-94	225	9	of	of	ADP
ajmpe-94	225	10	induced	induced	ADJ
ajmpe-94	225	11	pulmonary	pulmonary	ADJ
ajmpe-94	225	12	thrombosis	thrombosis	NOUN
ajmpe-94	225	13	and	and	CCONJ
ajmpe-94	225	14	has	have	VERB
ajmpe-94	225	15	antithrombotic	antithrombotic	ADJ
ajmpe-94	225	16	properties	property	NOUN
ajmpe-94	225	17	(	(	PUNCT
ajmpe-94	225	18	52	52	NUM
ajmpe-94	225	19	)	)	PUNCT
ajmpe-94	225	20	.	.	PUNCT
ajmpe-94	226	1	all	all	PRON
ajmpe-94	226	2	of	of	ADP
ajmpe-94	226	3	these	these	PRON
ajmpe-94	226	4	shows	show	NOUN
ajmpe-94	226	5	that	that	SCONJ
ajmpe-94	226	6	diffuse	diffuse	VERB
ajmpe-94	226	7	intravascular	intravascular	ADJ
ajmpe-94	226	8	coagulopathy	coagulopathy	ADJ
ajmpe-94	226	9	is	be	AUX
ajmpe-94	226	10	more	more	ADV
ajmpe-94	226	11	likely	likely	ADJ
ajmpe-94	226	12	in	in	ADP
ajmpe-94	226	13	covid-19	covid-19	PROPN
ajmpe-94	226	14	individuals	individual	NOUN
ajmpe-94	226	15	who	who	PRON
ajmpe-94	226	16	are	be	AUX
ajmpe-94	226	17	magnesium	magnesium	NOUN
ajmpe-94	226	18	deficiency	deficiency	NOUN
ajmpe-94	226	19	.	.	PUNCT
ajmpe-94	227	1	rare	rare	ADJ
ajmpe-94	227	2	clinical	clinical	ADJ
ajmpe-94	227	3	data	datum	NOUN
ajmpe-94	227	4	available	available	ADJ
ajmpe-94	227	5	on	on	ADP
ajmpe-94	227	6	the	the	DET
ajmpe-94	227	7	serum	serum	NOUN
ajmpe-94	227	8	cu	cu	PROPN
ajmpe-94	227	9	status	status	NOUN
ajmpe-94	227	10	of	of	ADP
ajmpe-94	227	11	covid-19	covid-19	PROPN
ajmpe-94	227	12	patients	patient	NOUN
ajmpe-94	227	13	.	.	PUNCT
ajmpe-94	228	1	the	the	DET
ajmpe-94	228	2	severity	severity	NOUN
ajmpe-94	228	3	of	of	ADP
ajmpe-94	228	4	the	the	DET
ajmpe-94	228	5	condition	condition	NOUN
ajmpe-94	228	6	was	be	AUX
ajmpe-94	228	7	positively	positively	ADV
ajmpe-94	228	8	correlated	correlate	VERB
ajmpe-94	228	9	with	with	ADP
ajmpe-94	228	10	higher	high	ADJ
ajmpe-94	228	11	serum	serum	NOUN
ajmpe-94	228	12	copper	copper	NOUN
ajmpe-94	228	13	levels	level	NOUN
ajmpe-94	228	14	among	among	ADP
ajmpe-94	228	15	covid-19	covid-19	PROPN
ajmpe-94	228	16	patients	patient	NOUN
ajmpe-94	228	17	in	in	ADP
ajmpe-94	228	18	this	this	DET
ajmpe-94	228	19	study	study	NOUN
ajmpe-94	228	20	table	table	NOUN
ajmpe-94	228	21	(	(	PUNCT
ajmpe-94	228	22	1	1	NUM
ajmpe-94	228	23	)	)	PUNCT
ajmpe-94	228	24	.	.	PUNCT
ajmpe-94	229	1	similar	similar	ADJ
ajmpe-94	229	2	findings	finding	NOUN
ajmpe-94	229	3	from	from	ADP
ajmpe-94	229	4	previous	previous	ADJ
ajmpe-94	229	5	studies	study	NOUN
ajmpe-94	229	6	have	have	AUX
ajmpe-94	229	7	also	also	ADV
ajmpe-94	229	8	shown	show	VERB
ajmpe-94	229	9	that	that	SCONJ
ajmpe-94	229	10	copper	copper	NOUN
ajmpe-94	229	11	increased	increase	VERB
ajmpe-94	229	12	concentrations	concentration	NOUN
ajmpe-94	229	13	,	,	PUNCT
ajmpe-94	229	14	with	with	ADP
ajmpe-94	229	15	small	small	ADJ
ajmpe-94	229	16	deviations	deviation	NOUN
ajmpe-94	229	17	only	only	ADV
ajmpe-94	229	18	in	in	ADP
ajmpe-94	229	19	comparison	comparison	NOUN
ajmpe-94	229	20	to	to	ADP
ajmpe-94	229	21	the	the	DET
ajmpe-94	229	22	healthy	healthy	ADJ
ajmpe-94	229	23	control	control	NOUN
ajmpe-94	229	24	group	group	NOUN
ajmpe-94	230	1	[	[	X
ajmpe-94	230	2	53	53	NUM
ajmpe-94	230	3	]	]	PUNCT
ajmpe-94	230	4	.	.	PUNCT
ajmpe-94	231	1	additionally	additionally	ADV
ajmpe-94	231	2	,	,	PUNCT
ajmpe-94	231	3	a	a	DET
ajmpe-94	231	4	study	study	NOUN
ajmpe-94	231	5	conducted	conduct	VERB
ajmpe-94	231	6	in	in	ADP
ajmpe-94	231	7	wuhan	wuhan	PROPN
ajmpe-94	231	8	,	,	PUNCT
ajmpe-94	231	9	china	china	PROPN
ajmpe-94	231	10	,	,	PUNCT
ajmpe-94	231	11	found	find	VERB
ajmpe-94	231	12	that	that	SCONJ
ajmpe-94	231	13	patients	patient	NOUN
ajmpe-94	231	14	with	with	ADP
ajmpe-94	231	15	more	more	ADV
ajmpe-94	231	16	severe	severe	ADJ
ajmpe-94	231	17	diseases	disease	NOUN
ajmpe-94	231	18	had	have	VERB
ajmpe-94	231	19	generally	generally	ADV
ajmpe-94	231	20	higher	high	ADJ
ajmpe-94	231	21	cu	cu	PROPN
ajmpe-94	231	22	statuses	status	NOUN
ajmpe-94	231	23	,	,	PUNCT
ajmpe-94	231	24	without	without	ADP
ajmpe-94	231	25	finding	find	VERB
ajmpe-94	231	26	a	a	DET
ajmpe-94	231	27	difference	difference	NOUN
ajmpe-94	231	28	in	in	ADP
ajmpe-94	231	29	full	full	ADJ
ajmpe-94	231	30	blood	blood	NOUN
ajmpe-94	231	31	cu	cu	NOUN
ajmpe-94	231	32	between	between	ADP
ajmpe-94	231	33	survivors	survivor	NOUN
ajmpe-94	231	34	and	and	CCONJ
ajmpe-94	231	35	non	non	NOUN
ajmpe-94	231	36	-	-	NOUN
ajmpe-94	231	37	survivors	survivor	NOUN
ajmpe-94	231	38	[	[	X
ajmpe-94	231	39	54	54	NUM
ajmpe-94	231	40	]	]	PUNCT
ajmpe-94	231	41	.	.	PUNCT
ajmpe-94	232	1	zinc	zinc	NOUN
ajmpe-94	232	2	is	be	AUX
ajmpe-94	232	3	transiently	transiently	ADV
ajmpe-94	232	4	transferred	transfer	VERB
ajmpe-94	232	5	from	from	ADP
ajmpe-94	232	6	the	the	DET
ajmpe-94	232	7	serum	serum	NOUN
ajmpe-94	232	8	to	to	ADP
ajmpe-94	232	9	the	the	DET
ajmpe-94	232	10	organs	organ	NOUN
ajmpe-94	232	11	during	during	ADP
ajmpe-94	232	12	infection	infection	NOUN
ajmpe-94	232	13	and	and	CCONJ
ajmpe-94	232	14	inflammation	inflammation	NOUN
ajmpe-94	232	15	,	,	PUNCT
ajmpe-94	232	16	resulting	result	VERB
ajmpe-94	232	17	in	in	ADP
ajmpe-94	232	18	momentarily	momentarily	ADV
ajmpe-94	232	19	low	low	ADJ
ajmpe-94	232	20	serum	serum	NOUN
ajmpe-94	232	21	zinc	zinc	NOUN
ajmpe-94	232	22	levels	level	NOUN
ajmpe-94	232	23	,	,	PUNCT
ajmpe-94	232	24	which	which	PRON
ajmpe-94	232	25	return	return	VERB
ajmpe-94	232	26	to	to	ADP
ajmpe-94	232	27	normal	normal	ADJ
ajmpe-94	232	28	as	as	ADP
ajmpe-94	232	29	the	the	DET
ajmpe-94	232	30	inflammatory	inflammatory	ADJ
ajmpe-94	232	31	response	response	NOUN
ajmpe-94	232	32	decreases	decrease	NOUN
ajmpe-94	232	33	(	(	PUNCT
ajmpe-94	232	34	55,56	55,56	NOUN
ajmpe-94	232	35	)	)	PUNCT
ajmpe-94	232	36	.	.	PUNCT
ajmpe-94	233	1	when	when	SCONJ
ajmpe-94	233	2	fighting	fighting	NOUN
ajmpe-94	233	3	infections	infection	NOUN
ajmpe-94	233	4	,	,	PUNCT
ajmpe-94	233	5	a	a	DET
ajmpe-94	233	6	normal	normal	ADJ
ajmpe-94	233	7	zinc	zinc	NOUN
ajmpe-94	233	8	level	level	NOUN
ajmpe-94	233	9	is	be	AUX
ajmpe-94	233	10	essential	essential	ADJ
ajmpe-94	233	11	,	,	PUNCT
ajmpe-94	233	12	by	by	ADP
ajmpe-94	233	13	controlling	control	VERB
ajmpe-94	233	14	the	the	DET
ajmpe-94	233	15	pro	pro	ADJ
ajmpe-94	233	16	-	-	ADJ
ajmpe-94	233	17	inflammatory	inflammatory	ADJ
ajmpe-94	233	18	response	response	NOUN
ajmpe-94	233	19	,	,	PUNCT
ajmpe-94	233	20	zinc	zinc	NOUN
ajmpe-94	233	21	signals	signal	NOUN
ajmpe-94	233	22	have	have	VERB
ajmpe-94	233	23	an	an	DET
ajmpe-94	233	24	anti	anti	ADJ
ajmpe-94	233	25	-	-	ADJ
ajmpe-94	233	26	inflammatory	inflammatory	ADJ
ajmpe-94	233	27	effect	effect	NOUN
ajmpe-94	233	28	during	during	ADP
ajmpe-94	233	29	infection	infection	NOUN
ajmpe-94	233	30	.	.	PUNCT
ajmpe-94	234	1	(	(	PUNCT
ajmpe-94	234	2	57	57	NUM
ajmpe-94	234	3	)	)	PUNCT
ajmpe-94	234	4	higher	high	ADJ
ajmpe-94	234	5	il-6	il-6	NOUN
ajmpe-94	234	6	responses	response	NOUN
ajmpe-94	234	7	have	have	AUX
ajmpe-94	234	8	been	be	AUX
ajmpe-94	234	9	linked	link	VERB
ajmpe-94	234	10	to	to	ADP
ajmpe-94	234	11	zinc	zinc	NOUN
ajmpe-94	234	12	deficiency	deficiency	NOUN
ajmpe-94	234	13	.	.	PUNCT
ajmpe-94	235	1	when	when	SCONJ
ajmpe-94	235	2	covid-19	covid-19	PROPN
ajmpe-94	235	3	causes	cause	VERB
ajmpe-94	235	4	severe	severe	ADJ
ajmpe-94	235	5	lung	lung	NOUN
ajmpe-94	235	6	injury	injury	NOUN
ajmpe-94	235	7	,	,	PUNCT
ajmpe-94	235	8	il-6	il-6	PRON
ajmpe-94	235	9	is	be	AUX
ajmpe-94	235	10	essential	essential	ADJ
ajmpe-94	235	11	.	.	PUNCT
ajmpe-94	236	1	when	when	SCONJ
ajmpe-94	236	2	compared	compare	VERB
ajmpe-94	236	3	to	to	ADP
ajmpe-94	236	4	mild	mild	ADJ
ajmpe-94	236	5	,	,	PUNCT
ajmpe-94	236	6	moderate	moderate	ADJ
ajmpe-94	236	7	,	,	PUNCT
ajmpe-94	236	8	and	and	CCONJ
ajmpe-94	236	9	controls	control	NOUN
ajmpe-94	236	10	in	in	ADP
ajmpe-94	236	11	this	this	DET
ajmpe-94	236	12	study	study	NOUN
ajmpe-94	236	13	,	,	PUNCT
ajmpe-94	236	14	it	it	PRON
ajmpe-94	236	15	was	be	AUX
ajmpe-94	236	16	found	find	VERB
ajmpe-94	236	17	that	that	SCONJ
ajmpe-94	236	18	the	the	DET
ajmpe-94	236	19	severe	severe	ADJ
ajmpe-94	236	20	stage	stage	NOUN
ajmpe-94	236	21	had	have	AUX
ajmpe-94	236	22	significantly	significantly	ADV
ajmpe-94	236	23	lower	low	ADJ
ajmpe-94	236	24	serum	serum	NOUN
ajmpe-94	236	25	zinc	zinc	NOUN
ajmpe-94	236	26	levels	level	NOUN
ajmpe-94	236	27	see	see	VERB
ajmpe-94	236	28	figure	figure	NOUN
ajmpe-94	236	29	(	(	PUNCT
ajmpe-94	236	30	4	4	NUM
ajmpe-94	236	31	)	)	PUNCT
ajmpe-94	236	32	.	.	PUNCT
ajmpe-94	237	1	similar	similar	ADJ
ajmpe-94	237	2	findings	finding	NOUN
ajmpe-94	237	3	were	be	AUX
ajmpe-94	237	4	reported	report	VERB
ajmpe-94	237	5	by	by	ADP
ajmpe-94	237	6	jothimani	jothimani	PROPN
ajmpe-94	237	7	et	et	PROPN
ajmpe-94	237	8	al	al	PROPN
ajmpe-94	237	9	.	.	PROPN
ajmpe-94	237	10	,	,	PUNCT
ajmpe-94	237	11	who	who	PRON
ajmpe-94	237	12	found	find	VERB
ajmpe-94	237	13	that	that	SCONJ
ajmpe-94	237	14	patients	patient	NOUN
ajmpe-94	237	15	with	with	ADP
ajmpe-94	237	16	decreased	decrease	VERB
ajmpe-94	237	17	zinc	zinc	NOUN
ajmpe-94	237	18	levels	level	NOUN
ajmpe-94	237	19	had	have	VERB
ajmpe-94	237	20	more	more	ADV
ajmpe-94	237	21	serious	serious	ADJ
ajmpe-94	237	22	problems	problem	NOUN
ajmpe-94	237	23	and	and	CCONJ
ajmpe-94	237	24	required	require	VERB
ajmpe-94	237	25	longer	long	ADJ
ajmpe-94	237	26	hospitalizations	hospitalization	NOUN
ajmpe-94	237	27	in	in	ADP
ajmpe-94	237	28	hospitals	hospital	NOUN
ajmpe-94	237	29	[	[	X
ajmpe-94	237	30	29	29	NUM
ajmpe-94	237	31	]	]	PUNCT
ajmpe-94	237	32	.	.	PUNCT
ajmpe-94	238	1	numerous	numerous	ADJ
ajmpe-94	238	2	other	other	ADJ
ajmpe-94	238	3	studies	study	NOUN
ajmpe-94	238	4	[	[	X
ajmpe-94	238	5	58	58	NUM
ajmpe-94	238	6	,	,	PUNCT
ajmpe-94	238	7	59	59	NUM
ajmpe-94	238	8	]	]	PUNCT
ajmpe-94	238	9	reported	report	VERB
ajmpe-94	238	10	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	238	11	american	american	PROPN
ajmpe-94	238	12	journal	journal	PROPN
ajmpe-94	238	13	of	of	ADP
ajmpe-94	238	14	medical	medical	ADJ
ajmpe-94	238	15	and	and	CCONJ
ajmpe-94	238	16	physical	physical	ADJ
ajmpe-94	238	17	education	education	NOUN
ajmpe-94	238	18	vol.1	vol.1	PROPN
ajmpe-94	238	19	,	,	PUNCT
ajmpe-94	238	20	issue	issue	NOUN
ajmpe-94	238	21	1	1	NUM
ajmpe-94	238	22	;	;	PUNCT
ajmpe-94	238	23	july	july	PROPN
ajmpe-94	238	24	2023	2023	NUM
ajmpe-94	238	25	;	;	PUNCT
ajmpe-94	238	26	1252	1252	NUM
ajmpe-94	238	27	columbia	columbia	PROPN
ajmpe-94	238	28	rd	rd	PROPN
ajmpe-94	238	29	nw	nw	PROPN
ajmpe-94	238	30	,	,	PUNCT
ajmpe-94	238	31	washington	washington	PROPN
ajmpe-94	238	32	dc	dc	PROPN
ajmpe-94	238	33	,	,	PUNCT
ajmpe-94	238	34	united	united	PROPN
ajmpe-94	238	35	states	states	PROPN
ajmpe-94	238	36	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	238	37	;	;	PUNCT
ajmpe-94	238	38	mail	mail	NOUN
ajmpe-94	238	39	:	:	PUNCT
ajmpe-94	238	40	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	239	1	79	79	NUM
ajmpe-94	240	1	|	|	ADV
ajmpe-94	240	2	a	a	DET
ajmpe-94	240	3	m	m	NOUN
ajmpe-94	240	4	e	e	NOUN
ajmpe-94	240	5	r	r	NOUN
ajmpe-94	241	1	i	i	NOUN
ajmpe-94	241	2	c	c	VERB
ajmpe-94	241	3	a	a	DET
ajmpe-94	241	4	n	n	NOUN
ajmpe-94	242	1	j	j	NOUN
ajmpe-94	242	2	o	o	X
ajmpe-94	242	3	u	u	NOUN
ajmpe-94	242	4	r	r	NOUN
ajmpe-94	242	5	n	n	NOUN
ajmpe-94	242	6	a	a	DET
ajmpe-94	242	7	l	l	NOUN
ajmpe-94	242	8	o	o	X
ajmpe-94	243	1	f	f	X
ajmpe-94	243	2	m	m	NOUN
ajmpe-94	243	3	e	e	NOUN
ajmpe-94	244	1	d	d	NOUN
ajmpe-94	244	2	i	i	PRON
ajmpe-94	244	3	c	c	VERB
ajmpe-94	244	4	a	a	DET
ajmpe-94	244	5	l	l	NOUN
ajmpe-94	244	6	a	a	X
ajmpe-94	244	7	n	n	NOUN
ajmpe-94	245	1	d	d	NOUN
ajmpe-94	245	2	p	p	NOUN
ajmpe-94	245	3	h	h	NOUN
ajmpe-94	245	4	y	y	NOUN
ajmpe-94	245	5	s	s	VERB
ajmpe-94	246	1	i	i	INTJ
ajmpe-94	246	2	c	c	VERB
ajmpe-94	246	3	a	a	DET
ajmpe-94	246	4	l	l	NOUN
ajmpe-94	246	5	e	e	NOUN
ajmpe-94	246	6	d	d	X
ajmpe-94	246	7	u	u	X
ajmpe-94	246	8	c	c	PROPN
ajmpe-94	247	1	a	a	DET
ajmpe-94	247	2	t	t	NOUN
ajmpe-94	248	1	i	i	PRON
ajmpe-94	248	2	o	o	VERB
ajmpe-94	248	3	n	n	CCONJ
ajmpe-94	248	4	|	|	ADV
ajmpe-94	248	5	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	NUM
ajmpe-94	248	6	reduced	reduce	VERB
ajmpe-94	248	7	zinc	zinc	NOUN
ajmpe-94	248	8	levels	level	NOUN
ajmpe-94	248	9	in	in	ADP
ajmpe-94	248	10	covid-19	covid-19	PROPN
ajmpe-94	248	11	-	-	PUNCT
ajmpe-94	248	12	infected	infect	VERB
ajmpe-94	248	13	women	woman	NOUN
ajmpe-94	248	14	,	,	PUNCT
ajmpe-94	248	15	including	include	VERB
ajmpe-94	248	16	pregnant	pregnant	ADJ
ajmpe-94	248	17	women	woman	NOUN
ajmpe-94	248	18	.	.	PUNCT
ajmpe-94	249	1	muhammad	muhammad	PROPN
ajmpe-94	249	2	et	et	PROPN
ajmpe-94	249	3	al	al	PROPN
ajmpe-94	249	4	.	.	PUNCT
ajmpe-94	250	1	[	[	X
ajmpe-94	250	2	60	60	NUM
ajmpe-94	250	3	]	]	PUNCT
ajmpe-94	250	4	reported	report	VERB
ajmpe-94	250	5	similar	similar	ADJ
ajmpe-94	250	6	outcomes	outcome	NOUN
ajmpe-94	250	7	in	in	ADP
ajmpe-94	250	8	the	the	DET
ajmpe-94	250	9	nigerian	nigerian	ADJ
ajmpe-94	250	10	population	population	NOUN
ajmpe-94	250	11	.	.	PUNCT
ajmpe-94	251	1	in	in	ADP
ajmpe-94	251	2	several	several	ADJ
ajmpe-94	251	3	studies	study	NOUN
ajmpe-94	251	4	,	,	PUNCT
ajmpe-94	251	5	zinc	zinc	NOUN
ajmpe-94	251	6	supplements	supplement	NOUN
ajmpe-94	251	7	were	be	AUX
ajmpe-94	251	8	also	also	ADV
ajmpe-94	251	9	initiated	initiate	VERB
ajmpe-94	251	10	as	as	ADP
ajmpe-94	251	11	part	part	NOUN
ajmpe-94	251	12	of	of	ADP
ajmpe-94	251	13	the	the	DET
ajmpe-94	251	14	standard	standard	ADJ
ajmpe-94	251	15	treatment	treatment	NOUN
ajmpe-94	251	16	to	to	PART
ajmpe-94	251	17	confirm	confirm	VERB
ajmpe-94	251	18	the	the	DET
ajmpe-94	251	19	role	role	NOUN
ajmpe-94	251	20	of	of	ADP
ajmpe-94	251	21	zinc	zinc	NOUN
ajmpe-94	251	22	in	in	ADP
ajmpe-94	251	23	the	the	DET
ajmpe-94	251	24	progression	progression	NOUN
ajmpe-94	251	25	of	of	ADP
ajmpe-94	251	26	the	the	DET
ajmpe-94	251	27	disease	disease	NOUN
ajmpe-94	251	28	;	;	PUNCT
ajmpe-94	251	29	the	the	DET
ajmpe-94	251	30	groups	group	NOUN
ajmpe-94	251	31	who	who	PRON
ajmpe-94	251	32	were	be	AUX
ajmpe-94	251	33	not	not	PART
ajmpe-94	251	34	given	give	VERB
ajmpe-94	251	35	any	any	DET
ajmpe-94	251	36	supplements	supplement	NOUN
ajmpe-94	251	37	had	have	VERB
ajmpe-94	251	38	higher	high	ADJ
ajmpe-94	251	39	mortality	mortality	NOUN
ajmpe-94	251	40	than	than	SCONJ
ajmpe-94	251	41	the	the	DET
ajmpe-94	251	42	population	population	NOUN
ajmpe-94	251	43	taking	take	VERB
ajmpe-94	251	44	zinc	zinc	NOUN
ajmpe-94	251	45	supplements	supplement	NOUN
ajmpe-94	251	46	[	[	X
ajmpe-94	251	47	61	61	NUM
ajmpe-94	251	48	]	]	PUNCT
ajmpe-94	251	49	.	.	PUNCT
ajmpe-94	252	1	other	other	ADJ
ajmpe-94	252	2	findings	finding	NOUN
ajmpe-94	252	3	for	for	ADP
ajmpe-94	252	4	zinc	zinc	NOUN
ajmpe-94	252	5	and	and	CCONJ
ajmpe-94	252	6	trace	trace	NOUN
ajmpe-94	252	7	elements	element	NOUN
ajmpe-94	252	8	evaluated	evaluate	VERB
ajmpe-94	252	9	in	in	ADP
ajmpe-94	252	10	severe	severe	ADJ
ajmpe-94	252	11	covid-19	covid-19	PROPN
ajmpe-94	252	12	patients	patient	NOUN
ajmpe-94	252	13	are	be	AUX
ajmpe-94	252	14	similar	similar	ADJ
ajmpe-94	252	15	with	with	ADP
ajmpe-94	252	16	those	those	PRON
ajmpe-94	252	17	from	from	ADP
ajmpe-94	252	18	earlier	early	ADJ
ajmpe-94	252	19	studies	study	NOUN
ajmpe-94	252	20	.	.	PUNCT
ajmpe-94	253	1	when	when	SCONJ
ajmpe-94	253	2	compared	compare	VERB
ajmpe-94	253	3	to	to	ADP
ajmpe-94	253	4	mild	mild	ADJ
ajmpe-94	253	5	-	-	PUNCT
ajmpe-94	253	6	to	to	ADP
ajmpe-94	253	7	-	-	PUNCT
ajmpe-94	253	8	moderate	moderate	ADJ
ajmpe-94	253	9	covid-19	covid-19	PROPN
ajmpe-94	253	10	infection	infection	NOUN
ajmpe-94	253	11	,	,	PUNCT
ajmpe-94	253	12	serum	serum	PROPN
ajmpe-94	253	13	zn	zn	PROPN
ajmpe-94	253	14	levels	level	NOUN
ajmpe-94	253	15	have	have	AUX
ajmpe-94	253	16	been	be	AUX
ajmpe-94	253	17	reported	report	VERB
ajmpe-94	253	18	to	to	PART
ajmpe-94	253	19	be	be	AUX
ajmpe-94	253	20	reduced	reduce	VERB
ajmpe-94	253	21	[	[	PUNCT
ajmpe-94	253	22	62	62	NUM
ajmpe-94	253	23	]	]	PUNCT
ajmpe-94	253	24	.	.	PUNCT
ajmpe-94	254	1	skalny	skalny	PROPN
ajmpe-94	254	2	and	and	CCONJ
ajmpe-94	254	3	others	other	NOUN
ajmpe-94	254	4	,	,	PUNCT
ajmpe-94	254	5	2021	2021	NUM
ajmpe-94	254	6	(	(	PUNCT
ajmpe-94	254	7	63	63	NUM
ajmpe-94	254	8	)	)	PUNCT
ajmpe-94	254	9	.	.	PUNCT
ajmpe-94	255	1	additionally	additionally	ADV
ajmpe-94	255	2	,	,	PUNCT
ajmpe-94	255	3	it	it	PRON
ajmpe-94	255	4	was	be	AUX
ajmpe-94	255	5	found	find	VERB
ajmpe-94	255	6	that	that	SCONJ
ajmpe-94	255	7	as	as	ADP
ajmpe-94	255	8	compared	compare	VERB
ajmpe-94	255	9	to	to	ADP
ajmpe-94	255	10	controls	control	NOUN
ajmpe-94	255	11	,	,	PUNCT
ajmpe-94	255	12	increasing	increase	VERB
ajmpe-94	255	13	covid-19	covid-19	PROPN
ajmpe-94	255	14	severity	severity	NOUN
ajmpe-94	255	15	is	be	AUX
ajmpe-94	255	16	linked	link	VERB
ajmpe-94	255	17	to	to	ADP
ajmpe-94	255	18	a	a	DET
ajmpe-94	255	19	large	large	ADJ
ajmpe-94	255	20	,	,	PUNCT
ajmpe-94	255	21	steady	steady	ADJ
ajmpe-94	255	22	decline	decline	NOUN
ajmpe-94	255	23	in	in	ADP
ajmpe-94	255	24	serum	serum	NOUN
ajmpe-94	255	25	zinc	zinc	NOUN
ajmpe-94	255	26	levels	level	NOUN
ajmpe-94	255	27	as	as	ADV
ajmpe-94	255	28	well	well	ADV
ajmpe-94	255	29	as	as	ADP
ajmpe-94	255	30	declines	decline	NOUN
ajmpe-94	255	31	in	in	ADP
ajmpe-94	255	32	serum	serum	NOUN
ajmpe-94	255	33	calcium	calcium	NOUN
ajmpe-94	255	34	,	,	PUNCT
ajmpe-94	255	35	iron	iron	NOUN
ajmpe-94	255	36	,	,	PUNCT
ajmpe-94	255	37	and	and	CCONJ
ajmpe-94	255	38	selenium	selenium	NOUN
ajmpe-94	255	39	levels	level	NOUN
ajmpe-94	255	40	.	.	PUNCT
ajmpe-94	256	1	however	however	ADV
ajmpe-94	256	2	,	,	PUNCT
ajmpe-94	256	3	there	there	PRON
ajmpe-94	256	4	are	be	VERB
ajmpe-94	256	5	higher	high	ADJ
ajmpe-94	256	6	levels	level	NOUN
ajmpe-94	256	7	of	of	ADP
ajmpe-94	256	8	serum	serum	PROPN
ajmpe-94	256	9	cu	cu	PROPN
ajmpe-94	256	10	and	and	CCONJ
ajmpe-94	256	11	,	,	PUNCT
ajmpe-94	256	12	in	in	ADP
ajmpe-94	256	13	particularly	particularly	ADV
ajmpe-94	256	14	,	,	PUNCT
ajmpe-94	256	15	the	the	DET
ajmpe-94	256	16	cu	cu	PROPN
ajmpe-94	256	17	zn	zn	PROPN
ajmpe-94	256	18	ratio	ratio	PROPN
ajmpe-94	256	19	[	[	X
ajmpe-94	256	20	63	63	NUM
ajmpe-94	256	21	]	]	PUNCT
ajmpe-94	256	22	.	.	PUNCT
ajmpe-94	257	1	additionally	additionally	ADV
ajmpe-94	257	2	,	,	PUNCT
ajmpe-94	257	3	according	accord	VERB
ajmpe-94	257	4	to	to	ADP
ajmpe-94	257	5	the	the	DET
ajmpe-94	257	6	study	study	NOUN
ajmpe-94	257	7	,	,	PUNCT
ajmpe-94	257	8	there	there	PRON
ajmpe-94	257	9	is	be	VERB
ajmpe-94	257	10	no	no	DET
ajmpe-94	257	11	obvious	obvious	ADJ
ajmpe-94	257	12	gender	gender	NOUN
ajmpe-94	257	13	difference	difference	NOUN
ajmpe-94	257	14	in	in	ADP
ajmpe-94	257	15	the	the	DET
ajmpe-94	257	16	mean	mean	ADJ
ajmpe-94	257	17	levels	level	NOUN
ajmpe-94	257	18	of	of	ADP
ajmpe-94	257	19	sodium	sodium	NOUN
ajmpe-94	257	20	and	and	CCONJ
ajmpe-94	257	21	potassium	potassium	NOUN
ajmpe-94	257	22	in	in	ADP
ajmpe-94	257	23	covid-19	covid-19	PROPN
ajmpe-94	257	24	patients	patient	NOUN
ajmpe-94	257	25	(	(	PUNCT
ajmpe-94	257	26	p	p	NOUN
ajmpe-94	257	27	-	-	PUNCT
ajmpe-94	257	28	value	value	NOUN
ajmpe-94	257	29	0.05	0.05	NUM
ajmpe-94	257	30	)	)	PUNCT
ajmpe-94	257	31	.	.	PUNCT
ajmpe-94	258	1	this	this	DET
ajmpe-94	258	2	result	result	NOUN
ajmpe-94	258	3	is	be	AUX
ajmpe-94	258	4	in	in	ADP
ajmpe-94	258	5	contrast	contrast	NOUN
ajmpe-94	258	6	a	a	DET
ajmpe-94	258	7	study	study	NOUN
ajmpe-94	258	8	by	by	ADP
ajmpe-94	258	9	vahidy	vahidy	PROPN
ajmpe-94	258	10	et	et	PROPN
ajmpe-94	258	11	al	al	PROPN
ajmpe-94	258	12	.	.	PROPN
ajmpe-94	259	1	(	(	PUNCT
ajmpe-94	259	2	64	64	NUM
ajmpe-94	259	3	)	)	PUNCT
ajmpe-94	259	4	who	who	PRON
ajmpe-94	259	5	found	find	VERB
ajmpe-94	259	6	that	that	SCONJ
ajmpe-94	259	7	male	male	ADJ
ajmpe-94	259	8	patients	patient	NOUN
ajmpe-94	259	9	hospitalized	hospitalize	VERB
ajmpe-94	259	10	for	for	ADP
ajmpe-94	259	11	covid-19	covid-19	PROPN
ajmpe-94	259	12	had	have	VERB
ajmpe-94	259	13	a	a	DET
ajmpe-94	259	14	larger	large	ADJ
ajmpe-94	259	15	proportion	proportion	NOUN
ajmpe-94	259	16	of	of	ADP
ajmpe-94	259	17	abnormal	abnormal	ADJ
ajmpe-94	259	18	laboratory	laboratory	NOUN
ajmpe-94	259	19	values	value	NOUN
ajmpe-94	259	20	than	than	ADP
ajmpe-94	259	21	female	female	ADJ
ajmpe-94	259	22	patients	patient	NOUN
ajmpe-94	259	23	.	.	PUNCT
ajmpe-94	260	1	the	the	DET
ajmpe-94	260	2	short	short	ADJ
ajmpe-94	260	3	sample	sample	NOUN
ajmpe-94	260	4	size	size	NOUN
ajmpe-94	260	5	and	and	CCONJ
ajmpe-94	260	6	environmental	environmental	ADJ
ajmpe-94	260	7	changes	change	NOUN
ajmpe-94	260	8	can	can	AUX
ajmpe-94	260	9	be	be	AUX
ajmpe-94	260	10	used	use	VERB
ajmpe-94	260	11	as	as	ADP
ajmpe-94	260	12	an	an	DET
ajmpe-94	260	13	explanation	explanation	NOUN
ajmpe-94	260	14	for	for	ADP
ajmpe-94	260	15	this	this	DET
ajmpe-94	260	16	difference	difference	NOUN
ajmpe-94	260	17	.	.	PUNCT
ajmpe-94	261	1	potassium	potassium	NOUN
ajmpe-94	261	2	and	and	CCONJ
ajmpe-94	261	3	sodium	sodium	NOUN
ajmpe-94	261	4	have	have	VERB
ajmpe-94	261	5	a	a	DET
ajmpe-94	261	6	high	high	ADJ
ajmpe-94	261	7	negative	negative	ADJ
ajmpe-94	261	8	significant	significant	ADJ
ajmpe-94	261	9	link	link	NOUN
ajmpe-94	261	10	(	(	PUNCT
ajmpe-94	261	11	r	r	NOUN
ajmpe-94	261	12	=	=	SYM
ajmpe-94	261	13	-.736	-.736	PROPN
ajmpe-94	261	14	,	,	PUNCT
ajmpe-94	261	15	p	p	NOUN
ajmpe-94	261	16	=	=	NOUN
ajmpe-94	261	17	.000	.000	NUM
ajmpe-94	261	18	)	)	PUNCT
ajmpe-94	261	19	according	accord	VERB
ajmpe-94	261	20	to	to	ADP
ajmpe-94	261	21	the	the	DET
ajmpe-94	261	22	correlation	correlation	NOUN
ajmpe-94	261	23	study	study	NOUN
ajmpe-94	261	24	.	.	PUNCT
ajmpe-94	262	1	this	this	PRON
ajmpe-94	262	2	is	be	AUX
ajmpe-94	262	3	similar	similar	ADJ
ajmpe-94	262	4	to	to	ADP
ajmpe-94	262	5	zhou	zhou	PROPN
ajmpe-94	262	6	et	et	PROPN
ajmpe-94	262	7	al	al	PROPN
ajmpe-94	262	8	.	.	PUNCT
ajmpe-94	263	1	(	(	PUNCT
ajmpe-94	263	2	65	65	NUM
ajmpe-94	263	3	)	)	PUNCT
ajmpe-94	263	4	,	,	PUNCT
ajmpe-94	263	5	which	which	PRON
ajmpe-94	263	6	discovered	discover	VERB
ajmpe-94	263	7	a	a	DET
ajmpe-94	263	8	high	high	ADJ
ajmpe-94	263	9	correlation	correlation	NOUN
ajmpe-94	263	10	between	between	ADP
ajmpe-94	263	11	the	the	DET
ajmpe-94	263	12	severity	severity	NOUN
ajmpe-94	263	13	of	of	ADP
ajmpe-94	263	14	the	the	DET
ajmpe-94	263	15	disease	disease	NOUN
ajmpe-94	263	16	and	and	CCONJ
ajmpe-94	263	17	decreasing	decrease	VERB
ajmpe-94	263	18	blood	blood	NOUN
ajmpe-94	263	19	levels	level	NOUN
ajmpe-94	263	20	of	of	ADP
ajmpe-94	263	21	sodium	sodium	NOUN
ajmpe-94	263	22	and	and	CCONJ
ajmpe-94	263	23	potassium	potassium	NOUN
ajmpe-94	263	24	.	.	PUNCT
ajmpe-94	264	1	the	the	DET
ajmpe-94	264	2	correlation	correlation	NOUN
ajmpe-94	264	3	study	study	NOUN
ajmpe-94	264	4	revealed	reveal	VERB
ajmpe-94	264	5	a	a	DET
ajmpe-94	264	6	weak	weak	ADJ
ajmpe-94	264	7	relationship	relationship	NOUN
ajmpe-94	264	8	between	between	ADP
ajmpe-94	264	9	calcium	calcium	NOUN
ajmpe-94	264	10	and	and	CCONJ
ajmpe-94	264	11	phosphate	phosphate	NOUN
ajmpe-94	264	12	(	(	PUNCT
ajmpe-94	264	13	r	r	NOUN
ajmpe-94	264	14	=	=	SYM
ajmpe-94	264	15	0.02	0.02	NUM
ajmpe-94	264	16	,	,	PUNCT
ajmpe-94	264	17	p	p	NOUN
ajmpe-94	264	18	=	=	NOUN
ajmpe-94	264	19	0.8	0.8	NUM
ajmpe-94	264	20	and	and	CCONJ
ajmpe-94	264	21	r	r	NOUN
ajmpe-94	264	22	=	=	SYM
ajmpe-94	264	23	-0.02	-0.02	NUM
ajmpe-94	264	24	,	,	PUNCT
ajmpe-94	264	25	p=0.9	p=0.9	NOUN
ajmpe-94	264	26	,	,	PUNCT
ajmpe-94	264	27	respectively	respectively	ADV
ajmpe-94	264	28	)	)	PUNCT
ajmpe-94	264	29	.	.	PUNCT
ajmpe-94	265	1	this	this	PRON
ajmpe-94	265	2	is	be	AUX
ajmpe-94	265	3	in	in	ADP
ajmpe-94	265	4	contrast	contrast	NOUN
ajmpe-94	265	5	to	to	ADP
ajmpe-94	265	6	yang	yang	PROPN
ajmpe-94	265	7	's	's	PART
ajmpe-94	265	8	study	study	NOUN
ajmpe-94	265	9	,	,	PUNCT
ajmpe-94	265	10	which	which	PRON
ajmpe-94	265	11	found	find	VERB
ajmpe-94	265	12	a	a	DET
ajmpe-94	265	13	significantly	significantly	ADV
ajmpe-94	265	14	positive	positive	ADJ
ajmpe-94	265	15	link	link	NOUN
ajmpe-94	265	16	between	between	ADP
ajmpe-94	265	17	the	the	DET
ajmpe-94	265	18	severity	severity	NOUN
ajmpe-94	265	19	of	of	ADP
ajmpe-94	265	20	the	the	DET
ajmpe-94	265	21	disease	disease	NOUN
ajmpe-94	265	22	and	and	CCONJ
ajmpe-94	265	23	reduced	reduce	VERB
ajmpe-94	265	24	blood	blood	NOUN
ajmpe-94	265	25	levels	level	NOUN
ajmpe-94	265	26	of	of	ADP
ajmpe-94	265	27	phosphate	phosphate	NOUN
ajmpe-94	265	28	and	and	CCONJ
ajmpe-94	265	29	calcium	calcium	NOUN
ajmpe-94	265	30	.	.	PUNCT
ajmpe-94	266	1	acute	acute	PROPN
ajmpe-94	266	2	complications	complication	NOUN
ajmpe-94	266	3	caused	cause	VERB
ajmpe-94	266	4	on	on	ADP
ajmpe-94	266	5	by	by	ADP
ajmpe-94	266	6	the	the	DET
ajmpe-94	266	7	virus	virus	NOUN
ajmpe-94	266	8	can	can	AUX
ajmpe-94	266	9	include	include	VERB
ajmpe-94	266	10	acute	acute	ADJ
ajmpe-94	266	11	kidney	kidney	NOUN
ajmpe-94	266	12	damage	damage	NOUN
ajmpe-94	266	13	(	(	PUNCT
ajmpe-94	266	14	aki	aki	NOUN
ajmpe-94	266	15	)	)	PUNCT
ajmpe-94	266	16	and	and	CCONJ
ajmpe-94	266	17	digestive	digestive	ADJ
ajmpe-94	266	18	issues	issue	NOUN
ajmpe-94	266	19	for	for	ADP
ajmpe-94	266	20	the	the	DET
ajmpe-94	266	21	patient	patient	NOUN
ajmpe-94	266	22	.	.	PUNCT
ajmpe-94	267	1	fluid	fluid	ADJ
ajmpe-94	267	2	and	and	CCONJ
ajmpe-94	267	3	electrolyte	electrolyte	ADJ
ajmpe-94	267	4	abnormalities	abnormality	NOUN
ajmpe-94	267	5	are	be	AUX
ajmpe-94	267	6	one	one	NUM
ajmpe-94	267	7	of	of	ADP
ajmpe-94	267	8	the	the	DET
ajmpe-94	267	9	side	side	NOUN
ajmpe-94	267	10	effects	effect	NOUN
ajmpe-94	267	11	of	of	ADP
ajmpe-94	267	12	kidney	kidney	NOUN
ajmpe-94	267	13	and	and	CCONJ
ajmpe-94	267	14	gi	gi	NOUN
ajmpe-94	267	15	involvement	involvement	NOUN
ajmpe-94	267	16	in	in	ADP
ajmpe-94	267	17	covid-19	covid-19	PROPN
ajmpe-94	267	18	.	.	PUNCT
ajmpe-94	268	1	the	the	DET
ajmpe-94	268	2	most	most	ADV
ajmpe-94	268	3	prevalent	prevalent	NOUN
ajmpe-94	268	4	of	of	ADP
ajmpe-94	268	5	these	these	DET
ajmpe-94	268	6	conditions	condition	NOUN
ajmpe-94	268	7	are	be	AUX
ajmpe-94	268	8	hyponatremia	hyponatremia	PROPN
ajmpe-94	268	9	,	,	PUNCT
ajmpe-94	268	10	hypernatremia	hypernatremia	PROPN
ajmpe-94	268	11	,	,	PUNCT
ajmpe-94	268	12	hypokalemia	hypokalemia	PROPN
ajmpe-94	268	13	,	,	PUNCT
ajmpe-94	268	14	hypocalcemia	hypocalcemia	PROPN
ajmpe-94	268	15	,	,	PUNCT
ajmpe-94	268	16	hypochloremia	hypochloremia	NOUN
ajmpe-94	268	17	,	,	PUNCT
ajmpe-94	268	18	hypervolemia	hypervolemia	NOUN
ajmpe-94	268	19	,	,	PUNCT
ajmpe-94	268	20	and	and	CCONJ
ajmpe-94	268	21	hypovolemia	hypovolemia	NOUN
ajmpe-94	268	22	.	.	PUNCT
ajmpe-94	269	1	if	if	SCONJ
ajmpe-94	269	2	untreated	untreate	VERB
ajmpe-94	269	3	,	,	PUNCT
ajmpe-94	269	4	these	these	DET
ajmpe-94	269	5	conditions	condition	NOUN
ajmpe-94	269	6	can	can	AUX
ajmpe-94	269	7	lead	lead	VERB
ajmpe-94	269	8	to	to	ADP
ajmpe-94	269	9	a	a	DET
ajmpe-94	269	10	variety	variety	NOUN
ajmpe-94	269	11	of	of	ADP
ajmpe-94	269	12	complications	complication	NOUN
ajmpe-94	269	13	for	for	ADP
ajmpe-94	269	14	patients	patient	NOUN
ajmpe-94	269	15	and	and	CCONJ
ajmpe-94	269	16	even	even	ADV
ajmpe-94	269	17	increase	increase	VERB
ajmpe-94	269	18	mortality	mortality	NOUN
ajmpe-94	269	19	(	(	PUNCT
ajmpe-94	269	20	66	66	NUM
ajmpe-94	269	21	)	)	PUNCT
ajmpe-94	269	22	.	.	PUNCT
ajmpe-94	270	1	additionally	additionally	ADV
ajmpe-94	270	2	,	,	PUNCT
ajmpe-94	270	3	changes	change	NOUN
ajmpe-94	270	4	in	in	ADP
ajmpe-94	270	5	fluid	fluid	NOUN
ajmpe-94	270	6	,	,	PUNCT
ajmpe-94	270	7	electrolyte	electrolyte	ADJ
ajmpe-94	270	8	,	,	PUNCT
ajmpe-94	270	9	and	and	CCONJ
ajmpe-94	270	10	trace	trace	NOUN
ajmpe-94	270	11	element	element	NOUN
ajmpe-94	270	12	levels	level	NOUN
ajmpe-94	270	13	can	can	AUX
ajmpe-94	270	14	be	be	AUX
ajmpe-94	270	15	a	a	DET
ajmpe-94	270	16	good	good	ADJ
ajmpe-94	270	17	indicator	indicator	NOUN
ajmpe-94	270	18	of	of	ADP
ajmpe-94	270	19	disease	disease	NOUN
ajmpe-94	270	20	progression	progression	NOUN
ajmpe-94	270	21	,	,	PUNCT
ajmpe-94	270	22	this	this	PRON
ajmpe-94	270	23	is	be	AUX
ajmpe-94	270	24	due	due	ADJ
ajmpe-94	270	25	to	to	ADP
ajmpe-94	270	26	the	the	DET
ajmpe-94	270	27	risk	risk	NOUN
ajmpe-94	270	28	of	of	ADP
ajmpe-94	270	29	fluid	fluid	NOUN
ajmpe-94	270	30	,	,	PUNCT
ajmpe-94	270	31	electrolyte	electrolyte	ADJ
ajmpe-94	270	32	,	,	PUNCT
ajmpe-94	270	33	and	and	CCONJ
ajmpe-94	270	34	trace	trace	NOUN
ajmpe-94	270	35	element	element	NOUN
ajmpe-94	270	36	disturbance	disturbance	NOUN
ajmpe-94	270	37	complications	complication	NOUN
ajmpe-94	270	38	requires	require	VERB
ajmpe-94	270	39	special	special	ADJ
ajmpe-94	270	40	attention	attention	NOUN
ajmpe-94	270	41	from	from	ADP
ajmpe-94	270	42	clinicians	clinician	NOUN
ajmpe-94	270	43	in	in	ADP
ajmpe-94	270	44	order	order	NOUN
ajmpe-94	270	45	to	to	PART
ajmpe-94	270	46	manage	manage	VERB
ajmpe-94	270	47	patients	patient	NOUN
ajmpe-94	270	48	'	'	PART
ajmpe-94	270	49	fluid	fluid	ADJ
ajmpe-94	270	50	and	and	CCONJ
ajmpe-94	270	51	electrolyte	electrolyte	ADJ
ajmpe-94	270	52	status	status	NOUN
ajmpe-94	270	53	,	,	PUNCT
ajmpe-94	270	54	in	in	ADP
ajmpe-94	270	55	addition	addition	NOUN
ajmpe-94	270	56	to	to	ADP
ajmpe-94	270	57	trace	trace	NOUN
ajmpe-94	270	58	element	element	NOUN
ajmpe-94	270	59	supplements	supplement	NOUN
ajmpe-94	270	60	.	.	PUNCT
ajmpe-94	271	1	conclusion	conclusion	NOUN
ajmpe-94	271	2	in	in	ADP
ajmpe-94	271	3	conclusion	conclusion	NOUN
ajmpe-94	271	4	,	,	PUNCT
ajmpe-94	271	5	based	base	VERB
ajmpe-94	271	6	on	on	ADP
ajmpe-94	271	7	our	our	PRON
ajmpe-94	271	8	results	result	NOUN
ajmpe-94	271	9	there	there	PRON
ajmpe-94	271	10	was	be	VERB
ajmpe-94	271	11	a	a	DET
ajmpe-94	271	12	significant	significant	ADJ
ajmpe-94	271	13	decrease	decrease	NOUN
ajmpe-94	271	14	in	in	ADP
ajmpe-94	271	15	serum	serum	NOUN
ajmpe-94	271	16	levels	level	NOUN
ajmpe-94	271	17	of	of	ADP
ajmpe-94	271	18	sodium	sodium	NOUN
ajmpe-94	271	19	,	,	PUNCT
ajmpe-94	271	20	potassium	potassium	NOUN
ajmpe-94	271	21	,	,	PUNCT
ajmpe-94	271	22	and	and	CCONJ
ajmpe-94	271	23	calcium	calcium	NOUN
ajmpe-94	271	24	in	in	ADP
ajmpe-94	271	25	covid-19	covid-19	PROPN
ajmpe-94	271	26	patients	patient	NOUN
ajmpe-94	271	27	when	when	SCONJ
ajmpe-94	271	28	compared	compare	VERB
ajmpe-94	271	29	with	with	ADP
ajmpe-94	271	30	the	the	DET
ajmpe-94	271	31	control	control	NOUN
ajmpe-94	271	32	group	group	NOUN
ajmpe-94	271	33	.	.	PUNCT
ajmpe-94	272	1	in	in	ADP
ajmpe-94	272	2	addition	addition	NOUN
ajmpe-94	272	3	,	,	PUNCT
ajmpe-94	272	4	there	there	PRON
ajmpe-94	272	5	was	be	VERB
ajmpe-94	272	6	a	a	DET
ajmpe-94	272	7	significantly	significantly	ADV
ajmpe-94	272	8	strong	strong	ADJ
ajmpe-94	272	9	negative	negative	ADJ
ajmpe-94	272	10	correlation	correlation	NOUN
ajmpe-94	272	11	between	between	ADP
ajmpe-94	272	12	serum	serum	NOUN
ajmpe-94	272	13	levels	level	NOUN
ajmpe-94	272	14	of	of	ADP
ajmpe-94	272	15	sodium	sodium	NOUN
ajmpe-94	272	16	,	,	PUNCT
ajmpe-94	272	17	potassium	potassium	NOUN
ajmpe-94	272	18	,	,	PUNCT
ajmpe-94	272	19	calcium	calcium	NOUN
ajmpe-94	272	20	,	,	PUNCT
ajmpe-94	272	21	and	and	CCONJ
ajmpe-94	272	22	severity	severity	NOUN
ajmpe-94	272	23	of	of	ADP
ajmpe-94	272	24	patients	patient	NOUN
ajmpe-94	272	25	of	of	ADP
ajmpe-94	272	26	covid-19	covid-19	PROPN
ajmpe-94	272	27	.	.	PUNCT
ajmpe-94	273	1	no	no	DET
ajmpe-94	273	2	biochemical	biochemical	ADJ
ajmpe-94	273	3	change	change	NOUN
ajmpe-94	273	4	in	in	ADP
ajmpe-94	273	5	serum	serum	NOUN
ajmpe-94	273	6	level	level	NOUN
ajmpe-94	273	7	of	of	ADP
ajmpe-94	273	8	phosphate	phosphate	NOUN
ajmpe-94	273	9	and	and	CCONJ
ajmpe-94	273	10	magnesium	magnesium	NOUN
ajmpe-94	273	11	among	among	ADP
ajmpe-94	273	12	patients	patient	NOUN
ajmpe-94	273	13	of	of	ADP
ajmpe-94	273	14	covid-19	covid-19	PROPN
ajmpe-94	273	15	.	.	PUNCT
ajmpe-94	273	16	serum	serum	NOUN
ajmpe-94	273	17	level	level	NOUN
ajmpe-94	273	18	of	of	ADP
ajmpe-94	273	19	zinc	zinc	NOUN
ajmpe-94	273	20	decrease	decrease	NOUN
ajmpe-94	273	21	and	and	CCONJ
ajmpe-94	273	22	serum	serum	NOUN
ajmpe-94	273	23	copper	copper	NOUN
ajmpe-94	273	24	levels	level	NOUN
ajmpe-94	273	25	increase	increase	VERB
ajmpe-94	273	26	when	when	SCONJ
ajmpe-94	273	27	compared	compare	VERB
ajmpe-94	273	28	to	to	ADP
ajmpe-94	273	29	mild	mild	ADJ
ajmpe-94	273	30	,	,	PUNCT
ajmpe-94	273	31	moderate	moderate	ADJ
ajmpe-94	273	32	and	and	CCONJ
ajmpe-94	273	33	sever	sever	VERB
ajmpe-94	273	34	ill	ill	ADJ
ajmpe-94	273	35	patients	patient	NOUN
ajmpe-94	273	36	of	of	ADP
ajmpe-94	273	37	covid-19.according	covid-19.accorde	VERB
ajmpe-94	273	38	to	to	ADP
ajmpe-94	273	39	our	our	PRON
ajmpe-94	273	40	findings	finding	NOUN
ajmpe-94	273	41	,	,	PUNCT
ajmpe-94	273	42	serum	serum	NOUN
ajmpe-94	273	43	levels	level	NOUN
ajmpe-94	273	44	of	of	ADP
ajmpe-94	273	45	calcium	calcium	NOUN
ajmpe-94	273	46	were	be	AUX
ajmpe-94	273	47	slightly	slightly	ADV
ajmpe-94	273	48	lower	low	ADJ
ajmpe-94	273	49	in	in	ADP
ajmpe-94	273	50	covid-19	covid-19	PROPN
ajmpe-94	273	51	patients	patient	NOUN
ajmpe-94	273	52	.	.	PUNCT
ajmpe-94	274	1	acknowledgment	acknowledgment	PROPN
ajmpe-94	274	2	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	274	3	american	american	PROPN
ajmpe-94	274	4	journal	journal	PROPN
ajmpe-94	274	5	of	of	ADP
ajmpe-94	274	6	medical	medical	ADJ
ajmpe-94	274	7	and	and	CCONJ
ajmpe-94	274	8	physical	physical	ADJ
ajmpe-94	274	9	education	education	NOUN
ajmpe-94	274	10	vol.1	vol.1	PROPN
ajmpe-94	274	11	,	,	PUNCT
ajmpe-94	274	12	issue	issue	NOUN
ajmpe-94	274	13	1	1	NUM
ajmpe-94	274	14	;	;	PUNCT
ajmpe-94	274	15	july	july	PROPN
ajmpe-94	274	16	2023	2023	NUM
ajmpe-94	274	17	;	;	PUNCT
ajmpe-94	274	18	1252	1252	NUM
ajmpe-94	274	19	columbia	columbia	PROPN
ajmpe-94	274	20	rd	rd	PROPN
ajmpe-94	274	21	nw	nw	PROPN
ajmpe-94	274	22	,	,	PUNCT
ajmpe-94	274	23	washington	washington	PROPN
ajmpe-94	274	24	dc	dc	PROPN
ajmpe-94	274	25	,	,	PUNCT
ajmpe-94	274	26	united	united	PROPN
ajmpe-94	274	27	states	states	PROPN
ajmpe-94	274	28	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	274	29	;	;	PUNCT
ajmpe-94	274	30	mail	mail	NOUN
ajmpe-94	274	31	:	:	PUNCT
ajmpe-94	274	32	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	275	1	80	80	NUM
ajmpe-94	276	1	|	|	ADV
ajmpe-94	276	2	a	a	DET
ajmpe-94	276	3	m	m	NOUN
ajmpe-94	276	4	e	e	NOUN
ajmpe-94	276	5	r	r	NOUN
ajmpe-94	277	1	i	i	NOUN
ajmpe-94	277	2	c	c	VERB
ajmpe-94	277	3	a	a	DET
ajmpe-94	277	4	n	n	NOUN
ajmpe-94	278	1	j	j	NOUN
ajmpe-94	278	2	o	o	X
ajmpe-94	278	3	u	u	NOUN
ajmpe-94	278	4	r	r	NOUN
ajmpe-94	278	5	n	n	NOUN
ajmpe-94	278	6	a	a	DET
ajmpe-94	278	7	l	l	NOUN
ajmpe-94	278	8	o	o	X
ajmpe-94	279	1	f	f	X
ajmpe-94	279	2	m	m	NOUN
ajmpe-94	279	3	e	e	NOUN
ajmpe-94	280	1	d	d	NOUN
ajmpe-94	280	2	i	i	PRON
ajmpe-94	280	3	c	c	VERB
ajmpe-94	280	4	a	a	DET
ajmpe-94	280	5	l	l	NOUN
ajmpe-94	280	6	a	a	X
ajmpe-94	280	7	n	n	NOUN
ajmpe-94	281	1	d	d	NOUN
ajmpe-94	281	2	p	p	NOUN
ajmpe-94	281	3	h	h	NOUN
ajmpe-94	281	4	y	y	NOUN
ajmpe-94	281	5	s	s	VERB
ajmpe-94	282	1	i	i	INTJ
ajmpe-94	282	2	c	c	VERB
ajmpe-94	282	3	a	a	DET
ajmpe-94	282	4	l	l	NOUN
ajmpe-94	282	5	e	e	NOUN
ajmpe-94	282	6	d	d	X
ajmpe-94	282	7	u	u	X
ajmpe-94	282	8	c	c	PROPN
ajmpe-94	283	1	a	a	DET
ajmpe-94	283	2	t	t	NOUN
ajmpe-94	284	1	i	i	PRON
ajmpe-94	284	2	o	o	VERB
ajmpe-94	285	1	n	n	CCONJ
ajmpe-94	285	2	|	|	ADV
ajmpe-94	285	3	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	NOUN
ajmpe-94	285	4	we	we	PRON
ajmpe-94	285	5	would	would	AUX
ajmpe-94	285	6	like	like	VERB
ajmpe-94	285	7	to	to	PART
ajmpe-94	285	8	thank	thank	VERB
ajmpe-94	285	9	the	the	DET
ajmpe-94	285	10	biomedical	biomedical	ADJ
ajmpe-94	285	11	scientist	scientist	NOUN
ajmpe-94	285	12	who	who	PRON
ajmpe-94	285	13	collected	collect	VERB
ajmpe-94	285	14	samples	sample	NOUN
ajmpe-94	285	15	during	during	ADP
ajmpe-94	285	16	the	the	DET
ajmpe-94	285	17	period	period	NOUN
ajmpe-94	285	18	of	of	ADP
ajmpe-94	285	19	research	research	NOUN
ajmpe-94	285	20	and	and	CCONJ
ajmpe-94	285	21	the	the	DET
ajmpe-94	285	22	staff	staff	NOUN
ajmpe-94	285	23	of	of	ADP
ajmpe-94	285	24	the	the	DET
ajmpe-94	285	25	therapeutic	therapeutic	ADJ
ajmpe-94	285	26	hospital	hospital	NOUN
ajmpe-94	285	27	for	for	ADP
ajmpe-94	285	28	patients	patient	NOUN
ajmpe-94	285	29	of	of	ADP
ajmpe-94	285	30	covid-19	covid-19	PROPN
ajmpe-94	285	31	in	in	ADP
ajmpe-94	285	32	khartoum	khartoum	PROPN
ajmpe-94	285	33	state(nursing	state(nursing	PROPN
ajmpe-94	285	34	,	,	PUNCT
ajmpe-94	285	35	doctors	doctor	NOUN
ajmpe-94	285	36	,	,	PUNCT
ajmpe-94	285	37	and	and	CCONJ
ajmpe-94	285	38	medical	medical	ADJ
ajmpe-94	285	39	laboratory	laboratory	NOUN
ajmpe-94	285	40	specialists	specialist	NOUN
ajmpe-94	285	41	)	)	PUNCT
ajmpe-94	285	42	for	for	ADP
ajmpe-94	285	43	providing	provide	VERB
ajmpe-94	285	44	facilities	facility	NOUN
ajmpe-94	285	45	for	for	ADP
ajmpe-94	285	46	this	this	DET
ajmpe-94	285	47	work	work	NOUN
ajmpe-94	285	48	.	.	PUNCT
ajmpe-94	286	1	references	reference	NOUN
ajmpe-94	286	2	wang	wang	PROPN
ajmpe-94	286	3	,	,	PUNCT
ajmpe-94	286	4	l.-f	l.-f	NOUN
ajmpe-94	286	5	.	.	PUNCT
ajmpe-94	286	6	;	;	PUNCT
ajmpe-94	286	7	shi	shi	PROPN
ajmpe-94	286	8	,	,	PUNCT
ajmpe-94	286	9	z.	z.	PROPN
ajmpe-94	286	10	;	;	PUNCT
ajmpe-94	286	11	zhang	zhang	PROPN
ajmpe-94	286	12	,	,	PUNCT
ajmpe-94	286	13	s.	s.	PROPN
ajmpe-94	286	14	;	;	PUNCT
ajmpe-94	286	15	field	field	NOUN
ajmpe-94	286	16	,	,	PUNCT
ajmpe-94	286	17	h.	h.	PROPN
ajmpe-94	286	18	;	;	PUNCT
ajmpe-94	286	19	daszak	daszak	NOUN
ajmpe-94	286	20	,	,	PUNCT
ajmpe-94	286	21	p.	p.	PROPN
ajmpe-94	286	22	;	;	PUNCT
ajmpe-94	287	1	eaton	eaton	PROPN
ajmpe-94	287	2	,	,	PUNCT
ajmpe-94	287	3	b.t	b.t	PROPN
ajmpe-94	287	4	.	.	PROPN
ajmpe-94	287	5	review	review	NOUN
ajmpe-94	287	6	of	of	ADP
ajmpe-94	287	7	bats	bat	NOUN
ajmpe-94	287	8	and	and	CCONJ
ajmpe-94	287	9	sars	sar	NOUN
ajmpe-94	287	10	.	.	PUNCT
ajmpe-94	288	1	emerg	emerg	PROPN
ajmpe-94	288	2	.	.	PUNCT
ajmpe-94	289	1	infect	infect	VERB
ajmpe-94	289	2	.	.	PUNCT
ajmpe-94	290	1	dis	dis	PROPN
ajmpe-94	290	2	.	.	PUNCT
ajmpe-94	290	3	,2006	,2006	PUNCT
ajmpe-94	290	4	;	;	PUNCT
ajmpe-94	290	5	12	12	NUM
ajmpe-94	290	6	:	:	PUNCT
ajmpe-94	290	7	1834–1840	1834–1840	NUM
ajmpe-94	290	8	.	.	PUNCT
ajmpe-94	291	1	ashikujaman	ashikujaman	PROPN
ajmpe-94	291	2	s.	s.	PROPN
ajmpe-94	291	3	coronavirus	coronavirus	PROPN
ajmpe-94	291	4	:	:	PUNCT
ajmpe-94	291	5	a	a	DET
ajmpe-94	291	6	mini	mini	NOUN
ajmpe-94	291	7	-	-	NOUN
ajmpe-94	291	8	review	review	NOUN
ajmpe-94	291	9	.	.	PUNCT
ajmpe-94	292	1	int	int	NOUN
ajmpe-94	292	2	.	.	PUNCT
ajmpe-94	293	1	j.	j.	PROPN
ajmpe-94	293	2	curr	curr	PROPN
ajmpe-94	293	3	.	.	PUNCT
ajmpe-94	294	1	res	re	NOUN
ajmpe-94	294	2	.	.	PUNCT
ajmpe-94	295	1	med	med	PROPN
ajmpe-94	295	2	.	.	PUNCT
ajmpe-94	295	3	sci.202	sci.202	PROPN
ajmpe-94	295	4	;	;	PUNCT
ajmpe-94	295	5	6(1	6(1	NUM
ajmpe-94	295	6	):	):	PUNCT
ajmpe-94	295	7	8	8	NUM
ajmpe-94	295	8	-	-	SYM
ajmpe-94	295	9	10	10	NUM
ajmpe-94	295	10	.	.	PUNCT
ajmpe-94	296	1	huang	huang	PROPN
ajmpe-94	296	2	,	,	PUNCT
ajmpe-94	296	3	c.	c.	PROPN
ajmpe-94	296	4	,	,	PUNCT
ajmpe-94	296	5	wang	wang	PROPN
ajmpe-94	296	6	,	,	PUNCT
ajmpe-94	296	7	y.	y.	PROPN
ajmpe-94	296	8	,	,	PUNCT
ajmpe-94	296	9	li	li	PROPN
ajmpe-94	296	10	,	,	PUNCT
ajmpe-94	296	11	x.	x.	PROPN
ajmpe-94	296	12	,	,	PUNCT
ajmpe-94	296	13	et	et	PROPN
ajmpe-94	296	14	al	al	PROPN
ajmpe-94	296	15	.	.	PUNCT
ajmpe-94	297	1	clinical	clinical	ADJ
ajmpe-94	297	2	features	feature	NOUN
ajmpe-94	297	3	of	of	ADP
ajmpe-94	297	4	patients	patient	NOUN
ajmpe-94	297	5	infected	infect	VERB
ajmpe-94	297	6	with	with	ADP
ajmpe-94	297	7	2019	2019	NUM
ajmpe-94	297	8	novel	novel	ADJ
ajmpe-94	297	9	coronavirus	coronavirus	NOUN
ajmpe-94	297	10	in	in	ADP
ajmpe-94	297	11	wuhan	wuhan	PROPN
ajmpe-94	297	12	,	,	PUNCT
ajmpe-94	297	13	china	china	PROPN
ajmpe-94	297	14	.	.	PUNCT
ajmpe-94	298	1	the	the	DET
ajmpe-94	298	2	lancet	lancet	PROPN
ajmpe-94	298	3	,	,	PUNCT
ajmpe-94	298	4	(	(	PUNCT
ajmpe-94	298	5	2020	2020	NUM
ajmpe-94	298	6	)	)	PUNCT
ajmpe-94	298	7	.	.	PUNCT
ajmpe-94	299	1	395(10223	395(10223	NUM
ajmpe-94	299	2	)	)	PUNCT
ajmpe-94	299	3	,	,	PUNCT
ajmpe-94	299	4	pp.497	pp.497	NOUN
ajmpe-94	299	5	-	-	PUNCT
ajmpe-94	299	6	506	506	NUM
ajmpe-94	299	7	.	.	PUNCT
ajmpe-94	300	1	carlos	carlos	PROPN
ajmpe-94	300	2	wg	wg	PROPN
ajmpe-94	300	3	,	,	PUNCT
ajmpe-94	300	4	dela	dela	PROPN
ajmpe-94	300	5	cruz	cruz	PROPN
ajmpe-94	300	6	cs	cs	PROPN
ajmpe-94	300	7	,	,	PUNCT
ajmpe-94	300	8	cao	cao	PROPN
ajmpe-94	300	9	b	b	PROPN
ajmpe-94	300	10	,	,	PUNCT
ajmpe-94	300	11	pasnick	pasnick	NOUN
ajmpe-94	300	12	s	s	PROPN
ajmpe-94	300	13	,	,	PUNCT
ajmpe-94	300	14	jamil	jamil	PROPN
ajmpe-94	300	15	s.	s.	PROPN
ajmpe-94	300	16	novel	novel	PROPN
ajmpe-94	300	17	wuhan	wuhan	PROPN
ajmpe-94	300	18	(	(	PUNCT
ajmpe-94	300	19	2019	2019	NUM
ajmpe-94	300	20	-	-	PUNCT
ajmpe-94	300	21	ncov	ncov	NOUN
ajmpe-94	300	22	)	)	PUNCT
ajmpe-94	300	23	coronavirus	coronavirus	NOUN
ajmpe-94	300	24	.	.	PUNCT
ajmpe-94	301	1	am	be	AUX
ajmpe-94	301	2	j	j	PROPN
ajmpe-94	301	3	respir	respir	NOUN
ajmpe-94	301	4	crit	crit	PROPN
ajmpe-94	301	5	care	care	NOUN
ajmpe-94	301	6	med	me	VERB
ajmpe-94	301	7	.	.	PUNCT
ajmpe-94	302	1	(	(	PUNCT
ajmpe-94	302	2	2020	2020	NUM
ajmpe-94	302	3	)	)	PUNCT
ajmpe-94	303	1	;	;	PUNCT
ajmpe-94	303	2	201	201	NUM
ajmpe-94	303	3	:	:	PUNCT
ajmpe-94	304	1	p7–8	p7–8	NOUN
ajmpe-94	304	2	.	.	PUNCT
ajmpe-94	305	1	holshue	holshue	NOUN
ajmpe-94	305	2	,	,	PUNCT
ajmpe-94	305	3	m.	m.	NOUN
ajmpe-94	305	4	,	,	PUNCT
ajmpe-94	305	5	debolt	debolt	NOUN
ajmpe-94	305	6	,	,	PUNCT
ajmpe-94	305	7	c.	c.	PROPN
ajmpe-94	305	8	,	,	PUNCT
ajmpe-94	305	9	lindquist	lindquist	PROPN
ajmpe-94	305	10	,	,	PUNCT
ajmpe-94	305	11	s	s	VERB
ajmpe-94	305	12	et	et	NOUN
ajmpe-94	305	13	al	al	PROPN
ajmpe-94	305	14	.	.	PUNCT
ajmpe-94	306	1	first	first	ADJ
ajmpe-94	306	2	case	case	NOUN
ajmpe-94	306	3	of	of	ADP
ajmpe-94	306	4	2019	2019	NUM
ajmpe-94	306	5	novel	novel	ADJ
ajmpe-94	306	6	coronavirus	coronavirus	NOUN
ajmpe-94	306	7	in	in	ADP
ajmpe-94	306	8	the	the	DET
ajmpe-94	306	9	united	united	PROPN
ajmpe-94	306	10	states	states	PROPN
ajmpe-94	306	11	.	.	PUNCT
ajmpe-94	307	1	new	new	PROPN
ajmpe-94	307	2	england	england	PROPN
ajmpe-94	307	3	journal	journal	PROPN
ajmpe-94	307	4	of	of	ADP
ajmpe-94	307	5	medicine	medicine	NOUN
ajmpe-94	307	6	,	,	PUNCT
ajmpe-94	307	7	2020	2020	NUM
ajmpe-94	307	8	;	;	PUNCT
ajmpe-94	307	9	382(10	382(10	NUM
ajmpe-94	307	10	)	)	PUNCT
ajmpe-94	307	11	,	,	PUNCT
ajmpe-94	307	12	pp.929	pp.929	PROPN
ajmpe-94	307	13	-	-	PUNCT
ajmpe-94	307	14	936	936	NUM
ajmpe-94	307	15	.	.	PUNCT
ajmpe-94	308	1	terry	terry	PROPN
ajmpe-94	308	2	j.	j.	PROPN
ajmpe-94	308	3	the	the	DET
ajmpe-94	308	4	major	major	ADJ
ajmpe-94	308	5	electrolytes	electrolyte	NOUN
ajmpe-94	308	6	:	:	PUNCT
ajmpe-94	308	7	sodium	sodium	NOUN
ajmpe-94	308	8	,	,	PUNCT
ajmpe-94	308	9	potassium	potassium	NOUN
ajmpe-94	308	10	,	,	PUNCT
ajmpe-94	308	11	and	and	CCONJ
ajmpe-94	308	12	chloride	chloride	NOUN
ajmpe-94	308	13	.	.	PUNCT
ajmpe-94	309	1	j	j	PROPN
ajmpe-94	309	2	intraven	intraven	PROPN
ajmpe-94	309	3	nurs	nur	VERB
ajmpe-94	309	4	.	.	PUNCT
ajmpe-94	310	1	(	(	PUNCT
ajmpe-94	310	2	2018	2018	NUM
ajmpe-94	310	3	)	)	PUNCT
ajmpe-94	310	4	17(5):240	17(5):240	NUM
ajmpe-94	310	5	-	-	SYM
ajmpe-94	310	6	7	7	NUM
ajmpe-94	310	7	.	.	PUNCT
ajmpe-94	311	1	pmid	pmid	NOUN
ajmpe-94	311	2	:	:	PUNCT
ajmpe-94	311	3	7965369	7965369	NUM
ajmpe-94	311	4	.	.	PUNCT
ajmpe-94	312	1	shrimanker	shrimanker	PROPN
ajmpe-94	312	2	i	i	PRON
ajmpe-94	312	3	,	,	PUNCT
ajmpe-94	312	4	bhattarai	bhattarai	PROPN
ajmpe-94	312	5	s.	s.	PROPN
ajmpe-94	312	6	electrolytes	electrolytes	PROPN
ajmpe-94	312	7	.	.	PUNCT
ajmpe-94	312	8	.	.	PUNCT
ajmpe-94	313	1	in	in	ADP
ajmpe-94	313	2	statpearls	statpearl	NOUN
ajmpe-94	314	1	[	[	X
ajmpe-94	314	2	internet	internet	NOUN
ajmpe-94	314	3	]	]	PUNCT
ajmpe-94	314	4	.	.	PUNCT
ajmpe-94	315	1	treasure	treasure	NOUN
ajmpe-94	315	2	island	island	NOUN
ajmpe-94	315	3	(	(	PUNCT
ajmpe-94	315	4	fl	fl	PROPN
ajmpe-94	315	5	):	):	PUNCT
ajmpe-94	315	6	statpearls	statpearl	NOUN
ajmpe-94	315	7	publishing	publishing	NOUN
ajmpe-94	315	8	;	;	PUNCT
ajmpe-94	315	9	2021	2021	NUM
ajmpe-94	315	10	jan–.	jan–.	PUNCT
ajmpe-94	316	1	pmid	pmid	NOUN
ajmpe-94	316	2	:	:	PUNCT
ajmpe-94	316	3	(	(	PUNCT
ajmpe-94	316	4	2020	2020	NUM
ajmpe-94	316	5	)	)	PUNCT
ajmpe-94	316	6	31082167	31082167	NUM
ajmpe-94	316	7	.	.	PUNCT
ajmpe-94	317	1	lippi	lippi	PROPN
ajmpe-94	317	2	g	g	PROPN
ajmpe-94	317	3	,	,	PUNCT
ajmpe-94	317	4	south	south	PROPN
ajmpe-94	317	5	am	am	PROPN
ajmpe-94	317	6	,	,	PUNCT
ajmpe-94	317	7	henry	henry	PROPN
ajmpe-94	317	8	bm	bm	PROPN
ajmpe-94	317	9	electrolyte	electrolyte	PROPN
ajmpe-94	317	10	imbalances	imbalance	NOUN
ajmpe-94	317	11	in	in	ADP
ajmpe-94	317	12	patients	patient	NOUN
ajmpe-94	317	13	with	with	ADP
ajmpe-94	317	14	severe	severe	ADJ
ajmpe-94	317	15	coronavirus	coronavirus	NOUN
ajmpe-94	317	16	disease	disease	NOUN
ajmpe-94	317	17	2019	2019	NUM
ajmpe-94	317	18	(	(	PUNCT
ajmpe-94	317	19	covid19	covid19	NOUN
ajmpe-94	317	20	)	)	PUNCT
ajmpe-94	317	21	.	.	PUNCT
ajmpe-94	318	1	ann	ann	PROPN
ajmpe-94	318	2	clin	clin	PROPN
ajmpe-94	318	3	biochem	biochem	PROPN
ajmpe-94	318	4	(	(	PUNCT
ajmpe-94	318	5	2020	2020	NUM
ajmpe-94	318	6	)	)	PUNCT
ajmpe-94	318	7	57(3):262–265	57(3):262–265	NOUN
ajmpe-94	318	8	.	.	PUNCT
ajmpe-94	319	1	9	9	NUM
ajmpe-94	319	2	..	..	SYM
ajmpe-94	319	3	berni	berni	PROPN
ajmpe-94	319	4	a	a	X
ajmpe-94	319	5	,	,	PUNCT
ajmpe-94	319	6	malandrino	malandrino	NOUN
ajmpe-94	319	7	d	d	NOUN
ajmpe-94	319	8	,	,	PUNCT
ajmpe-94	319	9	parenti	parenti	NOUN
ajmpe-94	319	10	g	g	PROPN
ajmpe-94	319	11	,	,	PUNCT
ajmpe-94	319	12	maggi	maggi	PROPN
ajmpe-94	319	13	m	m	PROPN
ajmpe-94	319	14	,	,	PUNCT
ajmpe-94	319	15	poggesi	poggesi	PROPN
ajmpe-94	319	16	l	l	NOUN
ajmpe-94	319	17	,	,	PUNCT
ajmpe-94	319	18	peri	peri	VERB
ajmpe-94	319	19	a	a	DET
ajmpe-94	319	20	hyponatremia	hyponatremia	NOUN
ajmpe-94	319	21	,	,	PUNCT
ajmpe-94	319	22	il-6	il-6	NOUN
ajmpe-94	319	23	,	,	PUNCT
ajmpe-94	319	24	and	and	CCONJ
ajmpe-94	319	25	sars	sar	NOUN
ajmpe-94	319	26	-	-	PUNCT
ajmpe-94	319	27	cov-2	cov-2	PART
ajmpe-94	319	28	(	(	PUNCT
ajmpe-94	319	29	covid19	covid19	NOUN
ajmpe-94	319	30	)	)	PUNCT
ajmpe-94	319	31	.	.	PUNCT
ajmpe-94	320	1	(	(	PUNCT
ajmpe-94	320	2	2020	2020	NUM
ajmpe-94	320	3	)	)	PUNCT
ajmpe-94	320	4	.	.	PUNCT
ajmpe-94	321	1	10	10	NUM
ajmpe-94	321	2	-	-	PUNCT
ajmpe-94	321	3	rink	rink	NOUN
ajmpe-94	321	4	l	l	NOUN
ajmpe-94	321	5	,	,	PUNCT
ajmpe-94	321	6	gabriel	gabriel	PROPN
ajmpe-94	321	7	p.	p.	PROPN
ajmpe-94	321	8	zinc	zinc	PROPN
ajmpe-94	321	9	and	and	CCONJ
ajmpe-94	321	10	the	the	DET
ajmpe-94	321	11	immune	immune	ADJ
ajmpe-94	321	12	system	system	NOUN
ajmpe-94	321	13	.	.	PUNCT
ajmpe-94	322	1	proc	proc	NOUN
ajmpe-94	322	2	nutr	nutr	PROPN
ajmpe-94	322	3	soc	soc	PROPN
ajmpe-94	322	4	.	.	PUNCT
ajmpe-94	323	1	(	(	PUNCT
ajmpe-94	323	2	2000	2000	NUM
ajmpe-94	323	3	)	)	PUNCT
ajmpe-94	323	4	;	;	PUNCT
ajmpe-94	324	1	59:541–52	59:541–52	NOUN
ajmpe-94	324	2	.	.	PUNCT
ajmpe-94	325	1	doi	doi	NOUN
ajmpe-94	325	2	:	:	PUNCT
ajmpe-94	325	3	10.1017	10.1017	NUM
ajmpe-94	325	4	/	/	SYM
ajmpe-94	325	5	s0029665100000781	s0029665100000781	PROPN
ajmpe-94	325	6	allen	allen	PROPN
ajmpe-94	325	7	ji	ji	PROPN
ajmpe-94	325	8	,	,	PUNCT
ajmpe-94	325	9	perri	perri	PROPN
ajmpe-94	325	10	rt	rt	PROPN
ajmpe-94	325	11	,	,	PUNCT
ajmpe-94	325	12	mcclain	mcclain	PROPN
ajmpe-94	325	13	cj	cj	PROPN
ajmpe-94	325	14	,	,	PUNCT
ajmpe-94	325	15	kay	kay	PROPN
ajmpe-94	325	16	ne	ne	PROPN
ajmpe-94	325	17	.	.	PUNCT
ajmpe-94	326	1	alterations	alteration	NOUN
ajmpe-94	326	2	in	in	ADP
ajmpe-94	326	3	human	human	ADJ
ajmpe-94	326	4	natural	natural	ADJ
ajmpe-94	326	5	killer	killer	NOUN
ajmpe-94	326	6	cell	cell	NOUN
ajmpe-94	326	7	activity	activity	NOUN
ajmpe-94	326	8	and	and	CCONJ
ajmpe-94	326	9	monocyte	monocyte	NOUN
ajmpe-94	326	10	cytotoxicity	cytotoxicity	NOUN
ajmpe-94	326	11	induced	induce	VERB
ajmpe-94	326	12	by	by	ADP
ajmpe-94	326	13	zinc	zinc	NOUN
ajmpe-94	326	14	deficiency	deficiency	NOUN
ajmpe-94	326	15	.	.	PUNCT
ajmpe-94	327	1	j	j	PROPN
ajmpe-94	327	2	lab	lab	PROPN
ajmpe-94	327	3	clin	clin	PROPN
ajmpe-94	327	4	med	med	PROPN
ajmpe-94	327	5	.	.	PUNCT
ajmpe-94	328	1	(	(	PUNCT
ajmpe-94	328	2	1983	1983	NUM
ajmpe-94	328	3	)	)	PUNCT
ajmpe-94	328	4	102:577–89	102:577–89	NUM
ajmpe-94	328	5	.	.	PUNCT
ajmpe-94	329	1	kardos	kardos	PROPN
ajmpe-94	329	2	j	j	PROPN
ajmpe-94	329	3	,	,	PUNCT
ajmpe-94	329	4	héja	héja	PROPN
ajmpe-94	329	5	l	l	NOUN
ajmpe-94	329	6	,	,	PUNCT
ajmpe-94	329	7	simon	simon	PROPN
ajmpe-94	329	8	á	á	PROPN
ajmpe-94	329	9	,	,	PUNCT
ajmpe-94	329	10	jablonkai	jablonkai	PROPN
ajmpe-94	329	11	i	i	PRON
ajmpe-94	329	12	,	,	PUNCT
ajmpe-94	329	13	kovács	kovács	PROPN
ajmpe-94	329	14	r	r	NOUN
ajmpe-94	329	15	,	,	PUNCT
ajmpe-94	329	16	jemnitz	jemnitz	PROPN
ajmpe-94	329	17	k	k	PROPN
ajmpe-94	329	18	.	.	PUNCT
ajmpe-94	330	1	copper	copper	NOUN
ajmpe-94	330	2	signaling	signaling	NOUN
ajmpe-94	330	3	:	:	PUNCT
ajmpe-94	330	4	causes	cause	NOUN
ajmpe-94	330	5	and	and	CCONJ
ajmpe-94	330	6	consequences	consequence	NOUN
ajmpe-94	330	7	.	.	PUNCT
ajmpe-94	331	1	ccs	ccs	PROPN
ajmpe-94	331	2	2018	2018	NUM
ajmpe-94	331	3	;	;	PUNCT
ajmpe-94	331	4	16(1):1–22	16(1):1–22	NUM
ajmpe-94	331	5	ilbäck	ilbäck	NOUN
ajmpe-94	331	6	n	n	CCONJ
ajmpe-94	331	7	-	-	PUNCT
ajmpe-94	331	8	g	g	NOUN
ajmpe-94	331	9	,	,	PUNCT
ajmpe-94	331	10	frisk	frisk	NOUN
ajmpe-94	331	11	p	p	NOUN
ajmpe-94	331	12	,	,	PUNCT
ajmpe-94	331	13	tallkvist	tallkvist	ADJ
ajmpe-94	331	14	j	j	PROPN
ajmpe-94	331	15	,	,	PUNCT
ajmpe-94	331	16	gadhasson	gadhasson	NOUN
ajmpe-94	331	17	i	i	PROPN
ajmpe-94	331	18	-	-	PROPN
ajmpe-94	331	19	l	l	PROPN
ajmpe-94	331	20	,	,	PUNCT
ajmpe-94	331	21	blomberg	blomberg	PROPN
ajmpe-94	331	22	j	j	PROPN
ajmpe-94	331	23	,	,	PUNCT
ajmpe-94	331	24	friman	friman	NOUN
ajmpe-94	331	25	g	g	NOUN
ajmpe-94	331	26	.	.	PUNCT
ajmpe-94	332	1	gastrointestinal	gastrointestinal	ADJ
ajmpe-94	332	2	uptake	uptake	NOUN
ajmpe-94	332	3	of	of	ADP
ajmpe-94	332	4	trace	trace	NOUN
ajmpe-94	332	5	elements	element	NOUN
ajmpe-94	332	6	are	be	AUX
ajmpe-94	332	7	changed	change	VERB
ajmpe-94	332	8	during	during	ADP
ajmpe-94	332	9	a	a	DET
ajmpe-94	332	10	common	common	ADJ
ajmpe-94	332	11	human	human	ADJ
ajmpe-94	332	12	viral	viral	ADJ
ajmpe-94	332	13	(	(	PUNCT
ajmpe-94	332	14	coxsackievirus	coxsackievirus	NOUN
ajmpe-94	332	15	b3	b3	PROPN
ajmpe-94	332	16	)	)	PUNCT
ajmpe-94	332	17	infection	infection	NOUN
ajmpe-94	332	18	in	in	ADP
ajmpe-94	332	19	mice	mouse	NOUN
ajmpe-94	332	20	.	.	PUNCT
ajmpe-94	333	1	j	j	PROPN
ajmpe-94	333	2	trace	trace	NOUN
ajmpe-94	333	3	elem	elem	NOUN
ajmpe-94	333	4	med	med	ADJ
ajmpe-94	333	5	biol	biol	NOUN
ajmpe-94	333	6	2008	2008	NUM
ajmpe-94	333	7	;	;	PUNCT
ajmpe-94	333	8	22(2):120–130	22(2):120–130	PROPN
ajmpe-94	333	9	cernat	cernat	PROPN
ajmpe-94	333	10	r	r	PROPN
ajmpe-94	333	11	,	,	PUNCT
ajmpe-94	333	12	mihaescu	mihaescu	PROPN
ajmpe-94	333	13	t	t	PROPN
ajmpe-94	333	14	,	,	PUNCT
ajmpe-94	333	15	vornicu	vornicu	PROPN
ajmpe-94	333	16	m	m	PROPN
ajmpe-94	333	17	,	,	PUNCT
ajmpe-94	333	18	vione	vione	VERB
ajmpe-94	333	19	d	d	NOUN
ajmpe-94	333	20	,	,	PUNCT
ajmpe-94	333	21	olariu	olariu	ADJ
ajmpe-94	333	22	r	r	NOUN
ajmpe-94	333	23	,	,	PUNCT
ajmpe-94	333	24	arsene	arsene	PROPN
ajmpe-94	333	25	c	c	PROPN
ajmpe-94	333	26	.	.	PUNCT
ajmpe-94	334	1	serum	serum	NOUN
ajmpe-94	334	2	trace	trace	NOUN
ajmpe-94	334	3	metal	metal	NOUN
ajmpe-94	334	4	and	and	CCONJ
ajmpe-94	334	5	ceruloplasmin	ceruloplasmin	NOUN
ajmpe-94	334	6	variability	variability	NOUN
ajmpe-94	334	7	in	in	ADP
ajmpe-94	334	8	individuals	individual	NOUN
ajmpe-94	334	9	treated	treat	VERB
ajmpe-94	334	10	for	for	ADP
ajmpe-94	334	11	pulmonary	pulmonary	ADJ
ajmpe-94	334	12	tuberculosis	tuberculosis	NOUN
ajmpe-94	334	13	.	.	PUNCT
ajmpe-94	335	1	int	int	NOUN
ajmpe-94	335	2	j	j	PROPN
ajmpe-94	335	3	tuberc	tuberc	PROPN
ajmpe-94	335	4	lung	lung	PROPN
ajmpe-94	335	5	dis	dis	PROPN
ajmpe-94	335	6	2011	2011	NUM
ajmpe-94	335	7	;	;	PUNCT
ajmpe-94	335	8	15(9):1239	15(9):1239	NUM
ajmpe-94	335	9	–	–	PUNCT
ajmpe-94	335	10	1245	1245	NUM
ajmpe-94	335	11	besold	besold	VERB
ajmpe-94	335	12	an	an	PRON
ajmpe-94	335	13	,	,	PUNCT
ajmpe-94	335	14	culbertson	culbertson	PROPN
ajmpe-94	335	15	em	em	PRON
ajmpe-94	335	16	,	,	PUNCT
ajmpe-94	335	17	culotta	culotta	PROPN
ajmpe-94	335	18	vc	vc	PROPN
ajmpe-94	335	19	.the	.the	PROPN
ajmpe-94	335	20	yin	yin	PROPN
ajmpe-94	335	21	and	and	CCONJ
ajmpe-94	335	22	yang	yang	PROPN
ajmpe-94	335	23	of	of	ADP
ajmpe-94	335	24	copper	copper	NOUN
ajmpe-94	335	25	during	during	ADP
ajmpe-94	335	26	infection	infection	NOUN
ajmpe-94	335	27	.	.	PUNCT
ajmpe-94	336	1	j	j	PROPN
ajmpe-94	336	2	biol	biol	PROPN
ajmpe-94	336	3	inorg	inorg	PROPN
ajmpe-94	336	4	chem	chem	NOUN
ajmpe-94	336	5	2016	2016	NUM
ajmpe-94	336	6	;	;	PUNCT
ajmpe-94	336	7	21(2):137–144	21(2):137–144	PROPN
ajmpe-94	336	8	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	336	9	american	american	PROPN
ajmpe-94	336	10	journal	journal	PROPN
ajmpe-94	336	11	of	of	ADP
ajmpe-94	336	12	medical	medical	ADJ
ajmpe-94	336	13	and	and	CCONJ
ajmpe-94	336	14	physical	physical	ADJ
ajmpe-94	336	15	education	education	NOUN
ajmpe-94	336	16	vol.1	vol.1	PROPN
ajmpe-94	336	17	,	,	PUNCT
ajmpe-94	336	18	issue	issue	NOUN
ajmpe-94	336	19	1	1	NUM
ajmpe-94	336	20	;	;	PUNCT
ajmpe-94	336	21	july	july	PROPN
ajmpe-94	336	22	2023	2023	NUM
ajmpe-94	336	23	;	;	PUNCT
ajmpe-94	336	24	1252	1252	NUM
ajmpe-94	336	25	columbia	columbia	PROPN
ajmpe-94	336	26	rd	rd	PROPN
ajmpe-94	336	27	nw	nw	PROPN
ajmpe-94	336	28	,	,	PUNCT
ajmpe-94	336	29	washington	washington	PROPN
ajmpe-94	336	30	dc	dc	PROPN
ajmpe-94	336	31	,	,	PUNCT
ajmpe-94	336	32	united	united	PROPN
ajmpe-94	336	33	states	states	PROPN
ajmpe-94	336	34	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	336	35	;	;	PUNCT
ajmpe-94	336	36	mail	mail	NOUN
ajmpe-94	336	37	:	:	PUNCT
ajmpe-94	337	1	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	337	2	81	81	NUM
ajmpe-94	338	1	|	|	ADV
ajmpe-94	338	2	a	a	DET
ajmpe-94	338	3	m	m	NOUN
ajmpe-94	338	4	e	e	NOUN
ajmpe-94	338	5	r	r	NOUN
ajmpe-94	339	1	i	i	NOUN
ajmpe-94	339	2	c	c	VERB
ajmpe-94	339	3	a	a	DET
ajmpe-94	339	4	n	n	NOUN
ajmpe-94	340	1	j	j	NOUN
ajmpe-94	340	2	o	o	X
ajmpe-94	340	3	u	u	NOUN
ajmpe-94	340	4	r	r	NOUN
ajmpe-94	340	5	n	n	NOUN
ajmpe-94	340	6	a	a	DET
ajmpe-94	340	7	l	l	NOUN
ajmpe-94	340	8	o	o	X
ajmpe-94	341	1	f	f	X
ajmpe-94	341	2	m	m	NOUN
ajmpe-94	341	3	e	e	NOUN
ajmpe-94	342	1	d	d	NOUN
ajmpe-94	342	2	i	i	PRON
ajmpe-94	342	3	c	c	VERB
ajmpe-94	342	4	a	a	DET
ajmpe-94	342	5	l	l	NOUN
ajmpe-94	342	6	a	a	X
ajmpe-94	342	7	n	n	NOUN
ajmpe-94	343	1	d	d	NOUN
ajmpe-94	343	2	p	p	NOUN
ajmpe-94	343	3	h	h	NOUN
ajmpe-94	343	4	y	y	NOUN
ajmpe-94	343	5	s	s	VERB
ajmpe-94	344	1	i	i	INTJ
ajmpe-94	344	2	c	c	VERB
ajmpe-94	344	3	a	a	DET
ajmpe-94	344	4	l	l	NOUN
ajmpe-94	344	5	e	e	NOUN
ajmpe-94	344	6	d	d	X
ajmpe-94	344	7	u	u	X
ajmpe-94	344	8	c	c	PROPN
ajmpe-94	345	1	a	a	DET
ajmpe-94	345	2	t	t	NOUN
ajmpe-94	346	1	i	i	PRON
ajmpe-94	346	2	o	o	VERB
ajmpe-94	346	3	n	n	CCONJ
ajmpe-94	346	4	|	|	ADV
ajmpe-94	346	5	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	ADJ
ajmpe-94	346	6	kanellopoulou	kanellopoulou	PROPN
ajmpe-94	346	7	c	c	PROPN
ajmpe-94	346	8	,	,	PUNCT
ajmpe-94	346	9	george	george	PROPN
ajmpe-94	346	10	ab	ab	PROPN
ajmpe-94	346	11	,	,	PUNCT
ajmpe-94	346	12	masutani	masutani	PROPN
ajmpe-94	346	13	e	e	NOUN
ajmpe-94	346	14	,	,	PUNCT
ajmpe-94	346	15	cannons	cannon	NOUN
ajmpe-94	346	16	jl	jl	NOUN
ajmpe-94	346	17	,	,	PUNCT
ajmpe-94	346	18	ravell	ravell	VERB
ajmpe-94	346	19	jc	jc	PROPN
ajmpe-94	346	20	,	,	PUNCT
ajmpe-94	346	21	yamamoto	yamamoto	PROPN
ajmpe-94	346	22	tn	tn	PROPN
ajmpe-94	346	23	,	,	PUNCT
ajmpe-94	346	24	smelkinsonmg	smelkinsonmg	NOUN
ajmpe-94	346	25	,	,	PUNCT
ajmpe-94	346	26	jiang	jiang	PROPN
ajmpe-94	346	27	pd	pd	PROPN
ajmpe-94	346	28	,	,	PUNCT
ajmpe-94	346	29	matsuda	matsuda	NOUN
ajmpe-94	346	30	-	-	PUNCT
ajmpe-94	346	31	lennikov	lennikov	PROPN
ajmpe-94	346	32	m	m	PROPN
ajmpe-94	346	33	,	,	PUNCT
ajmpe-94	346	34	reilley	reilley	PROPN
ajmpe-94	346	35	j	j	PROPN
ajmpe-94	346	36	.	.	PUNCT
ajmpe-94	347	1	mg2	mg2	PROPN
ajmpe-94	347	2	+	+	NUM
ajmpe-94	347	3	regulation	regulation	NOUN
ajmpe-94	347	4	of	of	ADP
ajmpe-94	347	5	kinase	kinase	NOUN
ajmpe-94	347	6	signaling	signal	VERB
ajmpe-94	347	7	and	and	CCONJ
ajmpe-94	347	8	immune	immune	ADJ
ajmpe-94	347	9	function	function	NOUN
ajmpe-94	347	10	.	.	PUNCT
ajmpe-94	348	1	j	j	PROPN
ajmpe-94	348	2	exp	exp	NOUN
ajmpe-94	348	3	med	me	VERB
ajmpe-94	348	4	2019	2019	NUM
ajmpe-94	348	5	;	;	PUNCT
ajmpe-94	349	1	216(8):1828–1842	216(8):1828–1842	NUM
ajmpe-94	349	2	ye	ye	NUM
ajmpe-94	349	3	m	m	PROPN
ajmpe-94	349	4	,	,	PUNCT
ajmpe-94	349	5	li	li	PROPN
ajmpe-94	349	6	q	q	PROPN
ajmpe-94	349	7	,	,	PUNCT
ajmpe-94	349	8	xiao	xiao	PROPN
ajmpe-94	349	9	l	l	PROPN
ajmpe-94	349	10	,	,	PUNCT
ajmpe-94	349	11	zheng	zheng	PROPN
ajmpe-94	349	12	z	z	PROPN
ajmpe-94	349	13	.	.	PUNCT
ajmpe-94	350	1	serum	serum	PROPN
ajmpe-94	350	2	magnesium	magnesium	NOUN
ajmpe-94	350	3	and	and	CCONJ
ajmpe-94	350	4	fractional	fractional	ADJ
ajmpe-94	350	5	exhaled	exhale	VERB
ajmpe-94	350	6	nitric	nitric	ADJ
ajmpe-94	350	7	oxide	oxide	NOUN
ajmpe-94	350	8	about	about	ADP
ajmpe-94	350	9	the	the	DET
ajmpe-94	350	10	severity	severity	NOUN
ajmpe-94	350	11	in	in	ADP
ajmpe-94	350	12	asthma	asthma	NOUN
ajmpe-94	350	13	chronic	chronic	ADJ
ajmpe-94	350	14	obstructive	obstructive	ADJ
ajmpe-94	350	15	pulmonary	pulmonary	ADJ
ajmpe-94	350	16	disease	disease	NOUN
ajmpe-94	350	17	overlap	overlap	NOUN
ajmpe-94	350	18	.	.	PUNCT
ajmpe-94	351	1	biol	biol	ADJ
ajmpe-94	351	2	trace	trace	NOUN
ajmpe-94	351	3	elem	elem	NOUN
ajmpe-94	351	4	res.2020	res.2020	ADP
ajmpe-94	351	5	https://doi.org/10.1007/s12011-020-02314-5	https://doi.org/10.1007/s12011-020-02314-5	NUM
ajmpe-94	351	6	18	18	NUM
ajmpe-94	351	7	-	-	SYM
ajmpe-94	351	8	69	69	NUM
ajmpe-94	351	9	-	-	PUNCT
ajmpe-94	351	10	tietz	tietz	VERB
ajmpe-94	351	11	,	,	PUNCT
ajmpe-94	351	12	n.w	n.w	PROPN
ajmpe-94	351	13	.	.	PROPN
ajmpe-94	351	14	(	(	PUNCT
ajmpe-94	351	15	ed	ed	NOUN
ajmpe-94	351	16	)	)	PUNCT
ajmpe-94	351	17	fundamentals	fundamental	NOUN
ajmpe-94	351	18	of	of	ADP
ajmpe-94	351	19	clinical	clinical	ADJ
ajmpe-94	351	20	chemistry,2008	chemistry,2008	NOUN
ajmpe-94	351	21	;	;	PUNCT
ajmpe-94	351	22	6th	6th	ADJ
ajmpe-94	351	23	ed	ed	NOUN
ajmpe-94	351	24	.	.	PUNCT
ajmpe-94	351	25	p.836	p.836	PROPN
ajmpe-94	351	26	-	-	PUNCT
ajmpe-94	351	27	871	871	NUM
ajmpe-94	351	28	19	19	NUM
ajmpe-94	351	29	-	-	PUNCT
ajmpe-94	351	30	sergey	sergey	PROPN
ajmpe-94	351	31	makarychev	makarychev	PROPN
ajmpe-94	351	32	-mikhailov	-mikhailov	PROPN
ajmpe-94	351	33	,	,	PUNCT
ajmpe-94	351	34	alexey	alexey	PROPN
ajmpe-94	351	35	shvarev	shvarev	PROPN
ajmpe-94	351	36	,	,	PUNCT
ajmpe-94	351	37	eric	eric	PROPN
ajmpe-94	351	38	bakker	bakker	PROPN
ajmpe-94	351	39	new	new	ADJ
ajmpe-94	351	40	trend	trend	NOUN
ajmpe-94	351	41	in	in	ADP
ajmpe-94	351	42	iron	iron	NOUN
ajmpe-94	351	43	selective	selective	ADJ
ajmpe-94	351	44	electrode	electrode	NOUN
ajmpe-94	351	45	,	,	PUNCT
ajmpe-94	351	46	electrochemical	electrochemical	ADJ
ajmpe-94	351	47	sensor	sensor	NOUN
ajmpe-94	351	48	,	,	PUNCT
ajmpe-94	351	49	biosensor	biosensor	NOUN
ajmpe-94	351	50	and	and	CCONJ
ajmpe-94	351	51	their	their	PRON
ajmpe-94	351	52	applications	application	NOUN
ajmpe-94	351	53	2008;71	2008;71	NUM
ajmpe-94	351	54	-114	-114	PUNCT
ajmpe-94	352	1	d	d	X
ajmpe-94	352	2	j	j	PROPN
ajmpe-94	352	3	johnson	johnson	PROPN
ajmpe-94	352	4	,	,	PUNCT
ajmpe-94	352	5	yy	yy	PROPN
ajmpe-94	352	6	djuh	djuh	PROPN
ajmpe-94	352	7	,	,	PUNCT
ajmpe-94	352	8	j	j	PROPN
ajmpe-94	352	9	bruton	bruton	PROPN
ajmpe-94	352	10	,	,	PUNCT
ajmpe-94	352	11	hl	hl	PROPN
ajmpe-94	352	12	williams	williams	PROPN
ajmpe-94	352	13	,	,	PUNCT
ajmpe-94	352	14	improved	improve	VERB
ajmpe-94	352	15	colorimetric	colorimetric	ADJ
ajmpe-94	352	16	determination	determination	NOUN
ajmpe-94	352	17	of	of	ADP
ajmpe-94	352	18	serum	serum	NOUN
ajmpe-94	352	19	zinc	zinc	NOUN
ajmpe-94	352	20	clinical	clinical	ADJ
ajmpe-94	352	21	chemistry	chemistry	NOUN
ajmpe-94	352	22	1977	1977	NUM
ajmpe-94	352	23	;	;	PUNCT
ajmpe-94	352	24	23	23	NUM
ajmpe-94	352	25	,	,	PUNCT
ajmpe-94	352	26	1321	1321	NUM
ajmpe-94	352	27	1323	1323	NUM
ajmpe-94	352	28	wu	wu	PROPN
ajmpe-94	352	29	z	z	PROPN
ajmpe-94	352	30	,	,	PUNCT
ajmpe-94	352	31	mcgoogan	mcgoogan	PROPN
ajmpe-94	352	32	jm	jm	PROPN
ajmpe-94	352	33	.	.	PROPN
ajmpe-94	352	34	characteristics	characteristic	NOUN
ajmpe-94	352	35	of	of	ADP
ajmpe-94	352	36	and	and	CCONJ
ajmpe-94	352	37	important	important	ADJ
ajmpe-94	352	38	lessons	lesson	NOUN
ajmpe-94	352	39	from	from	ADP
ajmpe-94	352	40	the	the	DET
ajmpe-94	352	41	coronavirus	coronavirus	NOUN
ajmpe-94	352	42	disease	disease	NOUN
ajmpe-94	352	43	2019	2019	NUM
ajmpe-94	352	44	(	(	PUNCT
ajmpe-94	352	45	covid19	covid19	NOUN
ajmpe-94	352	46	)	)	PUNCT
ajmpe-94	352	47	outbreak	outbreak	NOUN
ajmpe-94	352	48	in	in	ADP
ajmpe-94	352	49	china	china	PROPN
ajmpe-94	352	50	:	:	PUNCT
ajmpe-94	352	51	summary	summary	NOUN
ajmpe-94	352	52	of	of	ADP
ajmpe-94	352	53	a	a	DET
ajmpe-94	352	54	report	report	NOUN
ajmpe-94	352	55	of	of	ADP
ajmpe-94	352	56	72,314	72,314	NUM
ajmpe-94	352	57	cases	case	NOUN
ajmpe-94	352	58	from	from	ADP
ajmpe-94	352	59	the	the	DET
ajmpe-94	352	60	chinese	chinese	ADJ
ajmpe-94	352	61	center	center	NOUN
ajmpe-94	352	62	for	for	ADP
ajmpe-94	352	63	disease	disease	NOUN
ajmpe-94	352	64	control	control	NOUN
ajmpe-94	352	65	and	and	CCONJ
ajmpe-94	352	66	prevention	prevention	NOUN
ajmpe-94	352	67	.	.	PUNCT
ajmpe-94	353	1	j	j	PROPN
ajmpe-94	353	2	am	be	AUX
ajmpe-94	353	3	med	med	ADJ
ajmpe-94	353	4	assoc	assoc	NOUN
ajmpe-94	353	5	;	;	PUNCT
ajmpe-94	353	6	(	(	PUNCT
ajmpe-94	353	7	2020	2020	NUM
ajmpe-94	353	8	)	)	PUNCT
ajmpe-94	353	9	;	;	PUNCT
ajmpe-94	353	10	323(13	323(13	NUM
ajmpe-94	353	11	):	):	PUNCT
ajmpe-94	353	12	1239	1239	NUM
ajmpe-94	353	13	-	-	SYM
ajmpe-94	353	14	42	42	NUM
ajmpe-94	353	15	.	.	PUNCT
ajmpe-94	354	1	chan	chan	PROPN
ajmpe-94	354	2	jfw	jfw	PROPN
ajmpe-94	354	3	,	,	PUNCT
ajmpe-94	354	4	yuan	yuan	PROPN
ajmpe-94	354	5	s	s	PROPN
ajmpe-94	354	6	,	,	PUNCT
ajmpe-94	354	7	kok	kok	PROPN
ajmpe-94	354	8	kh	kh	PROPN
ajmpe-94	354	9	,	,	PUNCT
ajmpe-94	354	10	to	to	ADP
ajmpe-94	354	11	kk	kk	PROPN
ajmpe-94	354	12	,	,	PUNCT
ajmpe-94	354	13	chu	chu	PROPN
ajmpe-94	354	14	h	h	PROPN
ajmpe-94	354	15	,	,	PUNCT
ajmpe-94	354	16	yang	yang	PROPN
ajmpe-94	354	17	j.	j.	PROPN
ajmpe-94	355	1	a	a	DET
ajmpe-94	355	2	familial	familial	ADJ
ajmpe-94	355	3	cluster	cluster	NOUN
ajmpe-94	355	4	of	of	ADP
ajmpe-94	355	5	pneumonia	pneumonia	NOUN
ajmpe-94	355	6	associated	associate	VERB
ajmpe-94	355	7	with	with	ADP
ajmpe-94	355	8	the	the	DET
ajmpe-94	355	9	2019	2019	NUM
ajmpe-94	355	10	novel	novel	ADJ
ajmpe-94	355	11	coronavirus	coronavirus	NOUN
ajmpe-94	355	12	indicating	indicate	VERB
ajmpe-94	355	13	person	person	NOUN
ajmpe-94	355	14	-	-	PUNCT
ajmpe-94	355	15	to	to	ADP
ajmpe-94	355	16	-	-	PUNCT
ajmpe-94	355	17	person	person	NOUN
ajmpe-94	355	18	transmission	transmission	NOUN
ajmpe-94	355	19	:	:	PUNCT
ajmpe-94	355	20	a	a	DET
ajmpe-94	355	21	study	study	NOUN
ajmpe-94	355	22	of	of	ADP
ajmpe-94	355	23	a	a	DET
ajmpe-94	355	24	family	family	NOUN
ajmpe-94	355	25	cluster	cluster	NOUN
ajmpe-94	355	26	.	.	PUNCT
ajmpe-94	356	1	lancet	lancet	PROPN
ajmpe-94	356	2	.	.	PUNCT
ajmpe-94	357	1	(	(	PUNCT
ajmpe-94	357	2	2020	2020	NUM
ajmpe-94	357	3	)	)	PUNCT
ajmpe-94	357	4	;	;	PUNCT
ajmpe-94	358	1	140	140	NUM
ajmpe-94	358	2	-	-	SYM
ajmpe-94	358	3	6736(20	6736(20	NUM
ajmpe-94	358	4	):	):	PUNCT
ajmpe-94	358	5	30154	30154	NUM
ajmpe-94	358	6	-	-	SYM
ajmpe-94	358	7	59	59	NUM
ajmpe-94	358	8	.	.	PUNCT
ajmpe-94	358	9	phan	phan	PROPN
ajmpe-94	358	10	lt	lt	PROPN
ajmpe-94	358	11	,	,	PUNCT
ajmpe-94	358	12	nguyen	nguyen	PROPN
ajmpe-94	358	13	tv	tv	PROPN
ajmpe-94	358	14	,	,	PUNCT
ajmpe-94	358	15	luong	luong	PROPN
ajmpe-94	358	16	qc	qc	PROPN
ajmpe-94	358	17	,	,	PUNCT
ajmpe-94	358	18	nguyen	nguyen	PROPN
ajmpe-94	358	19	tv	tv	PROPN
ajmpe-94	358	20	,	,	PUNCT
ajmpe-94	358	21	nguyen	nguyen	PROPN
ajmpe-94	358	22	ht	ht	PROPN
ajmpe-94	358	23	,	,	PUNCT
ajmpe-94	358	24	le	le	X
ajmpe-94	358	25	hq	hq	PROPN
ajmpe-94	358	26	,	,	PUNCT
ajmpe-94	358	27	et	et	PROPN
ajmpe-94	358	28	al	al	PROPN
ajmpe-94	358	29	importation	importation	NOUN
ajmpe-94	358	30	and	and	CCONJ
ajmpe-94	358	31	human	human	NOUN
ajmpe-94	358	32	-	-	PUNCT
ajmpe-94	358	33	to	to	ADP
ajmpe-94	358	34	-	-	PUNCT
ajmpe-94	358	35	human	human	ADJ
ajmpe-94	358	36	transmission	transmission	NOUN
ajmpe-94	358	37	of	of	ADP
ajmpe-94	358	38	a	a	DET
ajmpe-94	358	39	novel	novel	ADJ
ajmpe-94	358	40	coronavirus	coronavirus	NOUN
ajmpe-94	358	41	in	in	ADP
ajmpe-94	358	42	vietnam	vietnam	PROPN
ajmpe-94	358	43	.	.	PUNCT
ajmpe-94	359	1	n	n	PROPN
ajmpe-94	359	2	engl	engl	PROPN
ajmpe-94	359	3	j	j	PROPN
ajmpe-94	359	4	med	med	PROPN
ajmpe-94	359	5	2020	2020	NUM
ajmpe-94	359	6	,	,	PUNCT
ajmpe-94	359	7	382(9	382(9	NUM
ajmpe-94	359	8	):	):	PUNCT
ajmpe-94	359	9	87274	87274	NUM
ajmpe-94	359	10	.	.	PUNCT
ajmpe-94	360	1	hct	hct	PROPN
ajmpe-94	360	2	&	&	CCONJ
ajmpe-94	360	3	unct	unct	PROPN
ajmpe-94	360	4	.	.	PUNCT
ajmpe-94	361	1	sudancoronaviruscovid-19	sudancoronaviruscovid-19	PROPN
ajmpe-94	361	2	country	country	NOUN
ajmpe-94	361	3	preparedness	preparedness	NOUN
ajmpe-94	361	4	and	and	CCONJ
ajmpe-94	361	5	response	response	NOUN
ajmpe-94	361	6	plan	plan	NOUN
ajmpe-94	361	7	[	[	X
ajmpe-94	361	8	internet	internet	NOUN
ajmpe-94	361	9	]	]	PUNCT
ajmpe-94	361	10	.	.	PUNCT
ajmpe-94	362	1	(	(	PUNCT
ajmpe-94	362	2	2020	2020	NUM
ajmpe-94	362	3	)	)	PUNCT
ajmpe-94	362	4	team	team	NOUN
ajmpe-94	362	5	tncpere	tncpere	NOUN
ajmpe-94	362	6	.	.	PUNCT
ajmpe-94	363	1	the	the	DET
ajmpe-94	363	2	epidemiological	epidemiological	ADJ
ajmpe-94	363	3	characteristics	characteristic	NOUN
ajmpe-94	363	4	of	of	ADP
ajmpe-94	363	5	an	an	DET
ajmpe-94	363	6	outbreak	outbreak	NOUN
ajmpe-94	363	7	of	of	ADP
ajmpe-94	363	8	2019	2019	NUM
ajmpe-94	363	9	novel	novel	ADJ
ajmpe-94	363	10	coronavirus	coronavirus	NOUN
ajmpe-94	363	11	diseases	disease	NOUN
ajmpe-94	363	12	(	(	PUNCT
ajmpe-94	363	13	covid19	covid19	NOUN
ajmpe-94	363	14	)	)	PUNCT
ajmpe-94	363	15	in	in	ADP
ajmpe-94	363	16	china	china	PROPN
ajmpe-94	363	17	.	.	PUNCT
ajmpe-94	364	1	chin	chin	PROPN
ajmpe-94	364	2	j	j	PROPN
ajmpe-94	364	3	epidemiol	epidemiol	PROPN
ajmpe-94	364	4	.	.	PUNCT
ajmpe-94	365	1	20202(8),113	20202(8),113	NUM
ajmpe-94	365	2	-	-	SYM
ajmpe-94	365	3	122	122	NUM
ajmpe-94	365	4	.	.	PUNCT
ajmpe-94	366	1	carvalho	carvalho	PROPN
ajmpe-94	366	2	hugo	hugo	PROPN
ajmpe-94	366	3	de	de	PROPN
ajmpe-94	366	4	,	,	PUNCT
ajmpe-94	366	5	marie	marie	PROPN
ajmpe-94	366	6	caroline	caroline	PROPN
ajmpe-94	366	7	richard	richard	PROPN
ajmpe-94	366	8	,	,	PUNCT
ajmpe-94	366	9	tahar	tahar	PROPN
ajmpe-94	366	10	chouihed	chouihe	VERB
ajmpe-94	366	11	,	,	PUNCT
ajmpe-94	366	12	nicolas	nicolas	PROPN
ajmpe-94	366	13	goffinet	goffinet	PROPN
ajmpe-94	366	14	and	and	CCONJ
ajmpe-94	366	15	quentin	quentin	PROPN
ajmpe-94	366	16	le	le	PROPN
ajmpe-94	366	17	bastard	bastard	PROPN
ajmpe-94	366	18	et	et	PROPN
ajmpe-94	366	19	al	al	PROPN
ajmpe-94	366	20	.	.	PROPN
ajmpe-94	366	21	electrolyte	electrolyte	PROPN
ajmpe-94	366	22	imbalance	imbalance	NOUN
ajmpe-94	366	23	in	in	ADP
ajmpe-94	366	24	covid‑19	covid‑19	PROPN
ajmpe-94	366	25	patients	patient	NOUN
ajmpe-94	366	26	admitted	admit	VERB
ajmpe-94	366	27	to	to	ADP
ajmpe-94	366	28	the	the	DET
ajmpe-94	366	29	emergency	emergency	NOUN
ajmpe-94	366	30	department	department	NOUN
ajmpe-94	366	31	:	:	PUNCT
ajmpe-94	366	32	a	a	DET
ajmpe-94	366	33	case	case	NOUN
ajmpe-94	366	34	-	-	PUNCT
ajmpe-94	366	35	control	control	NOUN
ajmpe-94	366	36	study	study	NOUN
ajmpe-94	366	37	.	.	PUNCT
ajmpe-94	367	1	internal	internal	ADJ
ajmpe-94	367	2	and	and	CCONJ
ajmpe-94	367	3	emergency	emergency	NOUN
ajmpe-94	367	4	medicine.2021	medicine.2021	PROPN
ajmpe-94	367	5	;	;	PUNCT
ajmpe-94	367	6	1	1	NUM
ajmpe-94	367	7	-	-	SYM
ajmpe-94	367	8	6	6	NUM
ajmpe-94	367	9	.	.	PUNCT
ajmpe-94	368	1	lippi	lippi	PROPN
ajmpe-94	368	2	g	g	PROPN
ajmpe-94	368	3	,	,	PUNCT
ajmpe-94	368	4	south	south	PROPN
ajmpe-94	368	5	am	am	PROPN
ajmpe-94	368	6	,	,	PUNCT
ajmpe-94	368	7	henry	henry	PROPN
ajmpe-94	368	8	bm	bm	PROPN
ajmpe-94	368	9	.	.	PROPN
ajmpe-94	368	10	annals	annal	NOUN
ajmpe-94	368	11	express	express	VERB
ajmpe-94	368	12	electrolyte	electrolyte	ADJ
ajmpe-94	368	13	imbalances	imbalance	NOUN
ajmpe-94	368	14	in	in	ADP
ajmpe-94	368	15	patients	patient	NOUN
ajmpe-94	368	16	with	with	ADP
ajmpe-94	368	17	severe	severe	ADJ
ajmpe-94	368	18	coronavirus	coronavirus	NOUN
ajmpe-94	368	19	disease	disease	NOUN
ajmpe-94	368	20	2019(covid-19	2019(covid-19	NUM
ajmpe-94	368	21	)	)	PUNCT
ajmpe-94	368	22	.	.	PUNCT
ajmpe-94	369	1	ann	ann	PROPN
ajmpe-94	369	2	clin	clin	PROPN
ajmpe-94	369	3	biochem	biochem	PROPN
ajmpe-94	369	4	2020	2020	NUM
ajmpe-94	369	5	;	;	PUNCT
ajmpe-94	369	6	57(3	57(3	X
ajmpe-94	369	7	)	)	PUNCT
ajmpe-94	369	8	:	:	PUNCT
ajmpe-94	369	9	262	262	NUM
ajmpe-94	369	10	–	–	PUNCT
ajmpe-94	369	11	265	265	NUM
ajmpe-94	369	12	.	.	PUNCT
ajmpe-94	369	13	.	.	PUNCT
ajmpe-94	370	1	https://doi.org/10.1177/	https://doi.org/10.1177/	NOUN
ajmpe-94	370	2	0004563220922255	0004563220922255	NUM
ajmpe-94	370	3	28	28	NUM
ajmpe-94	370	4	.	.	PUNCT
ajmpe-94	371	1	dong	dong	PROPN
ajmpe-94	371	2	chen	chen	PROPN
ajmpe-94	371	3	jr	jr	PROPN
ajmpe-94	371	4	,	,	PUNCT
ajmpe-94	371	5	xiaokuni	xiaokuni	PROPN
ajmpe-94	371	6	li	li	PROPN
ajmpe-94	371	7	et	et	PROPN
ajmpe-94	371	8	al	al	PROPN
ajmpe-94	371	9	.	.	PROPN
ajmpe-94	372	1	hypokalemia	hypokalemia	PROPN
ajmpe-94	372	2	and	and	CCONJ
ajmpe-94	372	3	clinical	clinical	ADJ
ajmpe-94	372	4	implications	implication	NOUN
ajmpe-94	372	5	in	in	ADP
ajmpe-94	372	6	patients	patient	NOUN
ajmpe-94	372	7	with	with	ADP
ajmpe-94	372	8	coronavirus	coronavirus	NOUN
ajmpe-94	372	9	disease	disease	NOUN
ajmpe-94	372	10	2019	2019	NUM
ajmpe-94	372	11	(	(	PUNCT
ajmpe-94	372	12	covid19).who	covid19).who	PROPN
ajmpe-94	372	13	,	,	PUNCT
ajmpe-94	372	14	(	(	PUNCT
ajmpe-94	372	15	18	18	NUM
ajmpe-94	372	16	,	,	PUNCT
ajmpe-94	372	17	593	593	NUM
ajmpe-94	372	18	medrxiv	medrxiv	NOUN
ajmpe-94	372	19	)	)	PUNCT
ajmpe-94	372	20	,	,	PUNCT
ajmpe-94	372	21	2020	2020	NUM
ajmpe-94	372	22	;	;	PUNCT
ajmpe-94	372	23	p	p	NOUN
ajmpe-94	372	24	1	1	NUM
ajmpe-94	372	25	-	-	SYM
ajmpe-94	372	26	10	10	NUM
ajmpe-94	372	27	.	.	PUNCT
ajmpe-94	373	1	medrxiv	medrxiv	NOUN
ajmpe-94	373	2	2020	2020	NUM
ajmpe-94	373	3	.	.	PUNCT
ajmpe-94	374	1	https://doi.org/10.1101/2020.02.27.20028530	https://doi.org/10.1101/2020.02.27.20028530	PROPN
ajmpe-94	374	2	29	29	NUM
ajmpe-94	374	3	.	.	PUNCT
ajmpe-94	375	1	a.h.chowdhuryandd.n.lobo	a.h.chowdhuryandd.n.lobo	PROPN
ajmpe-94	375	2	,	,	PUNCT
ajmpe-94	375	3	"	"	PUNCT
ajmpe-94	375	4	fluidsandgastrointestinal	fluidsandgastrointestinal	ADJ
ajmpe-94	375	5	function	function	NOUN
ajmpe-94	375	6	,	,	PUNCT
ajmpe-94	375	7	"	"	PUNCT
ajmpe-94	375	8	current	current	ADJ
ajmpe-94	375	9	opinion	opinion	NOUN
ajmpe-94	375	10	in	in	ADP
ajmpe-94	375	11	clinical	clinical	ADJ
ajmpe-94	375	12	nutrition	nutrition	NOUN
ajmpe-94	375	13	and	and	CCONJ
ajmpe-94	375	14	metabolic	metabolic	NOUN
ajmpe-94	375	15	care	care	NOUN
ajmpe-94	375	16	,	,	PUNCT
ajmpe-94	375	17	2011	2011	NUM
ajmpe-94	375	18	;	;	PUNCT
ajmpe-94	375	19	vol	vol	NOUN
ajmpe-94	375	20	.	.	PROPN
ajmpe-94	376	1	14	14	NUM
ajmpe-94	376	2	,	,	PUNCT
ajmpe-94	376	3	no	no	INTJ
ajmpe-94	376	4	.	.	NOUN
ajmpe-94	376	5	5	5	NUM
ajmpe-94	376	6	,	,	PUNCT
ajmpe-94	376	7	pp	pp	ADJ
ajmpe-94	376	8	.	.	PUNCT
ajmpe-94	377	1	469–476	469–476	NUM
ajmpe-94	377	2	.	.	NOUN
ajmpe-94	377	3	30.-c	30.-c	NUM
ajmpe-94	377	4	.	.	PUNCT
ajmpe-94	378	1	huang	huang	PROPN
ajmpe-94	378	2	,	,	PUNCT
ajmpe-94	378	3	y.	y.	PROPN
ajmpe-94	378	4	wang	wang	PROPN
ajmpe-94	378	5	,	,	PUNCT
ajmpe-94	378	6	x.	x.	PROPN
ajmpe-94	378	7	li	li	PROPN
ajmpe-94	378	8	et	et	PROPN
ajmpe-94	378	9	al	al	PROPN
ajmpe-94	378	10	.	.	PROPN
ajmpe-94	378	11	,	,	PUNCT
ajmpe-94	378	12	“	"	PUNCT
ajmpe-94	378	13	clinical	clinical	ADJ
ajmpe-94	378	14	features	feature	NOUN
ajmpe-94	378	15	of	of	ADP
ajmpe-94	378	16	patients	patient	NOUN
ajmpe-94	378	17	infected	infect	VERB
ajmpe-94	378	18	with	with	ADP
ajmpe-94	378	19	2019	2019	NUM
ajmpe-94	378	20	novel	novel	ADJ
ajmpe-94	378	21	coronavirus	coronavirus	NOUN
ajmpe-94	378	22	in	in	ADP
ajmpe-94	378	23	wuhan	wuhan	PROPN
ajmpe-94	378	24	,	,	PUNCT
ajmpe-94	378	25	china	china	PROPN
ajmpe-94	378	26	,	,	PUNCT
ajmpe-94	378	27	”	"	PUNCT
ajmpe-94	378	28	the	the	DET
ajmpe-94	378	29	lancet,2020	lancet,2020	NOUN
ajmpe-94	378	30	;	;	PUNCT
ajmpe-94	378	31	vol	vol	NOUN
ajmpe-94	378	32	.	.	PROPN
ajmpe-94	379	1	395	395	NUM
ajmpe-94	379	2	,	,	PUNCT
ajmpe-94	379	3	no	no	NOUN
ajmpe-94	379	4	.	.	NOUN
ajmpe-94	379	5	10223	10223	NUM
ajmpe-94	379	6	,	,	PUNCT
ajmpe-94	379	7	pp	pp	ADP
ajmpe-94	379	8	.	.	PUNCT
ajmpe-94	380	1	497–506	497–506	NUM
ajmpe-94	380	2	.	.	PUNCT
ajmpe-94	381	1	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	381	2	https://doi.org/10.1007/s12011-020-02314-5	https://doi.org/10.1007/s12011-020-02314-5	PART
ajmpe-94	381	3	https://doi.org/10.1007/s12011-020-02314-5	https://doi.org/10.1007/s12011-020-02314-5	NUM
ajmpe-94	381	4	https://doi.org/10.1177/	https://doi.org/10.1177/	PROPN
ajmpe-94	381	5	https://doi.org/10.1177/	https://doi.org/10.1177/	PROPN
ajmpe-94	381	6	american	american	PROPN
ajmpe-94	381	7	journal	journal	PROPN
ajmpe-94	381	8	of	of	ADP
ajmpe-94	381	9	medical	medical	ADJ
ajmpe-94	381	10	and	and	CCONJ
ajmpe-94	381	11	physical	physical	ADJ
ajmpe-94	381	12	education	education	NOUN
ajmpe-94	381	13	vol.1	vol.1	PROPN
ajmpe-94	381	14	,	,	PUNCT
ajmpe-94	381	15	issue	issue	NOUN
ajmpe-94	381	16	1	1	NUM
ajmpe-94	381	17	;	;	PUNCT
ajmpe-94	381	18	july	july	PROPN
ajmpe-94	381	19	2023	2023	NUM
ajmpe-94	381	20	;	;	PUNCT
ajmpe-94	381	21	1252	1252	NUM
ajmpe-94	381	22	columbia	columbia	PROPN
ajmpe-94	381	23	rd	rd	PROPN
ajmpe-94	381	24	nw	nw	PROPN
ajmpe-94	381	25	,	,	PUNCT
ajmpe-94	381	26	washington	washington	PROPN
ajmpe-94	381	27	dc	dc	PROPN
ajmpe-94	381	28	,	,	PUNCT
ajmpe-94	381	29	united	united	PROPN
ajmpe-94	381	30	states	states	PROPN
ajmpe-94	381	31	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	381	32	;	;	PUNCT
ajmpe-94	381	33	mail	mail	NOUN
ajmpe-94	381	34	:	:	PUNCT
ajmpe-94	381	35	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	381	36	82	82	NUM
ajmpe-94	382	1	|	|	ADV
ajmpe-94	382	2	a	a	DET
ajmpe-94	382	3	m	m	NOUN
ajmpe-94	382	4	e	e	NOUN
ajmpe-94	382	5	r	r	NOUN
ajmpe-94	383	1	i	i	NOUN
ajmpe-94	383	2	c	c	VERB
ajmpe-94	383	3	a	a	DET
ajmpe-94	383	4	n	n	NOUN
ajmpe-94	384	1	j	j	NOUN
ajmpe-94	384	2	o	o	X
ajmpe-94	384	3	u	u	NOUN
ajmpe-94	384	4	r	r	NOUN
ajmpe-94	384	5	n	n	NOUN
ajmpe-94	384	6	a	a	DET
ajmpe-94	384	7	l	l	NOUN
ajmpe-94	384	8	o	o	X
ajmpe-94	385	1	f	f	X
ajmpe-94	385	2	m	m	NOUN
ajmpe-94	385	3	e	e	NOUN
ajmpe-94	386	1	d	d	NOUN
ajmpe-94	386	2	i	i	PRON
ajmpe-94	386	3	c	c	VERB
ajmpe-94	386	4	a	a	DET
ajmpe-94	386	5	l	l	NOUN
ajmpe-94	386	6	a	a	X
ajmpe-94	386	7	n	n	NOUN
ajmpe-94	387	1	d	d	NOUN
ajmpe-94	387	2	p	p	NOUN
ajmpe-94	387	3	h	h	NOUN
ajmpe-94	387	4	y	y	NOUN
ajmpe-94	387	5	s	s	VERB
ajmpe-94	388	1	i	i	INTJ
ajmpe-94	388	2	c	c	VERB
ajmpe-94	388	3	a	a	DET
ajmpe-94	388	4	l	l	NOUN
ajmpe-94	388	5	e	e	NOUN
ajmpe-94	388	6	d	d	X
ajmpe-94	388	7	u	u	X
ajmpe-94	388	8	c	c	PROPN
ajmpe-94	389	1	a	a	DET
ajmpe-94	389	2	t	t	NOUN
ajmpe-94	390	1	i	i	PRON
ajmpe-94	390	2	o	o	VERB
ajmpe-94	391	1	n	n	CCONJ
ajmpe-94	391	2	|	|	ADV
ajmpe-94	391	3	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	PROPN
ajmpe-94	391	4	w.	w.	PROPN
ajmpe-94	391	5	guan	guan	PROPN
ajmpe-94	391	6	,	,	PUNCT
ajmpe-94	391	7	z.	z.	PROPN
ajmpe-94	391	8	ni	ni	PROPN
ajmpe-94	391	9	,	,	PUNCT
ajmpe-94	391	10	y.	y.	PROPN
ajmpe-94	391	11	hu	hu	PROPN
ajmpe-94	391	12	et	et	PROPN
ajmpe-94	391	13	al	al	PROPN
ajmpe-94	391	14	.	.	PROPN
ajmpe-94	391	15	,	,	PUNCT
ajmpe-94	391	16	“	"	PUNCT
ajmpe-94	391	17	clinical	clinical	ADJ
ajmpe-94	391	18	characteristics	characteristic	NOUN
ajmpe-94	391	19	of	of	ADP
ajmpe-94	391	20	coronavirus	coronavirus	NOUN
ajmpe-94	391	21	disease	disease	NOUN
ajmpe-94	391	22	2019	2019	NUM
ajmpe-94	391	23	in	in	ADP
ajmpe-94	391	24	china	china	PROPN
ajmpe-94	391	25	,	,	PUNCT
ajmpe-94	391	26	”	"	PUNCT
ajmpe-94	391	27	the	the	DET
ajmpe-94	391	28	new	new	PROPN
ajmpe-94	391	29	england	england	PROPN
ajmpe-94	391	30	journal	journal	PROPN
ajmpe-94	391	31	of	of	ADP
ajmpe-94	391	32	medicine	medicine	NOUN
ajmpe-94	391	33	,	,	PUNCT
ajmpe-94	391	34	2020	2020	NUM
ajmpe-94	391	35	;	;	PUNCT
ajmpe-94	391	36	vol	vol	NOUN
ajmpe-94	391	37	.	.	PROPN
ajmpe-94	392	1	382	382	NUM
ajmpe-94	392	2	,	,	PUNCT
ajmpe-94	392	3	no	no	INTJ
ajmpe-94	392	4	.	.	NOUN
ajmpe-94	392	5	18	18	NUM
ajmpe-94	392	6	,	,	PUNCT
ajmpe-94	392	7	pp	pp	ADJ
ajmpe-94	392	8	.	.	PUNCT
ajmpe-94	393	1	1708–1720	1708–1720	NUM
ajmpe-94	393	2	g.	g.	NOUN
ajmpe-94	393	3	corona	corona	PROPN
ajmpe-94	393	4	,	,	PUNCT
ajmpe-94	393	5	c.giuliani	c.giuliani	PROPN
ajmpe-94	393	6	,	,	PUNCT
ajmpe-94	393	7	g.	g.	PROPN
ajmpe-94	393	8	parenti	parenti	PROPN
ajmpe-94	393	9	,	,	PUNCT
ajmpe-94	393	10	et	et	PROPN
ajmpe-94	393	11	al	al	PROPN
ajmpe-94	393	12	.	.	PROPN
ajmpe-94	393	13	,	,	PUNCT
ajmpe-94	393	14	"	"	PUNCT
ajmpe-94	393	15	moderate	moderate	ADJ
ajmpe-94	393	16	hyponatremia	hyponatremia	PROPN
ajmpe-94	393	17	is	be	AUX
ajmpe-94	393	18	associated	associate	VERB
ajmpe-94	393	19	with	with	ADP
ajmpe-94	393	20	increased	increase	VERB
ajmpe-94	393	21	risk	risk	NOUN
ajmpe-94	393	22	of	of	ADP
ajmpe-94	393	23	mortality	mortality	NOUN
ajmpe-94	393	24	:	:	PUNCT
ajmpe-94	393	25	evidence	evidence	NOUN
ajmpe-94	393	26	from	from	ADP
ajmpe-94	393	27	a	a	DET
ajmpe-94	393	28	meta	meta	ADJ
ajmpe-94	393	29	-	-	PUNCT
ajmpe-94	393	30	analysis	analysis	NOUN
ajmpe-94	393	31	,	,	PUNCT
ajmpe-94	393	32	"	"	PUNCT
ajmpe-94	393	33	plos	plos	PROPN
ajmpe-94	393	34	one	one	NUM
ajmpe-94	393	35	2013	2013	NUM
ajmpe-94	393	36	;	;	PUNCT
ajmpe-94	393	37	vol	vol	NOUN
ajmpe-94	393	38	.	.	NOUN
ajmpe-94	393	39	8	8	NUM
ajmpe-94	393	40	,	,	PUNCT
ajmpe-94	393	41	no	no	INTJ
ajmpe-94	393	42	.	.	NOUN
ajmpe-94	393	43	12	12	NUM
ajmpe-94	393	44	,	,	PUNCT
ajmpe-94	393	45	p.	p.	NOUN
ajmpe-94	393	46	e80451	e80451	PROPN
ajmpe-94	393	47	,	,	PUNCT
ajmpe-94	393	48	33	33	NUM
ajmpe-94	393	49	-	-	PUNCT
ajmpe-94	393	50	z.	z.	PROPN
ajmpe-94	393	51	belden	belden	PROPN
ajmpe-94	393	52	,	,	PUNCT
ajmpe-94	393	53	j.	j.	PROPN
ajmpe-94	393	54	a.	a.	PROPN
ajmpe-94	393	55	deiuliis	deiuliis	PROPN
ajmpe-94	393	56	,	,	PUNCT
ajmpe-94	393	57	m.	m.	NOUN
ajmpe-94	393	58	dobre	dobre	PROPN
ajmpe-94	393	59	,	,	PUNCT
ajmpe-94	393	60	and	and	CCONJ
ajmpe-94	393	61	s.	s.	PROPN
ajmpe-94	393	62	rajagopalan	rajagopalan	PROPN
ajmpe-94	393	63	,	,	PUNCT
ajmpe-94	393	64	“	"	PUNCT
ajmpe-94	393	65	the	the	DET
ajmpe-94	393	66	role	role	NOUN
ajmpe-94	393	67	of	of	ADP
ajmpe-94	393	68	the	the	DET
ajmpe-94	393	69	mineralocorticoid	mineralocorticoid	NOUN
ajmpe-94	393	70	receptor	receptor	NOUN
ajmpe-94	393	71	in	in	ADP
ajmpe-94	393	72	inflammation	inflammation	NOUN
ajmpe-94	393	73	:	:	PUNCT
ajmpe-94	393	74	focus	focus	VERB
ajmpe-94	393	75	on	on	ADP
ajmpe-94	393	76	kidney	kidney	NOUN
ajmpe-94	393	77	and	and	CCONJ
ajmpe-94	393	78	vasculature	vasculature	NOUN
ajmpe-94	393	79	,	,	PUNCT
ajmpe-94	393	80	”	"	PUNCT
ajmpe-94	393	81	american	american	ADJ
ajmpe-94	393	82	journal	journal	PROPN
ajmpe-94	393	83	of	of	ADP
ajmpe-94	393	84	nephrology	nephrology	NOUN
ajmpe-94	393	85	,	,	PUNCT
ajmpe-94	393	86	2017	2017	NUM
ajmpe-94	393	87	;	;	PUNCT
ajmpe-94	393	88	vol	vol	NOUN
ajmpe-94	393	89	.	.	PROPN
ajmpe-94	393	90	46	46	NUM
ajmpe-94	393	91	,	,	PUNCT
ajmpe-94	393	92	no	no	INTJ
ajmpe-94	393	93	.	.	NOUN
ajmpe-94	393	94	4	4	NUM
ajmpe-94	393	95	,	,	PUNCT
ajmpe-94	393	96	pp	pp	ADJ
ajmpe-94	393	97	.	.	PUNCT
ajmpe-94	394	1	298–314	298–314	NUM
ajmpe-94	394	2	.	.	PUNCT
ajmpe-94	395	1	y.-s	y.-	NOUN
ajmpe-94	395	2	.	.	PUNCT
ajmpe-94	396	1	fan	fan	PROPN
ajmpe-94	396	2	,	,	PUNCT
ajmpe-94	396	3	r.	r.	PROPN
ajmpe-94	396	4	l.	l.	PROPN
ajmpe-94	396	5	eddy	eddy	PROPN
ajmpe-94	396	6	,	,	PUNCT
ajmpe-94	396	7	m.	m.	NOUN
ajmpe-94	396	8	g.	g.	PROPN
ajmpe-94	396	9	byers	byers	PROPN
ajmpe-94	396	10	,	,	PUNCT
ajmpe-94	396	11	et	et	PROPN
ajmpe-94	396	12	al	al	PROPN
ajmpe-94	396	13	.	.	PROPN
ajmpe-94	396	14	,	,	PUNCT
ajmpe-94	396	15	"	"	PUNCT
ajmpe-94	396	16	the	the	DET
ajmpe-94	396	17	human	human	ADJ
ajmpe-94	396	18	mineral	mineral	NOUN
ajmpe-94	396	19	–	–	PUNCT
ajmpe-94	396	20	corticoid,.receptor	corticoid,.receptor	NOUN
ajmpe-94	396	21	gene	gene	NOUN
ajmpe-94	396	22	(	(	PUNCT
ajmpe-94	396	23	mlr	mlr	NOUN
ajmpe-94	396	24	)	)	PUNCT
ajmpe-94	396	25	islocatedonchromosome4at	islocatedonchromosome4at	PROPN
ajmpe-94	396	26	4	4	NUM
ajmpe-94	396	27	biomed	biome	VERB
ajmpe-94	396	28	research	research	NOUN
ajmpe-94	396	29	international	international	PROPN
ajmpe-94	396	30	q31	q31	PROPN
ajmpe-94	396	31	.	.	PROPN
ajmpe-94	396	32	2	2	NUM
ajmpe-94	396	33	,	,	PUNCT
ajmpe-94	396	34	"	"	PUNCT
ajmpe-94	396	35	cytogenetic	cytogenetic	ADJ
ajmpe-94	396	36	and	and	CCONJ
ajmpe-94	396	37	genome	genome	NOUN
ajmpe-94	396	38	research,1989	research,1989	VERB
ajmpe-94	396	39	;	;	PUNCT
ajmpe-94	396	40	vol	vol	NOUN
ajmpe-94	396	41	.	.	PROPN
ajmpe-94	397	1	52	52	NUM
ajmpe-94	397	2	,	,	PUNCT
ajmpe-94	397	3	no	no	INTJ
ajmpe-94	397	4	.	.	PUNCT
ajmpe-94	398	1	1–2	1–2	NUM
ajmpe-94	398	2	,	,	PUNCT
ajmpe-94	398	3	pp	pp	ADJ
ajmpe-94	398	4	.	.	PUNCT
ajmpe-94	399	1	83	83	NUM
ajmpe-94	399	2	-	-	SYM
ajmpe-94	399	3	84	84	NUM
ajmpe-94	399	4	.	.	PUNCT
ajmpe-94	400	1	p.	p.	NOUN
ajmpe-94	400	2	j.	j.	PROPN
ajmpe-94	400	3	fuller	fuller	PROPN
ajmpe-94	400	4	and	and	CCONJ
ajmpe-94	400	5	m.	m.	PROPN
ajmpe-94	400	6	j.	j.	PROPN
ajmpe-94	400	7	young	young	PROPN
ajmpe-94	400	8	,	,	PUNCT
ajmpe-94	400	9	"	"	PUNCT
ajmpe-94	400	10	mechanisms	mechanism	NOUN
ajmpe-94	400	11	of	of	ADP
ajmpe-94	400	12	mineralocorticoid	mineralocorticoid	NOUN
ajmpe-94	400	13	action	action	NOUN
ajmpe-94	400	14	,	,	PUNCT
ajmpe-94	400	15	"	"	PUNCT
ajmpe-94	400	16	hypertension	hypertension	NOUN
ajmpe-94	400	17	,	,	PUNCT
ajmpe-94	400	18	2005	2005	NUM
ajmpe-94	400	19	;	;	PUNCT
ajmpe-94	400	20	vol.46	vol.46	PROPN
ajmpe-94	400	21	,	,	PUNCT
ajmpe-94	400	22	no.6	no.6	PROPN
ajmpe-94	400	23	,	,	PUNCT
ajmpe-94	400	24	pp	pp	X
ajmpe-94	400	25	.	.	PUNCT
ajmpe-94	400	26	1227–1235	1227–1235	NUM
ajmpe-94	400	27	.	.	PUNCT
ajmpe-94	401	1	h.de	h.de	NOUN
ajmpe-94	401	2	carvalho	carvalho	NOUN
ajmpe-94	401	3	,	,	PUNCT
ajmpe-94	401	4	m.c.richard	m.c.richard	NOUN
ajmpe-94	401	5	,	,	PUNCT
ajmpe-94	401	6	t.chouihedetal	t.chouihedetal	ADJ
ajmpe-94	401	7	.	.	PUNCT
ajmpe-94	401	8	,	,	PUNCT
ajmpe-94	401	9	"	"	PUNCT
ajmpe-94	401	10	electrolyte	electrolyte	ADJ
ajmpe-94	401	11	imbalance	imbalance	NOUN
ajmpe-94	401	12	in	in	ADP
ajmpe-94	401	13	covid-19	covid-19	PROPN
ajmpe-94	401	14	patients	patient	NOUN
ajmpe-94	401	15	admitted	admit	VERB
ajmpe-94	401	16	to	to	ADP
ajmpe-94	401	17	the	the	DET
ajmpe-94	401	18	emergency	emergency	NOUN
ajmpe-94	401	19	department	department	NOUN
ajmpe-94	401	20	:	:	PUNCT
ajmpe-94	401	21	a	a	DET
ajmpe-94	401	22	case	case	NOUN
ajmpe-94	401	23	-	-	PUNCT
ajmpe-94	401	24	control	control	NOUN
ajmpe-94	401	25	study	study	NOUN
ajmpe-94	401	26	,	,	PUNCT
ajmpe-94	401	27	"	"	PUNCT
ajmpe-94	401	28	internal	internal	ADJ
ajmpe-94	401	29	and	and	CCONJ
ajmpe-94	401	30	emergency	emergency	NOUN
ajmpe-94	401	31	medicine	medicine	NOUN
ajmpe-94	401	32	,	,	PUNCT
ajmpe-94	401	33	2021	2021	NUM
ajmpe-94	401	34	;	;	PUNCT
ajmpe-94	401	35	vol	vol	NOUN
ajmpe-94	401	36	.	.	PROPN
ajmpe-94	401	37	23	23	NUM
ajmpe-94	401	38	,	,	PUNCT
ajmpe-94	401	39	pp	pp	ADJ
ajmpe-94	401	40	.	.	PUNCT
ajmpe-94	402	1	1–6	1–6	NUM
ajmpe-94	402	2	.	.	NOUN
ajmpe-94	403	1	37.g	37.g	NUM
ajmpe-94	403	2	.	.	PUNCT
ajmpe-94	404	1	lippi	lippi	PROPN
ajmpe-94	404	2	,	,	PUNCT
ajmpe-94	404	3	a.	a.	PROPN
ajmpe-94	404	4	m.	m.	PROPN
ajmpe-94	404	5	south	south	PROPN
ajmpe-94	404	6	,	,	PUNCT
ajmpe-94	404	7	and	and	CCONJ
ajmpe-94	404	8	b.	b.	PROPN
ajmpe-94	404	9	m.	m.	PROPN
ajmpe-94	404	10	henry	henry	PROPN
ajmpe-94	404	11	,	,	PUNCT
ajmpe-94	404	12	“	"	PUNCT
ajmpe-94	404	13	electrolyte	electrolyte	ADJ
ajmpe-94	404	14	imbalances	imbalance	NOUN
ajmpe-94	404	15	in	in	ADP
ajmpe-94	404	16	patients	patient	NOUN
ajmpe-94	404	17	with	with	ADP
ajmpe-94	404	18	severe	severe	ADJ
ajmpe-94	404	19	coronavirus	coronavirus	NOUN
ajmpe-94	404	20	disease	disease	NOUN
ajmpe-94	404	21	2019	2019	NUM
ajmpe-94	404	22	(	(	PUNCT
ajmpe-94	404	23	covid-19	covid-19	PROPN
ajmpe-94	404	24	)	)	PUNCT
ajmpe-94	404	25	,	,	PUNCT
ajmpe-94	404	26	”	"	PUNCT
ajmpe-94	404	27	annals	annals	NOUN
ajmpe-94	404	28	of	of	ADP
ajmpe-94	404	29	clinical	clinical	ADJ
ajmpe-94	404	30	biochemistry	biochemistry	NOUN
ajmpe-94	404	31	,	,	PUNCT
ajmpe-94	404	32	2020	2020	NUM
ajmpe-94	404	33	;	;	PUNCT
ajmpe-94	404	34	vol	vol	NOUN
ajmpe-94	404	35	.	.	PROPN
ajmpe-94	404	36	57	57	NUM
ajmpe-94	404	37	,	,	PUNCT
ajmpe-94	404	38	no	no	INTJ
ajmpe-94	404	39	.	.	NOUN
ajmpe-94	404	40	3	3	NUM
ajmpe-94	404	41	,	,	PUNCT
ajmpe-94	404	42	pp	pp	ADJ
ajmpe-94	404	43	.	.	PUNCT
ajmpe-94	405	1	262–265	262–265	NUM
ajmpe-94	405	2	.	.	PUNCT
ajmpe-94	405	3	m.	m.	NOUN
ajmpe-94	405	4	a.	a.	PROPN
ajmpe-94	405	5	zimmer	zimmer	PROPN
ajmpe-94	405	6	,	,	PUNCT
ajmpe-94	405	7	a.	a.	PROPN
ajmpe-94	405	8	k.	k.	PROPN
ajmpe-94	405	9	zink	zink	PROPN
ajmpe-94	405	10	,	,	PUNCT
ajmpe-94	405	11	c.	c.	PROPN
ajmpe-94	405	12	w.	w.	PROPN
ajmpe-94	405	13	weißer	weißer	PROPN
ajmpe-94	405	14	et	et	PROPN
ajmpe-94	405	15	al	al	PROPN
ajmpe-94	405	16	.	.	PROPN
ajmpe-94	405	17	,	,	PUNCT
ajmpe-94	405	18	“	"	PUNCT
ajmpe-94	405	19	hypernatremia	hypernatremia	NOUN
ajmpe-94	405	20	—	—	PUNCT
ajmpe-94	405	21	a	a	DET
ajmpe-94	405	22	manifestation	manifestation	NOUN
ajmpe-94	405	23	of	of	ADP
ajmpe-94	405	24	covid-19	covid-19	PROPN
ajmpe-94	405	25	:	:	PUNCT
ajmpe-94	405	26	a	a	DET
ajmpe-94	405	27	case	case	NOUN
ajmpe-94	405	28	series	series	NOUN
ajmpe-94	405	29	,	,	PUNCT
ajmpe-94	405	30	”	"	PUNCT
ajmpe-94	405	31	a&a	a&a	ADJ
ajmpe-94	405	32	practice	practice	NOUN
ajmpe-94	405	33	,	,	PUNCT
ajmpe-94	405	34	2020	2020	NUM
ajmpe-94	405	35	;	;	PUNCT
ajmpe-94	405	36	vol	vol	NOUN
ajmpe-94	405	37	.	.	PROPN
ajmpe-94	406	1	14	14	NUM
ajmpe-94	406	2	,	,	PUNCT
ajmpe-94	406	3	no	no	INTJ
ajmpe-94	406	4	.	.	NOUN
ajmpe-94	406	5	9	9	NUM
ajmpe-94	407	1	,	,	PUNCT
ajmpe-94	407	2	p.	p.	NOUN
ajmpe-94	407	3	e01295	e01295	PROPN
ajmpe-94	407	4	.	.	PUNCT
ajmpe-94	407	5	yongkangdong	yongkangdong	PROPN
ajmpe-94	407	6	,	,	PUNCT
ajmpe-94	407	7	li	li	PROPN
ajmpe-94	407	8	dong	dong	PROPN
ajmpe-94	407	9	novel	novel	PROPN
ajmpe-94	407	10	coronavirus	coronavirus	NOUN
ajmpe-94	407	11	epidemic	epidemic	NOUN
ajmpe-94	407	12	prevention	prevention	PROPN
ajmpe-94	407	13	and	and	CCONJ
ajmpe-94	407	14	control	control	PROPN
ajmpe-94	407	15	research	research	NOUN
ajmpe-94	407	16	project	project	NOUN
ajmpe-94	407	17	of	of	ADP
ajmpe-94	407	18	shanxi	shanxi	PROPN
ajmpe-94	407	19	province	province	PROPN
ajmpe-94	407	20	,	,	PUNCT
ajmpe-94	407	21	grant	grant	NOUN
ajmpe-94	407	22	/	/	SYM
ajmpe-94	407	23	award	award	NOUN
ajmpe-94	407	24	numbers	number	NOUN
ajmpe-94	407	25	the	the	DET
ajmpe-94	407	26	research	research	NOUN
ajmpe-94	407	27	project	project	NOUN
ajmpe-94	407	28	of	of	ADP
ajmpe-94	407	29	shanxi	shanxi	PROPN
ajmpe-94	407	30	health	health	PROPN
ajmpe-94	407	31	commission	commission	PROPN
ajmpe-94	407	32	.	.	PUNCT
ajmpe-94	408	1	:	:	PUNCT
ajmpe-94	408	2	202003d31002	202003d31002	X
ajmpe-94	408	3	/	/	SYM
ajmpe-94	408	4	gz	gz	NOUN
ajmpe-94	408	5	,	,	PUNCT
ajmpe-94	408	6	202003d31005	202003d31005	NUM
ajmpe-94	408	7	/	/	SYM
ajmpe-94	408	8	gz	gz	NOUN
ajmpe-94	408	9	.	.	PUNCT
ajmpe-94	408	10	e.	e.	PROPN
ajmpe-94	408	11	bove	bove	PROPN
ajmpe-94	408	12	-	-	PUNCT
ajmpe-94	408	13	fenderson	fenderson	NOUN
ajmpe-94	408	14	and	and	CCONJ
ajmpe-94	408	15	m.	m.	NOUN
ajmpe-94	408	16	mannstadt	mannstadt	NOUN
ajmpe-94	408	17	,	,	PUNCT
ajmpe-94	408	18	“	"	PUNCT
ajmpe-94	408	19	hypocalcemic	hypocalcemic	ADJ
ajmpe-94	408	20	disorders	disorder	NOUN
ajmpe-94	408	21	,	,	PUNCT
ajmpe-94	408	22	”	"	PUNCT
ajmpe-94	408	23	best	good	ADJ
ajmpe-94	408	24	practice	practice	NOUN
ajmpe-94	408	25	&	&	CCONJ
ajmpe-94	408	26	research	research	NOUN
ajmpe-94	408	27	.	.	PUNCT
ajmpe-94	409	1	clinical	clinical	ADJ
ajmpe-94	409	2	endocrinology	endocrinology	NOUN
ajmpe-94	409	3	&	&	CCONJ
ajmpe-94	409	4	metabolism,2018	metabolism,2018	PROPN
ajmpe-94	409	5	;	;	PUNCT
ajmpe-94	409	6	vol	vol	NOUN
ajmpe-94	409	7	.	.	PROPN
ajmpe-94	409	8	32	32	NUM
ajmpe-94	409	9	,	,	PUNCT
ajmpe-94	409	10	no	no	INTJ
ajmpe-94	409	11	.	.	NOUN
ajmpe-94	409	12	5	5	NUM
ajmpe-94	409	13	,	,	PUNCT
ajmpe-94	409	14	pp	pp	ADJ
ajmpe-94	409	15	.	.	PUNCT
ajmpe-94	410	1	639–656	639–656	NUM
ajmpe-94	410	2	.	.	X
ajmpe-94	411	1	16	16	NUM
ajmpe-94	411	2	..	..	PUNCT
ajmpe-94	411	3	pal	pal	ADJ
ajmpe-94	411	4	r	r	NOUN
ajmpe-94	411	5	,	,	PUNCT
ajmpe-94	411	6	ram	ram	NOUN
ajmpe-94	411	7	s	s	PART
ajmpe-94	411	8	,	,	PUNCT
ajmpe-94	411	9	zohmangaihi	zohmangaihi	PROPN
ajmpe-94	411	10	d	d	PROPN
ajmpe-94	411	11	biswas	biswas	PROPN
ajmpe-94	412	1	i	i	PRON
ajmpe-94	412	2	,	,	PUNCT
ajmpe-94	412	3	suri	suri	PROPN
ajmpe-94	412	4	v	v	PROPN
ajmpe-94	412	5	,	,	PUNCT
ajmpe-94	412	6	yaddanapudi	yaddanapudi	ADV
ajmpe-94	412	7	ln	ln	ADJ
ajmpe-94	412	8	,	,	PUNCT
ajmpe-94	412	9	malhotra	malhotra	PROPN
ajmpe-94	412	10	p	p	PROPN
ajmpe-94	412	11	,	,	PUNCT
ajmpe-94	412	12	soni	soni	PROPN
ajmpe-94	412	13	sl	sl	PROPN
ajmpe-94	412	14	,	,	PUNCT
ajmpe-94	412	15	puri	puri	PROPN
ajmpe-94	412	16	gd	gd	PROPN
ajmpe-94	412	17	,	,	PUNCT
ajmpe-94	412	18	bhalla	bhalla	PROPN
ajmpe-94	412	19	a	a	PROPN
ajmpe-94	412	20	and	and	CCONJ
ajmpe-94	412	21	bhadada	bhadada	PROPN
ajmpe-94	412	22	sk	sk	PROPN
ajmpe-94	412	23	.	.	PUNCT
ajmpe-94	413	1	high	high	ADJ
ajmpe-94	413	2	prevalence	prevalence	NOUN
ajmpe-94	413	3	of	of	ADP
ajmpe-94	413	4	hypocalcemia	hypocalcemia	NOUN
ajmpe-94	413	5	in	in	ADP
ajmpe-94	413	6	non	non	ADJ
ajmpe-94	413	7	-	-	ADJ
ajmpe-94	413	8	severe	severe	ADJ
ajmpe-94	413	9	covid-19	covid-19	PROPN
ajmpe-94	413	10	patients	patient	NOUN
ajmpe-94	413	11	:	:	PUNCT
ajmpe-94	413	12	a	a	DET
ajmpe-94	413	13	retrospective	retrospective	ADJ
ajmpe-94	413	14	case	case	NOUN
ajmpe-94	413	15	-	-	PUNCT
ajmpe-94	413	16	control	control	NOUN
ajmpe-94	413	17	study	study	NOUN
ajmpe-94	413	18	.	.	PUNCT
ajmpe-94	414	1	front	front	ADJ
ajmpe-94	414	2	.	.	PUNCT
ajmpe-94	415	1	med	med	ADJ
ajmpe-94	415	2	2021	2021	NUM
ajmpe-94	415	3	;	;	PUNCT
ajmpe-94	415	4	7:590805	7:590805	NUM
ajmpe-94	415	5	.	.	PUNCT
ajmpe-94	416	1	doi	doi	NOUN
ajmpe-94	416	2	:	:	PUNCT
ajmpe-94	416	3	10.3389	10.3389	NUM
ajmpe-94	416	4	/	/	SYM
ajmpe-94	416	5	fmed.2020.590805	fmed.2020.590805	PROPN
ajmpe-94	416	6	.	.	PUNCT
ajmpe-94	417	1	li	li	PROPN
ajmpe-94	417	2	t	t	PROPN
ajmpe-94	417	3	,	,	PUNCT
ajmpe-94	417	4	zhang	zhang	PROPN
ajmpe-94	417	5	y	y	PROPN
ajmpe-94	417	6	,	,	PUNCT
ajmpe-94	417	7	gong	gong	PROPN
ajmpe-94	417	8	c	c	X
ajmpe-94	417	9	,	,	PUNCT
ajmpe-94	417	10	et	et	PROPN
ajmpe-94	417	11	al	al	PROPN
ajmpe-94	417	12	.	.	PUNCT
ajmpe-94	418	1	prevalence	prevalence	NOUN
ajmpe-94	418	2	of	of	ADP
ajmpe-94	418	3	malnutrition	malnutrition	NOUN
ajmpe-94	418	4	and	and	CCONJ
ajmpe-94	418	5	analysis	analysis	NOUN
ajmpe-94	418	6	of	of	ADP
ajmpe-94	418	7	related	related	ADJ
ajmpe-94	418	8	factors	factor	NOUN
ajmpe-94	418	9	in	in	ADP
ajmpe-94	418	10	elderly	elderly	ADJ
ajmpe-94	418	11	patients	patient	NOUN
ajmpe-94	418	12	with	with	ADP
ajmpe-94	418	13	covid-19	covid-19	PROPN
ajmpe-94	418	14	in	in	ADP
ajmpe-94	418	15	wuhan	wuhan	PROPN
ajmpe-94	418	16	,	,	PUNCT
ajmpe-94	418	17	china	china	PROPN
ajmpe-94	418	18	.	.	PUNCT
ajmpe-94	419	1	eur	eur	PROPN
ajmpe-94	419	2	j	j	PROPN
ajmpe-94	419	3	clin	clin	PROPN
ajmpe-94	419	4	nutr	nutr	PROPN
ajmpe-94	419	5	.	.	PROPN
ajmpe-94	420	1	2020;74(6):871–875	2020;74(6):871–875	NUM
ajmpe-94	420	2	.	.	PUNCT
ajmpe-94	420	3	doi:10.1038	doi:10.1038	NOUN
ajmpe-94	420	4	/	/	SYM
ajmpe-94	420	5	s414300200642	s414300200642	PROPN
ajmpe-94	420	6	-	-	PUNCT
ajmpe-94	420	7	3	3	NUM
ajmpe-94	420	8	di	di	X
ajmpe-94	420	9	filippo	filippo	PROPN
ajmpe-94	420	10	l	l	PROPN
ajmpe-94	420	11	,	,	PUNCT
ajmpe-94	420	12	de	de	X
ajmpe-94	420	13	lorenzo	lorenzo	PROPN
ajmpe-94	420	14	r	r	NOUN
ajmpe-94	420	15	,	,	PUNCT
ajmpe-94	420	16	d'amico	d'amico	PROPN
ajmpe-94	420	17	m	m	PROPN
ajmpe-94	420	18	,	,	PUNCT
ajmpe-94	420	19	et	et	PROPN
ajmpe-94	420	20	al	al	PROPN
ajmpe-94	420	21	.	.	PUNCT
ajmpe-94	421	1	covid-19	covid-19	PROPN
ajmpe-94	421	2	is	be	AUX
ajmpe-94	421	3	associated	associate	VERB
ajmpe-94	421	4	with	with	ADP
ajmpe-94	421	5	clinically	clinically	ADV
ajmpe-94	421	6	significant	significant	ADJ
ajmpe-94	421	7	weight	weight	NOUN
ajmpe-94	421	8	loss	loss	NOUN
ajmpe-94	421	9	and	and	CCONJ
ajmpe-94	421	10	risk	risk	NOUN
ajmpe-94	421	11	of	of	ADP
ajmpe-94	421	12	malnutrition	malnutrition	NOUN
ajmpe-94	421	13	,	,	PUNCT
ajmpe-94	421	14	independent	independent	ADJ
ajmpe-94	421	15	of	of	ADP
ajmpe-94	421	16	hospitalization	hospitalization	NOUN
ajmpe-94	421	17	:	:	PUNCT
ajmpe-94	421	18	a	a	DET
ajmpe-94	421	19	posthoc	posthoc	NOUN
ajmpe-94	421	20	analysis	analysis	NOUN
ajmpe-94	421	21	of	of	ADP
ajmpe-94	421	22	a	a	DET
ajmpe-94	421	23	prospective	prospective	ADJ
ajmpe-94	421	24	cohort	cohort	NOUN
ajmpe-94	421	25	study	study	NOUN
ajmpe-94	421	26	.	.	PUNCT
ajmpe-94	422	1	clin	clin	PROPN
ajmpe-94	422	2	nutr	nutr	PROPN
ajmpe-94	422	3	.	.	PROPN
ajmpe-94	422	4	2021;40(4):2420–2426	2021;40(4):2420–2426	PROPN
ajmpe-94	422	5	.	.	PUNCT
ajmpe-94	423	1	doi:10.1016	doi:10.1016	PROPN
ajmpe-94	423	2	/	/	SYM
ajmpe-94	423	3	j.clnu.2020.10.043	j.clnu.2020.10.043	PROPN
ajmpe-94	423	4	yu	yu	PROPN
ajmpe-94	423	5	y	y	PROPN
ajmpe-94	423	6	,	,	PUNCT
ajmpe-94	423	7	ye	ye	PROPN
ajmpe-94	423	8	j	j	PROPN
ajmpe-94	423	9	,	,	PUNCT
ajmpe-94	423	10	chen	chen	PROPN
ajmpe-94	423	11	m	m	PROPN
ajmpe-94	423	12	,	,	PUNCT
ajmpe-94	423	13	et	et	PROPN
ajmpe-94	423	14	al	al	PROPN
ajmpe-94	423	15	.	.	PROPN
ajmpe-94	423	16	malnutrition	malnutrition	NOUN
ajmpe-94	423	17	prolongs	prolong	VERB
ajmpe-94	423	18	the	the	DET
ajmpe-94	423	19	hospitalization	hospitalization	NOUN
ajmpe-94	423	20	of	of	ADP
ajmpe-94	423	21	patients	patient	NOUN
ajmpe-94	423	22	with	with	ADP
ajmpe-94	423	23	covid-19	covid-19	PROPN
ajmpe-94	423	24	infection	infection	NOUN
ajmpe-94	423	25	:	:	PUNCT
ajmpe-94	423	26	a	a	DET
ajmpe-94	423	27	clinical	clinical	ADJ
ajmpe-94	423	28	epidemiological	epidemiological	ADJ
ajmpe-94	423	29	analysis	analysis	NOUN
ajmpe-94	423	30	.	.	PUNCT
ajmpe-94	424	1	j	j	PROPN
ajmpe-94	424	2	nutr	nutr	PROPN
ajmpe-94	424	3	health	health	NOUN
ajmpe-94	424	4	aging	aging	NOUN
ajmpe-94	424	5	.	.	PUNCT
ajmpe-94	425	1	2021;25(3):369–373	2021;25(3):369–373	X
ajmpe-94	425	2	.	.	PUNCT
ajmpe-94	425	3	doi:10.1007/	doi:10.1007/	PROPN
ajmpe-94	425	4	s12603	s12603	PROPN
ajmpe-94	425	5	-	-	PUNCT
ajmpe-94	425	6	0201541	0201541	NUM
ajmpe-94	425	7	-	-	PUNCT
ajmpe-94	425	8	y	y	PROPN
ajmpe-94	425	9	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	425	10	american	american	PROPN
ajmpe-94	425	11	journal	journal	PROPN
ajmpe-94	425	12	of	of	ADP
ajmpe-94	425	13	medical	medical	ADJ
ajmpe-94	425	14	and	and	CCONJ
ajmpe-94	425	15	physical	physical	ADJ
ajmpe-94	425	16	education	education	NOUN
ajmpe-94	425	17	vol.1	vol.1	PROPN
ajmpe-94	425	18	,	,	PUNCT
ajmpe-94	425	19	issue	issue	NOUN
ajmpe-94	425	20	1	1	NUM
ajmpe-94	425	21	;	;	PUNCT
ajmpe-94	425	22	july	july	PROPN
ajmpe-94	425	23	2023	2023	NUM
ajmpe-94	425	24	;	;	PUNCT
ajmpe-94	425	25	1252	1252	NUM
ajmpe-94	425	26	columbia	columbia	PROPN
ajmpe-94	425	27	rd	rd	PROPN
ajmpe-94	425	28	nw	nw	PROPN
ajmpe-94	425	29	,	,	PUNCT
ajmpe-94	425	30	washington	washington	PROPN
ajmpe-94	425	31	dc	dc	PROPN
ajmpe-94	425	32	,	,	PUNCT
ajmpe-94	425	33	united	united	PROPN
ajmpe-94	425	34	states	states	PROPN
ajmpe-94	425	35	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	425	36	;	;	PUNCT
ajmpe-94	425	37	mail	mail	NOUN
ajmpe-94	425	38	:	:	PUNCT
ajmpe-94	425	39	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	426	1	83	83	NUM
ajmpe-94	427	1	|	|	ADV
ajmpe-94	427	2	a	a	DET
ajmpe-94	427	3	m	m	NOUN
ajmpe-94	427	4	e	e	NOUN
ajmpe-94	427	5	r	r	NOUN
ajmpe-94	428	1	i	i	NOUN
ajmpe-94	428	2	c	c	VERB
ajmpe-94	428	3	a	a	DET
ajmpe-94	428	4	n	n	NOUN
ajmpe-94	429	1	j	j	NOUN
ajmpe-94	429	2	o	o	X
ajmpe-94	429	3	u	u	NOUN
ajmpe-94	429	4	r	r	NOUN
ajmpe-94	429	5	n	n	NOUN
ajmpe-94	429	6	a	a	DET
ajmpe-94	429	7	l	l	NOUN
ajmpe-94	429	8	o	o	X
ajmpe-94	430	1	f	f	X
ajmpe-94	430	2	m	m	NOUN
ajmpe-94	430	3	e	e	NOUN
ajmpe-94	431	1	d	d	NOUN
ajmpe-94	431	2	i	i	PRON
ajmpe-94	431	3	c	c	VERB
ajmpe-94	431	4	a	a	DET
ajmpe-94	431	5	l	l	NOUN
ajmpe-94	431	6	a	a	X
ajmpe-94	431	7	n	n	NOUN
ajmpe-94	432	1	d	d	NOUN
ajmpe-94	432	2	p	p	NOUN
ajmpe-94	432	3	h	h	NOUN
ajmpe-94	432	4	y	y	NOUN
ajmpe-94	432	5	s	s	VERB
ajmpe-94	433	1	i	i	INTJ
ajmpe-94	433	2	c	c	VERB
ajmpe-94	433	3	a	a	DET
ajmpe-94	433	4	l	l	NOUN
ajmpe-94	433	5	e	e	NOUN
ajmpe-94	433	6	d	d	X
ajmpe-94	433	7	u	u	X
ajmpe-94	433	8	c	c	PROPN
ajmpe-94	434	1	a	a	DET
ajmpe-94	434	2	t	t	NOUN
ajmpe-94	435	1	i	i	PRON
ajmpe-94	435	2	o	o	VERB
ajmpe-94	436	1	n	n	CCONJ
ajmpe-94	436	2	|	|	ADV
ajmpe-94	436	3	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	436	4	liu	liu	PROPN
ajmpe-94	436	5	a	a	PROPN
ajmpe-94	436	6	,	,	PUNCT
ajmpe-94	436	7	cong	cong	PROPN
ajmpe-94	436	8	j	j	PROPN
ajmpe-94	436	9	,	,	PUNCT
ajmpe-94	436	10	wang	wang	PROPN
ajmpe-94	436	11	q	q	PROPN
ajmpe-94	436	12	,	,	PUNCT
ajmpe-94	436	13	et	et	PROPN
ajmpe-94	436	14	al	al	PROPN
ajmpe-94	436	15	.	.	PROPN
ajmpe-94	437	1	risk	risk	NOUN
ajmpe-94	437	2	of	of	ADP
ajmpe-94	437	3	malnutrition	malnutrition	NOUN
ajmpe-94	437	4	is	be	AUX
ajmpe-94	437	5	common	common	ADJ
ajmpe-94	437	6	in	in	ADP
ajmpe-94	437	7	patients	patient	NOUN
ajmpe-94	437	8	with	with	ADP
ajmpe-94	437	9	coronavirus	coronavirus	NOUN
ajmpe-94	437	10	disease	disease	NOUN
ajmpe-94	437	11	2019	2019	NUM
ajmpe-94	437	12	(	(	PUNCT
ajmpe-94	437	13	covid19	covid19	NOUN
ajmpe-94	437	14	)	)	PUNCT
ajmpe-94	437	15	in	in	ADP
ajmpe-94	437	16	wuhan	wuhan	PROPN
ajmpe-94	437	17	,	,	PUNCT
ajmpe-94	437	18	china	china	PROPN
ajmpe-94	437	19	:	:	PUNCT
ajmpe-94	437	20	a	a	DET
ajmpe-94	437	21	cross	cross	ADJ
ajmpe-94	437	22	-	-	ADJ
ajmpe-94	437	23	sectional	sectional	ADJ
ajmpe-94	437	24	study	study	NOUN
ajmpe-94	437	25	.	.	PUNCT
ajmpe-94	438	1	j	j	PROPN
ajmpe-94	438	2	nutr	nutr	PROPN
ajmpe-94	438	3	.	.	PUNCT
ajmpe-94	439	1	2021;151(6):1591–1596	2021;151(6):1591–1596	NUM
ajmpe-94	439	2	.	.	PUNCT
ajmpe-94	440	1	wei	wei	PROPN
ajmpe-94	440	2	c	c	PROPN
ajmpe-94	440	3	,	,	PUNCT
ajmpe-94	440	4	liu	liu	PROPN
ajmpe-94	440	5	y	y	PROPN
ajmpe-94	440	6	,	,	PUNCT
ajmpe-94	440	7	li	li	PROPN
ajmpe-94	440	8	y	y	PROPN
ajmpe-94	440	9	,	,	PUNCT
ajmpe-94	440	10	zhang	zhang	PROPN
ajmpe-94	440	11	y	y	PROPN
ajmpe-94	440	12	,	,	PUNCT
ajmpe-94	440	13	zhong	zhong	PROPN
ajmpe-94	440	14	m	m	PROPN
ajmpe-94	440	15	,	,	PUNCT
ajmpe-94	440	16	meng	meng	PROPN
ajmpe-94	440	17	x.	x.	NOUN
ajmpe-94	440	18	evaluation	evaluation	NOUN
ajmpe-94	440	19	of	of	ADP
ajmpe-94	440	20	the	the	DET
ajmpe-94	440	21	nutritional	nutritional	ADJ
ajmpe-94	440	22	status	status	NOUN
ajmpe-94	440	23	in	in	ADP
ajmpe-94	440	24	patients	patient	NOUN
ajmpe-94	440	25	with	with	ADP
ajmpe-94	440	26	covid-19	covid-19	PROPN
ajmpe-94	440	27	.	.	PUNCT
ajmpe-94	441	1	j	j	PROPN
ajmpe-94	441	2	clin	clin	PROPN
ajmpe-94	441	3	biochem	biochem	PROPN
ajmpe-94	441	4	nutr	nutr	PROPN
ajmpe-94	441	5	.	.	PUNCT
ajmpe-94	442	1	2020;67(2):116–121	2020;67(2):116–121	NUM
ajmpe-94	442	2	.	.	PUNCT
ajmpe-94	443	1	doi:10.3164	doi:10.3164	NOUN
ajmpe-94	443	2	/	/	SYM
ajmpe-94	443	3	jcbn.20	jcbn.20	PROPN
ajmpe-94	443	4	-	-	PUNCT
ajmpe-94	443	5	91	91	NUM
ajmpe-94	443	6	zhou	zhou	PROPN
ajmpe-94	443	7	j	j	PROPN
ajmpe-94	443	8	,	,	PUNCT
ajmpe-94	443	9	ma	ma	PROPN
ajmpe-94	443	10	y	y	PROPN
ajmpe-94	443	11	,	,	PUNCT
ajmpe-94	443	12	liu	liu	PROPN
ajmpe-94	443	13	y	y	PROPN
ajmpe-94	443	14	,	,	PUNCT
ajmpe-94	443	15	et	et	PROPN
ajmpe-94	443	16	al	al	PROPN
ajmpe-94	443	17	.	.	PUNCT
ajmpe-94	444	1	a	a	DET
ajmpe-94	444	2	correlation	correlation	NOUN
ajmpe-94	444	3	analysis	analysis	NOUN
ajmpe-94	444	4	between	between	ADP
ajmpe-94	444	5	the	the	DET
ajmpe-94	444	6	nutritional	nutritional	ADJ
ajmpe-94	444	7	status	status	NOUN
ajmpe-94	444	8	and	and	CCONJ
ajmpe-94	444	9	prognosis	prognosis	NOUN
ajmpe-94	444	10	of	of	ADP
ajmpe-94	444	11	covid	covid	PROPN
ajmpe-94	444	12	19	19	NUM
ajmpe-94	444	13	patients	patient	NOUN
ajmpe-94	444	14	.	.	PUNCT
ajmpe-94	445	1	j	j	PROPN
ajmpe-94	445	2	nutr	nutr	PROPN
ajmpe-94	445	3	health	health	NOUN
ajmpe-94	445	4	aging	aging	NOUN
ajmpe-94	445	5	.	.	PUNCT
ajmpe-94	446	1	2021;25(1):84–93	2021;25(1):84–93	X
ajmpe-94	446	2	.	.	PUNCT
ajmpe-94	446	3	doi:10.1007	doi:10.1007	PROPN
ajmpe-94	446	4	/	/	SYM
ajmpe-94	446	5	s12603	s12603	NOUN
ajmpe-94	446	6	-	-	PUNCT
ajmpe-94	446	7	020	020	NUM
ajmpe-94	446	8	-	-	PUNCT
ajmpe-94	446	9	1457	1457	NUM
ajmpe-94	446	10	-	-	SYM
ajmpe-94	446	11	6	6	NUM
ajmpe-94	446	12	sobczak	sobczak	PROPN
ajmpe-94	446	13	ais	ais	PROPN
ajmpe-94	446	14	,	,	PUNCT
ajmpe-94	446	15	phoenix	phoenix	PROPN
ajmpe-94	446	16	fa	fa	PROPN
ajmpe-94	446	17	,	,	PUNCT
ajmpe-94	446	18	pitt	pitt	PROPN
ajmpe-94	446	19	sj	sj	PROPN
ajmpe-94	446	20	,	,	PUNCT
ajmpe-94	446	21	et	et	PROPN
ajmpe-94	446	22	al	al	PROPN
ajmpe-94	446	23	.	.	PROPN
ajmpe-94	447	1	reduced	reduce	VERB
ajmpe-94	447	2	plasma	plasma	NOUN
ajmpe-94	447	3	magnesium	magnesium	NOUN
ajmpe-94	447	4	levels	level	NOUN
ajmpe-94	447	5	in	in	ADP
ajmpe-94	447	6	type-1	type-1	PROPN
ajmpe-94	447	7	diabetes	diabetes	NOUN
ajmpe-94	447	8	associate	associate	VERB
ajmpe-94	447	9	with	with	ADP
ajmpe-94	447	10	prothrombotic	prothrombotic	ADJ
ajmpe-94	447	11	changes	change	NOUN
ajmpe-94	447	12	in	in	ADP
ajmpe-94	447	13	fibrin	fibrin	NOUN
ajmpe-94	447	14	clotting	clotting	NOUN
ajmpe-94	447	15	and	and	CCONJ
ajmpe-94	447	16	fibrinolysis	fibrinolysis	NOUN
ajmpe-94	447	17	.	.	PUNCT
ajmpe-94	448	1	thrombosis	thrombosis	NOUN
ajmpe-94	448	2	and	and	CCONJ
ajmpe-94	448	3	haemostasis	haemostasis	NOUN
ajmpe-94	448	4	.	.	PUNCT
ajmpe-94	449	1	2020	2020	NUM
ajmpe-94	449	2	;	;	PUNCT
ajmpe-94	449	3	120:243	120:243	NUM
ajmpe-94	449	4	–	–	PUNCT
ajmpe-94	449	5	52	52	NUM
ajmpe-94	449	6	.	.	PUNCT
ajmpe-94	450	1	[	[	X
ajmpe-94	450	2	pmc	pmc	PROPN
ajmpe-94	450	3	free	free	ADJ
ajmpe-94	450	4	article	article	NOUN
ajmpe-94	450	5	]	]	X
ajmpe-94	451	1	[	[	X
ajmpe-94	451	2	pubmed	pubmed	X
ajmpe-94	451	3	]	]	X
ajmpe-94	451	4	[	[	X
ajmpe-94	451	5	google	google	PROPN
ajmpe-94	451	6	scholar	scholar	NOUN
ajmpe-94	451	7	]	]	PUNCT
ajmpe-94	451	8	gromova	gromova	PROPN
ajmpe-94	451	9	oa	oa	PROPN
ajmpe-94	451	10	,	,	PUNCT
ajmpe-94	451	11	torshin	torshin	PROPN
ajmpe-94	451	12	iy	iy	PROPN
ajmpe-94	451	13	,	,	PUNCT
ajmpe-94	451	14	kobalava	kobalava	PROPN
ajmpe-94	451	15	zd	zd	PROPN
ajmpe-94	451	16	,	,	PUNCT
ajmpe-94	451	17	et	et	PROPN
ajmpe-94	451	18	al	al	PROPN
ajmpe-94	451	19	.	.	PUNCT
ajmpe-94	451	20	deficit	deficit	NOUN
ajmpe-94	451	21	of	of	ADP
ajmpe-94	451	22	magnesium	magnesium	NOUN
ajmpe-94	451	23	and	and	CCONJ
ajmpe-94	451	24	states	state	NOUN
ajmpe-94	451	25	of	of	ADP
ajmpe-94	451	26	hypercoagulation	hypercoagulation	NOUN
ajmpe-94	451	27	:	:	PUNCT
ajmpe-94	451	28	intellectual	intellectual	ADJ
ajmpe-94	451	29	analysis	analysis	NOUN
ajmpe-94	451	30	of	of	ADP
ajmpe-94	451	31	data	datum	NOUN
ajmpe-94	451	32	obtained	obtain	VERB
ajmpe-94	451	33	from	from	ADP
ajmpe-94	451	34	a	a	DET
ajmpe-94	451	35	sample	sample	NOUN
ajmpe-94	451	36	of	of	ADP
ajmpe-94	451	37	patients	patient	NOUN
ajmpe-94	451	38	aged	age	VERB
ajmpe-94	451	39	18–50	18–50	NUM
ajmpe-94	451	40	years	year	NOUN
ajmpe-94	451	41	from	from	ADP
ajmpe-94	451	42	medical	medical	ADJ
ajmpe-94	451	43	and	and	CCONJ
ajmpe-94	451	44	preventive	preventive	ADJ
ajmpe-94	451	45	facilities	facility	NOUN
ajmpe-94	451	46	in	in	ADP
ajmpe-94	451	47	russia	russia	PROPN
ajmpe-94	451	48	.	.	PUNCT
ajmpe-94	452	1	kardiologiia	kardiologiia	PROPN
ajmpe-94	452	2	.	.	PUNCT
ajmpe-94	453	1	2018	2018	NUM
ajmpe-94	453	2	;	;	PUNCT
ajmpe-94	454	1	58:22–35	58:22–35	NUM
ajmpe-94	454	2	.	.	PUNCT
ajmpe-94	455	1	[	[	X
ajmpe-94	455	2	pubmed	pubmed	X
ajmpe-94	455	3	]	]	X
ajmpe-94	455	4	[	[	X
ajmpe-94	455	5	google	google	PROPN
ajmpe-94	455	6	scholar	scholar	NOUN
ajmpe-94	455	7	]	]	PUNCT
ajmpe-94	455	8	çiçek	çiçek	PROPN
ajmpe-94	455	9	g	g	PROPN
ajmpe-94	455	10	,	,	PUNCT
ajmpe-94	455	11	açıkgoz	açıkgoz	VERB
ajmpe-94	455	12	sk	sk	ADP
ajmpe-94	455	13	,	,	PUNCT
ajmpe-94	455	14	yayla	yayla	NOUN
ajmpe-94	455	15	ç	ç	X
ajmpe-94	455	16	,	,	PUNCT
ajmpe-94	455	17	et	et	PROPN
ajmpe-94	455	18	al	al	PROPN
ajmpe-94	455	19	.	.	PROPN
ajmpe-94	455	20	magnesium	magnesium	NOUN
ajmpe-94	455	21	as	as	ADP
ajmpe-94	455	22	a	a	DET
ajmpe-94	455	23	predictor	predictor	NOUN
ajmpe-94	455	24	of	of	ADP
ajmpe-94	455	25	acute	acute	ADJ
ajmpe-94	455	26	stent	stent	NOUN
ajmpe-94	455	27	thrombosis	thrombosis	NOUN
ajmpe-94	455	28	in	in	ADP
ajmpe-94	455	29	patients	patient	NOUN
ajmpe-94	455	30	with	with	ADP
ajmpe-94	455	31	stsegment	stsegment	NOUN
ajmpe-94	455	32	elevation	elevation	NOUN
ajmpe-94	455	33	myocardial	myocardial	ADJ
ajmpe-94	455	34	infarction	infarction	NOUN
ajmpe-94	455	35	who	who	PRON
ajmpe-94	455	36	underwent	undergo	VERB
ajmpe-94	455	37	primary	primary	ADJ
ajmpe-94	455	38	angioplasty	angioplasty	NOUN
ajmpe-94	455	39	.	.	PUNCT
ajmpe-94	456	1	coron	coron	PROPN
ajmpe-94	456	2	artery	artery	NOUN
ajmpe-94	456	3	dis	dis	PROPN
ajmpe-94	456	4	.	.	PUNCT
ajmpe-94	457	1	2016	2016	NUM
ajmpe-94	457	2	;	;	PUNCT
ajmpe-94	457	3	27:47–51	27:47–51	NUM
ajmpe-94	457	4	.	.	PUNCT
ajmpe-94	458	1	[	[	X
ajmpe-94	458	2	pubmed	pubmed	X
ajmpe-94	458	3	]	]	X
ajmpe-94	459	1	[	[	X
ajmpe-94	459	2	google	google	NOUN
ajmpe-94	459	3	scholar	scholar	NOUN
ajmpe-94	459	4	]	]	PUNCT
ajmpe-94	459	5	shechter	shechter	NOUN
ajmpe-94	459	6	m	m	PROPN
ajmpe-94	459	7	,	,	PUNCT
ajmpe-94	459	8	merz	merz	PROPN
ajmpe-94	459	9	cn	cn	PROPN
ajmpe-94	459	10	,	,	PUNCT
ajmpe-94	459	11	rude	rude	ADJ
ajmpe-94	459	12	rk	rk	NOUN
ajmpe-94	459	13	,	,	PUNCT
ajmpe-94	459	14	et	et	PROPN
ajmpe-94	459	15	al	al	PROPN
ajmpe-94	459	16	.	.	PUNCT
ajmpe-94	459	17	low	low	ADJ
ajmpe-94	459	18	intracellular	intracellular	ADJ
ajmpe-94	459	19	magnesium	magnesium	NOUN
ajmpe-94	459	20	levels	level	NOUN
ajmpe-94	459	21	promote	promote	VERB
ajmpe-94	459	22	platelet	platelet	ADJ
ajmpe-94	459	23	-	-	PUNCT
ajmpe-94	459	24	dependent	dependent	ADJ
ajmpe-94	459	25	thrombosis	thrombosis	NOUN
ajmpe-94	459	26	in	in	ADP
ajmpe-94	459	27	patients	patient	NOUN
ajmpe-94	459	28	with	with	ADP
ajmpe-94	459	29	coronary	coronary	ADJ
ajmpe-94	459	30	artery	artery	NOUN
ajmpe-94	459	31	disease	disease	NOUN
ajmpe-94	459	32	.	.	PUNCT
ajmpe-94	460	1	american	american	ADJ
ajmpe-94	460	2	heart	heart	PROPN
ajmpe-94	460	3	journal	journal	PROPN
ajmpe-94	460	4	.	.	PUNCT
ajmpe-94	461	1	2000	2000	NUM
ajmpe-94	461	2	;	;	PUNCT
ajmpe-94	462	1	140:212–8	140:212–8	NUM
ajmpe-94	462	2	.	.	PUNCT
ajmpe-94	463	1	[	[	X
ajmpe-94	463	2	pubmed	pubmed	X
ajmpe-94	463	3	]	]	X
ajmpe-94	464	1	[	[	X
ajmpe-94	464	2	google	google	PROPN
ajmpe-94	464	3	scholar	scholar	NOUN
ajmpe-94	464	4	]	]	PUNCT
ajmpe-94	464	5	sheu	sheu	PROPN
ajmpe-94	464	6	jr	jr	PROPN
ajmpe-94	464	7	,	,	PUNCT
ajmpe-94	464	8	hsiao	hsiao	PROPN
ajmpe-94	464	9	g	g	PROPN
ajmpe-94	464	10	,	,	PUNCT
ajmpe-94	464	11	shen	shen	NOUN
ajmpe-94	464	12	my	my	PRON
ajmpe-94	464	13	,	,	PUNCT
ajmpe-94	464	14	et	et	PROPN
ajmpe-94	464	15	al	al	PROPN
ajmpe-94	464	16	.	.	PUNCT
ajmpe-94	465	1	antithrombotic	antithrombotic	ADJ
ajmpe-94	465	2	effects	effect	NOUN
ajmpe-94	465	3	of	of	ADP
ajmpe-94	465	4	magnesium	magnesium	NOUN
ajmpe-94	465	5	sulfate	sulfate	NOUN
ajmpe-94	465	6	in	in	ADP
ajmpe-94	465	7	vivo	vivo	ADJ
ajmpe-94	465	8	experiments	experiment	NOUN
ajmpe-94	465	9	.	.	PUNCT
ajmpe-94	466	1	int	int	NOUN
ajmpe-94	466	2	j	j	PROPN
ajmpe-94	466	3	hematol	hematol	NOUN
ajmpe-94	466	4	.	.	PUNCT
ajmpe-94	467	1	2003	2003	NUM
ajmpe-94	467	2	;	;	PUNCT
ajmpe-94	467	3	77:414–9	77:414–9	NUM
ajmpe-94	467	4	.	.	PUNCT
ajmpe-94	468	1	[	[	X
ajmpe-94	468	2	pubmed	pubmed	X
ajmpe-94	468	3	]	]	X
ajmpe-94	469	1	[	[	X
ajmpe-94	469	2	google	google	NOUN
ajmpe-94	469	3	scholar	scholar	NOUN
ajmpe-94	469	4	]	]	PUNCT
ajmpe-94	469	5	anuk	anuk	PROPN
ajmpe-94	469	6	a.t	a.t	PROPN
ajmpe-94	469	7	.	.	PROPN
ajmpe-94	469	8	,	,	PUNCT
ajmpe-94	469	9	polat	polat	PROPN
ajmpe-94	469	10	n.	n.	PROPN
ajmpe-94	469	11	,	,	PUNCT
ajmpe-94	469	12	akdas	akdas	PROPN
ajmpe-94	469	13	s.	s.	PROPN
ajmpe-94	469	14	,	,	PUNCT
ajmpe-94	469	15	erol	erol	PROPN
ajmpe-94	469	16	s.a	s.a	PROPN
ajmpe-94	469	17	.	.	PROPN
ajmpe-94	469	18	,	,	PUNCT
ajmpe-94	469	19	tanacan	tanacan	PROPN
ajmpe-94	469	20	a.	a.	PROPN
ajmpe-94	469	21	,	,	PUNCT
ajmpe-94	469	22	biriken	biriken	VERB
ajmpe-94	469	23	d.	d.	PROPN
ajmpe-94	469	24	,	,	PUNCT
ajmpe-94	469	25	keskin	keskin	PROPN
ajmpe-94	469	26	h.l	h.l	PROPN
ajmpe-94	469	27	.	.	PROPN
ajmpe-94	469	28	,	,	PUNCT
ajmpe-94	469	29	tekin	tekin	PROPN
ajmpe-94	469	30	o.m	o.m	PROPN
ajmpe-94	469	31	.	.	PROPN
ajmpe-94	469	32	,	,	PUNCT
ajmpe-94	469	33	yazihan	yazihan	PROPN
ajmpe-94	469	34	n.	n.	PROPN
ajmpe-94	469	35	,	,	PUNCT
ajmpe-94	469	36	sahin	sahin	PROPN
ajmpe-94	469	37	d.	d.	PROPN
ajmpe-94	469	38	the	the	DET
ajmpe-94	469	39	relation	relation	NOUN
ajmpe-94	469	40	between	between	ADP
ajmpe-94	469	41	trace	trace	NOUN
ajmpe-94	469	42	element	element	NOUN
ajmpe-94	469	43	status	status	NOUN
ajmpe-94	469	44	(	(	PUNCT
ajmpe-94	469	45	zinc	zinc	NOUN
ajmpe-94	469	46	,	,	PUNCT
ajmpe-94	469	47	copper	copper	NOUN
ajmpe-94	469	48	,	,	PUNCT
ajmpe-94	469	49	magnesium	magnesium	NOUN
ajmpe-94	469	50	)	)	PUNCT
ajmpe-94	469	51	and	and	CCONJ
ajmpe-94	469	52	clinical	clinical	ADJ
ajmpe-94	469	53	outcomes	outcome	NOUN
ajmpe-94	469	54	in	in	ADP
ajmpe-94	469	55	covid19	covid19	NOUN
ajmpe-94	469	56	infection	infection	NOUN
ajmpe-94	469	57	during	during	ADP
ajmpe-94	469	58	pregnancy	pregnancy	NOUN
ajmpe-94	469	59	.	.	PUNCT
ajmpe-94	470	1	biol	biol	PROPN
ajmpe-94	470	2	.	.	PUNCT
ajmpe-94	471	1	trace	trace	NOUN
ajmpe-94	471	2	elem	elem	NOUN
ajmpe-94	471	3	.	.	PUNCT
ajmpe-94	472	1	res	re	NOUN
ajmpe-94	472	2	.	.	PUNCT
ajmpe-94	473	1	2020:1–10	2020:1–10	X
ajmpe-94	473	2	.	.	PROPN
ajmpe-94	473	3	54	54	NUM
ajmpe-94	473	4	.	.	PUNCT
ajmpe-94	474	1	zeng	zeng	PROPN
ajmpe-94	474	2	h.l	h.l	PROPN
ajmpe-94	474	3	.	.	PROPN
ajmpe-94	474	4	,	,	PUNCT
ajmpe-94	474	5	yang	yang	PROPN
ajmpe-94	474	6	q.	q.	PROPN
ajmpe-94	474	7	,	,	PUNCT
ajmpe-94	474	8	yuan	yuan	PROPN
ajmpe-94	474	9	p.	p.	PROPN
ajmpe-94	474	10	,	,	PUNCT
ajmpe-94	474	11	wang	wang	PROPN
ajmpe-94	474	12	x.	x.	PROPN
ajmpe-94	474	13	,	,	PUNCT
ajmpe-94	474	14	cheng	cheng	PROPN
ajmpe-94	474	15	l.	l.	PROPN
ajmpe-94	474	16	associations	associations	PROPN
ajmpe-94	474	17	of	of	ADP
ajmpe-94	474	18	essential	essential	ADJ
ajmpe-94	474	19	and	and	CCONJ
ajmpe-94	474	20	toxic	toxic	ADJ
ajmpe-94	474	21	metals	metal	NOUN
ajmpe-94	474	22	/	/	SYM
ajmpe-94	474	23	metalloids	metalloid	NOUN
ajmpe-94	474	24	in	in	ADP
ajmpe-94	474	25	whole	whole	ADJ
ajmpe-94	474	26	blood	blood	NOUN
ajmpe-94	474	27	with	with	ADP
ajmpe-94	474	28	both	both	DET
ajmpe-94	474	29	disease	disease	NOUN
ajmpe-94	474	30	severity	severity	NOUN
ajmpe-94	474	31	and	and	CCONJ
ajmpe-94	474	32	mortality	mortality	NOUN
ajmpe-94	474	33	in	in	ADP
ajmpe-94	474	34	patients	patient	NOUN
ajmpe-94	474	35	with	with	ADP
ajmpe-94	474	36	covid-19	covid-19	PROPN
ajmpe-94	474	37	.	.	PROPN
ajmpe-94	474	38	faseb	faseb	PROPN
ajmpe-94	474	39	j.	j.	PROPN
ajmpe-94	474	40	2021;35	2021;35	PROPN
ajmpe-94	474	41	:	:	PUNCT
ajmpe-94	474	42	e21392	e21392	PROPN
ajmpe-94	474	43	.	.	PUNCT
ajmpe-94	474	44	doi	doi	NOUN
ajmpe-94	474	45	:	:	PUNCT
ajmpe-94	474	46	10.1096	10.1096	NUM
ajmpe-94	474	47	/	/	SYM
ajmpe-94	474	48	fj.202002346rr	fj.202002346rr	NUM
ajmpe-94	474	49	.	.	PUNCT
ajmpe-94	475	1	[	[	X
ajmpe-94	475	2	pmc	pmc	PROPN
ajmpe-94	475	3	free	free	ADJ
ajmpe-94	475	4	article	article	NOUN
ajmpe-94	475	5	]	]	X
ajmpe-94	476	1	[	[	X
ajmpe-94	476	2	pubmed	pubmed	X
ajmpe-94	476	3	]	]	X
ajmpe-94	477	1	[	[	X
ajmpe-94	477	2	crossref	crossref	X
ajmpe-94	477	3	]	]	X
ajmpe-94	477	4	[	[	X
ajmpe-94	477	5	google	google	NOUN
ajmpe-94	477	6	scholar	scholar	NOUN
ajmpe-94	477	7	]	]	PUNCT
ajmpe-94	477	8	wessels	wessels	PROPN
ajmpe-94	477	9	i	i	PROPN
ajmpe-94	477	10	,	,	PUNCT
ajmpe-94	477	11	maywald	maywald	PROPN
ajmpe-94	477	12	m	m	PROPN
ajmpe-94	477	13	,	,	PUNCT
ajmpe-94	477	14	rink	rink	NOUN
ajmpe-94	477	15	l.	l.	PROPN
ajmpe-94	477	16	zinc	zinc	PROPN
ajmpe-94	477	17	as	as	ADP
ajmpe-94	477	18	a	a	DET
ajmpe-94	477	19	gatekeeper	gatekeeper	NOUN
ajmpe-94	477	20	of	of	ADP
ajmpe-94	477	21	immune	immune	ADJ
ajmpe-94	477	22	function	function	NOUN
ajmpe-94	477	23	.	.	PUNCT
ajmpe-94	478	1	nutrients	nutrient	NOUN
ajmpe-94	478	2	.	.	PUNCT
ajmpe-94	479	1	(	(	PUNCT
ajmpe-94	479	2	2017	2017	NUM
ajmpe-94	479	3	)	)	PUNCT
ajmpe-94	479	4	;	;	PUNCT
ajmpe-94	480	1	9:1286	9:1286	X
ajmpe-94	480	2	.	.	PUNCT
ajmpe-94	480	3	doi	doi	NOUN
ajmpe-94	480	4	:	:	PUNCT
ajmpe-94	480	5	10.3390	10.3390	NUM
ajmpe-94	480	6	/	/	SYM
ajmpe-94	480	7	nu9121286	nu9121286	ADJ
ajmpe-94	480	8	maywald	maywald	PROPN
ajmpe-94	480	9	m	m	PROPN
ajmpe-94	480	10	,	,	PUNCT
ajmpe-94	480	11	wessels	wessels	PROPN
ajmpe-94	480	12	i	i	PRON
ajmpe-94	480	13	,	,	PUNCT
ajmpe-94	480	14	rink	rink	NOUN
ajmpe-94	480	15	l.	l.	PROPN
ajmpe-94	480	16	zinc	zinc	NOUN
ajmpe-94	480	17	signals	signal	NOUN
ajmpe-94	480	18	and	and	CCONJ
ajmpe-94	480	19	immunity	immunity	NOUN
ajmpe-94	480	20	.	.	PUNCT
ajmpe-94	481	1	int	int	PROPN
ajmpe-94	481	2	j	j	PROPN
ajmpe-94	481	3	mol	mol	ADP
ajmpe-94	481	4	sci	sci	PROPN
ajmpe-94	481	5	.	.	PUNCT
ajmpe-94	482	1	(	(	PUNCT
ajmpe-94	482	2	2017	2017	NUM
ajmpe-94	482	3	)	)	PUNCT
ajmpe-94	482	4	;	;	PUNCT
ajmpe-94	483	1	18:2222	18:2222	X
ajmpe-94	483	2	.	.	PUNCT
ajmpe-94	483	3	doi	doi	NOUN
ajmpe-94	483	4	:	:	PUNCT
ajmpe-94	483	5	10.3390	10.3390	NUM
ajmpe-94	483	6	/	/	SYM
ajmpe-94	483	7	ijms18102222	ijms18102222	PROPN
ajmpe-94	483	8	57	57	NUM
ajmpe-94	483	9	.	.	PUNCT
ajmpe-94	484	1	wessels	wessels	PROPN
ajmpe-94	484	2	i	i	PROPN
ajmpe-94	484	3	,	,	PUNCT
ajmpe-94	484	4	cousins	cousins	PROPN
ajmpe-94	484	5	rj	rj	PROPN
ajmpe-94	484	6	.	.	PUNCT
ajmpe-94	484	7	zinc	zinc	NOUN
ajmpe-94	484	8	dyshomeostasis	dyshomeostasis	NOUN
ajmpe-94	484	9	during	during	ADP
ajmpe-94	484	10	polymicrobial	polymicrobial	ADJ
ajmpe-94	484	11	sepsis	sepsis	NOUN
ajmpe-94	484	12	in	in	ADP
ajmpe-94	484	13	mice	mice	NOUN
ajmpe-94	484	14	involves	involve	VERB
ajmpe-94	484	15	zinc	zinc	NOUN
ajmpe-94	484	16	transporter	transporter	NOUN
ajmpe-94	484	17	zip14	zip14	NOUN
ajmpe-94	484	18	and	and	CCONJ
ajmpe-94	484	19	can	can	AUX
ajmpe-94	484	20	be	be	AUX
ajmpe-94	484	21	overcome	overcome	VERB
ajmpe-94	484	22	by	by	ADP
ajmpe-94	484	23	zinc	zinc	NOUN
ajmpe-94	484	24	supplementation	supplementation	NOUN
ajmpe-94	484	25	.	.	PUNCT
ajmpe-94	485	1	am	be	AUX
ajmpe-94	485	2	j	j	PROPN
ajmpe-94	485	3	physiol	physiol	PROPN
ajmpe-94	485	4	gastrointest	gastrointest	PROPN
ajmpe-94	485	5	liver	liver	PROPN
ajmpe-94	485	6	physiol	physiol	PROPN
ajmpe-94	485	7	.	.	PUNCT
ajmpe-94	486	1	(	(	PUNCT
ajmpe-94	486	2	2015	2015	NUM
ajmpe-94	486	3	)	)	PUNCT
ajmpe-94	486	4	;	;	PUNCT
ajmpe-94	486	5	309	309	NUM
ajmpe-94	486	6	:	:	PUNCT
ajmpe-94	486	7	g768–78	g768–78	PROPN
ajmpe-94	486	8	.	.	PROPN
ajmpe-94	486	9	doi	doi	PROPN
ajmpe-94	486	10	:	:	PUNCT
ajmpe-94	486	11	10.1152	10.1152	NUM
ajmpe-94	486	12	/	/	SYM
ajmpe-94	486	13	ajpgi.00179.2015	ajpgi.00179.2015	PROPN
ajmpe-94	486	14	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	PROPN
ajmpe-94	486	15	american	american	PROPN
ajmpe-94	486	16	journal	journal	PROPN
ajmpe-94	486	17	of	of	ADP
ajmpe-94	486	18	medical	medical	ADJ
ajmpe-94	486	19	and	and	CCONJ
ajmpe-94	486	20	physical	physical	ADJ
ajmpe-94	486	21	education	education	NOUN
ajmpe-94	486	22	vol.1	vol.1	PROPN
ajmpe-94	486	23	,	,	PUNCT
ajmpe-94	486	24	issue	issue	NOUN
ajmpe-94	486	25	1	1	NUM
ajmpe-94	486	26	;	;	PUNCT
ajmpe-94	486	27	july	july	PROPN
ajmpe-94	486	28	2023	2023	NUM
ajmpe-94	486	29	;	;	PUNCT
ajmpe-94	486	30	1252	1252	NUM
ajmpe-94	486	31	columbia	columbia	PROPN
ajmpe-94	486	32	rd	rd	PROPN
ajmpe-94	486	33	nw	nw	PROPN
ajmpe-94	486	34	,	,	PUNCT
ajmpe-94	486	35	washington	washington	PROPN
ajmpe-94	486	36	dc	dc	PROPN
ajmpe-94	486	37	,	,	PUNCT
ajmpe-94	486	38	united	united	PROPN
ajmpe-94	486	39	states	states	PROPN
ajmpe-94	486	40	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	486	41	;	;	PUNCT
ajmpe-94	486	42	mail	mail	NOUN
ajmpe-94	486	43	:	:	PUNCT
ajmpe-94	486	44	topacademicjournals@gmail.com	topacademicjournals@gmail.com	X
ajmpe-94	487	1	84	84	NUM
ajmpe-94	488	1	|	|	ADV
ajmpe-94	488	2	a	a	DET
ajmpe-94	488	3	m	m	NOUN
ajmpe-94	488	4	e	e	NOUN
ajmpe-94	488	5	r	r	NOUN
ajmpe-94	488	6	i	i	NOUN
ajmpe-94	488	7	c	c	VERB
ajmpe-94	488	8	a	a	DET
ajmpe-94	488	9	n	n	NOUN
ajmpe-94	489	1	j	j	NOUN
ajmpe-94	489	2	o	o	X
ajmpe-94	489	3	u	u	NOUN
ajmpe-94	489	4	r	r	NOUN
ajmpe-94	489	5	n	n	NOUN
ajmpe-94	489	6	a	a	DET
ajmpe-94	489	7	l	l	NOUN
ajmpe-94	489	8	o	o	X
ajmpe-94	490	1	f	f	X
ajmpe-94	490	2	m	m	NOUN
ajmpe-94	490	3	e	e	NOUN
ajmpe-94	491	1	d	d	NOUN
ajmpe-94	491	2	i	i	PRON
ajmpe-94	491	3	c	c	VERB
ajmpe-94	491	4	a	a	DET
ajmpe-94	491	5	l	l	NOUN
ajmpe-94	491	6	a	a	X
ajmpe-94	491	7	n	n	NOUN
ajmpe-94	492	1	d	d	NOUN
ajmpe-94	492	2	p	p	NOUN
ajmpe-94	492	3	h	h	NOUN
ajmpe-94	492	4	y	y	NOUN
ajmpe-94	492	5	s	s	VERB
ajmpe-94	493	1	i	i	INTJ
ajmpe-94	493	2	c	c	VERB
ajmpe-94	493	3	a	a	DET
ajmpe-94	493	4	l	l	NOUN
ajmpe-94	493	5	e	e	NOUN
ajmpe-94	493	6	d	d	X
ajmpe-94	493	7	u	u	X
ajmpe-94	493	8	c	c	PROPN
ajmpe-94	494	1	a	a	DET
ajmpe-94	494	2	t	t	NOUN
ajmpe-94	495	1	i	i	PRON
ajmpe-94	495	2	o	o	VERB
ajmpe-94	496	1	n	n	CCONJ
ajmpe-94	496	2	|	|	ADV
ajmpe-94	496	3	https://topjournals.org/index.php/ajmpe	https://topjournals.org/index.php/ajmpe	VERB
ajmpe-94	496	4	arrieta	arrieta	PROPN
ajmpe-94	496	5	f	f	PROPN
ajmpe-94	496	6	,	,	PUNCT
ajmpe-94	496	7	martinez	martinez	PROPN
ajmpe-94	496	8	-	-	PROPN
ajmpe-94	496	9	vaello	vaello	PROPN
ajmpe-94	496	10	v	v	PROPN
ajmpe-94	496	11	,	,	PUNCT
ajmpe-94	496	12	bengoa	bengoa	NOUN
ajmpe-94	496	13	n	n	CCONJ
ajmpe-94	496	14	,	,	PUNCT
ajmpe-94	496	15	et	et	PROPN
ajmpe-94	496	16	al	al	PROPN
ajmpe-94	496	17	.	.	PUNCT
ajmpe-94	497	1	serum	serum	PROPN
ajmpe-94	497	2	zinc	zinc	PROPN
ajmpe-94	497	3	and	and	CCONJ
ajmpe-94	497	4	copper	copper	NOUN
ajmpe-94	497	5	in	in	ADP
ajmpe-94	497	6	people	people	NOUN
ajmpe-94	497	7	with	with	ADP
ajmpe-94	497	8	covid-19	covid-19	PROPN
ajmpe-94	497	9	and	and	CCONJ
ajmpe-94	497	10	zinc	zinc	NOUN
ajmpe-94	497	11	supplementation	supplementation	NOUN
ajmpe-94	497	12	in	in	ADP
ajmpe-94	497	13	parenteral	parenteral	ADJ
ajmpe-94	497	14	nutrition	nutrition	NOUN
ajmpe-94	497	15	.	.	PUNCT
ajmpe-94	498	1	nutrition	nutrition	NOUN
ajmpe-94	498	2	2021	2021	NUM
ajmpe-94	498	3	;	;	PUNCT
ajmpe-94	498	4	91–92:111467	91–92:111467	NUM
ajmpe-94	498	5	.	.	PUNCT
ajmpe-94	499	1	https://	https://	PROPN
ajmpe-94	499	2	doi	doi	PROPN
ajmpe-94	499	3	.	.	PUNCT
ajmpe-94	500	1	org/	org/	PRON
ajmpe-94	500	2	10	10	NUM
ajmpe-94	500	3	.	.	PUNCT
ajmpe-94	501	1	1016	1016	NUM
ajmpe-94	501	2	/	/	SYM
ajmpe-94	501	3	j.	j.	PROPN
ajmpe-94	501	4	nut	nut	PROPN
ajmpe-94	501	5	.	.	PROPN
ajmpe-94	501	6	2021	2021	NUM
ajmpe-94	501	7	.	.	PUNCT
ajmpe-94	501	8	111467	111467	NUM
ajmpe-94	501	9	anuk	anuk	NOUN
ajmpe-94	501	10	at	at	ADP
ajmpe-94	501	11	,	,	PUNCT
ajmpe-94	501	12	polat	polat	NOUN
ajmpe-94	501	13	n	n	CCONJ
ajmpe-94	501	14	,	,	PUNCT
ajmpe-94	501	15	akdas	akdas	PROPN
ajmpe-94	501	16	s	s	PROPN
ajmpe-94	501	17	et	et	NOUN
ajmpe-94	501	18	al	al	PROPN
ajmpe-94	501	19	.	.	PUNCT
ajmpe-94	502	1	the	the	DET
ajmpe-94	502	2	relation	relation	NOUN
ajmpe-94	502	3	between	between	ADP
ajmpe-94	502	4	trace	trace	NOUN
ajmpe-94	502	5	element	element	NOUN
ajmpe-94	502	6	status	status	NOUN
ajmpe-94	502	7	(	(	PUNCT
ajmpe-94	502	8	zinc	zinc	NOUN
ajmpe-94	502	9	,	,	PUNCT
ajmpe-94	502	10	copper	copper	NOUN
ajmpe-94	502	11	,	,	PUNCT
ajmpe-94	502	12	magnesium	magnesium	NOUN
ajmpe-94	502	13	)	)	PUNCT
ajmpe-94	502	14	and	and	CCONJ
ajmpe-94	502	15	clinical	clinical	ADJ
ajmpe-94	502	16	outcomes	outcome	NOUN
ajmpe-94	502	17	in	in	ADP
ajmpe-94	502	18	covid-19	covid-19	PROPN
ajmpe-94	502	19	infection	infection	NOUN
ajmpe-94	502	20	during	during	ADP
ajmpe-94	502	21	pregnancy	pregnancy	NOUN
ajmpe-94	502	22	.	.	PUNCT
ajmpe-94	503	1	biol	biol	PROPN
ajmpe-94	503	2	trace	trace	NOUN
ajmpe-94	503	3	elem	elem	NOUN
ajmpe-94	503	4	res2021	res2021	NOUN
ajmpe-94	503	5	;	;	PUNCT
ajmpe-94	503	6	199:3608–3617	199:3608–3617	NUM
ajmpe-94	503	7	.	.	PUNCT
ajmpe-94	504	1	https://	https://	PROPN
ajmpe-94	504	2	doi	doi	PROPN
ajmpe-94	504	3	.	.	PUNCT
ajmpe-94	505	1	org/	org/	PRON
ajmpe-94	505	2	10	10	NUM
ajmpe-94	505	3	.	.	PUNCT
ajmpe-94	506	1	1007/	1007/	NUM
ajmpe-94	506	2	s1201102002496	s1201102002496	NOUN
ajmpe-94	506	3	-	-	PUNCT
ajmpe-94	506	4	y	y	PROPN
ajmpe-94	506	5	muhammad	muhammad	PROPN
ajmpe-94	506	6	y	y	PROPN
ajmpe-94	506	7	,	,	PUNCT
ajmpe-94	506	8	kani	kani	VERB
ajmpe-94	506	9	ya	ya	PROPN
ajmpe-94	506	10	,	,	PUNCT
ajmpe-94	506	11	iliya	iliya	PROPN
ajmpe-94	506	12	s	s	PROPN
ajmpe-94	506	13	,	,	PUNCT
ajmpe-94	506	14	et	et	PROPN
ajmpe-94	506	15	al	al	PROPN
ajmpe-94	506	16	(	(	PUNCT
ajmpe-94	506	17	2021	2021	NUM
ajmpe-94	506	18	)	)	PUNCT
ajmpe-94	506	19	deficiency	deficiency	NOUN
ajmpe-94	506	20	of	of	ADP
ajmpe-94	506	21	antioxidants	antioxidant	NOUN
ajmpe-94	506	22	and	and	CCONJ
ajmpe-94	506	23	increased	increase	VERB
ajmpe-94	506	24	oxidative	oxidative	ADJ
ajmpe-94	506	25	stress	stress	NOUN
ajmpe-94	506	26	in	in	ADP
ajmpe-94	506	27	covid19	covid19	NOUN
ajmpe-94	506	28	patients	patient	NOUN
ajmpe-94	506	29	:	:	PUNCT
ajmpe-94	506	30	a	a	DET
ajmpe-94	506	31	cross	cross	ADJ
ajmpe-94	506	32	-	-	ADJ
ajmpe-94	506	33	sectional	sectional	ADJ
ajmpe-94	506	34	comparative	comparative	ADJ
ajmpe-94	506	35	study	study	NOUN
ajmpe-94	506	36	in	in	ADP
ajmpe-94	506	37	jigawa	jigawa	PROPN
ajmpe-94	506	38	,	,	PUNCT
ajmpe-94	506	39	northwestern	northwestern	PROPN
ajmpe-94	506	40	nigeria	nigeria	PROPN
ajmpe-94	506	41	.	.	PUNCT
ajmpe-94	507	1	sage	sage	VERB
ajmpe-94	507	2	open	open	ADJ
ajmpe-94	507	3	med	med	ADJ
ajmpe-94	507	4	9:2050312121991246	9:2050312121991246	PROPN
ajmpe-94	507	5	.	.	PUNCT
ajmpe-94	508	1	https://	https://	PROPN
ajmpe-94	508	2	doi	doi	PROPN
ajmpe-94	508	3	.	.	PUNCT
ajmpe-94	509	1	org/	org/	PRON
ajmpe-94	509	2	10	10	NUM
ajmpe-94	509	3	.	.	PUNCT
ajmpe-94	510	1	1177/	1177/	NUM
ajmpe-94	510	2	20503	20503	NUM
ajmpe-94	510	3	12121	12121	NUM
ajmpe-94	510	4	991246	991246	NUM
ajmpe-94	510	5	carlucci	carlucci	NOUN
ajmpe-94	510	6	pm	pm	PROPN
ajmpe-94	510	7	,	,	PUNCT
ajmpe-94	510	8	ahuja	ahuja	PROPN
ajmpe-94	510	9	t	t	PROPN
ajmpe-94	510	10	,	,	PUNCT
ajmpe-94	510	11	petrilli	petrilli	PROPN
ajmpe-94	510	12	c	c	AUX
ajmpe-94	510	13	,	,	PUNCT
ajmpe-94	510	14	et	et	PROPN
ajmpe-94	510	15	al	al	PROPN
ajmpe-94	510	16	.	.	PUNCT
ajmpe-94	511	1	zinc	zinc	NOUN
ajmpe-94	511	2	sulfate	sulfate	NOUN
ajmpe-94	511	3	in	in	ADP
ajmpe-94	511	4	combination	combination	NOUN
ajmpe-94	511	5	with	with	ADP
ajmpe-94	511	6	a	a	DET
ajmpe-94	511	7	zinc	zinc	NOUN
ajmpe-94	511	8	ionophore	ionophore	NOUN
ajmpe-94	511	9	may	may	AUX
ajmpe-94	511	10	improve	improve	VERB
ajmpe-94	511	11	outcomes	outcome	NOUN
ajmpe-94	511	12	in	in	ADP
ajmpe-94	511	13	hospitalized	hospitalize	VERB
ajmpe-94	511	14	covid-19	covid-19	PROPN
ajmpe-94	511	15	patients	patient	NOUN
ajmpe-94	511	16	.	.	PUNCT
ajmpe-94	512	1	j	j	PROPN
ajmpe-94	512	2	med	med	PROPN
ajmpe-94	512	3	microbiol	microbiol	PROPN
ajmpe-94	512	4	2020	2020	NUM
ajmpe-94	512	5	;	;	PUNCT
ajmpe-94	512	6	69:1228–1234	69:1228–1234	X
ajmpe-94	512	7	.	.	PUNCT
ajmpe-94	513	1	https://	https://	PROPN
ajmpe-94	513	2	doi	doi	PROPN
ajmpe-94	513	3	.	.	PUNCT
ajmpe-94	514	1	org/	org/	PRON
ajmpe-94	514	2	10	10	NUM
ajmpe-94	514	3	.	.	PUNCT
ajmpe-94	515	1	1099/	1099/	NUM
ajmpe-94	515	2	jmm.0	jmm.0	PROPN
ajmpe-94	515	3	.	.	PUNCT
ajmpe-94	515	4	001250	001250	NUM
ajmpe-94	516	1	ishida	ishida	PROPN
ajmpe-94	516	2	t	t	PROPN
ajmpe-94	516	3	.	.	PUNCT
ajmpe-94	517	1	antiviral	antiviral	ADJ
ajmpe-94	517	2	activities	activity	NOUN
ajmpe-94	517	3	of	of	ADP
ajmpe-94	517	4	cu2	cu2	NOUN
ajmpe-94	517	5	+	+	NOUN
ajmpe-94	517	6	ions	ion	NOUN
ajmpe-94	517	7	in	in	ADP
ajmpe-94	517	8	viral	viral	ADJ
ajmpe-94	517	9	prevention	prevention	NOUN
ajmpe-94	517	10	,	,	PUNCT
ajmpe-94	517	11	replication	replication	NOUN
ajmpe-94	517	12	,	,	PUNCT
ajmpe-94	517	13	rna	rna	NOUN
ajmpe-94	517	14	degradation	degradation	NOUN
ajmpe-94	517	15	,	,	PUNCT
ajmpe-94	517	16	and	and	CCONJ
ajmpe-94	517	17	for	for	ADP
ajmpe-94	517	18	antiviral	antiviral	ADJ
ajmpe-94	517	19	efficacies	efficacy	NOUN
ajmpe-94	517	20	of	of	ADP
ajmpe-94	517	21	the	the	DET
ajmpe-94	517	22	lytic	lytic	ADJ
ajmpe-94	517	23	virus	virus	NOUN
ajmpe-94	517	24	,	,	PUNCT
ajmpe-94	517	25	ros	ros	PROPN
ajmpe-94	517	26	-	-	PUNCT
ajmpe-94	517	27	mediated	mediate	VERB
ajmpe-94	517	28	virus	virus	NOUN
ajmpe-94	517	29	,	,	PUNCT
ajmpe-94	517	30	copper	copper	NOUN
ajmpe-94	517	31	chelation	chelation	NOUN
ajmpe-94	517	32	.	.	PUNCT
ajmpe-94	518	1	world	world	NOUN
ajmpe-94	518	2	sci	sci	PROPN
ajmpe-94	518	3	news	news	PROPN
ajmpe-94	518	4	2018	2018	NUM
ajmpe-94	518	5	;	;	PUNCT
ajmpe-94	518	6	99:148–168	99:148–168	PROPN
ajmpe-94	518	7	te	te	PROPN
ajmpe-94	518	8	velthuis	velthuis	PROPN
ajmpe-94	518	9	ajw	ajw	PROPN
ajmpe-94	518	10	,	,	PUNCT
ajmpe-94	518	11	van	van	PROPN
ajmpe-94	518	12	den	den	PROPN
ajmpe-94	518	13	worm	worm	NOUN
ajmpe-94	518	14	she	she	PRON
ajmpe-94	518	15	,	,	PUNCT
ajmpe-94	518	16	sims	sim	NOUN
ajmpe-94	518	17	ac	ac	PROPN
ajmpe-94	518	18	et	et	PROPN
ajmpe-94	518	19	al	al	PROPN
ajmpe-94	518	20	(	(	PUNCT
ajmpe-94	518	21	2010	2010	NUM
ajmpe-94	518	22	)	)	PUNCT
ajmpe-94	518	23	zn	zn	PROPN
ajmpe-94	518	24	(	(	PUNCT
ajmpe-94	518	25	2	2	NUM
ajmpe-94	518	26	+	+	NOUN
ajmpe-94	518	27	)	)	PUNCT
ajmpe-94	518	28	inhibits	inhibit	VERB
ajmpe-94	518	29	coronavirus	coronavirus	NOUN
ajmpe-94	518	30	and	and	CCONJ
ajmpe-94	518	31	arterivirus	arterivirus	PROPN
ajmpe-94	518	32	rna	rna	NOUN
ajmpe-94	518	33	polymerase	polymerase	NOUN
ajmpe-94	518	34	activity	activity	NOUN
ajmpe-94	518	35	in	in	ADP
ajmpe-94	518	36	vitro	vitro	X
ajmpe-94	518	37	and	and	CCONJ
ajmpe-94	518	38	zinc	zinc	NOUN
ajmpe-94	518	39	ionophores	ionophore	NOUN
ajmpe-94	518	40	block	block	VERB
ajmpe-94	518	41	the	the	DET
ajmpe-94	518	42	replication	replication	NOUN
ajmpe-94	518	43	of	of	ADP
ajmpe-94	518	44	these	these	DET
ajmpe-94	518	45	viruses	virus	NOUN
ajmpe-94	518	46	in	in	ADP
ajmpe-94	518	47	cell	cell	NOUN
ajmpe-94	518	48	culture	culture	NOUN
ajmpe-94	518	49	.	.	PUNCT
ajmpe-94	519	1	plos	plos	PROPN
ajmpe-94	519	2	pathog	pathog	VERB
ajmpe-94	519	3	6	6	NUM
ajmpe-94	519	4	:	:	PUNCT
ajmpe-94	519	5	e1001176	e1001176	PROPN
ajmpe-94	519	6	.	.	PUNCT
ajmpe-94	520	1	https://	https://	PROPN
ajmpe-94	520	2	doi	doi	PROPN
ajmpe-94	520	3	.	.	PUNCT
ajmpe-94	521	1	org/	org/	PRON
ajmpe-94	521	2	10	10	NUM
ajmpe-94	521	3	.	.	PUNCT
ajmpe-94	522	1	1371/	1371/	NUM
ajmpe-94	522	2	journal	journal	NOUN
ajmpe-94	522	3	.	.	PUNCT
ajmpe-94	523	1	pp	pp	ADP
ajmpe-94	523	2	t.	t.	PROPN
ajmpe-94	523	3	10011	10011	NUM
ajmpe-94	523	4	76	76	NUM
ajmpe-94	523	5	vahidy	vahidy	NOUN
ajmpe-94	523	6	fs	fs	PROPN
ajmpe-94	523	7	,	,	PUNCT
ajmpe-94	523	8	pan	pan	PROPN
ajmpe-94	523	9	ap	ap	PROPN
ajmpe-94	523	10	,	,	PUNCT
ajmpe-94	523	11	ahnstedt	ahnstedt	PROPN
ajmpe-94	523	12	h	h	NOUN
ajmpe-94	523	13	,	,	PUNCT
ajmpe-94	523	14	munshi	munshi	PROPN
ajmpe-94	523	15	y	y	PROPN
ajmpe-94	523	16	,	,	PUNCT
ajmpe-94	523	17	choi	choi	NOUN
ajmpe-94	523	18	ha	ha	INTJ
ajmpe-94	523	19	,	,	PUNCT
ajmpe-94	523	20	tirunehy	tirunehy	VERB
ajmpe-94	523	21	,	,	PUNCT
ajmpe-94	523	22	et	et	NOUN
ajmpe-94	523	23	alsex	alsex	NOUN
ajmpe-94	523	24	differences	difference	NOUN
ajmpe-94	523	25	in	in	ADP
ajmpe-94	523	26	susceptibility	susceptibility	NOUN
ajmpe-94	523	27	,	,	PUNCT
ajmpe-94	523	28	severity	severity	NOUN
ajmpe-94	523	29	,	,	PUNCT
ajmpe-94	523	30	and	and	CCONJ
ajmpe-94	523	31	outcomes	outcome	NOUN
ajmpe-94	523	32	of	of	ADP
ajmpe-94	523	33	coronavirus	coronavirus	NOUN
ajmpe-94	523	34	disease	disease	NOUN
ajmpe-94	523	35	2019	2019	NUM
ajmpe-94	523	36	:	:	PUNCT
ajmpe-94	523	37	plosone	plosone	PROPN
ajmpe-94	523	38	journal	journal	NOUN
ajmpe-94	523	39	.	.	PUNCT
ajmpe-94	524	1	pone	pone	PROPN
ajmpe-94	524	2	2021	2021	NUM
ajmpe-94	524	3	;	;	PUNCT
ajmpe-94	524	4	16(1	16(1	NUM
ajmpe-94	524	5	):	):	PUNCT
ajmpe-94	524	6	e0245556.https://doi.org/10.1371/journal	e0245556.https://doi.org/10.1371/journal	PROPN
ajmpe-94	524	7	.	.	PUNCT
ajmpe-94	524	8	pone.0245556.(2021	pone.0245556.(2021	PROPN
ajmpe-94	524	9	)	)	PUNCT
ajmpe-94	525	1	zhang	zhang	PROPN
ajmpe-94	525	2	w	w	PROPN
ajmpe-94	525	3	,	,	PUNCT
ajmpe-94	525	4	du	du	PROPN
ajmpe-94	525	5	rh	rh	PROPN
ajmpe-94	525	6	,	,	PUNCT
ajmpe-94	525	7	li	li	PROPN
ajmpe-94	525	8	b.	b.	PROPN
ajmpe-94	525	9	correlation	correlation	NOUN
ajmpe-94	525	10	between	between	ADP
ajmpe-94	525	11	hyponatremia	hyponatremia	NOUN
ajmpe-94	525	12	and	and	CCONJ
ajmpe-94	525	13	severity	severity	NOUN
ajmpe-94	525	14	of	of	ADP
ajmpe-94	525	15	coronavirus	coronavirus	NOUN
ajmpe-94	525	16	disease	disease	NOUN
ajmpe-94	525	17	2019	2019	NUM
ajmpe-94	525	18	.	.	PUNCT
ajmpe-94	526	1	emerg	emerg	PROPN
ajmpe-94	526	2	microbes	microbe	NOUN
ajmpe-94	526	3	infect	infect	VERB
ajmpe-94	526	4	2020	2020	NUM
ajmpe-94	526	5	;	;	PUNCT
ajmpe-94	527	1	9:386–9	9:386–9	X
ajmpe-94	527	2	.	.	PUNCT
ajmpe-94	528	1	mohammad	mohammad	PROPN
ajmpe-94	528	2	pourfridoni	pourfridoni	PROPN
ajmpe-94	528	3	,	,	PUNCT
ajmpe-94	528	4	seyede	seyede	NOUN
ajmpe-94	528	5	mahsa	mahsa	NOUN
ajmpe-94	528	6	abbasnia	abbasnia	PROPN
ajmpe-94	528	7	,	,	PUNCT
ajmpe-94	528	8	fateme	fateme	NOUN
ajmpe-94	528	9	shafaei	shafaei	NOUN
ajmpe-94	528	10	,	,	PUNCT
ajmpe-94	528	11	javad	javad	PROPN
ajmpe-94	528	12	razaviyan	razaviyan	PROPN
ajmpe-94	528	13	,	,	PUNCT
ajmpe-94	528	14	and	and	CCONJ
ajmpe-94	528	15	reza	reza	PROPN
ajmpe-94	528	16	heidarisoureshjani	heidarisoureshjani	NOUN
ajmpe-94	528	17	,	,	PUNCT
ajmpe-94	528	18	fluid	fluid	ADJ
ajmpe-94	528	19	and	and	CCONJ
ajmpe-94	528	20	electrolyte	electrolyte	ADJ
ajmpe-94	528	21	disturbances	disturbance	NOUN
ajmpe-94	528	22	in	in	ADP
ajmpe-94	528	23	covid-19	covid-19	PROPN
ajmpe-94	528	24	and	and	CCONJ
ajmpe-94	528	25	their	their	PRON
ajmpe-94	528	26	complications	complication	NOUN
ajmpe-94	528	27	hindawi	hindawi	VERB
ajmpe-94	528	28	biomed	biome	VERB
ajmpe-94	528	29	research	research	NOUN
ajmpe-94	528	30	international	international	ADJ
ajmpe-94	528	31	volume	volume	NOUN
ajmpe-94	528	32	2021,article	2021,article	NUM
ajmpe-94	528	33	i	i	PROPN
ajmpe-94	528	34	d	d	PROPN
ajmpe-94	528	35	6667047	6667047	NUM
ajmpe-94	528	36	,	,	PUNCT
ajmpe-94	528	37	5	5	NUM
ajmpe-94	528	38	pages	page	NOUN
ajmpe-94	528	39	mailto:topacademicjournals@gmail.com	mailto:topacademicjournals@gmail.com	X